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SUMMARY 
I. Synthesis and inhibitory activity of sialic acid derivatives targeting viral 
sialate-O-acetylesterases and sialate-O-acetyltransferases 
Sialate-O-acetylation is a common structural modification of sialic acid, which has been 
associated with many human disease states (including cancer and autoimmune 
disease). This highly regulated and tissue-specific modification is carried out by sialate-
O-acetylesterase (SOAE) and sialate-O-acetyltransferase (SOAT) enzymes.  
The availability of these enzymes make inhibition studies a viable endeavour, 
considering that SOAT/SOAE inhibitors may provide interesting tools/drug leads for the 
development of antiviral compounds or treatments for various disease states. A 
synthesis of suitable 4-O- and 9-O-functionalised sialic acid derivatives has been 
established which enabled the investigation of 4- and 9-sialate-O-acetylesterase 
enzymes. Sialic acid derivatives were screened for the inhibition of a set of viral SOAEs 
and while no inhibition of 4-SOAE could be detected, a 9-O-methyl derivative showed 
inhibition of the recombinant influenza C virus SOAE. The functionalised sialic acid motif 
thus serves as an initial template for the design and synthesis of future sialic acid 
derivatives towards SOAT/SOAT inhibition. 
 
II. New tools for the characterization and investigation of influenza virus 
neuraminidases: towards novel influenza virus sensors 
Tamiflu (Oseltamivir), has been employed as a mimetic of the sialic acid 
“oxocarbenium” intermediate formed during enzymatic hydrolysis, leading to inhibition of 
virus-bound neuraminidase (NA) enzyme. Phospha-isosteres of oseltamivir provide 
access to monoesters which retain the efficacy of the pharmacophore and allow the 
synthesis of novel influenza neuraminidase-specific materials. 
Phospha-oseltamivir-stabilised gold nanoparticles (“TamiGold”) have been synthesised 
and NA inhibition studies with “small TamiGold” show activity against influenza virus 
strains investigated compared to control gold nanoparticles. The binding interactions 
displayed by “large TamiGold” may provide the basis for a colorimetric method of 
influenza detection and as such a novel prototype influenza sensor. To the best of our 
knowledge this is the first example of a multivalent approach to influenza virus binding 
utilising sialylmimetic scaffolds immobilised on a nanoparticle platform which specifically 
target the NA (instead of the hemagglutinin, HA). The synthesis of phospha-oseltamivir 
conjugates and their ligation to biological reporter groups afford small molecule tools with 
high affinity and selectivity towards influenza NA. These derivatives can be applied 
towards novel multivalent phospha-oseltamivir materials and used as novel diagnostics, 
independent of existing methods.
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Abstract 
Sialic acids are a group of biologically important 9-carbon sugars which decorate cell 
surface glycoconjugates, the glycocalyx and thus the cells of higher organisms. 
Sialate-O-acetylation is a common sialic acid structural modification which has been 
associated with human disease states (including tumour growth, leukaemia, microbial 
infection and autoimmune disease). This highly regulated and tissue-specific 
modification is carried out by sialate-O-acetylesterase (SOAE) and sialate-O-
acetyltransferase enzymes (SOAT).  
 
 
The bourgeoning availability of these enzymes make enzyme inhibition studies a viable 
and worthwhile endeavour, considering that inhibitors of SOAT/SOAE activity may 
provide interesting tools and potential drug leads for the development of new antiviral 
compounds or treatments for various disease states. 
The synthesis of suitable 4-O- and 9-O-functionalised sialic acid derivatives has enabled 
the investigation of 4- and 9-sialate-O-acetylesterase enzymes. Sialic acid derivatives 
were screened for the inhibition of a set of viral SOAEs and while no inhibition of 4-
SOAE could be detected, a 9-O-methyl derivative showed inhibition of the recombinant 
influenza C virus SOAE. The functionalised sialic acid motif thus serves as an initial 
template for the design and synthesis of future sialic acid derivatives which can be 
further developed towards SOAT/SOAT inhibition. 
 
 
14 
 
Influenza continues to be of major concern to health authorities globally. Tamiflu 
(oseltamivir), a leading anti-influenza prophylactic, has been employed as a mimetic of 
the sialic acid “oxocarbenium” intermediate formed during enzymatic α-
sialoglycoconjugate hydrolysis, leading to inhibition of virus-bound neuraminidase (NA) 
enzyme. Phospha-isosteres of oseltamivir provide access to a variety of monoesters 
which retain the efficacy of the pharmacophore and thus allow the design and synthesis 
of novel influenza neuraminidase-specific materials, diagnostic tools and NA inhibitors.  
Phospha-oseltamivir-stabilised gold nanoparticles (“TamiGold”) have been synthesised 
and preliminary NA inhibition studies with “small TamiGold” show distinct inhibitory 
activity against influenza virus strains investigated compared to control gold 
nanoparticles. The binding interaction and optical properties displayed by “large 
TamiGold” may provide the basis for a colorimetric method of influenza detection and as 
such a novel prototype influenza sensor. To the best of our knowledge this is the first 
example of a multivalent approach to influenza virus binding utilising sialylmimetic 
scaffolds immobilised on a nanoparticle platform which specifically target the NA (instead 
of the hemagglutinin, HA). The synthesis of phospha-oseltamivir conjugates and their 
ligation to useful biological reporter groups afford small molecule tools with high affinity 
and selectivity towards influenza NA. These derivatives can now be applied towards 
novel multivalent phospha-oseltamivir materials and used as novel diagnostics, 
independent of existing methods. 
 
P
H3N
AcHN
O
O
O
O NH4
"Tamiphosphor"
Phospha-oseltamivir
H3N
AcHN
O
Oseltamivir carboxylate
O
O
P
H3N
AcHN
O
O
O
O
R
R = conjugatable chemical handle,
biological reporter group
Phospha-oseltamivir derivatives
P
NH3
NHAc
O
O
O
O
S
"TamiGold"
Au
Phospha-oseltamivir materials and derivatives as novel diagnostics/tools for influenza NA
 
  
15 
 
Synthesis and inhibitory activity of sialic acid derivatives for targeting viral 
sialate-O-acetlylesterases and sialate-O-acetyltransferases 
 
I.1. Introduction 
 
I.1.1. Sialic acids: nature’s promiscuous carbohydrates  
Sialic acids are a family of approximately fifty derivatives (known currently) of the nine-
carbon sugar, neuraminic acid.1,2 As part of the nonulosonic family of 9-carbons sugars, 
they are widely distributed in nature though sialic acids are mostly found in the animal 
kingdom, particularly amongst higher organisms (including humans).1,2  
The major structural feature of these polyhydroxy-α-keto acids is the amino group at the 
C5 position and the carboxyl group at the C1 position which gives the acid a negative 
charge in the physiological pH range (pKa 2.2, therefore classed as strong organic 
acid).3  
Different types of sialic acids are common to different organisms in differing amounts4 
(see figure 1) and since this particular carbohydrate is not stable in the free-amino form, 
it is often found as an N-acylated derivative, with N-acetylneuraminic acid (Neu5Ac) and 
N-glycolylneuraminic acid (Neu5Gc) being the most common compounds (see figure 2).4 
Typically however, Neu5Ac and derivatives thereof tend to be the most common forms of 
sialic acid expressed in higher organisms.1,5,6  
 
 
 
Figure 1. The substitution pattern of naturally occurring sialic acids. The numbering system of 
sialic acid derivatives is highlighted (red). 
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Figure 2. The structures of N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid 
 
N-Glycolylneuraminic acid (Neu5Gc) is common in many animal species (particularly in 
other hominids and swine tissue)7,8 though not in humans,9,8 where the gene encoding 
for its formation is inactive.8 In fact, the divergence of the human lineage from that of the 
great apes and the absence of Neu5Gc in humans (through a gene mutation leading to 
loss of Neu5Gc expression)6 was the first biochemical feature noted with this lineage 
divergence, culminating in significant implications for human evolution, especially in 
infectious disease resistance.9,8 Such events, attributed to sialic acid expression in 
higher organisms highlight the importance of these carbohydrates. Indeed, it is believed 
that the appearance of these monosaccharides in animal biology has facilitated evolution 
in higher organisms.6  
It has been postulated that the human-specific genetic changes that have occurred with 
respect to sialic acid biology (genetic changes associated with both sialic acid 
expression and sialic acid recognising proteins) are not the result of random variation but 
that human evolution was associated with a “sialoquake” involving a series of related 
genetic events which influenced sialic acid biology.6  
 
Research into the biology of sialic acids has shown that there is almost no area in 
mammalian biology in which these carbohydrates are not involved.6,10  
Because of this “promiscuous” nature, errors in the expression and metabolic pathways 
of sialic acids have dramatic consequences particularly in disease states.1,5,6,11,12  
Found α-configured primarily at terminal positions on the carbohydrate moieties of 
glycoproteins and glycolipids3 (attached to the surface of our cells and other molecules)1 
sialic acids have a very specific glycosidic linkage pattern (see figure 3) and are found 
either α-2,3- or α-2,6-linked to other carbohydrates (or α-2,8-linked to other sialic acids, 
as exemplified by polysialic acid).6,10,2  
 
17 
 
 
Figure 3. The natural linkages of sialic acid (R = glycoconjugate). 
 
The structural diversity5 of sialic acids is reflected by the many biologically important 
processes in which they play a significant role, often related to cellular and molecular 
recognition events.1,6,13 
For example, the negatively charged nature of these carbohydrates lend themselves to 
the binding and transport of positively charged molecules and in the attraction/repulsion 
of cells (for example, erythrocytes in the bloodstream) and molecules (including 
pharmaceuticals).6 
As commonly occurring constituents of glycoproteins, sialic acids lead to the high 
viscosity of mucins of endothelial linings and regulate the conformation of gangliosides 
(important sialic acid carrying glycoconjugates)11 as well as being vital components of 
cell membrane supramolecular structures (thus influencing membrane components such 
as ion channels and hormone receptors).6,5   Another discovery is that sialic acid is an 
essential moiety of mucin as a hydroxyl radical scavenger.14 
Their exposed position in carbohydrate chains enable sialic acid to act as a protective 
barrier against glycoprotein degradation by protease enzymes,1,13 provides the immune 
system with a method of distinguishing between self and non-self structures according to 
their sialic acid pattern,6 and in many infection processes, bacterial colonisation can be 
limited by the sialic acid coat covering the host cell surface.6 
In contrast however, due to their accessibility and abundance,6,9 sialic acids are used by 
a variety of pathogenic agents such as viruses (for example, influenza), bacteria (for 
example, Helicobacter pylori) and protozoa (for example, Trypanosoma cruzi) to bind to 
host cells via sialic acid-containing receptors.6,13 
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I.1.1.1. Biosynthesis of sialic acids 
The biosynthesis of sialic acid varies slightly between different organisms. The abridged 
version of Neu5Ac biosynthesis (see scheme 1) begins in the cytosol (of the cell) with 
the condensation of phosphoenol-pyruvate with N-acetylmannosamine-6-phosphate 
(primarily by Neu5Ac-9-phosphate synthetase though also by sialic acid aldolase to a 
lesser extent) forming Neu5Ac-phosphate (Neu5AcP). A crucial enzyme in this long 
biosynthetic pathway is an epimerase, which converts UDP-N-acetylglucosamine into 
the N-acetylmannosamine-6-phosphate precursor.6,10 
Dephosphorylation of the Neu5AcP results in the free monosaccharide Neu5Ac, which is 
then activated to the important natural siayl donor, CMP-Neu5Ac (in the nucleus), which 
can then be transferred by a range of sialyltransferase enzymes (in the Golgi apparatus) 
onto nascent glycolipids and glycoproteins.6  
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Scheme 1. The biosynthesis of Neu5Ac from UDP-GlcNAc.  
Adapted from; Chemical Reviews 2002, 102, 439-469. 
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I.1.1.2. Chemical syntheses of sialic acid 
Sialic acid has generally been extracted from natural sources, these include the edible 
birds’ nest of the Collocalia swift, colominic acid, milk and egg yolk. However, yields are 
low and the associated purification processes are non-trivial.15,16  
The chemical synthesis of sialic acid has been carried out using the traditional Cornforth 
method (the Aldol reaction of N-acetyl-glucosamine and oxaloacetate in basic conditions 
with subsequent decarboxylation)17 and other asymmetric synthetic approaches.18 
However, these methodologies suffer from low yields (Cornforth method), material-
consuming protecting group strategies and the synthesis of unwanted intermediates or 
isomers, making direct synthetic methods unattractive both in terms of cost and 
labour.18,15  
The application of enzymatic (incorporating Neu5Ac aldolase or Neu5Ac synthase) and 
whole-cell based approaches (for example, engineered E. coli) towards sialic acid 
synthesis have improved the availability of sialic acid somewhat, though commercially 
available sialic acid is still moderately expensive.15  
 
I.1.2. O-Glycosylation of sialic acids: a specific problem 
Sialic acid glycosylation with sialic acid donors is an important step towards the 
synthesis of naturally occurring sialic acid containing biomolecules and synthetic non-
natural sialic acid derivatives for the investigation of sialic acid biology. 
The simple appearance of the reaction masks the subtle synthetic difficulty often 
encountered.19,20 Indeed, the formation of sialic acid glycosides (sialosides) is one of the 
“biggest challenges” in sialic acid chemistry.2 In biological systems, enzymatic reactions 
overcome many of the inherent problems of sialylation reactions which plague chemical 
synthetic approaches.  
The majority of naturally occurring sialic acids are α-ketosidically linked (that is, in the 
case of sialic acids, the anomeric substituent occupies an equatorial position)21 and thus 
with regards to the particular chair conformation of sialic acids (5C2), the anomeric 
substituent is occupying a position which is disfavoured by the stereoelectronic 
“anomeric effect”.19,20  
Typical O-glycosylation reactions proceed via nucleophilic substitution of a sialyl 
acceptor (R-OH) upon a suitable sialyl donor (for example, a β-2-chloro derivatives)22 
often using some type of reaction promoter, such as a Ag(I) salt (as in standard Koenigs-
Knorr glycosylation procedures).20,22The stereoselectivity of such reactions is often 
problematic due to the difficulty in getting a clean SN2 process at the anomeric centre, 
particularly since formation of the oxocarbenium intermediate gives an SN1 component 
to the reaction and thus frequently both α and β anomers are formed (see scheme 2).22 
21 
 
Solvent effects and the nature of the interaction between the metal-promoter and the 
oxocarbenium intermediate also strongly dictate the stereochemical outcome.20  
The selectivity issue of forming solely α-sialosides with sialic acids is even more 
complicated than in the case of simpler carbohydrates due to a number of structural 
features of sialic acid which make such selectivity difficult to achieve.20,19,21  
The presence of the carboxylate group (C1) at the anomeric carbon, for example, 
causes the oxocarbenium ion intermediate (formed during the glycosylation reaction) to 
be unstable due to its electron withdrawing effect and also interferes with the 
nucleophilic attack of the glycoside acceptor.19,21 
The lack of a substituent at the C3 position removes the possibility of neighbouring group 
participation (for example, ortho-ester formation) in directing the stereochemistry of the 
glycoside.19,20,21 Indeed, coupled with the effects of the carboxylate group, the lack of a 
C3 substituent also renders sialic acid derivatives susceptible to 2,3-elimnation reactions 
(glycal formation), a prevalent side product.19 Even the polyhydroxy-glycerol moiety (C7-
9) effects sialic acid glycosylation by reducing the reactivity of a sialyl donor through 
steric effects.21 
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Scheme 2. Heteroatom glycosylation with a sialic acid donor with competing elimination. 
 
Many unusual methods (including exotic sialyl-donors and novel protecting group 
strategies) applied to the sialylation reaction have been developed in order to improve 
the synthetic outcome compared to traditional methods.2 Very recent examples include 
the use of a novel N,N-diacetylsialyl chloride sialyl donor23  and highly α-selective sialyl-
phosphate donors.24 Though recent trends in the synthesis of sialic acid derivatives tend 
towards chemoenzymatic and whole-cell approaches to overcome synthetic problems.2  
 
I.1.3. Biological O-Acetylation of sialic acids  
The structure and substituents of sialic acid are highly changeable1,2 and as such, one 
important modification of sialic acid is O-acetylation at the hydroxy functional groups (C4, 
C7, C8 and C9 positions) (see figure 4).4,11  
23 
 
Side-chain
(7,8,9)-O-acetylation
Ring (4)-O-acetylation
AcHN
OH
O
OR
HO
OH
HO
CO2
2
3
4
5
67
8
9
 
 
Figure 4. The sites of O-acetylation on Neu5Ac 
 
O-Acetylation occurs principally on sialic acids α-2,6-linked to N-linked oligosaccharides 
on glycoproteins as well as on α-2,3-linked sialic acids on O-glycans of certain 
glycoproteins,5 with N-acetyl-9-O-acetylneuraminic acid (Neu5,9Ac2) being the most 
common O-acetylated sialic acid.1,25 It is a highly regulated tissue-specific modification.12 
Chemically, O-acetylation introduces a hydrophobic element to the sialic acid moiety, 
therefore changing the chemical characteristics of the molecule by altering size, net 
charge, hydrogen bonding and glycoconjugate conformation.5 
O-Acetylation of acetyl groups from the 7- and 8-OH to the 9-OH have been shown to 
migrate under physiological conditions. Because of this, it had been considered (until 
recently)26,27 that for O-acetylation of the sialic acid side-chain hydroxy functionality, a 
single enzyme was responsible (vide infra) for acetyl transfer to the 7-OH followed by 
migration to the 8- or 9-OH (enzymatically or non-enzymatically).10 
O-acetylation of sialic acids is apparent in many higher animals and in certain bacteria,11 
and plays a key role in modulating various biological processes (see figure 5).3,6,11 In 
fact, O-acetylated sialic acids play crucial roles in immune system regulation, organism 
development, cancer processes and a plethora of other biological and 
pathophysiological events.6,13 
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Figure 5. The biological significance of sialate-O-acetylation at the 4- and 9-positions. Adapted 
from; Glycoconjugate Journal 2000, 17, 485-499. 
 
The interest in sialate-O-acetylation in recent years has mainly focused upon O-
acetylation of the sialic acid poly-hydroxy side chain, which seems to be the more 
widespread acetylation modification, particularly in humans.28  
However, O-acetylation of the pyranose ring (4-O-acetylation) is also common, with 4-O-
sialic acids being discovered in horses, donkeys, echidnas, guinea pigs, rabbits, rats to 
name but a few species.28 
The effects of O-acetylation are wide ranging. For example, O-acetylation prevents the 
degradation of sialylated glycoconjugates by sialidase enzymes (which cleave the 
glycosidic bond) and other various sialic acid catabolic enzymes such as trans-sialidases 
and sialate-pyruvate-lyases.28,16 
Another example is the involvement of the O-acetylated GD3 ganglioside (a class of 
sialic acid-carrying glycoconjugate)11 in cell death (apoptosis).3 Increased O-acetylation 
acts as a regulatory process by reducing the apoptotic effect by accumulating in cell 
mitochondria.11 Indeed, O-acetylation of the GD3 ganglioside has also been implicated in 
cell growth and differentiation11 and more generally sialic acid O-acetylation (specifically 
Neu5,Ac2 expression) has been implicated in certain types of cancer (human basalioma 
and melanoma)11 where both under- and over-expression of O-acetylated sialic acids are 
involved in disease progression.1,11,25,29  
Neu5,9Ac2 is also aberrantly expressed in ovarian cancer, colorectal carcinoma and 
childhood acute lymphoblastic leukaemia (ALL).11,30 
The O-acetylation of sialic acid epitopes on cell surfaces also regulates the activity of 
specific types of sialic acid recognising proteins, the so-called, siglecs and selectins. The 
masking of sialic acid epitopes on siglecs such as sialoadhesin (Siglec-1), CD22 (Siglec-
2) and Myelin Associated Glycoprotein (MAG) affect their biological roles in the immune 
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and hematopoietic (blood-cell forming) systems or in the central nervous system (CNS) 
as their main functions are related to cell signalling and cell-cell interactions.13  
The same can be said for selectins (for example, L-selectin) where O-acetylation 
disrupts the interaction between the selectins and their recognition determinants (for 
example, the tetrasaccharides sialyl Lewisx and sialyl Lewisa) and thereby disrupting 
inflammation and immunological processes.13 
In many cases, O-acetylation renders sialic acids useless as molecular targets for 
foreign pathogens, as the site of action becomes hindered by the acetylated group.5 
This is particularly true for the binding of influenza A and B viruses, whereby 9-O-
acetylation of sialic acid inhibits the binding process.11 However, O-acetylation may also 
generate specific sialic acid receptors for certain pathogens, for example, influenza C 
virus and the mouse hepatitis-C virus (MHV).  
 
I.1.3.1. The processing enzymes of O-acetylated sialic acids 
The amount of O-acetylated sialic acid expressed in certain tissues appears to be 
dependent on the interplay between certain sialate-metabolising enzymes, in particular, 
sialate-O-acetyltransferases (SOATs) and sialate-O-acetylesterases (SOAEs) (vide 
infra),11,26 Along with sialidase enzymes (involved in glycosidic bond cleavage of 
glycans) SOATs and SOAEs play essential roles in sialic acid metabolism.16 
There are also hypotheses for the involvement of other sialic acid processing enzymes 
(such as certain sialyltransferases) and other more intricate levels of regulation in O-
acetylated sialic acid metabolism (disused below).11,12,26,28 
 
I.1.4. Sialate-O-acetyltransferases (SOATs) 
Sialate-O-acetyltransferases are the enzymes which transfer an acetyl moiety to one or 
more hydroxy groups on sialic acid molecules.5 There are two main mammalian SOAT 
systems known (as yet without complete isolation, purification and characterisation) 
which include guinea pig liver (4-SOAT) and rat liver, bovine submandibular glands and 
human colon 7(9)-SOAT (vide infra).26 
The sialate-7(9)- nomenclature stems from the fact that the O-Ac moiety can non-
enzymatically migrate from the 7-OH to the 8-OH and/or 9-OH (as mentioned) under 
physiological conditions.10  
SOAT activity is not limited to mammalian systems and is found wherever sialic acid O-
acetylation metabolism is present.27 Indeed, bacterial SOAT involvement in the O-
acetylation of polysialic species and their subsequent relationship to pathogenicity is 
increasing in evidence and as such clinical relevance.26 For example, Neisseria 
meningitidis group B and C cause meningitis and in the case of the mucosal pathogen 
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Campylobacter jejuni, cause gastroenteritis and in some strains, Guillain-Barre 
syndrome (GBS), a serious autoimmune degenerative disorder.10,27 
It is generally believed that more than one type of SOAT enzyme (predominantly 
associated with the Golgi membrane)10,26 are responsible for catalysing the O-acetylation 
of sialic acid hydroxy moieties with regards to mammalian systems.11 Their classification 
is dependent on the type of hydroxy group/s being acetylated, that is, whether on the 
poly-hydroxy side chain or the pyranose ring. As such, these enzymes are referred to as 
sialate-7(9)- and sialate-4-O-acetyltransferases.5 
Other research into SOAT activity26,27 suggests individual sialate-O-acetyltransferases 
for action upon the 7-OH and 9-OH  in some cases, potentially leading to a more diverse 
O-acetyltransferase family than previously thought (vide infra).  
Since O-acetylation of the polyhydroxy side chain appears to be the more prevalent 
Neu5Ac modification in man, 4-O-acetylation and interest in the 4-SOATs has been 
somewhat neglected in comparison to 7(9)-SOATs.28 
The identification of 4-OAc expression in man though in small amounts,31 and evidence 
of 4-O-acetylation of Neu4Ac5Gc (as part of the ganglioside GM3 implicated in human 
colon cancer),31 appear more widespread than currently presumed and have made 4-
SOATs as attractive targets as 7(9)-SOATs.10 
In terms of their substrate specificity, recent investigation of SOATs indicated that 
typically, larger disialylated substrates such as sialyl-oligosaccharides, sialyllactoses and 
even gangliosides (sialic acid containing glycosphingolipids, for example GD3) are better 
substrates than free Neu5Ac and (in turn) Neu5Gc with α-2,6 linkages being preffered to 
α-2,8 linkages (in the case of 4-SOAT from guinea pig liver).11,28  
In fact, there seems to be a remarkable variation of substrate and linkage specificity 
between SOATs of different origin, for example, between O-glycans and N-glycans and 
the type of sialic acid containing biomolecule, for example, gangliosides, glycoproteins, 
oligosaccharides and free sialic acids.10,28 
More generally, SOAT enzymes show mixed tolerances for substrate specificity. Some 
exhibit high specificity in their mode of action, with O-acetyl groups being found among 
glycolipids and glycoproteins in the same cell type and even between sialic acid residues 
on the same molecule32 whereas some SOATs (for example, the 4-SOAT from guinea 
pig liver which strictly esterifies only the 4-OH), have a wider substrate specificity (with 
various types of free and bound sialic acids) than many other SOATs identified.26 
 
I.1.4.1. Proposed mechanism of O-acetylation: post-sialylation 
The mechanism of O-acetylation by SOATs has been postulated in the literature over the 
past decade. Previous studies have concluded that the donor compound for O-
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acetylation is acetyl coenzyme A (AcCoA) from cytosolic sources32 and that in the 
majority of the early systems investigated, SOAT substrates have been shown to be 
glycosidically bound to sialyl-oligosaccharides.27 
One hypothesis corresponding to experimental SOAT data is based on a simplified 
mechanism where side chain O-acetylation occurs on a sialic acid residue post-
enzymatic sialylation (see figure 6), that is, after the formation of a sialyl-containing 
glycoprotein in the Golgi apparatus of a cell (from the sialyltransferase substrate CMP-
Neu5Ac).16 
The AcCoA donor (transported separately into the Golgi apparatus) is then provided to 
the SOAT enzyme which then transfers the acetyl moiety to the sialic acid (glycosidically 
bound) at the 7-OH, after which migration to the 9-OH can occur (refer to figure 7).5,16  
Supporting evidence from theoretical studies also suggests that the 7-OH is the most 
likely site of acetylation.33 It is presumed that the 4-SOAT would follow a similar 
pattern.6,16 
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Figure 6. A schematic of the proposed mechanism (post-sialylation) for side-chain O-acetylation 
of sialic acids. ST (sialyltransferase). Adapted from; Advances in Experimental Medicine and 
Biology: Metabolism and role of O-acetylated sialic acids; Molecular Immunology of Complex 
Carbohydrates 2; Kluwer Academic/Plenum Publishers,: New York, 2001; Vol. 491. 
 
I.1.4.2. Proposed mechanism of O-acetylation: pre-sialylation 
Another proposed mechanism is the possibility of O-acetylation of sialic acid whilst at the 
CMP-Neu5Ac (sialyl donor) stage, that is, before sialylation by a sialyltransferase 
enzyme (see figure 7).16 
O-acetylated CMP-Neu5Ac (in contrast to conflicting studies)32 is considered the most 
suitable substrate for both 7(9)-SOATs and 4-SOATs (under the experimental conditions 
used).28 This sheds doubt on the previous mechanism and instead tends to fit a 
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hypothesis where O-acetylation occurs pre-sialylation (at the sialyl donor stage) or as 
speculated in some scenarios34 via the formation of a protein-complex between the 
Golgi-bound SOAT, the CMP-Neu5Ac (or Neu5Gc) transporter and the sialyltransferase 
(transferring the final acetylated product) in the Golgi apparatus, possibly including an 
interaction with an acetylated sialic acid intermediate. This proposed mechanism is also 
put forward to describe 4-O-acetylation.6,11,12,16,28  
This overall reaction pathway proposed is based on a trans-membrane reaction 
consisting of two stages. The first step involves formation of an acetyl intermediate 
utilising exogenous AcCoA, followed by transfer from the acetyl intermediate to the sialic 
acid, with the hypothesised intermediate believed to be CMP-Neu5Ac.12 
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Figure 7. A schematic of the proposed mechanism (pre-sialylation) for side-chain O-acetylation of 
sialic acids via CMP-Neu5Ac precursor. ST (sialyltransferase). Adapted from; Biological 
Chemistry 2004, 385, 145-152. 
 
Research into the regulation of sialic acid in human colon mucosa indicates that CMP-
Neu5Ac and AcCoA transporters are of vital importance for SOAT activity, going so far 
as to provide evidence for the existence of a sialyltransferase enzyme capable of 
mediating the transfer of Neu5,9Ac2 to CMP-Neu5,9Ac2 to glycoproteins.12 
 
I.1.4.3. Speculation upon the catalytic nature of SOAT enzymes 
There appears to be a high level of sequence divergence among enzymes exhibiting 
SOAT activity and (somewhat speculatively) in the structural characteristics that define 
SOAT enzymes from various organisms.35 Without mechanistic knowledge of the SOAT 
reaction (particularly of mammalian systems), the elucidation of the SOAT reaction by 
various SOAT expressing organisms is difficult. 
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It has been speculated in accordance with the enzyme-complex mechanism that both a 
hydrolase activity and transferase activity are essential enzymatic steps in the 
mammalian O-acetylation procedure.11,34 However, without isolation and characterisation 
of a fully purified SOAT, this is cannot be verified. 
Studies on the solubilisation of a 4-SOAT from guinea pig liver uncovered another 
peculiar aspect of SOAT activity regarding speculation that an unknown co-factor is 
required for enzyme activity.28 
This unknown co-factor (lost during enzyme purification) resulted in loss of SOAT 
activity, hinting at the possibility of a previously unknown regulatory mechanism for O-
acetylation.36 The identity of this co-factor is not known, neither is it known if it is required 
for all SOATs or just certain subtypes. 
 
With regards to bacterial SOATs some structural information can be inferred from 
studies which identified several bacteria with genes that express SOAT activity. These 
included; Escherichia coli K1 (NeuO),37 Camphylobacter jejuni (NeuD),27 group B 
streptococci (NeuD),38  serogroup W-135 and Y meningococci (OatWY).35 These SOATS 
have been shown to belong to the NodL-LacA-CysE family,27 part of the hexapeptide 
repeat protein family (a large group consisting of general bacterial transferases which 
are restricted to microorganisms).39  
The recent discovery that the bacterial SOAT expressed by Neisseria meningitidis 
serogroup C (OatC) belongs to the same serine hydrolase family (α/β hydrolase 
enzymes) as viral SOAE enzymes and not the hexapeptide repeat protein family hints at 
the possibility that the structural characteristics and mechanisms of mammalian SOAT 
activity are likely to be similar to that of SOAE enzymes (vide infra).39 Therefore if 
mammalian SOAT enzymes express serine hydrolase structural characteristics a 
characteristic double-displacement (“ping-pong”) mechanism may be expected, utilising 
a “catalytic triad” of Ser-His-Asp within the enzyme active site (see scheme 3).39  
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Scheme 3. Proposed reaction mechanism of the OatC-catalyzed O-acetylation of the capsular 
polysaccharide of Neisseria meningitides C (NmC-CPS). The OatC enzyme is a type of bacterial-
SOAT and is believed to utilise a double-displacement mechanism for O-acetyl hydrolysis.  
 
Studies carried out to date have shown that there are most likely many types of SOAT 
with specific O-acetylation activity independent of the type of organism.1,26,27   
For example, the determination of O-acetylation at the 7-OH of sialic acids by 
mammalian SOAT from bovine submandibular glands1,26 and the bacterial SOAT 
expressed by Neisseria meningitidis serogroup C (OatC).39  
In contrast however, the SOAT from the bacteria Campylobacter jejuni was conclusively 
determined from NMR studies (of the site of O-acetylation by the SOAT enzyme) that 
SOAT activity was specific in this case to the 9-OH and categorically did not involve 
migration of an acetyl moiety from the 7-OH as indicated by SOATs from other biological 
sources.26,27 
33 
 
It has even been postulated that in events where the 7-OH is the target, the 7-O-
acetylated product may have particular advantageous chemical and/or time-limited 
characteristics necessary for processing/transport of a particular glycoconjugate or for a 
time-limited biological response.27 
 
Examples of the variety of specificity (in terms of substrate and site of action) and even 
potential mechanistic discrepancies between SOATs from various organisms hint at the 
possibility of a wide ranging family of SOATs.12,26 Where O-acetylation appears to be 
highly regulated by many different pathways/mechanisms, specific to the organism, 
tissue type, growth regulation and even specific to sialyltransferase activity.28,11,10 
If you also include the example of bacterial group B Streptococcus, where sialic acids 
are O-acetylated before sialic acid activation, that is, pre-CMP-Neu5Ac formation (in 
contrast to the proposed mechanisms of SOAT activity)27 points toward the conclusion 
that there are (conceivably) three parallel pathways which have developed for sialate-O-
acetylation; from free Neu5Ac,40 after conversion to the sialyl donor species CMP-
Neu5Ac,12,36or after sialyl transfer to glycan.27 
This diverse SOAT complexity may in some form may be a reason why SOATs, 
particularly of eukaryotic origin have evaded identification and purification for so long, 
with many obstacles preventing the cloning and purification of these SOATs. Particularly 
their membrane (Golgi) bound nature and the potential co-dependence of other 
proteins/co-factors for activity.27 If one also adds regulation by substrate specificity and 
sialic acid linkage preference (that is, α-2,6- vs. α-2,8- vs. α-2,3-), the complexity of 
SOAT activity increases further.12,27,28,11 
 
I.1.5. Sialate-O-acetylesterases (SOAEs) 
O-Acetyl groups are removed from sialic acids in biological processes during the life 
cycle of the compound. This process is carried out by sialate-O-acetylesterase enzymes 
(SOAE)1,25,41 
These SOAEs are found in a variety of organisms and pathogens.42 In mammals, there 
are two forms, one operating in the cytoplasm and the other in the lysosomal 
compartment of cells, being able to hydrolyse acetyl functionality on glycosidically linked 
or free sialic acid.29,32,41   
An example of the important role SOAE enzymes play in human biology is the regulation 
(negatively) of the activity of B-cell receptors by masking the CD22 (Siglec-2) binding 
sites (α-2,6 sialylated glycans) through 9-O-acetylation.43,44  
A recent study showed the expression of a defective SOAE in patients with auto-immune 
disease (including Crohn’s disease, Sjogren’s disease and lupus erythmatosus) led to 
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enhanced B-cell receptor mediated expression of 9-O-acetylated sialic acid. Therefore, 
since the SOAE function contributes to the maintenance and balance of B-cell activation, 
a causal link is suggested between loss of SOAE activity and autoimmune disease.45  
Various bacteria also produce this enzyme to help bacterial colonisation by making sialic 
acid more susceptible towards microbial sialidase action (enzymes which cleave the 
glycosidic bond) (refer to figure 8).5  
Because O-acetylated  sialic acids are typically considered to be poor substrates of 
certain sialyltransferases and CMP-sialic acid synthase enzymes, SOAE activity in the 
cytoplasm is thought to recycle O-acetylated sialic acids that have been transported to 
the cytoplasm (from lysosomes) whereas the other SOAE type, working in the lysosomal 
compartment of cells, can traverse the endoplasmic reticulum whilst sequestered in its 
compartments.32 
The main target of SOAE action is most commonly the removal of 9-O-acetylated groups 
from sialic acid, however, some organisms and pathogens make use of 4-O-acetylated 
groups as their specific receptor determinant.41,42,46  
However, sialate-O-acetylesterases corresponding to deacetylation at the C7 and C8 
position have so far not been isolated from any organism or pathogen.25 
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Figure 8. The site of action for sialate-O-acetylesterase in comparison to sialidase “receptor 
destroying enzymes” using a 9-O-acetylated sialylated glycan as a substrate (R = 
glycoconjugate). 
 
I.1.5.1. Viral and bacterial sialate-O-acetylesterases 
Evidence is accumulating that SOAEs are involved in host infection by certain bacterial 
and viral species.26,47 For example, recent studies suggest that bacterial SOAEs regulate 
O-acetyl expression in polysaccharide chains found on the bacterial surface.41 
Several viruses make use of O-acetylated sialic acid to bind to target cells because of 
their accessibility and abundance on various cellular glycoconjugates.3,48  
Indeed, certain types of viruses.1,25,49 though originally associated with the influenza C 
virus,50 not only bind to these modified O-acetylated sialic acids but also concurrently 
express acetylesterase activity with the ability to de-O-acetylate the sialic acid 
receptors.3,4 
It is because of this that such viral O-acetylesterases are termed “receptor destroying 
enzymes” (RDE’s) (likened to the sialidase enzymes of the influenza A and B viruses 
(refer to figure 9),3,4 the RDE of influenza C being the archetypal SOAE enzyme (vide 
infra).5,51 Influenza C itself is known to cause upper respiratory tract infections and has a 
risk of producing complications leading to lower-respiratory tract infections in young 
children.49 
Viral RDE’s with such O-acetylesterase functionality are known as Hemagglutinin-
Esterase (HE) proteins,51 or as in the case of influenza C, where the viral surface 
glycoprotein which exhibits this RDE functionality, also plays a part in viral membrane 
fusion (and subsequently infection),50,49 the term Hemagglutinin-Esterase-Fusion (HEF)  
protein is used.48-53  
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The abundance of sialic acid receptors from a viral perspective has a drawback, that is, 
the reduced infectivity of a viral species due to the high avidity (highly selective) binding 
nature of virions to non-target cell sialic acid receptors (resulting in non-reversible 
binding and loss of viral infectivity).48,54 Loss of infectivity may result also from newly 
formed viral progeny becoming bound to O-acetylated sialic acid receptors whilst exiting 
the cell membrane.1  
The RDE function of the viral O-acetylesterases therefore provides an escape ticket for 
certain viruses, allowing high-affinity yet reversible binding to sialic acid receptor 
determinants,54 whilst also preventing viral aggregate formation, allowing the progeny to 
maintain the infectivity of the virus.55 
Initially it seems counter-intuitive that a bifunctional protein carries two conflicting 
functions, however the balance between the functions appears essential for efficient viral 
replication.10 
The main sialic acid receptor determinants that SOAEs of certain viruses show 
specificity for are 9-O-acetylated or 4-O-acetylated sialic acid substrates (see table 1).3,5 
Interestingly, all sialic acid O-acetylesterases so far identified cannot hydrolyse 7-O-
acetylated groups (with the exception of the di-acetylated substrate preferred by bovine 
torovirus esterase).26 For example, influenza C, BCoV (bovine coronavirus) and certain 
porcine viruses possess sialate-9-O-acetylesterase (deacetylation at C9), whilst other 
viruses such as infectious salmon anaemia virus (ISAV), murine hepatitis virus (MHV), 
puffinosis coronavirus (PV)9,56 possess sialate-4-O-acetylesterase (deacetylation at 
C4).42,50,51 BCoV (bovine coronavirus) in particular are of relevance to the livestock 
industry to the livestock industry through the infection of calves and adult cattle (causing 
a reduction in productivity).49  The closely related human respiratory viruses HCoV-OC43 
and HKU1 are also implicated in human illness and disease, for example, they are 
known to cause gastroenteritis and neurological disorders.57,58  
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Family Genus Species Substrate 
Orthomyxoviridae 
Influenza C 
virus 
Influenza C virus Neu5,9Ac2 
 Isavirus Infectious salmon anemia virus Neu4,5Ac2 
Coronaviridae Coronavirus Human coronavirus OC43 Neu5,9Ac2 
  Bovine coronavirus Neu5,9Ac2 
  
Hemagglutinating 
encephalomyelitis virus 
Neu5,9Ac2 
  Mouse hepatitis virus Neu4,5Ac2 
  Puffinosis coronavirus Neu4,5Ac2 
  Sialodacryoadenitis virus Neu4,5Ac2 
 Torovirus Bovine torovirus 
Neu5,9Ac2 
Neu5,7,9Ac3 
  Porcine torovirus  Neu5,9Ac2 
 
Table 1. Examples of viruses which utilise sialate-O-acetylesterase enzymes and their respective 
O-acetylated sialic acid substrate. Adapted from; Glycoconjugate Journal 2004, 20, 551-561 and 
European Journal of Medicinal Chemistry 2011, 46, 2852-2860. 
 
I.1.5.1. HEF of influenza C: the archetypal SOAE 
Most data concerning the structural characterisation of viruses that exhibit sialate-O-
acetylesterase action relate to the influenza C virus, which shows specific activity for 9-
O-acetylated substrates (see figure 9) with only a few primary structures of other viral HE 
proteins known.1,50 
The HEF of influenza C consists of three HEF subunits (making the HEF a trimeric 
protein) which can be further divided into the HEF1 and HEF2 regions. The HEF 
monomer is divided into three domains; an elongated protein stem involved in 
membrane fusion, an esterse domain (E) and a receptor binding domain (R) (the R and 
E domains are in close proximity to each other).50   
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Figure 9. (A) The structure of the influenza C virus HEF trimer showing the HEF1 (blue) and 
HEF2 (red); (B) a surface representation of the HEF monomer showing the receptor and esterase 
binding site; (C) a ribbon diagram of the HEF monomer with protein sequence segments coloured 
by domain (fusion, red; esterase, green; receptor, blue); the fusion peptide is shown in yellow. 
(Reprinted with permission from Macmillan Publishers Ltd.; Nature 1998, 396, 92-96.) 
 
The elucidation of the Influenza C HEF X-ray crystal structure,50,54 revealed that the RDE 
contains a Ser-Asp-His catalytic triad, with Ser-57 being the main catalytic amino acid 
residue.54 Also, as found in the active sites of more general serine-based esterase and 
protease enzymes such as chymotrypsin and trypsin,46 the SOAE consists of a 
consensus amino acid motif of Phe-Gly-Asp-Ser.54 
The HEF1 protein subunit (see figure 9) consists of two distinct areas where the 
Neu5,9Ac2 substrate can be accommodated.48,54 The amino acid residues of Tyr-127, 
Thr-170 and Gly-172 are involved in binding to Neu5,9Ac2, with the critical interaction 
between the protein and the 9-O-acetyl group being mediated by the hydroxy group of 
Tyr-227 and Arg-236 (see figure 10).50 
 
A B C 
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Figure 10. O-Acetylated sialic acid determinant bound to the receptor binding site of the influenza 
C HEF. (Reprinted with permission from Macmillan Publishers Ltd.; Nature 1998, 396, 92-96.) 
 
This essential interaction is also helped by the formation of a non-polar pocket in the 
binding site to accommodate the acetyl methyl group (formed by Phe-225, Phe-293 and 
Pro-271).50 
The esterase (SOAE) active site itself (see figure 11) consists of the residues Ser-57 
along with His-355 and Asp-352 (the catalytic triad) which render the essential serine 
residue more nucleophilic, thus allowing the deacetylation reaction to occur (see scheme 
4). 
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Figure 11. The HEF enzymatic active site, indicating the catalytic triad (green) and the sialic acid 
substrate (yellow). (Reprinted with permission from Macmillan Publishers Ltd.; Nature 1998, 396, 
92-96.) 
 
Other amino acid residues, such as Gly-85 (the NH group), Asn-117 (the side chain) and 
Ser-57 (the NH group) form an “oxyanion” hole, used for the stabilization of tetrahedral 
transition state formed during deacetylation reaction,46 whereas Arg-322 is thought to 
contribute to binding by contributing two hydrogen bonds to the sialoside carboxylate 
group.49,54 Substitution (by active mutagenesis) of Ser-57 and His-355 by Ala resulted in 
reduced esterase activity by approximately 90%, thus confirming the important catalytic 
role of the residues.54 
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Scheme 4. The mechanism of deacetylation of Neu5,9Ac2 by the SOAE (a serine hydrolase) of 
the Influenza C HEF.  
 
NMR and molecular modelling studies have elucidated the mechanism and mode of 
action of O-acetylesterases (based upon the Influenza-C and BCoV esterase).49 These 
studies concluded that two major pharmacophoric groups are absolutely essential for 
SOAE activity, the α-configuration of the substrate at the anomeric centre and the 
presence of the carboxylate group for binding to the Arg-322 residue in the enzyme 
active site (mentioned above).49 
Interestingly, molecular modelling results concluded that though a β-configured substrate 
could theoretically fit in to the enzyme active site, the important carboxylate-Arg-322 
interaction is disrupted. As such, the loss of this interaction provides a rationalisation as 
to why β-configured substrates are not suitable substrates for Influenza-C and 
coronavirus SOAEs.49 
This study also highlighted a number of other interesting factors that contribute to a 
better understanding of viral SOAE activity. Firstly, that the release of the acetate moiety 
via enzymatic hydrolysis is independent of the nature of the alglycone (determined from 
NMR experiments with various sialylated species incubated with Influenza-C and BCoV 
esterase) which is essentially attributed to the low amount of interaction between the 
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protein surface and the aglycone (determined by modelling studies).49 Secondly, the 
discovery that the Ser-57 catalytic residue is essential for binding and correct substrate 
orientation, as well as esterase activity. This stems from the fact that upon complexation 
of a suitable substrate to the enzyme active site, the carbonyl group of the Ser-57 moves 
from its original position (where it blocks the “oxyanion” hole) to facilitate an internal 
hydrogen bond with a His-355 ring nitrogen, thus opening up the “oxyanion” hole for 
substrate binding of the 9-OAc moiety.49 Moreover, research has indicated a similar 
mode of action between both types of viral esterases investigated, supporting the notion 
of conservation of enzyme active site and mechanistic processes between different 
SOAE species.49 
Other studies have also highlighted the conservation of the esterase active sites of 
HE(F) proteins between viral species compared to the active site of influenza C 
SOAE.46,48,52,59 
Those residues that make up the important “oxyanion” hole are also often conserved in 
an equivalent manner, for example, in bovine torovirus (BToV) HEs, Gly85 is substituted 
by Ser.54  
 
In other respects however, there are differences between HE(F) proteins of viral species. 
For example, differences in quaternary protein structure between influenza C virus 
(trimeric) and coronavirus HE proteins (di-sulphide bonded homodimers),50,52 differences 
in protein sequence identity (with the general exception of catalytic active site residues) 
between the influenza C HEF and other viral HEs (for example, ISAV-HE, TCoV, BCoV) 
and variation in the receptor binding domain of HEs between and among orthomyxo- and 
coronaviral HEs.50,52,59 
It is obvious that the SOAE family displays varied substrate specificity from exclusive 
hydrolysis of a single O-acetylated derivative to hydrolysing more than one type of O-
acetylated substrate.41 For example, the SOAE enzymes of horse liver (which show both 
4- and 9-SOAE activity) could potentially be isoenzymes of the same structure.41 Such 
structures may reveal similarities and difference between enzyme active sites for SOAEs 
of varied specificity. 
The major hindrance in resolving such arguments is the lack of information regarding 
mechanism and structure of these SOAE enzymes since there is only limited sequence 
information available48,50 and detailed information regarding structural differences 
between the two main types of SOAE enzyme (4- and 9-SOAE) is also somewhat 
limited.  
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I.1.6. Synthetic sialic acid derivatives towards SOATs  
Previous research by Striecher et al. has included the development of potential 
substrates for SOAT enzymes for use as investigative tools for probing enzyme 
specificity and activity (see figure 12).60  These substrates are α- and β-configured (the 
less common anomer) sialosides and were synthesised using established Koenigs-Knorr 
methodology.60 The sialoside derivatives possessed a negatively charged group in 
addition to the anomeric carboxylate (speculated for successful enzyme recognition of 
the important sialyl donor CMP-Neu5Ac) and a fluorescent tag in order to aid conjugate 
detection during enzyme study. To date, these derivatives have not been used to 
investigate SOAT activity. 
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Figure 12. Potential synthetic substrates for SOAT enzymes and the important natural 
sialyldonor, CMP-N-acetylneuraminic acid (CMP-Neu5Ac). 
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I.2. Results and discussion 
 
I.2.1. Project rationalisation 
Being important biological molecules, O-acetylated sialic acids and their respective 
metabolising enzymes (SOAEs and SOATs) are of significant interest and are clear 
targets for investigation by the glycobiology community at large.  
The bourgeoning availability of these enzymes make systematic inhibition studies a 
viable possibility and potentially worthwhile endeavour. This is particularly as information 
about enzyme structure and properties is currently limited and has only begun to be 
studied in detail in mammalian systems.26  
As mentioned previously, infections relating to the HE activity of certain viral pathogens, 
though often mild and subclinical can be associated with severe human and animal 
disease. With the potential of future viral epidemics and the ability of certain viruses to 
exhibit animal to human transmission (for example, coronaviruses such as SARS),61 new 
treatment(s) and diagnostic tools for the investigation of various disease states where O-
acetylated sialic acids and their metabolising enzymes are implicated would be of 
interest. 
Highly conserved sites in the SOAE domains of HE(F)proteins of viral species compared 
to the archetypal domain of influenza C SOAE have been observed.46,48,50,59  
Therefore, with regards to viral activity the SOAE active site could be considered a 
logical target for broad-spectrum antivirals against sialate-O-acetylesterases of both 
orthomyxo- and coronaviruses and potential tools for investigation of SOAT enzymes.  
 
I.2.1.1. Inhibitor design 
Early studies into the nature of SOAEs have postulated that two pharmacophoric groups 
are essential for enzyme-substrate interaction. Firstly, the carboxylate group (at C2) is 
considered essential for esterase action and secondly, the 9-O- or 4-O-acetylated 
hydroxy group.4,49 The limited studies upon the specificity of SOATs also indicate that 
these functional groups are also most likely essential recognition components for 
successful enzyme catalysis.39,44,57  
With these structural prerequisites in mind, the synthesis of an α-glycosidically linked 
sialoside derivative (thus imitating the natural α-ketosidic anomeric linkage)4,62 was 
required and which could be synthetically manipulated to allow preferential access to the 
4- and 9-hydroxy groups. The α-aglycone must be tolerated by and be chemically stable 
to other reactions involved in 4- and 9-hydroxy group functionalisation as well as having 
the capacity for further functionalisation or immobilisation (see figure 13).  
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Figure 13. Requirements for potential SOAE and SOAT inhibitors. R = aglycone (with capacity for 
further modification); R’ = inhibitor functionality for 4- or 9-SOAE/SOAT investigation at the 4-OH 
or 9-OH. 
 
I.2.2. Synthesis of the α-sialoside precursor 
The initial step towards α-allyl sialoside 4 is the protection of the carboxy functionality as 
a methyl ester, by treatment of Neu5Ac with MeOH and Amberlite IR-120 (H+) ion-
exchange resin to yield compound 1. 
With compound 1 in hand, attention could be turned to forming a sialoside donor. The 
formation of a 2-chloro-β-sialoside 2 was achieved by the treatment of compound 1 with 
a solution of AcCl/AcOH and a small volume of MeOH (in order to generate HCl gas) 
and was isolated and used in subsequent steps without further purification. Other 
methods of sialoside donor formation are known, however chloro-donors are easily 
synthesised whilst generally giving good selectivity, usually with α-anomeric sialosides 
formed in higher ratio20 than β-derivatives, which is synthetically useful for sialoside 
derivatives required in this project. Koenigs-Knorr sialylation of compound 2 with 
AgCO3/AgClO4 yielded the crude sialylated product with in an approximate 10:1 α:β ratio 
and gave compound 3 in good yield after purification. Subsequent Zemplen deprotection 
(NaOMe/MeOH) of compound 3 gave the desired α-allyl sialoside 4.  
α-Allyl sialoside 4, derived from per-acetylated precursor 3, fulfilled the above  
requirements63 and served as an intermediate for all syntheses towards 4-SOAE and 9-
SOAE inhibitors and was conveniently synthesised in 3 steps from commercially 
available Neu5Ac using a established Koenigs-Knorr methodology (see scheme 5).64,63  
  
46 
 
 
Scheme 5. Reagents and conditions; (a) IR-120(H+); MeOH; (b) AcCl, MeOH, AcOH, 0 °C; (c) 
Ag2CO3/AgClO4, allyl alcohol; (d) i. MeOH/NaOMe, ii. Amberlite IR-120 (H+). 
 
I.2.3. Potential inhibitors 
As mentioned previously, studies on the SOAE active sites revealed the existence of an 
important carboxylate-stabilising arginine amino-acid residue and the “oxyanion hole” 
(suspected to stabilise the tetrahedral transition state formed during ester hydrolysis)54,49 
which are thought to be essential for correct substrate binding and recognition.  
Speculatively, some of these sites may be present in the active sites of SOAT enzymes. 
These attributes can be used to the advantage of a potential inhibitor (see scheme 6). 
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Scheme 6. Potential mechanism for sialate deacetylation by SOAE enzyme (A) and the potential 
mechanism for sialate acetylation by a SOAT (B) (*using AcCoA as a co-factor or via a 
speculated “enzyme-complex”). A 4-O-acetylated α-sialoside is used as an example substrate. 
 
In order to probe the active sites of both 4-SOAE and 9-SOAE two types of structural 
modification were introduced at the 4-OH and the 9-OH of sialic acid target compounds 5 
to 8 (see Figure 14). 
Methylation of the 4-hydroxy group resulting in compound 5 and the 9-OH resulting in 
compound 7 should provide information regarding the role of the respective hydroxy 
group as a hydrogen bond donor and moreover would provide information regarding the 
contribution of hydrophobic interactions to substrate binding within the enzyme active 
site.  
Methylphosphonate groups were introduced as mimetics of the suspected tetrahedral 
transition state of acetyl hydrolysis. In theory, compounds 6 and 8 could interact with this 
polar transition state, including the “oxyanion hole‟. 
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Figure 14. Targeted α-O-allyl sialosides containing methyl- (compounds 5 and 7) or 
methylphosphonyl- (compounds 6 and 8) functionality at the 4- or 9-hydroxy group. 
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I.2.4. Synthesis of 4-O-modified sialoside derivatives 
 
I.2.4.1. Methylation of the 4-hydroxy group 
Selective methylation of the 4-hydroxy group was achieved through the introduction of a 
cyclic isopropylidene ketal blocking the 8- and 9-hydroxy groups via an acid catalysed 
reaction of compound 4 with 2,2-dimethoxypropane to yield compound 9 in 85% yield 
(see scheme 7). 
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Scheme 7. Reagents and conditions; (a) DMP, acetone, TsOH; (b) pyridine, acetic anhydride; (c) 
dimethyl sulfate, NaH, acetonitrile, 0 °C; (d) i. 80% AcOH (aq.); ii. NaOH (0.1 M); iii. gel 
permeation chromatography.  
 
Per-acetylation of compound 9 to give compound 10 aided in the 1H NMR spectroscopic 
identification of compound 9. 
Initial methylation attempts of compound 9 with NaH and MeI were unsuccessful. The 
application of Williamson conditions65 using dimethyl sulfate as the alkylating agent 
produced compound 11 in 50% yield. The reaction was extremely sensitive to the 
addition of NaH and pushing the reaction towards completion led initially to multiple 
product formation observed by TLC with the eventual increase in baseline spot 
concentration. Best results were achieved by adding the NaH in small portions rather 
than concurrently at the beginning of the reaction. A one-pot deprotection sequence 
using 80% AcOH to remove the cyclic ketal followed by methyl ester saponification with 
NaOH (aq.) gave compound 5 after gel permeation chromatography (see scheme 7). 
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I.2.4.2. Phosphonylation of the 4-hydroxy group 
Introduction of a phosphonate moiety at the 4-hydroxy group was attempted with methyl 
methylphosphonylchloridate66 and pyridine. These initial phosphonylation attempts were 
unsuccessful with compound 4 as the reaction conditions were sufficiently acidic (pH 1-
2, indicator paper) to remove the isopropylidene protecting group without successful 
phosphonylation occurring.  
A base labile protecting group strategy was therefore pursued whereby the 8- and 9-
hydroxy groups were protected as a cyclic carbonate. The protection step was initially 
carried out with carbonyl diimidazole using pyridine and pyridine/DCM mixtures but was 
unsuccessful.  
The use of diphosgene and dimethylaminopyridine was successfully implemented to give 
compound 12 in 60% yield (see scheme 8). Per-acetylation of compound 12 to give 
compound 13 allowed for the unambiguous 1H NMR spectroscopic determination of 
compound 12. 
Introduction of the phosphonate functionality was successfully achieved with methyl 
methylphosphonylchloridate and DIPEA to give compound 14.  
Compound 14 is obtained as a set of two diastereoisomers due to the chirality of the 
phosphorous centre. Two sets of resonances are consequently being observed in NMR 
spectroscopy. In 1H NMR, the P-CH3 and P-OCH3 signals (doublets, respectively) are 
particularly useful for the determination of the ratio of the diastereoisomers. No attempt 
to separate the mixture of diastereoisomers has been made as this effect is only 
transient in the synthesis. 
The position of the phosphonylation at the 4-hydroxy group was in part confirmed by 
acetylation of the remaining hydroxy group at the 7-hydroxy group to give mono-
acetylated compound 15 (see scheme 8). 
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Scheme 8. Reagents and conditions; (a) Diphosgene, DMAP, DCM, 0 °C; (b) pyridine, acetic 
anhydride; (c) P(O)(OCH3)CH3Cl, DIPEA, DCM; (d) i. thiophenol, NEt3, THF; ii. Py/NEt3/H2O; iii. 
gel permeation chromatography.  
 
To yield the target compound 6, deprotection of the phosphonate monoester and 
carboxy-methyl ester of compound 14 was initially undertaken using a variety of 
conditions. These included a reaction with 0.1 M NaOH (aq.), heating compound 14 to 
reflux in a 1:1:1 mixture of pyridine/triethylamine/H2O and reaction with TMSBr.67 These 
deprotection strategies were unsuccessful and led to a complex mixture of products 
which were not isolated or purified further. It is likely that these products were the result 
of mixed phosphonate ester cleavage under the deprotection conditions used.  
Selective deprotection of the phosphonic acid methyl ester 14 using thiophenol and 
triethylamine68 followed by basic hydrolysis of the carboxy-methyl ester with NaOH (aq.) 
was successfully used to generate target compound 6 after gel permeation 
chromatography in good yield (50%) (see scheme 8). 
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I.2.5. Synthesis of 9-O-modified sialoside derivatives 
 
I.2.5.1. Methylation of the 9-hydroxl group 
The methylation of the 9-hydroxy group using α-allyl sialoside 4 was initially approached 
using identical Williamson conditions as described in the synthesis of compound 11, with 
the rationalisation that the slightly greater chemical reactivity of the primary 9-hydroxy 
group would allow for regioselective alkylation (over the secondary 4-, 7- and 8-hydroxy 
groups). The lack of protecting group manipulations would therefore lead to a more 
expedient synthesis of target compound 7.  
This approach was unsuccessful and generated a complex mixture of products which 
could not be purified successfully. Indeed, alkylation reactions at the glycerol side chains 
of sialic acid derivatives are known to be problematic.69  
In order to overcome this selectivity problem, syntheses were undertaken towards a 
suitably protected sialic acid derivative with access to the 9-hydroxy group for further 
functional group manipulation. 
Compound 4 was protected selectively at the 9-hydroxy group as a silyl ether with 
TBDMSCl to give compound 16 (see scheme 9). Brief synthetic investigations were 
made into protecting the free 7- and 8-hydroxy groups with a cyclic ketal and as a cyclic 
carbonate in a similar vein to the intermediates towards target compounds 7 and 8. This 
was however unsuccessful. It is speculated that the glycerol side chain may be too 
sterically demanding for this protection strategy, although carbonate protection of trans-
diols is known in the literature.70  
In a second strategy, compound 4 was per-benzoylated at the free 4-, 7- and 8-hydroxy 
groups, thus maintaining an orthogonal deprotection relationship between the protecting 
group patterns and avoiding the potential migratory issues often seen with acetyl 
protecting group strategies with sialic acid derivatives (see scheme 9).2  
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Scheme 9. Reagents and conditions; (a) TBDMSCl, imidazole, DMF, 0 °C; (b) BzCl, DMAP, 
pyridine. 
 
Compound 18 was obtained, but was not the major product formed in the reaction. 
Pushing the reaction towards product formation led to the formation of the unwanted side 
product 17 and as such this route was abandoned.  
A third strategy towards selective access to the 9-hydroxy group involved the per- 
silylation of α-allyl sialoside 4 to give compound 19, followed by selective deprotection of 
the primary 9-OTBDMS using catalytic amounts of carbon tetrabromide under photolytic 
conditions (see scheme 10).71  
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Scheme 10. Reagents and conditions; (a) TBDMSOTf, lutidine, DCM; (b) hν (30 minutes), 
MeOH, CBr4; (c) pyridine, acetic anhydride. 
 
Initial studies using per-silylated compound 19 led to the formation of compound 20 and 
α-allyl sialoside 4 (via complete deprotection of compound 19). It is suggested that the 
use of sodium hydrogen carbonate (NaHCO3 (s)) in the work-up procedure led to the 
migration of a silyl protecting group to the 9-hydroxy group. Silyl group migration is 
known to occur under basic conditions.70 Acetylation of the remaining free hydroxy group 
gave compound 21 (and led to the unambiguous spectroscopic identification of 
compound 20) (see scheme 10). After the optimisation of reaction conditions (type and 
power of UV source, time of UV exposure and concentration of CBr4) and work-up 
procedure (direct evaporation and subsequent chromotographic purification instead of 
basic NaHCO3 work-up), compound 22 was synthesised in good yield of 60% (see 
scheme 11). 
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Scheme 11. Reagents and conditions; (a) hν (10 minutes), MeOH, CBr4. 
 
With compound 22 in hand methylation of the 9-hydroxy group was attempted but was 
unsuccessful using Williamson conditions.  
The difficulties encountered when synthesising sialic acid derivatives with selective 
access to the 9-hydroxy group led to chemistry being conducted where possible directly 
from α-allyl sialoside 4 using limited protecting group manipulation in order to avoid time 
consuming and costly protection strategies. 
Therefore an alternative route to target compound 7 was used whereby α-allyl sialoside 
4 was tosylated with TsCl to give compound 23 (see scheme 12).72   
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Scheme 12. Reagents and conditions; (a) TsCl, Pyridine, 0 °C; (b) pyridine, acetic anhydride; (c) 
NaOMe, MeOH; (d) Amberlite IR-120 (H+), MeOH; (e) pyridine, acetic anhydride; (f) i. NaOH 
(0.05M), dioxane; ii. gel permeation chromatography. 
 
As with previous examples, per-acetylation of tosylated compound 23 gave compound 
24 and was used in the spectroscopic identification of tosylated compound 23. 
Compound 23 was subsequently treated with sodium methoxide in MeOH to give the 
8,9-epoxide 25.69  
 
Methylation at the 9-hydroxy group in moderate yield (45%) was achieved through the 
acid-mediated opening of the epoxide in MeOH with Amberlite ion-exchange resin (H+). 
Though the reaction can be carried out with compound 25 after purification, slightly 
better results were obtained when the methylation reaction was carried out directly in situ 
from the tosylated precursor 23. 
The per-acetylation of compound 26 generated compound 27 which aided in the 
unambiguous characterisation of compound 26. Saponification of the methyl ester with 
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NaOH (aq.) and subsequent gel permeation chromatography yielded the desired target 
compound 7 (see scheme 12). 
 
I.2.5.2. Phosphonylation of the 9-hydroxy group 
As in the synthesis of compound 14, the introduction of the phosphonate functionality at 
the 9-hydroxy group was attempted with compound 22 using methyl 
methylphosphonylchloridate and DIPEA. It was hoped that the use of a sialic acid 
derivative with access to the 9-hydroxy would prevent the formation of unwanted per-
phosphonylated side products. However, the reaction was unsuccessful and did not lead 
to the formation of the desired 9-O-phosphonylated compound.  
With the failure of the protecting group strategy to produce the desired phosphonylated 
intermediate, the direct reaction of α-allyl sialoside 4 with methyl 
methylphosphonylchloridate and DIPEA was successful and produced regioselectively 
compound 28 in moderate yield (30%) (see scheme 13). This route slightly improves the 
synthetic methodology towards 9-O-phosphonylated compounds (with particular 
reference to the ease of purification in comparison to alternative methods).73   
As described for compound 14, the chiral phosphorous centre allows the formation of 
two diastereoisomers and consequently two signal sets in NMR. In contrast to the 
former, this was however not observed in the case of compound 28 with the most likely 
explanation being that only on isomer has been formed.  
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Scheme 13. Reagents and conditions; (a) P(O)(OCH3)CH3Cl, DIPEA, DCM, -15 °C; (b) pyridine, 
acetic anhydride; (c) i. thiophenol, NEt3, THF; ii. Py/NEt3/H2O; iii. gel permeation chromatography.  
 
However, selectivity of phosphonylation becomes problematic when driving the reaction 
towards completion, as a diphosphonylated derivative (at the 8- and 9-hydroxy groups) 
appears to be formed (determined from 1H NMR and 1H-31P SED-NMR) but was not fully 
characterised. Starting material α-allyl sialoside 4 can (in part) be retained if the reaction 
is stopped before this point is reached. 
The selective deprotection of the phosphonate ester of compound 28 with thiophenol 
and triethylamine, followed by basic saponification of the methyl carboxylate ester 
(NaOH (aq.)) gave both the 9-O-methylphosphonate compound 8 and also the 8-O-
methylphosphonate. 
Per-acetylation and 1H NMR analysis of the products formed after treatment with 
thiophenol/triethylamine indicated the presence of two products believed to be the 8- and 
9-methylphosphonic acid intermediates (which then subsequently undergo basic 
hydrolysis). It is therefore speculated that the 8-hydroxy group is participating in an 
intramolecular transfer from the 9-hydroxy group to the 8-hydroxy group, leading to the 
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formation of the unwanted 8-O-methylphosphonate derivative, the exact mechanism of 
which has not been elucidated.  
In order to avoid the formation of the unwanted 8-O-methylphosphonate, synthesis of 
compound 28 was followed by per-O-acetylation to give compound 29 (see scheme 13). 
The deprotection of compound 29 was then carried out with thiophenol and 
triethylamine, followed by basic saponification of the methyl carboxylate ester to give 
target compound 8 after gel permeation chromatography in 20% yield (4 steps).  
As a control sample for SOAE or SOAT studies, compound 30 was synthesised from 
compound 4 by basic saponification and subsequent gel permeation chromatography 
(see scheme 14). 
 
 
 
Scheme 14. Reagents and conditions; (a) i. NaOH (0.1 M); ii. gel permeation chromatography. 
 
I.2.6. Towards non-competitive (irreversible) inhibitors 
Synthesis was carried out towards an irreversible (suicide) inhibitor of SOAE and SOAT 
enzymes based upon the 8,9-epoxide compound 25.  For SOAE/SOAT studies, 
irreversible inhibitors need reactive functionality at the 9-hydroxy group (or 4-hydroxy 
group) in order to covalently bind to the nucleophilic serine residue in the active site. By 
trapping out the active site residues, more detailed information regarding enzyme 
structure and properties can be obtained.  
The epoxide functionality is a potentially viable covalent (suicide) inhibitor for SOAE and 
SOAT applications but only if the methyl carboxylate ester of precursor 25 can be 
removed (thus providing access to the biologically active compound) without disturbing 
the chemical stability of the epoxide (see scheme 15). 
Enzymatic cleavage of the carboxy-methyl ester of compound 25 appeared to be a 
selective method for methyl ester deprotection without compromising the 8,9-epoxide 
functionality. PLE (porcine liver esterase) has been shown to successfully cleave methyl 
carboxylate esters and O-acetylated moieties in good to moderate yields, and 
importantly, even in the presence of epoxide functionality.74-76  
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Scheme 15. Proposed enzymatic conversion of compound 25 to the deprotected epoxide, a 
potential suicide (non-competitive) inhibitor. (a) PLE (porcine liver esterase). 
 
Initial studies involved assessing the stability of both the 8,9-epoxide derivative 25 and 
the α-O-allyl sialoside 4 in both D2O and enzyme buffer solution (PBS, pH 8, made with 
D2O). Both the α-O-allyl sialoside 4 and the 8,9-epoxide derivative 25 showed no sign of 
hydrolysis (or epoxide opening with respect to compound 25). 
The PLE reactions proved unsuccessful in hydrolysing the carboxy-methyl ester at all 
under any of the reaction conditions tested (see appendix 1: PLE experiments, page 
259). 
NMR analysis and TLC studies indicated that after prolonged reaction times the 
compounds tested failed to show any evidence of ester hydrolysis.  
Enzymatic reactions with the methyl-ester sialoside 1 also showed no ester hydrolysis, 
indicating that enzymatic activity is independent of carboxy-functional group 
conformation at the anomeric centre. 
Inactivity of the PLE enzyme was eliminated as a reason for unsuccessful enzymatic 
hydrolysis reactions by incubating 3-cyclohexene-1-carboxylic acid methyl ester with 
PLE to hydrolyse the substrate to the respective 3-cyclohexene-1-carboxylic acid. 1H 
NMR indicated the hydrolysis was successful. (see appendix 1: PLE experiments, page 
259).77 The lack of PLE enzymatic activity with the α-O-allyl sialoside derivatives 
indicates that the α-O-allyl sialoside derivatives are not suitable PLE substrates. Other 
methods, both enzymatic and chemical have to be considered as alternatives for future 
work. 
 
I.2.7. Investigation of the inhibitory activity against viral SOAEs 
With target compounds 5 to 8 now available, a study was embarked upon in 
collaboration with Prof. R. Vlasak (Salzburg, Austria) with the aim of finding competitive 
inhibition with viral SOAE expressing enzymes.78  
Inhibition of the SOAE activity of three viruses, influenza C virus (INF-C),50,49 bovine 
coronavirus (BCoV)79,80 and mouse hepatitis virus strain S (MHV-S).42,81 and of two 
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chimeric recombinant viral haemagglutinin esterases, from influenza C/Cal/78 virus 
(HE12-GFP) and sialodacryoadenitis virus (SDAV-HE) was investigated.3  
The effectiveness of inhibitor compounds 7 and 8 toward the 9-SOAE activities of HE12-
GFP, INFC virus and BCoV and of compounds 5 and 6 toward the 4-SOAE activity of 
SDAV-HE and MHV-S were determined by an pNPA assay. This assay is based upon 
the spectrophotometric detection of the enzymatic hydrolysis product of p-nitrophenyl 
acetate in the presence of an esterase inhibitor. Inhibition of esterase activity results in a 
reduction in the amount of hydrolysis product and as such a reduction is hydrolysis 
product detected, which is related to the concentration of esterase inhibitor present.78  
 
I.2.7.1. Results and discussion of inhibition studies 
The sialate-O-acetylesterases were incubated with the sialoside target compounds 5 to 8 
(and negative control compound 30) of different concentrations.  
The 9-O-methyl sialoside compound 7 has been identified as a potential inhibitor of 
HE12-GFP. The 9-O-methyl sialoside compound 7 inhibited SOAE approximately 86% of 
SOAE activity (at 5mM concentration) (see table 2).78 The negative control, α-allyl 
sialoside 30 did not show detectable inhibition of any of the enzymes investigated. 
The inhibitory effect of compound 7 was reduced when using whole influenza C virus 
particles suggesting that the differing conformation of the haemagglutinin protein 
between HE12-GFP (monomeric) and whole virus particles (trimeric) may have an 
impact on the binding and therefore the inhibitory effect of compound 7. 
This is also the case with the 9-SOAE of BCoV, where compound 7 also showed 
reduced inhibitory activity in the fluorimetric assay. It has been suggested that BCoV is 
more dependent on the nature of the aglycone than the SOAE of influenza C virus which 
may provide an explanation for the reduced inhibitory activity observed.78,49  
 
Sialoside 
conc. 
HE12-GFP INF-C virus BCoV 
7 8 7 8 7 8 
0.5 mM 22.95% 1.06% 7.01% < 0% 2.86% 9.78% 
1 mM 22.42% 6.08% 8.63% 3.85% 9.00% 2.70% 
2 mM 33.03% 7.91% 7.05% 7.39% < 0% < 0% 
5 mM 85.79% - - - - - 
 
Table 2.  Inhibition (%) of viral 9-SOAEs by α-sialoside target compounds determined by the 
catalysed hydrolysis of p-nitrophenyl acetate (pNPA). 
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It is clear when comparing the results for inhibitory activities of compound 7 (9-O-methyl) 
to 8 (9-O-methylphosphonate) that the original reasoning for use of methylphosphonate 
functionality (mimicry of the proposed tetrahedral intermediate formed during acetyl 
hydrolysis) is not supported, as the charged methylphosphonate does not lead to 
improved binding and inhibition in comparison to the unmodified negative control, 
compound 30 (see table 2). The effect of the hydrophobic methyl group of compound 7 
however shows a significant effect which could be exploited by further functional group 
modification at the 9-hydroxy group. It should also be mentioned that the results 
obtained in this initial study (for influenza C virus esterase) support those from an earlier 
investigation where a Ki of 4.2 mM was determined for a 9-acetamido-9-deoxy-sialic acid 
derivative.72  
 
Sialoside 
conc. 
MHV-S SDAV-HE 
5 6 5 6 
0.1 mM 4.00% 5.00% 2.13% 8.30% 
0.5 mM 0% 2.36% 2.56% 2.89% 
1 mM 8.31% 11.89% 0.51% 0.65% 
2 mM 7.73% 7.81% 8.73% 10.96% 
 
 
Table 3. Inhibition (%) of viral 4-SOAEs by α-sialoside target compounds determined by the 
catalysed hydrolysis of p-nitrophenyl acetate (pNPA). 
 
Unfortunately no significant inhibition was observed in the pNPA assay when 
investigating the effects of the target compounds 5 (4-O-methyl) and 6 (4-O-
methylphosphonate) towards the 4-SOAEs expressed by MHV-S and SDAV-HE (see 
Table 3). The fact that at higher inhibitor concentrations there was no inhibitory activity 
observed indicates that the scope for further functional group modification at the 4-
hydroxy group is limited towards SOAE inhibition. It should be kept in mind however that 
the mode of action of 4-SOAEs may not be the same as 9-SOAEs. 
 
I.2.8. Conclusion 
To conclude, a set of structurally modified sialosides (compounds 5 to 8) have been 
synthesised and have proved useful tools for studying the active sites of viral 4-SOAE 
and 9-SOAE enzymes investigated in preliminary assays. Though inhibition of 4-SOAEs 
was not observed, the 9-O-methyl derivative 7 showed inhibition of the recombinant 
SOAE from influenza C virus though not significantly with whole virus particles (as 
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mentioned above). Although it can be speculated that this is a result of it being a 
monomer rather than the native trimer, further studies are required with optimised 
inhibitors of higher affinity to corroborate this speculation. 
Further studies based upon these inhibitors and variants thereof would be able to 
develop high-affinity inhibitors of the viral SOAE enzymes as potential drug lead 
compounds and investigative tools.  
The sialosides developed are in no way limited to viral applications and could also be 
applied to SOAE and SOAT enzymes expressed by other organisms and disease states 
where O-acetylation of sialic acids are implicated. 
 
I.2.9. Future scope 
The synthesis of further α-O-allyl sialoside derivatives displaying functional group 
modifications at the 9-hydroxy are currently in the groups’ pipeline. It is hoped that 
compounds displaying hydrophobic moieties of a varied chemical nature (for example, 
alkyl vs. aromatic substituents) at this position will be available to further investigate of 
the effect of hydrophobic substitution with regards to SOAE inhibition. 
The continued development of the non-competitive suicide inhibitor based upon the 8,9-
epoxide compound 25 is also of interest. Continuing the enzymatic route towards 
carboxy-methyl ester hydrolysis is an option using a different hydrolytic enzyme such as 
PPL (porcine pancreatic lipase), which also is considered a versatile enzyme for 
synthetic applications.74,77,75  
Chemical methods of methyl ester hydrolysis (in the presence of the epoxide moiety) will 
also need to be assessed. One particular method of interest is the use of trimethyltin 
hydroxide (SnMe3OH) as a mild hydrolysis reagent.82  
It is also of interest for the α-O-allyl sialoside derivatives developed here to be 
investigated for their inhibitory potency of SOATs, particularly of mammalian SOAT 
systems where little structural information is known.  
It may be the case that synthetic methodologies towards larger di-, tri-, multi-sialylated 
compounds containing the inhibitor functionalities seen in compounds 5 to 8 would need 
to be developed in order to investigate SOAT enzyme properties if simple α-O-allyl 
sialoside inhibitors are found to be unsuitable substrates (to the 9-SOAT).27  
The functionalisation of α-O-allyl sialoside derivatives onto solid 
supports/surfaces/quantum dots are another area which could be developed with the aim 
of synthesising SOAE/SOAT diagnostics. 
Methodologies to conjugate the allyl group will therefore need to be investigated. One 
possible direction of research includes metathesis reactions because of the O-allyl 
functionality at the aglycone. Recent developments in the synthesis of novel dimers of C-
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allyl sialosides83 have utilised Grubbs-type catalysts in metathesis reactions with 
success and as such is a good indication that such methods may be applicable to α-O-
allyl sialoside derivatives.  
Thiol-ene coupling chemistry also lends itself to the functionalisation of α-O-allyl 
sialoside derivatives and also would allow a convenient method for bioconjugation84 as 
well as other more conventional (amino-coupling chemistry) methods for linker ligation.63  
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New Tools for the characterisation and investigation of influenza virus 
neuraminidases: towards novel influenza virus sensors 
 
II.1. Introduction 
 
II.1.1. Introduction to the Influenza Virus 
Influenza viruses are enveloped, single-stranded RNA viruses belonging to the 
Orthomyxoviridae family. They are further classified into three serologically distinct 
types; influenza A, B, and C viruses.85 However, only influenza virus A and B are 
considered highly pathogenic (causing seasonal and pandemic disease) towards the 
human population.86,87  
Influenza A viruses are divided again based upon the distinctive antigenic behaviour of 
the two main influenza virus surface proteins; a hemagglutinin (HA) and a neuraminidase 
(NA).85,88 With respect to Influenza A virus subtypes, these include 16 for Hemagglutinin 
(H1-H16) and 9 for neuraminidase (N1-N9).88  
A third membrane protein, the M2 protein, is present in small quantities in influenza A 
viruses but is not considered a significant factor towards viral pathogenicity.89  
 
II.1.1.1. Influenza A virus 
Influenza A viruses have obtained a certain degree of notoriety having been the cause of 
all major human influenza pandemics.90 The most deadly of which occurred in the 
twentieth century and resulted in the deaths of approximately 1% of the global 
population, the so-called “Spanish flu” pandemic of 1918 (influenza A H1N1). Other 
influenza pandemics have since occurred (for example, Asian flu, 1957 (H2N2) and 
Hong-Kong flu, 1968 (H3N2)) but have not had the same level of global impact to date.91  
In humans, the influenza virus causes acute viral infection of the respiratory tract (more 
specifically, the epithelium lining the trachea) where common symptoms include fever, 
sore throat, muscular pain and fatigue.89 It is the risk of secondary infection/complication 
(for example, pneumonia) or hypercytokinemia (“cytokine storm”))92 amongst at-risk 
populations (typically the very young and old) which give influenza infection high 
morbidity and mortality rates, particularly during pandemics and severe seasonal 
outbreaks.93,94  
Influenza A viruses are known to infect a wide range of host organisms and are believed 
to have originated among the avian population, of which wild birds (ducks, geese, 
swans, and shore birds) are considered to be a large natural repository of influenza 
viruses. It is noteworthy to point out that all of the known influenza A virus 16 HA and 9 
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NA subtypes have been found in these wild bird populations, however the jumping of 
subtypes from avian to mammalian species is rare.89  
The virus is asymptomatic in many avian species and as such they are referred to as low 
pathogenic avian influenza (LPAI) viruses. It is the adaptation of these viruses into new 
aggressive influenza strains which allow increased pathogenicity towards human 
populations and/or other host species.95,90  
This ability of cross-species transmission and subsequent rapid transmission and 
infection in the human population comes as a result of changes in the virus RNA 
genome. The evolution of an existing influenza virus through point mutations (“antigenic 
drift”) or the reassortment of RNA segments between influenza viruses of different 
species (“antigenic shift”) can lead to the creation of a new influenza subtype which has 
the potential of causing severe consequences for human health.96,90,97 
 
II.1.1.2. Pandemic influenza (H1N1, H5N1) 
The most recent global influenza concerns have centred around the 2008-2009 influenza 
pandemic as a result of the pandemic H1N1 (“Swine Flu”, “Mexican Flu”) virus and the 
currently limited global outbreaks of the H5N1 (“bird flu”, “avian flu”) virus to which 
substantial fears of a future global pandemic have been attributed. 
Though less deadly than initially feared and now moving into a post-pandemic period (as 
of April 2011), the pandemic H1N1 (“Swine Flu”, “Mexican Flu”) virus initially spread 
rapidly around the world through human-human transmission after early outbreaks in 
North America.98,99 
The pandemic H1N1 virus exhibited patterns of infectivity and mortality not normally 
attributed to seasonal influenza outbreaks, with a higher than expected proportion of 
deaths effecting younger, otherwise healthy individuals. As of 2009 the number of 
laboratory confirmed fatalities occurring as a result of the pandemic H1N1 virus is 
believed to be >16,000 cases.99 
Fortunately however, the pandemic H1N1 virus did not appear to develop any significant 
resistance to anti-viral prophylactic treatments (vide infra) and mutation did not lead to a 
more virulent form of the virus.100  
Considered to be a highly pathogenic avian influenza (HPAI) virus (as opposed to 
previously mentioned LPAI viruses), the recent emergence and spread of the H5N1 
influenza virus subtype has heightened global concerns of a future influenza 
pandemic.90,101  
First identified in Hong-Kong (1997) and subsequently seen in limited outbreaks 
amongst avian populations (mostly localised to south-east Asia), human-human 
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transmission appears to be infrequent and occasional though the mortality rate of the 
H5N1 virus when contracted is associated with severe and often fatal outcomes.89,96  
The H5N1 virus, though not classed as a pandemic, has met two of three relevant 
criteria; 1) the emergence of a virus strain to which there exists no natural immunity in 
the human population; 2) the successful transmission and infection of the virus strain to 
humans.89,101  
The spread of this influenza strain has become endemic in many poultry and wild bird 
populations in Asia which only serves to increase the chances of a successful virus 
variation (through “antigenic shift” or “antigenic drift”) towards the human population as a 
consequence of increased human-animal (avian) interactions.89,90  
This fear is exacerbated by clinical evidence which indicates the resistance of certain 
H5N1 variants to anti-viral treatments which may retain high levels of pathogenicity as 
seen in the wild-type virus in humans.102,103  
As of April 2011, The WHO (World Health Organization) confirmed 549 cases of H5N1 in 
humans globally, 320 of which were fatal.104  
The consequences of a severe influenza outbreak (such as the H5N1 subtype) and its 
obvious detrimental health and socioeconomic impact upon the global population mean 
that the WHO continues to monitor the disease globally and influenza research 
constitutes a global R&D investment in excess of $7 billion in 2009. 95,105 
 
II.1.2. The role of neuraminidase and hemagglutinin in influenza virus replication 
As previously mentioned the influenza virus has two main surface proteins, HA and NA.  
Both surface proteins (the ratio of which is approximately 10:1 HA to NA respectively) 
play a major role in the replicative fitness of the influenza virus infection process.106   
Both the HA and NA are carbohydrate-recognising proteins (lectins) which utilise 
terminally-bound sialic acid (linked to an underlying galactose moiety on glycoproteins 
and glycolipids) as the main receptor determinant.107   
The influenza viruses follow a typical replicative path (see figure 15). The HA is primarily 
responsible for initial sialic acid mediated attachment of the virus to the host cell surface 
and is also responsible for viral entry into the host cell via endocytosis and fusion of the 
virus with the host cell.108  
The process of viral entry by the HA is critically helped by the M2 protein channels 
(previously mentioned) on the virus surface. These small membrane-bound structures 
act as proton channels, allowing the acidification of intracellular compartments of the 
host cell on HA binding therefore enabling viral uncoating and the escape of viral RNA 
into the host cell.109  
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The viral RNA is then replicated within the nucleus of the host cell whereby new viral 
progeny are packaged and transported to the host cell surface where budding of virus 
particles occurs. Newly formed virus progeny are then released from the host cell 
surface.  It is here that the NA comes into action by cleaving the glycosidic linkages of 
terminal sialic acids from the host cell surface which allows the newly generated viral 
progeny to be released unimpeded, thus allowing the viral infection to propagate.108 
Without the receptor-destroying function of NA, influenza infection would be limited and 
as such its disease-causing potential curtailed.108 It has also been suggested that NA 
action aids viral infection of a host organism by hydrolysing sialic acid residues present 
on the mucin which lines epithelial cells in the respiratory tract of the host organism.110  
 
 
Figure 15. Influenza virus replicative cycle. Viral infection is started with hemagglutinin (HA) 
binding to sialylated cell surface structures. This induces the virus endocytosis and subsequent 
release and replication of RNA and viral proteins. The new virions bud from the cell surface and 
are released on cleavage of terminal sialic acid epitopes by the neuraminidase (NA). (Reprinted 
with permission from Springer+Business Media; Analytical and Bioanaytical Chemistry 2005, 381, 
156-164.) 
 
II.1.2.1. Hemagglutinin 
The binding interactions of HA to α-ketosidically linked sialic acids on glycoconjugates 
are multivalent in nature as the affinity for a single-receptor (monomeric sialic acid) is 
characterised by weak binding (Kdiss > 10-4 M).86,111  
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The HA consists of three subunits and as such is classed as a trimer (see figure 16). It is 
roughly cylindrical in shape and is anchored to the virus via the viral lipid 
membrane.107,112 The surface of an influenza virion consists of approximately 300-500 
trimeric subunits which are found to be equally distributed over the virion surface.113 It 
has been approximated that the distance between HAs on the same trimer is ~40Å and 
estimated that the distance between HAs of adjacent trimers to be ≤ 55Å.114,115  
 
 
 
Figure 16. (A) Ribbon diagram of the trimer of an H5 (A/Dk/Sing/97) avian HA and (B) a ribbon 
diagram of an H3 swine (A/Sw/9/98) HA. The sialic acid binding domain is coloured blue. 
(Reprinted with permission from Macmillan Publishers Ltd.; EMBO Journal 2002, 21, 865-875.)  
 
Each subunit of HA consists of a further two subunits classed as HA1 and HA2 and 
overall the HA divided into two distinct regions; 1) A triple-stranded coiled area of α-
helices anchored in the membrane by HA2. Both HA1 and HA2 are contained in this 
region. 2) A globular region (containing only HA1 subunits) consisting of anti-parallel β-
sheets which is placed atop of the previous region. It is this second region which 
contains the sialic acid binding site and is also the location of antibody binding sites 
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(antigenic determinants) generated by the host-immune response to the viral 
infection.112,90,116  
 
It has been shown that the binding affinity of the HA to the host sialic acid allows for the 
host specificity of influenza A viruses.90  
This specificity is believed to arise from a limited number of amino acid substitutions 
within the HA receptor pocket which enable preferential binding of the HA to terminal 
sialylated glycosylated biological structures.97,96,90,117  
This receptor specificity can be best illustrated by comparing avian- and human-specific 
influenza viruses. Influenza strains with specificity towards humans bind to α-2,6-
sialylgalactosides preferentially whereas avian (and equine) influenza viruses 
preferentially recognise α-2,3-sialylgalactosides (see figure 17). This comes as a 
consequence of the predominant expression of a particular sialylgaloctoside regioisomer 
found in these particular species.89,90  
 
 
 
Figure 17.  α-2,6-sialylgalactosides vs. α-2,3-sialylgalactosides (R = glycoconjugate). 
 
This preference for receptor specificity in swine is often not as stringent. Swine are 
susceptible to both human and avian influenza viruses because the epithethial cells of 
the respiratory tract in these animals contain both types of sialylgalactoside linkage (α-
2,6- and α-2,3-). Therefore, swine is considered a non-selective host for the evolution of 
new influenza strains (from the mixing of species specific influenza strains) and as such 
are considered a source of pandemic influenza strains towards the human population 
(for example pandemic H1N1 “swine flu”).89,90  
Significant differences in the binding conformations of α-2,6- and α-2,3-sialosides to HA 
have been observed118,119 and as such indicates that for successful viral adaptation to 
human populations from avian species, the virus must adapt to address these 
conformational changes in order to successfully infect and replicate. It is understood that 
the development of an avian influenza strain with the ability to bind preferentially to α-
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2,6-sialylgalactosides is a major prerequisite in the generation of pandemic influenza 
strains with risk to human health.  
Recent studies have added even further complexity to HA binding by indicating that the 
topology of α-sialylated glycans (the structural conformation presented on the host cell 
surface) is important for differentiation between influenza strains beyond the anomeric 
linkage.120 More specifically, the binding of influenza HA to α-sialylated glycans 
displaying “umbrella” or “cone” conformations appears essential for the adaptation and 
transmission of influenza viruses between organisms.121,122,123  
 
II.1.2.2. Neuraminidase 
The role played by the NA in the influenza life cycle can be described as that of a 
“receptor destroying enzyme” as it cleaves the sialic acid residues on the host cell 
surface (see scheme 16) which are needed for initial viral attachment (by the HA) but 
which also prevent the escape and subsequent infectivity of newly formed viral progeny.  
 
 
 
Scheme 16. Simplified schematic of the hydrolysis reaction of the NA upon sialylated biological 
structures. 
 
As alluded to earlier, influenza virus infectivity is a delicate balance between the HA and 
NA.107  
The determination of X-ray crystal structures of the NA glycoprotein has shown that a 
distinction can be drawn between the influenza A subtypes. These investigations have 
shown that the NA of influenza A viruses (subtypes N1-N9) can be separated into two 
phylogenetically and structurally distinct groups; group-1 (N1, 4, 5 and 8) and group-2 
(N2, 3, 6, 7 and 9) NA.88,96,124,125,126  
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The NA (of influenza A and B) is made up of four identical subunits and as such is 
referred to as a tetramer (see figure 18) and like the HA, is also attached to the viral 
membrane surface. But unlike the HA, the NA is not the major target site for the host 
immune system.90 Each NA monomer subunit is arranged into a propeller formation 
through the arrangement of six anti-parallel β-sheets.88 The surface of an influenza virion 
consists of approximately 50 tetrameric subunits (based on X31 H3N2) of a distance of 
approximately 45-50Å between each subunit and unlike HA are not equally distributed 
over the virion surface (neuraminidase patches).113,124  
 
 
 
Figure 18. Ribbon diagrams of the group-1 (N1) neuraminidase tetramer (A). The upper right 
monomer (of the tetramer) is highlighted to emphasize the canonical six-bladed β-propeller 
structure. Expansions of the NA active site are shown (B and C). Superposition of the active sites 
of three NAs from group-1 (B), show the similarities between various influenza strains: N1, green, 
N4, gold, and N8, blue. The superposition of the active site of N1 (green) and N9 (yellow) NAs 
highlight the difference between the N9 and N1 HA in the 150-loop region. Conserved residues 
such as Glu 119, Asp 151 and Glu 276 and the hydrophobic residue at position 149 are shown in 
a stick representation. (Reprinted with permission from Macmillan Publishers Ltd.; Nature 2006, 
443, 45-49.)   
A B 
C 
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The active sites of all influenza NA appear highly conserved, particularly between 
viruses of the same subtype.88,107 The highly conserved areas, in particular the amino 
acid residues in the enzyme active site which bind to sialic acid, are considered invariant 
(for example, the “arginine triad”). 
Structural differences between group-1 and group-2 NA have been determined despite 
these similarities. These distinctive differences centre on the display of a flexible protein 
loop (referred to as the “150 loop”, between amino acid residues 147-152) and a 
hydrophobic cavity (referred to as the “150 cavity”) near the NA active site which is 
present in group-1 NA (and which is “closed” in group-2 NA).96,88  
The conformational rearrangement of the flexible “150-loop” from the “open” form (lower-
energy in the apo-structure) to the “closed” form which occurs on binding of a NA 
inhibitor (oseltamivir, vide infra) is a slow process.88  
Recent theoretical research has indicated that the electrostatic interactions between the 
NA inhibitor pharmacophore and the amino-acid residues present on the “150-loop” are 
essential in determining the binding selectivity (with larger basic functional groups 
potentially favouring binding to the “open” conformation in group-1 NA).127  
This potentially can create new opportunities for NA-inhibitor drug design (based on 
existing NA based inhibitors) as a larger active site is presented as a result of this protein 
loop (increased width of approximately 5Å).96,88   
Such inhibitors could show greater specificity and activity towards group-1 NA and as 
such may serve as lead compounds to target the avian influenza A/H5N1 virus.88 There 
has been recent synthetic work described in the literature towards compounds which 
exploit the “150 loop” for increased binding to NA.128,87,129  
With regards to substrate specificity towards α-2,3- and α-2,6-linked sialylgalactosides 
the preference for NA is less certain than the case with HA. The α-2,3- linkage seems to 
be preferentially cleaved by both avian and human influenza A viruses though the α-2,6-
sialylgalactoside is also normally a substrate to some degree.107,130,131,132  
 
II.1.3. Influenza therapeutics 
Options are available for the alleviation of the impact of influenza infection, with anti-viral 
treatments and vaccines being the first choice. 
Vaccine production and vaccination are time consuming approaches with a limited shelf-
life for the vaccine itself as well as having an initial inoculation period of approximately 1 
month to be fully effective against the respective influenza strain/s. 
Moreover, the “antigenic drift” and “antigenic shift” of influenza viruses inevitably lead to 
the redundancy of vaccines after each subsequent season of infection which means that 
during a severe influenza outbreak, vaccination is often not an immediate preventitive 
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treatment option. The alternative to this strategy are anti-viral drug treatments, in 
particular NA inhibitors to combat influenza infection.91,103  
 
Many aspects of the influenza life cycle have been the target for chemotherapeutic 
intervention and accordingly, anti-influenza drugs and therapies can be divided into 
different classes depending on their mode of action. Some examples of which are 
outlined below. 
 
II.1.3.1. Neuraminidase inhibitors  
Targeting the NA function of influenza viruses has proved to be an effective strategy 
towards anti-influenza therapeutics (see figure 19).133 The neuramindase inhibitors work 
by interfering with the NA function of the influenza virus, preventing the successful 
release of viral progeny from infected host cells and thus preventing the further spread of 
infection.108  
 
 
 
Figure 19. The mode of action by Neuraminidase Inhibitors. Neuraminidase is not inhibited, 
allowing the continued replication of influenza and therefore infection (A). The replication is 
blocked by neuraminidase inhibitors which prevent virions from being released from the surface 
of infected cells causing virion aggregation (B). (Reprinted with permission from Massachusetts 
Medical Society (MMS); New England Journal of Medicine 2005, 353, 1363-1373.) 
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Such inhibitors are used as both prophylactics and therapeutics against all NA subtypes 
and by extension against all strains of influenza A and B viral infections.108  
The use of NA inhibitors comes with low toxicity and a decreased susceptibility to viral 
resistance. As such, NA inhibitors (oseltamivir, zanamivir and peramivir) are continually 
being developed and stockpiled as a first line of defence against future influenza 
outbreaks (see figure 20).108  
It is anticipated that the modes of inhibition displayed new types of NA inhibitors are 
altered significantly from those of the main (therapeutically used) NA inhibitors with 
respect to binding interactions within the neuraminidase active site. An example of which 
is the alternative hydrophobic binding approach of pyrrolidine-based NA inhibitors which 
render the C4 guanidino and amino substituents (of zanamivir and osetamivir 
respectively) obselete.134,135 Such compounds are therefore considered therapeutically 
useful as they may lack cross-resistance with the oseltamivir pharmacophore. 136,137,138  
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Figure 20.  Structures of common NA inhibitors. 
 
II.1.3.2. M2 protein blockers 
M2 protein inhibitors such as the amandatine-derivatives (amantadine and rimantadine) 
combat influenza infection by interfering with the M2-proteins’ role as a proton-channel 
(as previously mentioned, important in viral-host membrane fusion and viral replication) 
(see figure 21). These drugs are only active against influenza A viruses and though 
initially highly active, drug resistance to these inhibitors rapidly developed along with side 
effects relating to the CNS (central nervous system).97,133  
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Figure 21. Structures of common M2 protein blockers. 
 
II.1.3.3. IMP dehydrogenase inhibitors 
Inosine 5’-monophosphate (IMP) dehydrogenase inhibitors (see figure 22) target an 
important enzyme (IMP dehydrogenase) involved in viral RNA synthesis.133  
Though having showed limited activity towards treatment of influenza A (H1N1) infection, 
Ribavirin and Viramidine (a ribavarin prodrug) is active against the H5N1 influenza 
subtype and is used as a preferred therapeutic method to treat acute influenza viral 
infection. However, the high doses required often lead to the break down of red-blood 
cells.97,133 
 
 
 
Figure 22. Structures of IMP dehydrogenase inhibitors. 
 
II.1.3.4. RNA polymerase inhibitors  
This activity of this type of inhibitor is based upon the recognition of the pyrazine 
derivatives (for example, T705 and flutimide) as nucleobases (see figure 23), which after 
conversion to a triphosphorylated ribonucleotide, is postulated to inhibit the influenza 
viral RNA polymerase enzyme competitively.97 T705 has exhibited inhibitory activity 
towards influenza A, B and C in vitro and in vivo.133,97  
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Figure 23. Structures of RNA polymerase inhibitors. 
 
Other treatments under development for influenza viral infection include biological 
approaches such as, the application of interferons (natural proteins produced by the cells 
of the immune system) and siRNAs.97  
 
II.1.4. Oseltamivir: a neuraminidase inhibitor 
As mentioned above, the most widely used and applicable anti-influenza treatments are 
the NA inhibitors. The development of oseltamivir (as well as zanamivir, its forebear) was 
based upon successful structure-based inhibitor design methodology using the structural 
data of group-2 NA (and also NA of influenza B) obtained via X-ray crystallographic 
methods.124,125,129  
Developed by Gilead Sciences139,140,141 and marketed in a phosphate salt formulation by 
Hoffmann-La Roche under the trade name TamifluTM (the ethyl ester prodrug of 
oseltamivir carboxylate),142,76 oseltamivir was the first commercially developed orally 
active NA inhibitor for use against Influenza A and B viruses (see scheme 17).133  
 
 
 
Scheme 17. Oseltamivir, Tamiflu. 
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The mechanism of action displayed by these NA inhibitors is one of competitive inhibition 
within the NA active site. Oseltamivir mimics the proposed oxocarbenium intermediate 
formed during the enzymatic hydrolysis of the sialic acid receptor (at the glycosidic bond) 
by the by influenza virus neuraminidase (see scheme 18).133,107  
 
 
 
Scheme 18. Proposed mechanism of sialic acid hydrolysis by influenza NA. The enzyme active 
site stabilises the proposed oxocarbenium-intermediate. 
 
The proposed mechanism of sialic acid hydrolysis by influenza virus neuraminidase is 
based upon several important steps.107 The 2C5 chair conformation of the α-sialoside is 
distorted to that of a boat conformation through the interaction of the carboxylate moiety 
with an arginine triad within the enzyme active site. Protonation of the glycosidic oxygen 
leads to glycosidic bond breakage and the reaction proceeding through a proposed 
enzyme-stabilised oxocarbenium cation intermediate (half-chair conformation). This 
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oxocarbenium intermediate in turn reacts stereoselectively with H2O to generate α-sialic 
acid (which is then subject to mutarotation).143,144  
The effectiveness of oseltamivir (and structurally related molecules) to act as an inhibitor 
of influenza NA indicates that the formation of an oxocarbenium cation intermediate is a 
likely and important facet to the hydrolysis reaction at some stage during its 
progression.107  
Within the enzyme active site, interactions with oseltamivir are mainly electrostatic in 
nature and are primarily derived from the interaction of ionisable functional groups on the 
oseltamivir structural motif with charge-corresponding amino-acid residues (see figure 
24). 
 
N
H3N
O
O
OH
O
H2O
OH2
Arg 292
Arg 371
Arg 118
Asp 151
Glu 119
Glu 227
Trp 178
Arg 152
lle 222
Arg 224
Ala 246
Glu 276
Trp 178
 
 
Figure 24. Oseltamivir carboxylate interactions in the neuramindase active site. 
 
Of primary importance is the interaction between the negatively charged carboxylate 
group with the positively charged “arginine triad” (consisting of Arg 118, Arg 292 and Arg 
371). Of secondary importance is the interaction of the basic amino functionality (or 
guanidino functionality in zanamivir) with the negatively charged Glu 119, Glu 227 and 
Asp 151 residues. The remaining interactions are a result of a combination of hydrogen 
bonding, electrostatic and nonpolar interactions. These include the pentyl chain of the 
ether group with the residues Ile 222, Arg 224, Ala 246 and Glu 276 (hydrophobic 
contributions) and the hydrogen bond-donating and hydrogen bond-accepting 
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interactions of the charged amino and acetamido functionalities under physiological 
conditions.133,107  
 
II.1.4.1. Oseltamivir vs. influenza virus: emerging resistance  
The highly conserved nature of NA active sites across various influenza strains and 
subtypes mean that the potential mutation of active-site amino acid residues would 
compromise NA activity and therefore reduce the replicative viability of the virus. 
However some active site mutations which render NA less susceptible to NA inhibitors 
are known to occur. 
Some known point mutations which are known to occur in both group-1 and/or group-2 
NA and correspond to mutations (isolated from influenza viruses) which show a high to 
intermediate level of resistance to oseltamivir include; 1) His274Tyr (H5N1, H1N1) 2) 
Asn294Ser (H3N1, H5N1) 3) Glu119Val (H3N2) 4) Arg292Lys (H3N2) 5) Tyr252His 
(H5N1) 6) Asn294Ser (H3N2, H5N1). 103,145,133 
It seems logical that mutations in the active site residues involved in substrate binding 
can generate resistance to NA inhibitors. In particular, the mutations His274Tyr and 
Asn294Ser have been shown to reduce the inhibition caused by oseltamivir with respect 
to group-1 NA and a similar effect has been observed with the Arg292Lys mutation in 
group-2 NA.103,102,145  
It is worth mentioning that zanamivir resistant influenza strains (for example, containing 
the mutation Arg292Lys as observed in H3N2) are uncommon to date. It has been 
speculated that this is because of the poor viability of viruses in receipt of this 
mutation.133,145  
With regards to the His274Tyr mutation, this oseltamivir resistant trait has been found to 
be more readily transmissible than other NA active site mutations.133 This is supported 
by the WHO, whose reports state that oseltamivir resistance observed in influenza virus 
strains remains mainly limited to seasonal H1N1 viruses with the His274Tyr mutation 
being the common resistance mutation in circulation.146,147  
It has been suggested that this mutation alters a hydrophobic pocket within the enzyme 
active site (essential for oseltamivir binding).103  
The fact that oseltamivir resistant mutations have also been found in resistant (and fatal) 
H5N1 influenza virus strains are a cause for concern. If mutations such as His274Tyr 
become common in avian H5N1 then the reasoning for using and stockpiling oseltamivir 
would be compromised.  Studies also suggest that these mutations remain viable and 
stable in nature in the many subtypes of viruses where they are expressed (that is, their 
pathogenicity is not detrimentally affected).102,103,133  
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II.1.4.2. Syntheses of oseltamivir 
The use of oseltamivir as the NA inhibitor of choice for the treatment of influenza 
infection globally comes as a result of its superior bioavailability and all-round efficacy 
against influenza strains compared to its nearest competitors (zanamivir, peramivir).133 It 
is produced annually on a several hundred metric tonne scale with sales in excess of $2 
billion.  
The current industrial synthesis of oseltamivir (see scheme 19) by Hoffman-La Roche 
makes use of (-)-shikimic acid as starting material and in a 10 step sequence (overall 
yield 35%) to generate oseltamivir phosphate (Tamiflu).76,142,148,149  
In brief, the synthesis proceeds via a 3,4-pentylidene 5-mesylshikimate derivative of (-)-
shikimic acid, which is then regioselectively reduced to the 4,5-epoxide intermediate. 
Stereoselective epoxide-opening results in the formation an aziridine derivative which is 
subsequently converted to the acetamido-azide derivative. Reduction of the azido-
functionality, followed by formation of the phosphate salt gives oseltamivir phosphate. 
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Scheme 19. Industrial Tamiflu synthesis. 
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There have been many synthetic endeavours, from both academic and industrial 
laboratories towards refining and improving the synthesis of oseltamivir, some of the 
reasons for which include; 1) the limited availability of the shikimic acid starting material 
(isolated naturally from star anise (Illicium verum) or produced via recombinant E.coli), 2) 
the economic benefit gained from improved synthetic routes which are both economically 
and chemically efficient and 3) the recent emergence of a influenza virus pandemic 
strain (H1N1 “swine flu”) and the potential threat from avian H5N1 (“bird flu”). 
Oseltamivir, though a small molecule, is densely functionalised and as such has posed a 
difficult synthetic target for laboratories specialising in natural product chemistry and total 
synthesis. As such, some interesting chemistry has been utilised recently towards 
oseltamivir synthesis.150,151,152  
 
II.1.4.3. A synthetic strategy towards phospha-isosteres of oseltamivir  
The phosphonate moiety is often used as a bio-isostere of carboxy-functional groups in 
drug design and synthesis and has been used in the synthesis of sialic acid 
phosphonate congeners.153-157  
Though first reported by Shie et al., the synthesis of the phosphonate congener of 
oseltamivir was heavily inspired by previous synthetic investigations by Streicher et al. 
based on a synthesis utilising chiral D- and L-xylose precursors153-155,158 and in a later 
synthetic approach via an azide-free synthesis.159  
The synthesis of the phosphonate congener of oseltamivir has been shown 
experimentally to be more potent than the original carboxylate congener against wild-
type NAs of H1N1 and H5N1.158  
In molecular modelling and docking studies, phospha-oseltamivir exhibited a slightly 
stronger contribution to electrostatic binding within the enzyme active site which is 
attributed to the extra negative charge it presents and as such suggests a reason for its 
slightly increased potency.127  
Recent work in the Streicher lab has resulted in the development 67,160,161 of an efficient 
synthesis of the cyclohexenephosphonate scaffold from chiral pool precursors via two 
key steps (see scheme 20); a modified Hunsdiecker-Barton iododecarboxylation and a 
Pd-mediated phosphite (Hiaro reaction) coupling step for the introduction of the 
phosphonate functionality.  
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Scheme 20. The two key synthetic steps towards phospha-isosteres of oseltamivir. 
 
These two key steps provided access to various phospha-isosteres of oseltamivir, 
including the phospha-isostere of oseltamivir carboxylate itself, “tamiphosphor” or 
“phospha-oseltamivir”.  
These phospha-isosteres are derived from the industrial oseltamivir “acetamido-azide” 
precursor, where a phosphonate or phosphonate monoester replaces the carboxylate 
without impairing the potency of the oseltamivir pharmacophore.67   
The monoester strategy developed by Streicher et al. allowed structural modification at 
the phosphonate ester and thus enabled the synthesis of a set of structurally diverse 
monoesters which retain the negative charge essential for activity under physiological 
conditions (see figure 25).67,161 As such, the pharmacophore was not compromised and 
all monoesters exhibited subnanomolar inhibition in the range of oseltamivir carboxylate. 
Of particular interest were the Phospha-oseltamivir derivatives synthesised as 
chemically stable mimetics of α-2,3- and α-2,6-linked sialylgalactosides which 
highlighted the preferential binding of certain NA subtypes to sialic acids of varying  
anomeric linkage to the underlying carbohydrate moiety.  
In the absence of structural data, inhibition values for the sialoside mimetics cannot be 
directly correlated with substrate specificity of the virus. However, the inhibition values 
obtained indicate that the ratio between the respective inhibition constants (of the 
sialoside mimetics) should show some form of proportionality to the ratio of the binding 
constants of the respective α-2,3- and α-2,6-linked sialylgalactoside substrates.161 
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Figure 25. Previous NA inhibitors synthesised by Streicher et al.;67,161 phospha-isosteres of 
oseltamivir which retain the potency of the oseltamivir pharmacophore. (*for influenza 
A/Norway/1758/07 (H1N1)). 
  
85 
 
II.1.5. The concept of multivalency to achieve stronger binding 
Qualitatively, multivalency can be employed for the achievement of strong ligand binding 
to a target substrate through the use of multiple ligand interactions. Such multivalent 
systems are known to often exhibit enhanced binding potency in comparison to 
monovalent ligands for a particular system. For a multiple-ligand displaying system the 
observed enhancement of interaction must be expressed on a “valence (ligand) 
corrected basis”.162 Put another way, it can be expressed as “a relative potency per 
ligand” compared to the monovalent analogue.163  
In biology, multivalent interactions are the foundation of many essential biological 
processes and interactions and a wide array of responses (as a result of multivalent 
binding) in biological systems are produced (for example, cellular activation, migration, 
and differentiation).164,1  
Synthetic multivalent ligand systems can be used to probe and interfere with such 
biological processes by acting as inhibitors or effectors of specific biological processes. 
Because of the increased complexity with which a multivalent ligand system can interact 
with a specific target in comparison to monovalent ligands, the mode of action attributed 
to a multivalent system can be tailored and optimised by altering the multivalent 
architecture of the ligand system.165  
The functioning of a multivalent system as an inhibitor results from the multiple 
presentation of specific ligands to a target which bind (ideally) with specificity and high-
avidity. In comparison, the functioning of a multivalent system as an effector results from 
the inducement of a specific biological response in the target system (for example, 
clustering of biological macromolecules).165  By changing the parameters of a synthetic 
multivalent system, the interaction and activity of that system with target is altered 
accordingly.165,163  
 
A good example of multivalent processes include carbohydrate-protein interactions, 
which are categorised by multiple copies of (individually) weak binding glycans exerting 
a stronger carbohydrate-protein binding interactions through high affinity multimeric 
interactions.163,164 This enhancement of ligand activity (in comparison to monovalent 
glycans) is referred to as the “cluster-glycoside effect”.162  
Multivalent ligands systems have been touted as providing new tools for the investigation 
of various biological problems and even potential drug-leads towards human diseases 
and infections where multivalent interactions play a role in the onset of sickness.166 
Common synthetic multivalency platforms in use include multivalent inhibitors based on 
functionalised organic frameworks (di-, tri-, tetra-, multi-), polymer architectures such as  
dendrimers, linear and branched polymers and nanoparticles.163 
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II.1.5.1. Mechanisms of binding enhancement 
The mechanisms by which multivalency exerts influence in biological systems are many 
and by no means is this section a thorough quantitative review of multivalent binding 
interactions. For illustrative purposes with regards to generic carbohydrate-protein 
binding interactions, multivalency mechanisms fall into two main classes; chelation 
effects and statistical (or proximity) binding effects.163  
 
II.1.5.2. Chelation effects 
Chelation effects (see figure 26) are dependent on a target substrate possessing 
multiple ligand binding sites which can bind to a multivalent ligand-presenting platform. 
The binding potency of subsequent ligand interactions (compared to the initial ligand 
binding event) are enhanced as entropic penalties of interaction are accounted for on 
initial ligand binding, albeit whilst incurring a minor conformational entropy cost.162,164,166  
Where chelation effects are observed to increase the binding potency of a multivalent 
ligand system, enhancements in binding in the order of 103-106 have been observed. 
However, chelation effects are heavily dependent on the spacer functionality between 
the respective functionalised ligands (orientation and distance).163  
 
II.1.5.3. Statistical rebinding 
Statistical (or proximity) binding effects (see figure 26) are best exemplified by statistical 
rebinding mechanisms which have multivalent origins. This binding mechanism arises in 
situations where only a single binding site is available for ligand-target interaction due to 
limitations of the spacer functionality. The spacer limitations thus prevent ligand 
interaction with other potential binding sites. Despite the physical binding limitation 
placed on the ligand system, multivalency effects are still observed and are attributed to 
the differences in binding rates between monomeric ligands and ligands as part of a 
multivalent platform. A net-increase in ligand affinity is observed for multivalent systems 
as a result of the slower dissociation rate (or “off-rate”) compared to monovalent 
ligands.163 This decreased “off-rate” is a consequence of the increased proximity of other 
ligands which can undergo a binding interaction after the initial ligand dissociation.163 
Non-chelation effects are typically regarded as weaker multivalent interaction 
mechanisms where chelation binding is effective.   
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Figure 26. Simple mechanisms of ligand binding; (A) Monovalent binding, (B) divalent ligand 
binding via chelation and (C) divalent ligand binding via statistical rebinding. Adapted from; 
Organic and Biomolecular Chemistry 2009, 7, 2013-2025. 
 
II.1.6. Multivalency with regards to influenza 
Monomeric sialic acids are bound by the HA with high selectivity but only with low 
affinity, as it is typical for carbohydrate-protein interactions.167  Indeed, the interaction 
between the sialylated receptor determinants and the HA active site are considered 
weak.86  As such, the interactions between the influenza HA and its sialylated receptor 
determinants is based upon the multivalent, cooperative interaction of sialylated glycans 
binding to the HA binding site. The high-avidity, multivalent nature of the interactions 
therefore compensate for the individually weak binding sialylated receptor 
determinants.121,166  
 
II.1.6.1. Synthetic platforms towards multivalency inhibitiors of Influenza virus HA 
and NA 
With regards to the application of synthetic multivalent platforms towards influenza 
viruses, the HA has been the main target for approaches using multivalent ligands as 
chemical probes or anchors for diagnostics and as possible therapeutic agents, for 
example, ‘anti-adhesion therapy’ (the inhibition of viral adhesion to the host cell with by 
A 
B 
C 
88 
 
employing a soluble receptor analogue)168 mainly because of the abundance of HA on 
the viral surface and its natural affinity for accessible sialic-containing derivatives.166  
Since the early 1990’s, synthetic work towards multivalent sialoside inhibitors/effectors 
have been undertaken. The outcome of the majority of this research, particularly towards 
a multivalent therapeutic has been on the whole moderate.86,169  
Although selective binding and relatively high affinities have been obtained in many 
instances (as a result of the “glycoside cluster effect”), such approaches suffer from 
intrinsic disadvantages that come with the use of sialic acid as the ligand, for example; 1) 
susceptibility of O-sialosides to chemical and enzymatic hydrolysis, 2) the low affinity of 
sialic acid as a monovalent receptor, 3) the potential for cross-reactivity with other 
biological sialic acid processing machinery.  
Below are some examples of multivalent systems which have been applied towards 
influenza viruses. 
 
II.1.6.2. Multivalent sialic acid derivatives: low molecular weight scaffolds 
A common approach towards HA inhibitors of influenza viruses are based on low 
molecular weight scaffolds of increasing multivalency. The inhibitory activities 
(determined from Hemagglutination inhibition assays) of divalent compounds (see figure 
27) presenting α-sialosides were found to be heavily dependent on linker (spacer) length 
between the sialoside moieties, with longer linker lengths (~50Å) of moderate 
conformational restriction being relatively successful, with binding localised to individual 
virions HAs (non-clustering effects).170  
 
 
 
Figure 27. Example of a dimeric α-O-sialoside. 
 
Another example of multivalent inhibitors of increasing valency includes α-sialoside 
presenting tetra-antennary peptides (see figure 28). These compounds exhibited binding 
to influenza virus and were able to inhibit viral adhesion 103 times more effectively than 
the native receptor, sialic acid.169  
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Figure 28. Example of a tetravalent O-sialoside. 
 
Other multivalent frameworks have also been used to increase the number of ligands 
presented by organic structures, a recent example for that are calixarenes.171 
Calix[4]arene based S-sialoclusters (tetra- and octa-valent) have been shown to inhibit 
influenza virus adsorption (and as such, viral infectivity) to host cells at submillimolar 
concentrations (see figure 29). It has been speculated that the moderate results 
observed with these scaffolds come as a consequence of the “glycoside cluster 
effect”.172  
 
Figure 29. Example an octavalent calixarene scaffold functionalised with α-S-sialosides (red). 
 
Inhibitors of increasing valency bound to relatively small organic frameworks highlight 
the importance of sialoside orientation and the distance between ligand functionalities in 
order to maximise binding to influenza viruses.169  
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II.1.6.3. Multivalent sialic acid derivatives: polymeric scaffolds 
As with di- and tetra-valent scaffolds, early synthetic research towards sialic-acid 
functionalised polymers and dendrimers applied towards influenza virus research and 
therapeutics began in the 1990’s.169  
Dendrimers (typically globular, branched oligomers) are hyperbranched scaffolds which 
allow the multiple presentation of various ligand types, including α-sialosides.173  Sialic 
acid decorated dendrimers have been shown to prevent erythrocyte agglutination (via a 
Hemagglutination inhibition assay) in the presence of influenza A (X31, H3N2) in the 
micromolar range.173 The use of contrasting dendrimer architectures has led to observed 
differences in influenza (H2N2 and H3N2) hemagglutination inhibition (up to 5 x 104 
times greater than Neu5Ac) and showed a dose-dependent reduction in influenza 
infection in vitro (see figure 30).174  
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Figure 30. Examples of contrasting dendrimer architectures which exhibit inhibition of influenza 
virus (H2N2 and H3N2) via hemagglutinin binding. 
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More recently, the application of dendrimer-based nanoparticles has been applied 
towards influenza virus with the aim of developing “anti-adhesion” therapeutics (see 
figure 31). Hyperbranched polyglycerols are dendritic polyether-polyols (water-soluble) 
which when functionalised with α-sialosides (O- and S-sialosides) inhibited influenza A 
virus (X31) binding and fusion up to 80% (using nanoparticles of diameter ~100 nm). 
The optimisation of ligand density and nanoparticle size to match that of the influenza 
virus size and receptor multiplicity were found to be essential for good inhibitory activity. 
This ensured that biological surface interactions closely resembled multivalent binding 
events involved in virus-cell surface binding.175 
 
 
 
 
Figure 31. Schematic representation of dendrimer-based nanoparticles used to inhibit influenza 
viral infection. (Reprinted with permission from Wiley-VCH Verlag GmbH & Co. KGaA; 
ChemBioChem 2011, 12 (6), 887–895.) 
 
HA inhibitors based on polymeric α-sialoside-functionalised architectures have been 
developed over last two decades. Synthetic backbones, typically amorphous linear 
polymers the majority of which being copolymers of acrylic acid esters176,177 copolymers 
of acrylamide esters178,176 or other backbones.179  
Generally, polymeric sialic-acid bearing systems exhibit millimolar to nanomolar 
inhibition of hemagglutination by influenza viruses when the scaffold structures are 
optimised, particularly, the chemical structure and topology of the ligand, its content in 
the polymer, and the structure of the polymer side chains.177,176  
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Polyacrylamide structures have tended to show greater inhibitory activity than highly 
branched dendrimeric structures but biological toxicity of the former is a concern.169 The 
inhibitory activity of large polymeric multivalent platforms has been attributed to the 
“glycoside cluster effect” but also achieved through the steric stabilisation of the 
influenza virus surface or via changes in solution viscosity and viral particle 
aggregation.169  
More recently, a rapidly synthesised (1-step) polymeric chitosan functionalised with 
sialylated glycans (for example, free sialyl glycan (FSG)) has shown inhibitory activity 
against influenza virus infection (micromolar IC50 values obtained in inhibition assays 
with influenza A H1N1) in comparison to free glycans (see figure 32).180  
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Figure 32. FSG-chitosan polymer, which exhibits inhibitory activity against influenza virus 
infection. The constituent parts of the polymer are highlighted; the terminal sialic acids (red), the 
underlying glycan structure (black) and the chitosan polymer backbone (blue). 
 
II.1.6.4. Multivalent sialic acid derivatives: other scaffolds 
Though not strictly speaking multivalent scaffolds in the same vein as those presented 
previously, recent examples have made use of multivalent α-sialoside-mediated 
interactions with influenza for the development of influenza detection methods. A biotin-
labeled biantennary scaffold functionalised with α-sialosides (see figure 33) has been 
used to develop a reporter assay (based on the sandwich immunoassay method) using 
glycans only rather than virus-specific antibodies. The well-known biotin-
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avidin/streptavidin interaction181 can therefore be used to immobilise the α-sialoside 
biantennary structure and through multivalent interaction with influenza HA, immobilise 
influenza virus.  The position of ligand, orientation, density, linker length and ancillary 
groups influence the binding and selectivity to influenza.120  
 
 
 
Figure 33. Biotin (blue)-labelled biantennary scaffold functionalised with a α-S-sialosides 
containing glycan (red). 
 
II.1.6.5. Multivalency and influenza therapeutics: targeting the NA 
With regards to the targeting of the HA of influenza viruses, to date no multi- or 
polyvalent α-sialoside scaffolds are used therapeutically for the treatment of influenza 
viral infection. This is due mainly to inconsistency problems and problems with the 
pharmacokinetics of polymer-based systems.169,168  
Many of these problems can be attributed to those outlined above regarding multivalent 
approaches to HA targeting. Though some problems associated to these approaches 
can be overcome (for example the use of S- and C-sialosides instead of O-sialosides)86 
the essential problem, that of increasing monovalent ligand affinity towards the HA, has 
remained challenging. 
 
II.1.6.6. Multivalent sialylmimetics: low molecular weight scaffolds 
Whilst the NA has so far prevailed against the HA as drug target it has not been utilised 
as frequently as a target for “anti-adhesion therapies”, mainly as a result of the non-
participation of NA in viral hemagglutination.170  
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Multivalency concepts have been applied to NA inhibitor scaffolds (mainly zanamivir) in 
the same vein as small organic molecule scaffolds (low molecular weight clusters) and 
polymeric scaffolds.182,183 The inhibitory potency and affinity of these sialylmimetics 
towards NA is significantly greater than the corresponding affinity of α-sialosides for HA 
and hence their appeal in multivalent applications. 
The synthesis of divalent NA inhibitors based on the zanamivir structure (optimum linker 
length ~20Å, ~10-18 methylene linker units)184 have shown in vitro and in vivo inhibition 
of influenza virus replication and were found to be approximately 100-fold more active 
than monovalent zanamivir (see figure 34). However, NA inhibition levels were 
compromised slightly. As such, improved influenza inhibition is attributed to multivalency 
effects (viral cross-linking and clustering) rather than improved NA inhibition.184,185 Such 
divalent inhibitors have exhibited a longer retention time and greater efficacy and thus 
potentially offer a low-dose therapeutic treatment for influenza infection.96,184,185,186  
 
 
 
Figure 34. Examples of dimeric zanamivir structures. 
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A recent multivalent inhibitor presenting tetravalent zanamivir upon a porphyrin scaffold 
has shown decreased activity towards NA inhibition but inhibits influenza virus replication 
approximately 100 times more potently than monovalent zanamivir (see figure 35). 
The enhanced inhibition activity has been attributed to a photosensitisation process 
causing NA inactivation directly, as well as multivalency effects.187  
 
H
N
N
N
H
N
OO
O O
O
CO2AcHN
NH
HO
H2N NH2
O
HO
O
NH
N
NN
N
CH2OCH2
O
H 4
R
RR
R = Zanamivir conjugate + spacer
 
 
Figure 35. A tetravalent zanamivir-porphyrin structure. The zanamivir conjugate (red) and spacer 
(blue) and porphyrin scaffold (black) are highlighted.  
 
II.1.6.7. Multivalent sialylmimetics: polymeric scaffolds 
A recent example of zanamivir conjugated to poly-L-glutamine via a flexible linker (see 
figure 36) exhibits inhibition of group-2 NA influenza strains (both oseltamivir and 
zanamivir resistant) and wild-type viruses up to approximately 2 x 104 greater than 
monovalent zanamivir (during the plaque reduction and binding affinity assays). It is 
speculated that the polyvalent presentation of zanamivir compensates for reduced NA 
inhibition by monovalent zanamivir with resistant influenza strains.188  
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Figure 36. Polymeric (poly-L-glutamic acid) zanamivir. The zanamivir scaffold is highlighted (red).  
 
II.1.6.8. Multivalent sialylmimetics: other scaffolds 
Zanamivir appears the more applicable NA inhibitor for use in multivalent inhibitor 
platforms (as a result of the ease in conjugation without significant pharmacophore 
compromise). Oseltamivir functionalised materials are rare. An example of the use of the 
oseltamivir scaffold in a multivalent fashion is the attachment of the oseltamivir scaffold, 
modified at the traditional pentyl-ether linkage, to solid-phase resin beads (see figure 37) 
for application to affinity chromatography (towards influenza virus isolation and 
purification). Only minor binding events were observed with H1N1 NA but were not 
quantified. The lack of effective multivalent interactions and subsequent influenza 
binding is more likely a result of the compromised oseltamivir pharmacophore, resulting 
in a greatly reduced binding affinity to influenza NA.189  
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Figure 37. Immobilised oseltamivir analogue. The oseltamivir core is linked to an affinity-
chromatographic resin via a short methylene spacer (right). Unfunctionalised oseltamivir (left) is 
shown for comparison. Adapted from; Tetrahedron Letters 2009, 50, 3205-3208. 
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II.1.7. Nanoparticles 
Nanoparticle research has developed into a broad scientific discipline over the past two 
decades.190  
The significant interest generated by nanoparticle platforms comes as a result of the 
unusual physical and electronic properties and as a result of their structure, particularly 
“quantum size effects” (vide infra). Nanoparticle suspensions are best described as 
colloidal systems, though they are at the lower end of the colloidal range (1nm - 1µm) 
(see figure 38).191  
 
 
 
Figure 38. The size scale of nanoparticles. (Reprinted with permission from Elsevier; Biochimica 
et Biophysica Acta (BBA) 2006, 1760, 636 - 651.) 
 
A common method of inorganic nanoparticle stabilisation is the functionalisation of the 
metal surface with organic ligands, akin to self-assembled monolayers of 2D 
surfaces.192,193  
Self-assembled monolayers (or the ligand shell) simultaneously stabilise the nanoparticle 
surface (preventing core agglomeration) and present chemical functionality at the 
particle-solvent interface. As such, properties of nanoparticles are heavily determined by 
the nature of the surrounding ligand shell.193,194  
Inorganic nanoparticles have been constructed from a variety of elements and are not 
restricted to any particular metal. However, gold has become a standard platform for 
nanoparticle applications. It is a reasonably inert metal, is widely studied and is widely 
used as a platform in other spectroscopic and analytical methods.193  
As a consequence of the widespread use of gold as the nanoparticle core, sulfur-
containing stabilising ligands (alkylthiolates derived from thiols or disulfides) are most 
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commonly used as the stabilising ligand shell because of the thiophillic nature of 
gold.193,195  
Nanoparticles have emerged as a popular scaffold for the presentation of multiple copies 
of bioactive motifs en route to developing novel tools and sensors for investigation 
biological systems and processes.  Of particular interest to this project has been the use 
of nanoparticles as probes for the study of carbohydrate–protein and carbohydrate–
carbohydrate interactions, providing an alternative to traditional multivalent ligand 
presenting platforms. This comes as a result of the advantage of using nanoparticle 
platforms to investigate multivalency effects as the three-dimensional globular structure 
can be used as a model system for the dense glycan coverage found on cell 
surfaces.196,197,198  
The properties of gold-nanoparticles (on account of their low-level of cellular toxicity)193 
in particular have led to many developments towards applications in towards biology and 
medicine, some recent examples of which include; cellular imaging,199 antibacterial 
agents200 and potential therapeutics and therapeutic delivery agents.201,202  
 
II.1.7.1. Gold nanoparticles: quantum size effect 
The physical properties of nanoparticles occupy a middle ground between that of bulk 
materials and molecular compounds and reflect the electronic band structure of 
nanoparticles of this size as predicted by quantum-mechanics, that is, unlike bulk metals 
there is a distinction between the valence and conduction bands. When the de Broglie 
wavelength of the valence band electrons is the same order as the nanoparticle size, 
then nanoparticles behave electronically as zero-dimensional “quantum dots”.195  
It is in part the behaviour of these zero-dimensional “quantum dots” which give rise to 
novel size- and shape-dependent optical and electronic properties (along with a high 
surface/volume ratio and varied surface functionalisation) which give nanoparticles their 
interesting properties and has led to many potential applications of colloidal 
nanoparticles (in comparison to bulk materials).203,190 
 
II.1.7.2. Gold nanoparticles: bonding  
The nature of bonding between the stabilising sulphur-terminated ligands and the gold 
core is complicated but can be broadly categorised as thiolate-gold interactions of 
significant covalent character.204,195 Experimental evidence suggests that the formation 
of gold nanoparticles from thiols- or disulfides yield a monolayer coating of equivalent 
structure.193  
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However, this bonding picture does indicate a significant degree of charge transfer from 
the gold to the sulphur moiety and not strictly speaking a gold (AuI) sulphide 
interaction.193,195  
The surface stabilisation by sulphur-terminated ligands is a reversible process (energy 
barrier approximately -30 kcal/mol) and place-exchange reactions by other sulphur 
terminated ligands are possible though the process is not facile (vide infra).193 
Although the thiolate-bonding model is widely held, experimental and theoretical 
investigations into small gold-nanoparticle structures (less than 2 nm in diameter) have 
developed a bonding picture of greater complexity. Stabilising ligands are bonded to 
surrounding ligands and gold atoms in a bridging co-ordinated fashion. It is also 
apparent that the nanoparticle gold atoms are not strictly part of the core but exist as 
discrete co-ordinated “staple” structures as part of nanoparticle superstructure. Though 
this bonding picture has not been proved or developed for larger gold 
nanoparticles.205,190  
Other stabilising ligands with different functionalities to sulphur are known to stabilise 
gold nanoparticles. These include amines, phosphines, and carboxylates. However, 
these interactions are known to be weaker (thermodynamically)206 than the Au-S 
interaction (approximately -50 kcal/mol) and often the stability of other terminating 
ligands comes as a result of kinetic stabilisation only.195,207  
 
II.1.8. Gold nanoparticle synthesis and characterisation 
The two most widely applied methodologies for the synthesis of gold nanoparticles are; 
1) the in situ synthesis of gold nanoparticles from the reduction of AuIII by a reducing 
agent in the presence of a suitable sulphur-containing ligand (the Brüst-Shiffrin 
method)208,209 or 2) the synthesis of pre-formed gold nanoparticles from the reduction of 
AuIII by a mild reducing agent (the Turkevitch method) followed by ligand-exchange 
reaction upon the gold surface with thio-functionalised ligands.210  
With regards to the Brüst-Shiffrin method, nucleation and gold cluster formation is 
achieved by rapid addition of reducing agent, whereas gold nanoparticles produced by 
the Turkevitch method rely upon the decomposition of the AuIII precursor at elevated 
temperatures.193  
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II.1.8.1. Brüst-Shiffrin method 
The Brüst-Shiffrin method allows the rapid synthesis of gold nanoparticles of reduced 
size and polydispersity, with particle diameters typically ranging from approximately 1 to 
10 nm (depending on reaction conditions and reagents).195  
The limitation to small nanoparticle size distributions comes as a result of the slow rate 
of desorption of thiolate ligands on gold. The binding of thiolate ligands to the gold 
surface retards the growth of the surface through the stabilising influence of the ligands, 
thus defining nanoparticle size. The size of the nanoparticles obtained by this method 
can be altered therefore by the Au:thiolate-ligand ratio used and also by controlling the 
temperature and the rate at which the reducing agent (commonly sodium borohydride) is 
added. The manipulation of these variables alters the rate at which the gold precursors 
nucleate and grow to form nanoparticle clusters.195,193,211  
Originally based on a two-phase transfer method, initially involving the reaction of auric 
acid with tetraoctylammonium bromide (TOAB) followed by thiol or disulfide nanoparticle 
functionalisation,208 the Brüst-Shiffrin method was thought to follow this simplified 
reaction pathway; 1) The reduction of the AuIII precursor to AuI by the stabilising ligand, 
2) the formation of an AuI polymeric structure bridged by thiolate-sulphur atoms and 3) 
the further reduction (by sodium borohydride) of the AuI-SR to Au0 and the formation of 
stabilised gold clusters (see figure 39). 
 
(1) AuIII + 3SR  AuISR + RSSR 
 
(2) nAuISR  (AuI / SR)n polymer 
 
(3) 4(AuI / SR)n + nBH4-  Aux(SR)y + 2nH2 
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Figure 39. Simplified schematic depicting of gold nanoparticle synthesis via the Brüst-Shiffrin 
method. Numbers (1), (2) and (3) refer to the stages in nanoparticle synthesis as given by the 
equations above. Adapted from; Chemistry: A European Journal 2010, 16, 1459-1463. 
 
Recent research has demonstrated that this mechanistic picture is misleading when 
applied to the original two-phase Brüst-Shiffrin method as AuI polymeric structures are 
not observed (by NMR) and that AuIII and AuI tetraalkylammonium ([AuX2][NR4] and 
[AuX4][NR4])  species are the precursors present in solution prior to the addition of 
reducing agent (see figure 40).212  
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Figure 40. Simplified schematic depicting of gold nanoparticle synthesis via the Brüst-Shiffrin 
method including the formation of Au-tetraalkylammonium species.  
 
Moreover, current research has corroborated this mechanistic correction (via 
Raman/DLS spectroscopy) and has indicated the formation of reverse-micelle structures 
in solution prior to reducing agent addition. These reverse-micelles encapsulate water 
and as such act as the repositories for the intermediate gold tetraalkylammonium 
species. Thiolate functionalisation of Au0 subsequently proceeds (on the addition of 
reducing agent) via ligand diffusion through the micelle structure resulting in the 
formation of discrete Au-S bonds.213  
The original Brüst-Shiffrin method has been modified by carrying out the reaction in 
MeOH or MeOH/water mixtures and can tolerate considerable variation in stabilising 
ligand functionality beyond simple alkylthiol species in order to produce gold 
nanoparticles with the necessary attributes (for example, water solubility) for biological 
applications.209,214-217  
The use of ligands with ionisable groups often provides an electrostatic barrier to gold 
nanoparticle formation with irreversible aggregation of gold observed on the addition of 
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reducing agent.  The decrease of solution pH during nanoparticle synthesis prevents 
core-core coalescence and is an essential adjustment to the Brüst-Shiffrin method when 
water-soluble gold nanoparticles are desired.214 Mechanistically, the Brüst-Shiffrin 
method is believed to follow the originally proposed pathway in highly polar solvents (that 
is, the formation of intermediate AuI polymeric structures as single-phase nanoparticle 
precursors). This is attributed to the prevention of gold-quaternary cation ion-pairs 
formation through solvent coordination effects.212  
 
II.1.8.2. Turkevitch method with ligand-exchange 
The Turkevitch method (and Ligand-exchange) is generally considered the more popular 
method of gold nanoparticle synthesis190 because of the larger diameter, lower 
polydispersity and heterogeneity of the nanoparticles produced (in comparison to the 
Brüst-Shiffrin method). It is based upon the formation of gold nanoparticles stabilised by 
weakly bound citrate molecules. The resulting gold colloid is stabilised via the 
electrostatic interaction between the citrate and the gold surface, however the 
stabilisation process initially requires elevated temperatures.195 Maintaining elevated 
temperatures is critical to nanoparticle synthesis. Reducing the temperature during 
synthesis causes irregular shapes and larger diameters in the gold nanoparticles 
obtained.218  
The ratio of the reducing agent (usually trisodium citrate) and AuIII precursor is used to 
generate nanoparticles of approximately 10-20 nm in diameter. 
The faster rate of desorption of weaker citrate co-ordinating ligands in comparison to the 
thiolate-ligands of the Brüst-Shiffrin method leads to larger nanoparticle sizes.193  
A recent mechanistic suggestion for gold nanoparticle synthesis by the citrate reduction 
method includes the following mechanistic processes (see figure 41); 1) a ligand 
exchange process with citrate, 2) a rate-determining ring-closure step where 
decarboxylation and AuIII to AuI reduction occur and 3) the disproportionation of AuI 
species which subsequently form the Au0 core of the nanoparticles.219  
The dicarboxyacetone formed is believed to form an extended molecular complex with 
AuI species in solution and as such is heavily implicated in the disproportionation 
process. More specifically, it is suggested that the balance between the rate of Au0 
nucleation and dicarboxyacetone degradation (generating acetone and carbon dioxide) 
affects the nanoparticle size obtained during the reaction, as well as the initial citrate/Au 
ratio.220,219  
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Figure 41. Proposed mechanism towards the formation of gold nanoparticles by the reduction of 
AuIII salts by trisodium citrate (Turkevitch method).  
 
The loosely-affiliated citrate molecules which stabilise the gold core can be exchanged 
for stabilising ligands which have a greater affinity for gold (thio-functionalised ligands) 
and in this way the citrate can be exchanged from the nanoparticle surface. The 
exchange reaction can be assumed to reach completion with the use of excess 
stabilising ligand.190  
The main advantage offered by this technique is that gold nanoparticles can be rapidly 
functionalised displaying various ligand functionalities without impairing the 
characteristics of the gold core, which is a synthetic issue for the Brüst-Shiffrin 
method.196  
 
II.1.8.3. Place exchange reactions: further functionalisation 
Alkylthiolate-stabilised gold nanoparticles can be subject to further place-exchange 
reactions by other sulphur-containing ligands after initial functionalisation. As such, 
place-exchange reactions open up gold nanoparticles to further functionalisation. 
The rate of ligand exchange is heavily dependent on the nature of the ligands involved, 
more specifically, the ratio between the incoming- and outgoing-ligand, the linker lengths 
and steric bulk of the incoming- and outgoing-ligand.195  
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Experimentally it has been determined that ligands bound at vertices and edges of gold 
nanoparticles have higher rate of exchange than ligands bound at planar faces221 and an 
increased exchange rate is also observed with increasing positive charge on the 
nanoparticle core.222  
Alkylthiolate place-exchange reactions have a characteristic 1:1 stoichiometry, are based 
on an associative mechanism, yield the displaced ligand in solution as a thiol and are 
known not to involve disulfides or oxidized sulfur species.204  
 
II.1.9. Characterisation of gold nanoparticles 
II.1.9.1. Gold nanoparticles: size and shape 
Gold nanoparticles stabilised by thiolate ligands tend to adopt a roughly spherical shape 
with the exception of small nanoparticles (<1 nm diameter), which tend to exhibit 
octahedral or cubo-octahedral morphologies. The roughly spherical shape adopted by 
larger gold nanoparticles comes as a result of the similar affinity of thiolate ligands for all 
gold crystalline faces and as such the overall shape of the nanoparticle is not 
preferentially controlled by thiolate binding to gold.193  
It has also been observed that the ligand surface coverage of gold nanoparticles is 
greater than that observed with two dimensional self-assembled monolayers. It is 
understood that this high surface coverage results from higher ligand-to-gold binding 
ratios or nanoparticle core edges and vertices.195 
The degree of ligand organisation on the surface of a gold nanoparticle is very much 
dependent on the nature of the ligand itself (for example, ligand size, steric bulk and 
terminal functionality). In order to minimise the free energy of the ligand shell, the thiolate 
anchored ligands adopt conformations which enable inter-ligand interactions (for 
example, Van der Waal interactions or hydrogen bonding). Interactions of this type result 
in a secondary level of ligand organisation on a nanoparticle surface.193  
 
II.1.9.2. Stability of gold nanoparticles 
The need for stabilising ligands upon gold nanoparticles is a result of the need to shield 
the gold cores from particle-particle agglomeration on the account of the high surface 
energy of the gold nanoparticle core.223  
Brownian motion (the random movement of particles in a fluid due to continuous 
interaction from molecules of the surrounding medium) alone is insufficient to form 
dispersions capable of preventing such interactions. The physical barrier (stabilising 
ligands) is therefore required, and these barriers are typically based around electrostatic 
or steric stabilising processes.224  
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The stability of colloidal gold systems can be described qualitatively as being dependent 
on the type and nature of the forces used to stabilise the colloidal system, these forces 
can be quantified to some degree by DVLO (Derjaguin-Landau-Verwey-Overbeek) 
theory. Qualitatively, DVLO theory describes colloidal stability in terms of the total free 
energy of interaction (G) and is composed of the sum of the Van der Waal interactions 
and electrostatic interactions (G = GVDW + Gelectrostatic), where Van der Waal interactions 
(GVDW) take on an attractive force as opposed to the repulsive force offered by 
electrostatic interactions (Gelectrostatic). It is the balance between these two forces which 
determines the energy barrier needed to overcome colloidal stability.225  
Though DVLO theory can be used in many cases to describe colloidal stability it cannot 
be used to accurately describe the interaction and stability of colloidal nanoparticle 
systems over small particle-particle distances because of the effects of non-DVLO forces 
also involved in colloidal stability. These forces include, hydrophobic, steric and solvation 
interactions, which can be stronger than DVLO forces depending on the nature or 
stabilisation method of the colloidal system (at both large and small particle 
separations).225  
 
The balance between colloidal stabilising forces is no more sensitive and essential than 
in aqueous systems where water-soluble nanoparticles are of interest towards biological 
applications. The synthesis of functionalised gold nanoparticles containing ionisable 
ligand functionality (for example, amino- or carboxylate-groups) is challenging and 
problematic.226  
The incorporation of ionisable ligands into nanoparticle systems can lead to the 
destabilisation of the colloid at physiological conditions. This takes the form of 
nanoparticle aggregation, which can be irreversible and/or reversible in nature 
depending on the nature of the interaction and the physical factors leading to the 
instability.227,228  
As previously mentioned, the properties and colloidal stability of gold nanoparticles are 
heavily dependent on the nature of the terminal functionality of the thiolate stabilising 
ligand. As such, the functionality of a terminal thiolate ligand has dramatic effects of 
nanoparticle stability in aqueous systems. 
In many cases, the synthesis of water-soluble gold nanoparticles by the Brüst-Shiffrin 
method shows limited or mixed success (ligand dependent) with nanoparticles displaying 
limited colloidal stability over time.229 The situation is often pronounced for larger 
nanoparticles synthesised by ligand-exchange methodologies where it is a non-trivial 
process to maintain the electrostatic stability of a colloid and assemble a protective 
monolayer with a desired ligand (if the ligand is unable to form stabilising monolayer).230  
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It has often been observed that carboxy-terminated ligands show increased colloidal 
stability towards aggregation when used as nanoparticle stabilising ligands compared to 
amine-terminated ligands. The stability of such ligands in gold nanoparticle systems is 
heavily dependent on the ionic strength and pH of the surrounding medium in relation to 
the pKa of the ionisable functional groups.222,231 Changes in these conditions, particularly 
decreases in solution pH lead to ligand-induced nanoparticle aggregation through 
hydrogen-bonding networks (and subsequent nanoparticle aggregation through 
irreversible VDW interactions between the gold nanoparticle cores). The modulation of 
these conditions therefore overcomes the electrostatic repulsive forces which maintain 
colloidal stability (particularly when ionisable groups are involved).230,227,231  
Aggregation is also dependent to a large extent on the linker length between the 
anchoring thiolate and the terminal functionality. Longer linker lengths are equated with 
slower rates of aggregation in colloidal systems susceptible to such instabilities as a 
result of the higher energy barrier to aggregation (on account of favourable hydrophobic 
interactions between longer alkyl linkers). However, where ionisable ligands are 
involved, electrostatic forces often play the dominate role in determining colloidal 
stability.227  
Unlike proteins where stability in aqueous systems can be maintained by protein folding 
and the subsequent energetic stabilisation of both hydrophobic and hydrophilic groups, 
nanoparticles which display ionisable ligands cannot rearrange to prevent unwanted 
electrostatic aggregation, particularly to prevent the attractive interactions from 
ammonium and carboxylate functionalities at physiological pH. It is therefore not 
surprising that gold nanoparticles are known to aggregate in aqueous solutions when 
thiol-containing amino acids/peptides are used as terminating ligands.232  
Various synthetic methodologies (both novel and modifications to existing 
methodologies) have been developed to try and overcome these problems, often with 
success (towards a specific goal or application) but have yet to reach the simplicity of 
synthesis and the wide level of acceptance gained by the Brüst-Shifrrin and 
Turkevitch/ligand-exchange methods for gold nanoparticle synthesis. Examples include; 
peptide-capped gold nanoparticle precursors,232 a two-phase synthetic process, where 
the initial gold colloid is place-exchanged with intermediate anionic-stabilising ligands230 
and alternative gold-precursor capping agents such as, DMAP, amino acids and Bünte 
salts (salts of S-alkylthiosulfuric acids).226,233,234  
 
II.1.9.3. Analysis of gold nanoparticles 
The most common techniques to analyse gold nanoparticle preparations include electron 
microscopy techniques (TEM, HRTEM, SEM, AFM), light scattering methods (DLS, 
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SLS), X-ray diffraction and mass spectrometry (if applicable). Such methods are used for 
core visualisation and particle distribution analyses.195 With regards to nanoparticle 
composition, other analytical methods such as elemental analysis, X-ray photoelectron 
spectroscopy or thermogravimetric analysis (TGA) are used.195 These various 
techniques are often used in a complementary fashion to build up an overall picture of 
the nanoparticle preparation in order to overcome shortcomings with individual 
techniques.  
Direct 1H/13C NMR analysis of gold nanoparticles particles often show a broadening or 
total absence of NMR resonance peaks (relative to the non-functionalised organic 
ligand) with increasing proximity to the Au-S bond.192  
The main reasons attributed to NMR resonance broadening include; 1) the difference in 
ligand packing density on the nanoparticle (-CH2- resonances closer to the Au-S bond 
experience faster spin relaxation effects from dipolar interactions), 2) the difference in 
ligand binding sites on highly faceted nanoparticles (vertices vs. edges vs. terraces) and 
3) spin-spin relaxation (T2) broadening which is dependent of the rate of tumbling of 
nanoparticles in solution (analogous to large macromolecules or proteins rotating in 
solution).235  
 
II.1.9.4. Surface plasmon resonance (SPR) band 
As a result of the “quantum size effect” of gold nanoparticles, the absorption of 
electromagnetic radiation induces a collective electron oscillation of the free (metal-) 
valence electrons which gives rise to an enhanced electromagnetic field at the 
nanoparticle surface and subsequently a characteristic absorption band observable in 
the UV-Vis spectra of gold nanoparticles. This is termed the surface plasmon resonance 
band (SPR band) and is typically observed at approximately 520nm for particles 
approximately 5-20 nm in diameter. It is this SPR band which gives rise to the red-wine 
colour of gold nanoparticle preparations in this size range.195,224  
The excitation wavelength observed for gold nanoparticles is sensitive to a number of 
factors including the composition, particle size, particle shape, inter-particle distance and 
environment (dielectric properties) of the gold nanoparticles and surrounding 
solvent.195,224  
The SPR band is absent in gold nanoparticle preparations smaller than approximately 
3nm in diameter. At these size ranges, gold nanoparticles are no longer considered 
“metallic” in nature (that is, they do not possess a mobile valence band of electrons) but 
can be treated quantum-mechanically as molecular entities (molecular-orbital 
description). Without the oscillation of free (metal-) valence electrons, the SPR band is 
not observed.224  
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The extinction coefficients of gold nanoparticles have been found to be high (up to 1011 
M-1 cm-1) as a result of the SPR band, which makes them much more sensitive than 
standard spectroscopic probes used in UV-Vis applications.224 
The SPR band is also an essential tool for understanding the stability of the gold 
nanoparticles in colloidal suspension. Aggregation of gold nanoparticles (as mentioned 
above in relation to ionisable ligands) results in the red-shifting of the SPR band. This is 
due to interactions of the plasmon resonances of individual gold nanoparticles which 
shift the absorbance to lower energies at reduced inter-particle distances (see figure 
42).236,237  
 
 
Figure 42. Schematic illustration of the effect of decreasing interparticle distance on the SPR 
band of gold nanoparticles. Reducing interparticle distance leads to a “red-shift” in the observed 
UV-Vis spectrum of gold nanoparticles. 
 
With particular reference to gold nanoparticles, when the distance between the gold 
cores is small compared to the core radii, additional plasmon resonances occur at longer 
wavelengths than the resonances of the isolated gold nanoparticles (typically, ~600nm in 
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UV-Vis spectrum).227 The red-shifting of the SPR-band occurs concurrently with a 
change in the colour of the colloidal suspension as the SPR band moves to loner 
wavelengths (red-to-blue colour change observed). 
It is the sensitivity of the SPR band of gold nanoparticles to their surroundings that 
makes gold nanoparticle systems the basis for novel labelling, detection, diagnostic and 
sensing probes for biological applications.195,224,238  
Colorimetric detection methods and assays follow the general principle of inducing 
nanoparticle aggregation through the specific binding (and recognition) interaction of 
functionalised ligands upon a nanoparticle with a target analyte.238  
There are now many examples of such colorimetric assays for a wide range of purposes 
and biological applications, these include; the detection of DNA and biological 
proteins,239,240 the investigation of carbohydrate-protein and carbohydrate-carbohydrate 
interactions,237,241,217 the detection of biological toxins, bacteria and viruses,242,243,244 and 
the detection of various biological analytes.245,246  
 
II.1.10. Influenza and gold nanoparticles 
With regards to influenza infection, common methods of detection utilising gold are 
based on 2D surfaces247,248,249 or gold nanoparticles250,251 but these methods are typically 
gold-immunoassays which target the HA and only rarely the NA.252  
With particular reference to nanoparticle applications, gold nanoparticles are commonly 
used as scaffolds for various biological recognition elements (for example, antibodies or 
other biological molecules) and are only a minor part of often complicated, multi-
sequence procedures towards influenza detection. As such, rather than being the 
exclusive detection element, gold nanoparticles are often non-participatory and of 
secondary importance to the main detection element of a particular assay or detection 
method.253  
Nevertheless, an interesting example of influenza detection which makes use of gold 
nanoparticles includes a genomic microarray assay where oligonucleotide- 
functionalised gold nanoparticles (15nm in diameter) are used to bind (indirectly) to a 
complementary influenza viral (H5N1, H1N1, H3N2) RNA sequence (immobilised on a 
glass silde) through a sequence of complementary oligonucleotide interactions (see 
figure 43).254 The final detection of viral RNA is achieved using silver-staining 
(enhancement of nanoparticle light scattering) of the oligonucleotide-bound gold 
nanoparticle and subsequent detection of the scattered light. Although a sensitive 
technique it is multi-sequence assay, requires skilled personnel and can be sensitive to 
background interference because of its low detection limit.254  
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Figure 43. A simplified schematic of a gold-nanoparticle based microassay used to detect 
influenza (via viral RNA detection). The sequence of events includes; the capture of viral RNA to 
a complmentary oligonucleotide sequence (step 1), the binding of gold nanoparticles to 
additional, complementary oligonucletide sequences (step 2), and the enhancement of light 
scattering for detection of viral RNA via silver staining of the gold nanoparticle (step 3). (Reprinted 
with permission from BioMed Central Ltd.; BMC Biotechnology, 2010, 10, 74) 
 
It is possible to say that the use of gold nanoparticles towards influenza detection is not 
uncommon if one includes immunoassay-based applications. However, the use of 
functionalised gold nanoparticles, independent of immunoassay methods with the aim of 
specific and discrete binding to whole influenza virions (and not viral RNA or isolated 
antigens) is not common. 
Such an approach has been achieved only recently using a multivalency platform based 
upon α-sialoside functionalised gold nanoparticles targeting the influenza HA (as a 
potential anti-adhesion therapeutic).255  
Though sialic acid functionalised gold nanoparticles have been synthesised by other 
groups,256,257 the research carried out by Papp et al. show the binding of sialic-acid-
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terminated glycerol dendrimers to 14nm gold nanoparticles (see figure 44). The 
incubation of these nanoparticles with influenza A (X31) followed by visualisation with 
TEM and cryo-TEM (cryogenic transmission electron microscopy) indicated nanoparticle 
binding to the viral surface.255 The results obtained by this investigation indicated that for 
efficient HA binding, flexibility is required in the ligand presenting scaffold and the size of 
the gold nanoparticle platform is paramount. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. Schematic representation of sialic-acid-terminated glycerol dendrimers immobilised on 
gold nanoparticles (A). TEM images of the gold nanoparticles binding to influenza A virus via the 
HA (B). (Reprinted with permission from Wiley-VCH Verlag GmbH & Co. KGaA; Small, 2010, 6 
(24), 2900–2906.) 
 
Another recent study has used gold nanoparticles (~4nm in diameter) functionalised with 
simple anionic capped thiolate-ligands (mercaptoethansulfonate, MES, and 
mercaptosuccinic acid, MAS) to inhibit influenza virus infection (determined by ELISA 
and hemagglutination assays).258  
The primary method of interaction here appears to be based upon electrostatic attraction 
between charged surfaces on the nanoparticle and the virus surface and not a high 
affinity, high specificity interaction with the influenza surface proteins. Although, counter-
intuitively, the MES capped gold nanoparticles showed greater inhibitory potential than 
the MAS capped particles, which has a slightly higher surface charge (which suggests 
electrostatic charge may not be the sole determining factor for virus interaction). 
B A 
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The inhibitory activity observed is attributed to the blocking of viral attachment to the cell 
surface (via multivalency interactions) and the potential inhibition the viral fusion process 
with the host cell surface.258  
Improving the selectivity and specificity (towards influenza viruses in the presence of 
other charged biological structures) based purely on generic electrostatic interactions 
would obviously be a difficult hurdle to overcome in terms of developing a selective 
therapeutic treatment.  
 
II.1.11. Influenza and other nanoparticles 
Other types of nanoparticles have also recently been applied towards influenza virus 
detection. As previously mentoned, dendrimeric-nanoparticles have been shown to bind 
to influenza virus (see page 92)175 but also the use of magnetic iron-oxide nanoparticles 
as an alternative to the gold nanoparticle core.259  
In another example of an immunoassay approach, these “electrically active” iron-oxide 
nanoparticles (coated with polyaniline and bound to immobilised anti-influenza HA 
antibodies) have been used as part of a multi-step, charge-transfer biosensor for the 
detection and (magnetic) separation of influenza HA (not whole influenza virus) from 
biological media (mouse serum matrix).259 The HA antibody is the recognition element 
and the polyaniline nanoparticle coating acts as an electrical transducer. Following HA 
binding, HA-bound nanoparticles are separated and a positive HA-detection result is 
elicited on completion of an electrical circuit.259  
 
II.1.12. Novel colorimetric methods of influenza detection 
The colorimetric detection of respiratory viruses such as influenza using functionalised 
gold-nanoparticles to date has not been achieved. The development of colorimetric 
methods to detect such biological pathogens is extremely attractive owing to the high 
sensitivity, rapid detection time and the lack of specialist equipment and instruments 
required for detection in comparison to standard clinical methods (or example, RNA/DNA 
based and immunoassay approaches).260,261  
With regards to influenza detection, the developments in colorimetric methods of 
detection have not made use of nanoparticle scaffolds but have used immobilised bilayer 
and polymeric systems.  
The use of a glass-slide coated with a bilayer system composed of octadecylsilane and 
polydiacetylene and terminally functionalised with α-sialoside derivatives provides an 
example of a colorimetric method for influenza detection (see figure 45). Detection of 
influenza HA binding is signalled by a colorimetric transition caused by conformational 
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changes to the conjugated ene-yne polymer backbone on binding of influenza A (X31) 
(blue to red colour change observed).262  
 
HO HO
OO
HN HO
OO
HO
O
O
O
O
NH
O
AcHN
OH
O
HO OH
OH
CO2H
Microscope slide
 
 
Figure 45. Novel colorimetric influenza detection system based upon an immobilised a bilayer 
system. The important elements of this system are highlighted; the influenza binding α-C-
sialoside (red), the chromatic detection element (green) and the monolayer support (blue). 
Adapted from; Science 1993, 261, 585-588. 
 
Another approach towards colorimetric influenza detection was based upon the 
synthesis of water-soluble α-sialyl polythiophenes (see figure 46). On binding of 
influenza virus a red-shift was observed in the visible spectra as a result of the disruption 
of the intermolecular interactions which maintain the polymer conformation. Influenza 
binding converted the polymer backbone from a twisted conformation to a more planar 
conformation.263  
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Figure 46. Structure of water soluble α-O-sialyl polythiophenes used in a colorimetric detection 
method for influenza virus.  
 
As is common with research towards multivalent scaffolds (mentioned above) to inhibit 
influenza virus binding and infection, the use of sialic acid as the receptor ligand for 
influenza HA is also used in these approaches. As such, these approaches suffer from 
the same potential shortcoming and weaknesses in using this recognition ligand. 
However, these methodologies do show that colorimetric sensing/detection platforms are 
an achievable goal towards the influenza virus and could offer levels of sensitivity when 
optimised to complement traditional influenza laboratory-based (PCR assays and HI 
assays) and potentially rival clinical point-of-care kits (rapid influenza diagnostic tests, 
RIDTs).264,261  
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II.2. Results and discussion 
 
II.2.1. Project rationalisation 
With a synthetic strategy towards phospha-isosteres of oseltamivir already 
established,161,67 research undertaken in this project is broadly based upon designing 
and synthesising novel influenza neuraminidase-specific materials and inhibitors 
presenting the oseltamivir phospha-isostere structural motif. As a target for multivalent 
binding strategies, the tetrameric NA should offer the same options as the commonly 
targeted trimeric HA but with the advantage that high-affinity, low molecular weight 
ligands are readily available in the form of influenza NA inhibitors. 
Powerful sialidase inhibitors such as oseltamivir carboxylate (and as such their phospha-
isosteres) are considered strongly-binding, high-affinity ligands for the influenza NA. 
Oseltamivir has a pharmacophore of decreased similarity to sialic acid (in comparison to 
zanamivir) and therefore exhibits minimal cross-reactivity with other proteins and 
biological molecules which use sialic acid as a receptor determinant in complex 
biological systems.265   
Because of such structural characteristics and specificities, the development of these 
compounds and their potential application as new types of influenza diagnostic tools (for 
example, used in the detection and quantification of NA on influenza virus surface, the 
investigation of influenza neuraminidase topology and their ligation to useful reporter 
groups or solid supports) is of significant interest. 
The main synthetic goal is directed towards nanoparticle synthesis and small molecule 
inhibitors (dimeric and conjugatable inhibitors) for displaying the phospha-oseltamivir 
motif. 
Gold nanoparticles have been chosen as a reference system for our approach to target 
the influenza virus via its NA due to their emergence as a popular scaffold for the 
presentation of multiple copies of bioactive motifs en route to the development of various 
sensors and diagnostics,266 particularly gold nanoparticles as colorimetric sensors.  
With respect to small molecule inhibitors and their conjugation to useful reporter groups, 
the popularity of chemical ligation techniques such as the Huisgen-1,3-dipolar 
cycloaddition (an example of “click-chemistry”)267 or conjugation via more conventional 
amino-coupling chemistry, could be used to ligate the phospha-oseltamivir scaffold to 
other molecules such as biotin and fluorescent probes. 
By incorporating conjugatable chemical handles into phospha-oseltamivir derivatives, 
these popular conjugation methodologies and the compounds that result from their 
application could be exploited to create widely applicable chemical research tools for 
influenza virology. 
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II.2.2. Strategies towards gold nanoparticles derivatised with phospha-oseltamivir 
The industrial Tamiflu precursor “acetamido-azide” was the starting material for all of the 
chemical transformations towards the important monophosphonate precursor 35 (see 
scheme 21). The “acetamido-azide” was saponified with NaOH (aq.) to give the free acid 
in 97 % yield. The free acid 31 then underwent a radical halodecarboxylation procedure 
initially using the Vilsmeier reagent (generated by the reaction of a stoichiometric ratio of 
DMF and thionylchloride) to generate the acid chloride in situ, followed by the irradiation 
of the solution (using a broad spectrum, 300W UV lamp) in the presence of CF3CH2I (the 
iodo-source), DMAP and 1-Hydroxypyridine-2-thione, to yield vinyl iodide 32 after 
purification in good yield 71% (based on recovered starting material). 
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Scheme 21. Reagents and conditions; (a) NaOH (0.5 M), dioxane; (b) i. Vilsmeier reagent, DCM; 
ii. N-hydroxypyridine-2-thione, DMAP, CF3CH2I, DCM, hv; (c) i. PMe3, THF, ii. BocON, THF iii. 
H2O; (d) dimethylphosphite, Pd(PPh3)4, NEt3, toluene; (e) NaOH (0.25 M), dioxane. 
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It is important to note that during the synthesis towards compound 32 the significance of 
using high purity 1-hydroxypyridine-2-thione was discovered. It was found that 
commercially available 1-hydroxypyridine-2-thione is oxidised to its respective disulfide 
over time (determined by NMR spectroscopy and HR-MS). As such, the use of this 
disulfide hinders the halodecarboxylation strategy significantly, with synthetic yields of 
compound 32 dropping to <5%. To ensure successful synthesis of important iodo-
precursor 32, freshly prepared 1-hydroxypyridine-2-thione (obtained by acidification of 
the commercially available 1-hydroxypyridine-2-thione sodium salt, followed by 
recrystallisation from EtOH/H2O)268 was used in the halodecarboxylation. 
The azido-moiety of compound 32 was then reduced and protected as a tert-butyl 
carbamate in a one-pot sequence using PMe3 in THF (Staudinger reaction) followed by 
treatment with BocON to give compound 33 (72%). 
The palladium-mediated coupling step (Hirao reaction) of compound 33 with 
dimethylphosphite furnished the phosphonate diester 34 in 80% yield. Mono-
saponification of compound 34 was then achieved using NaOH (aq.) to afford monoester 
35 in 96% yield. Monoester 35 was the important precursor for all subsequent chemical 
modifications (41% overall yield over 5 steps). 
 
II.2.2.1. Synthesis of dimeric phospha-oseltamivir 
The synthesis of the dimeric phospha-oseltamivir constitutes a simple dimeric NA 
inhibitor. Subsequent investigation of its inhibitory potential would indicate whether any 
effects on observed NA inhibition are a result of enhanced substrate binding through 
multivalency effects or a result of purely statistical rebinding. Moreover, the disulfide 
could be directly applied to the synthesis of functionalised gold nanoparticles (vide infra). 
The length of the linker (6 methylene units) was incorporated into the phospha-
oseltamivir derivatives. This is a compromise to provide adequate linker length (>10 
methylene units for the dimeric derivative) to mimic the structure of successful dimeric 
zanamivir compounds184 and to be short enough to maximise aggregation effects 
between gold nanoparticles (as longer linker lengths are known to cause functionalised 
colloidal gold nanoparticles to aggregate more slowly when subjected to conditions 
which induce aggregation) towards a potential influenza sensor.227 As such, with the 
development of a gold nanoparticle based influenza sensor in mind, the aggregation 
caused by nanoparticle-analyte interaction should be maximised (in part) by using a 
relatively short linker. 
Linker compound 42, used as a precursor to dimeric compound 45 has already been 
synthesised via a palladium mediated coupling of vinyl iodide 33 with O-methyl O-(ω-
thioacetyl hexyl) phosphonic acid 41, synthesised from dimethyl chlorophosphonate, 36 
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and compound 40.  Compound 40 itself was synthesised from hexan-1,6-diol in 4 steps 
(see scheme 22).269 
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Scheme 22. Reagents and conditions; (a) imidazole, TIPSCl;  (b) TsCl, DMAP, pyridine;  (c) 
KSAc, pyridine; (d) TBAF, AcOH, THF; (e) chloro(dimethyl)phosphine 38, DIPEA, DCM; (f) 
Pd(PPh3)4, NEt3, toluene. 
 
The synthetic yield of this palladium-mediated reaction was improved slightly in this work 
through a modified reaction procedure (specifically, the use a more stringent inert 
atmosphere and an optimised order of reagent addition) from a 36% to a 52% yield. 
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Although the coupling reaction developed for compound 42 had been improved, a highly 
pure analytical sample was difficult to obtain because of triphenylphosphine oxide 
impurities (originating from Pd(PPh3)4 as a result of the aqueous work-up procedure) 
which could not be completely removed. An alternative strategy was therefore used to 
form compound 42 which relied upon the alkylation of the monomethylphosphonate 35 
with a suitably functionalised alkyl triflate (see scheme 23). 
Triflate 43 was synthesised by the reaction of compound 40 with trifluoromethansulfonic 
anhydride at reduced temperature. It was found that triflate 43 was not stable for 
prolonged periods of time and decomposed over the course of 48 to 72 hours (-20 °C 
refrigeration) and decomposed rapidly when heated to above moderate temperatures 
(>30 °C). 
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Scheme 23. Reagents and conditions; (a) Trifluoromethanesulfonic anhydride, lutidine, DCM,  
-60 °C; (b) i. compound 37 lyophilised with NEt3; ii. Acetonitrile, compound 43. 
 
Reactivity studies (via TLC) indicated that the triflate 43 decomposed rapidly (less than 5 
minutes) when stirred in polar solvents necessary for the alkylation reaction (these 
included DMF, DMSO, and THF). Only in anhydrous acetonitrile was the decomposition 
of triflate 43 slow enough to allow the alkylation reaction to proceed in competition. 
Both strategies yielded compound 42 in similar yields (when disregarding recovered 
starting material), however, the synthesis of compound 42 via the triflate alkylation 
method was safer (as it did not require the synthesis of compound 36) and more 
economical (as it was palladium-free). Moreover, starting material from the triflate 
method could be reclaimed and reused. 
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The synthesis of disulfide 44 was achieved by dimerisation of compound 42 with sodium 
methoxide in MeOH in the presence of O2(g) (see scheme 24).  
Initial investigations towards deprotection of compound 44 included basic hydrolysis of 
the phosphonate methyl ester (attempted using both NaOH (aq.) and KOH (aq.), 0.1M) 
which was unsuccessful and led to mixed ester cleavage. A selective 
thiophenol/triethylamine phosphonate ester deprotection strategy was also unsuccessful. 
Successful deprotection of the phosphonate methyl ester of compound 44 was achieved 
using Finkelstein conditions (NaI in refluxing anhydrous acetone) followed by removal of 
the tert-butyl carbamate protecting group with 50% TFA/H2O and 1,4-dioxane which 
resulted in compound 45 after gel permeation chromatography (72% yield). 
 
 
 
 
Scheme 24. Reagents and conditions; (a) NaOMe/MeOH, O2(g); (b) i. NaI, acetone, reflux; ii. 
TFA/H2O (50%); iii. gel permeation chromatography. 
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II.2.2.2. Neuraminidase (NA) inhibition studies with dimeric phospha-oseltamivir 
Compound 45 was investigated for NA inhibitory activity in collaboration with the NIMR 
(National Institute of Medical Research).  
The inhibition constant Ki is obtained by measuring the effect of the inhibitor on the rate 
of MUNANA hydrolysis and is a standard assay widely used in influenza research. 
 
compound 45 hexyl-conjugate Oseltamivir 
0.10 ± 0.01 0.22 ± 0.03 0.14 ± 0.02 
 
Table 4. Inhibition constant (Ki [nM]) for target dimeric phospha-oseltamivir, compound 45 in 
comparison to known NA inhibitors.  
(Inhibition of MUNANA hydrolysis catalysed by neuraminidase from influenza virus 
A/Norway/1758/07; inhibition constants were determined as described in experimental section; 
Inhibition of neuraminidase activity of influenza viruses from allantoic fluid from infected eggs; KM 
for MUNANA = 6.4 ± 0.6 µM). For hexyl-conjugate, see figure 25, page 84). 
 
Improved inhibition was found for compound 45 (Ki = 0.10 ± 0.01 nM) compared to the 
hexyl-conjugate and to oseltamivir (see table 4) and indicates that the potency of 
inhibition is approximately twice that of the hexyl-conjugate (Ki = 0.22 ± 0.03 nM).67 This 
suggests that the binding and subsequent inhibition of NA activity is a result of statistical 
rebinding of compound 45 with the NA opposed to multivalency effects. 
 
II.2.3. Synthesis of functionalised gold nanoparticles 
The synthesis of phospha-oseltamivir stabilised gold nanoparticles was pursued using 
two synthetic methodologies, a modified Brüst-Shiffrin protocol and a ligand-exchange 
procedure upon pre-synthesised gold nanoparticles via the Turkevitch protocol. Both 
methodologies are well-established and widely used to generate nanoparticles of varied 
size. 
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II.2.3.1. Brüst-Shiffrin method 
Model compound 46 was synthesised initially from compound 40 (see scheme 25). The 
purpose of compound 46 was to allow preliminary gold nanoparticle synthetic studies to 
be carried out in preparation for the synthesis of phospha-oseltamivir gold nanoparticles. 
A modified Brüst-Shiffrin method198,217 using aqueous auric acid in a methanolic solution 
of disulfide 46 (3:1 molar equivalents compared to auric acid) followed by the addition of 
sodium borohydride, was used to synthesise small functionalised gold nanoparticles. 
 
 
 
Scheme 25. Reagents and conditions; (a) NaOMe/MeOH, O2(g). 
 
Although a characteristic brown/black solution was formed on the addition of sodium 
borohydride, the purification of nanoparticles from excess disulfide 46 was problematic. 
A centrifugation-based purification procedure217 was attempted unsuccessfully (small 
molecule impurities were present in the 1H NMR following the centrifugation process). 
The nanoparticles synthesised were not highly water suspendible and as such 
methanolic nanoparticle solutions were used during centrifugation which leached small 
molecule impurities from the centrifugal filtration device. The lack of water suspendibility 
of the nanoparticles did not lend this system to optimising the Brüst-Shiffrin procedure 
towards phospha-tamiflu-stabilised gold particles (which were expected to form a 
suspension in water). As such, the development of compound 46 as a template for 
nanoparticle synthesis was abandoned.  
 
II.2.3.2. “Small” methylphosphonate-stabilised gold nanoparticles as a control 
sample 
With the aim of finding an alternative to nanoparticles synthesised from compound 46, 
disulfide 49 was synthesised with two main objectives in mind (see scheme 26). Firstly, 
the spacered methylphosphonate compound 49 would provide a more suitable platform 
for attempting and optimising nanoparticle synthesis before using phospha-oseltamivir 
derivatives (because of the polar terminal methylphosphonate moiety). Secondly, 
monomethylphosphonate stabilised gold nanoparticles are a perfect platform as a control 
sample in inhibition studies (because the methylphosphonate moiety retains the negative 
126 
 
charge so important to phospha-oseltamivir binding but is devoid of the other essential 
recognition elements for successful NA inhibition). 
 
 
 
Scheme 26. Reagents and conditions; (a) P(O)(OCH3)(CH3)Cl, DIPEA, DCM; (b) NaOMe/MeOH, 
O2(g); (c) i. NaI, acetone, reflux; ii. gel permeation chromatography. 
 
Compound 47 was synthesised from compound 40 and methyl 
methylphosophonochloridate66 in good yield (79%). Dimerisation to give protected 
disulfide 48 and subsequent deprotection gave compound 49 and was achieved using 
the same reaction conditions as used in the synthesis of phospha-oseltamivir disulfide 
45 in an overall yield of 64% over 3 steps (see scheme 26). 
Methylphosphonate-stabilised gold nanoparticles were synthesised using the modified 
Brüst-Shiffrin procedure however, the procedure was unsuccessful and on the addition 
of sodium borohydride, an insoluble black solid was formed (assumed to be a result of 
the reduction of AuIII to Au0).  
The use of a small quantity of acetic acid (30:1 molar equivalents compared to auric 
acid) was used to prevent the formation of this insoluble black solid (bulk Au0) by 
preventing the high pH induced irreverisble gold core coalescence (in the presence of 
ionisable sulfur-containing ligands) under these experimental conditions.209,214 No sound 
physical basis or justification however has been provided in the literature for the use of 
acetic acid for this purpose beyond improving the solubility of nascent thiolate-capped 
gold nanoparticles (which have limited solubility in MeOH). 
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The methylphosphonate-stabilised gold nanoparticles obtained could be suspended in 
water (see figure 47) and were purified by a repeated centrifugation/resuspension 
procedure (until unreacted staring material 49 was no longer detected). Subsequently 
the methylphosphonate-stabilised gold nanoparticles underwent prolonged dialysis to 
remove small molecule impurities (see scheme 27).  
Unreacted disulfide 49 was reclaimed and was chemically unchanged after the 
functionalisation procedure (determined by 1H NMR). 
 
II.2.3.3. Phospha-oseltamivir-stabilised gold nanoparticles: “small TamiGold” 
Using the same modified Brüst-Shiffrin methodology, phospha-oseltamivir-stabilised gold 
nanoparticles (henceforth referred to as “small TamiGold”) were synthesised (see 
scheme 28).  
As was the case with “small” methylphosphonate-stabilised gold nanoparticles, 
unreacted starting material (in this case, disulfide 45) was reclaimed and appeared 
chemically unaltered after the functionalisation procedure (determined by 1H NMR).  
 
 
 
 
Figure  47. Images of gold nanoparticles synthesised by the Brüst-Shiffrin method; “small 
TamiGold”, ~0.5 mg/mL (left) and “small” methylphosphonate stabilised gold nanoparticles, ~1 
mg/mL (right). 
 
. 
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Scheme 27. Synthesis of monomethylphosphonate stabilised gold nanoparticles. 
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II.2.3.4. Turkevitch method and ligand exchange  
Citrate-capped nanoparticles were synthesised via the Turkevitch method using auric 
acid and trisodium citrate as described in the literature, forming a wine-red coloured 
colloidal gold solution and giving a characteristic SPR band at approximately 519 
nm.238  
 
II.2.3.5. “Large” methylphosphonate-stabilised gold nanoparticles as a control 
sample 
Methylphosphonate-stabilised gold nanoparticles were synthesised using the citrate-
capped gold nanoparticles generated from the Turkevitch method mentioned above (as 
a means of optimising nanoparticle synthesis and purification for phospha-oseltamivir 
stabilised gold nanoparticles).  
Ligand exchange of compound 49 with freshly citrate-capped gold nanoparticles over 
72 hours lead to the formation of methylphosphonate-stabilised gold nanoparticles.  
The ligand-exchange process itself was easily carried out but initial attempts at 
purification using both gel permeation chromatography (10mM phosphate buffer, pH 
7.6) and dialysis (against 10mM phosphate buffer, pH 7.6) were not sufficient to 
completely remove unfunctionalised compound 49 or excess citrate.270  
Centrifugation/resuspension purification procedures were also initially unsuccessful 
with methylmonophosphonate stabilised gold nanoparticles. Ultracentrifugation as 
described in the purification of other functionalised gold nanoparticles227 often resulted 
in permanent aggregation of the nanoparticles (signified by a red to purple colour 
change of the resulting pellet). Prolonged dialysis (> 7 days) using deionised water (pH 
~7) also resulted in the aggregation of the nanoparticle suspensions during purification. 
It was clear that the delicate colloidal stability of the methylphosphonate-stabilised gold 
nanoparticles required careful purification through a combination of methods to 
maintain stability. This was eventually achieved through gel permeation 
chromatography, a limited centrifugation/resuspension sequence and prolonged 
dialysis (10mM phosphate buffer, pH 7.6) to produce methylphosphonate-stabilised 
gold nanoparticles, which exhibited a characteristic SPR band at 524 nm and remained 
stable for prolonged lengths of time (months) with limited flocculation (at pH 7.6 during 
refrigeration at 4 °C in the absence of light). 
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II.2.3.6. Phospha-oseltamivir-stabilised gold nanoparticles: “large TamiGold” 
The ligand exchange reaction of disulfide 45 generated phospha-oseltamivir stabilised 
gold nanoparticles henceforth referred to as “large TamiGold”. Lessons learned in the 
synthesis of methylphosphonate-stabilised gold nanoparticles were however not 
entirely applicable to “large TamiGold”. 
The initial ligand exchange reaction was marked by aggregation of the gold 
nanoparticles (red to purple colour change, which was not observed in the synthesis of 
methylphosphonate-stabilised gold nanoparticles) which was only reversed by the 
addition of 0.1 M NaOH (aq.) over the course of the reaction (see figure 48) 
As shown below, the aggregation of the gold nanoparticles occurs on addition of 
compound 45 resulting in a red-shift of the SPR band which can be reversed by the 
addition of NaOH (aq.). It is also important to point out that this behaviour is not 
observed with the citrate-capped control sample (same conditions but without 
compound 45) and that increasing solution pH of citrate-capped gold nanoparticles 
appears to have no detrimental effect on colloidal stability or the SPR band. 
 
 
 
Figure 48. UV-Vis spectra of initial “large TamiGold" synthesis. The SPR band was returned to 
525 nm on increasing solution pH.  
 
The aggregation behaviour of “large TamiGold” observed during the initial syntheses 
did not appear to hinder the ligand exchange reaction as UV studies (vide infra) still 
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indicated a distinctive difference between the behaviour of non-thiolate functionalised 
citrate-capped gold nanoparticles and those reacted with phospha-oseltamivir disulfide 
45. 
 
It is reasoned that this behaviour is attributed to the interaction of cationic functionality 
present on gold-immobilised ligands with neighbouring functionalised gold 
nanoparticles. It appears that this effect is pronounced with functionalised ligands of a 
zwitterionic or cationic nature because of their ability to act as nanoparticle cross-
linking agents.270 This is the case in conditions where the pKa of capping ligand and 
solution pH is not optimised towards the stability of the gold capping agent in aqueous 
solution. In this example, at physiological pH (~pH 7.6) the primary amino-group (pKa 
~12.5) is present as its conjugate acid and is speculated therefore to prevent gold 
nanoparticle colloidal stability through electrostatic interactions between other 
phospha-oseltamivir structures and the gold nanoparticles. Aqueous solution of pH > 9 
prevented this aggregation behaviour of “large TamiGold”.  
This synthetic issue was overcome by first dissolving compound 45 in phosphate buffer 
(pH 7.6) then continuing the standard ligand exchange procedure. 
The subsequent nanoparticle purification procedure was more straight forward and 
used a centrifugation/resuspension process followed by prolonged dialysis against Tris 
buffer (10 mM, pH 9.3) to give “large TamiGold”, which exhibited a characteristic SPR 
band at 525 nm and appeared red in colour (see figure 49 ). 
 
 
  
 
Figure 49. Images of gold nanoparticles synthesised by the ligand exchange/Turkevitch 
method; “large TamiGold” (left, right) and “large” methylphosphonate stabilised gold 
nanoparticles (middle). 
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II.2.4. Gold nanoparticle characterisation: “small TamiGold” and control sample 
 
II.2.4.1. UV-Vis spectroscopy 
UV-Vis spectroscopy revealed that both “small” methylphosphonate-stabilised gold 
nanoparticles and “small TamiGold” did not display an SPR band in their spectra. As 
previously mentioned, the SPR band is commonly displayed by gold nanoparticles of a 
larger particle diameter (typically greater than 5 nm) thus supporting the conclusion of 
successful gold nanoparticle synthesis with a particle diameter of less than 3 nm (see 
figure 50 and figure 51).271 
 
 
Figure 50. UV-Vis spectrum of “small” methylphosphonate-stabilised gold nanoparticles 
(~1 mg/mL). 
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Figure 51. UV-Vis spectrum of “small TamiGold” (~ 0.5 mg/mL). 
 
II.2.4.2. High resolution transmission electron microscopy (HRTEM) 
High resolution transmission electron microscopy (HRTEM) of “small” 
methylphosphonate-stabilised gold nanoparticles gave an average particle diameter of 
2.4 nm with a particle size range of 1 - 4 nm (see figure 52). 
  
Figure 52. HRTEM images and size distribution histogram of “small” 
stabilised gold nanoparticles.
 
HRTEM analysis of “small TamiGold” gave an average particle diameter of 2.0 nm with 
a particle size range of 1 
a similar size and distribution (see figure 5
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- 4 nm. This shows that both gold nanoparticle samples are of 
3).  
methylphosphonate- 
 Figure 53. HRTEM images and size distribution histogram of “small TamiGold”
 
In general, there may be some bias in particle counting and the 
distribution analysis resulting from limitations in HRTEM image acquisition of <1nm 
particle populations (due to decreased particle image contrast compared to the carbon 
grid background). 
Rudimentary visual inspection of the HRT
stabilised gold nanoparticles indicates some clustering of particles, accounting for the 
non-regular particle size distribution on the sample grid which is not observed for “small 
TamiGold” (where the particle distribution appear
associated with “small” methylphosphonat
the polar terminal methyl
considered that these clustering observations may also be 
down process and HRTEM sample preparation on the carbon grid.
Lattice fringes related to the FCC 111 “bulk” gold crystal lattice (literature value 0.235 
nm)272 are observable from the HRTEM images of “small TamiGold” (observed value 
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0.239 nm). The deviation from the bulk gold is due to the small size of the gold 
nanoparticles produced by the Brüst-Shiffrin method, whereby there are typically more 
gold atoms at the gold nanoparticle surface rather than in the bulk which causes an 
alteration to the observed crystal structure.272 
 
II.2.4.3. Diffusion ordered spectroscopy (DOSY) NMR 
DOSY-NMR experiments with “small” methylphosphonate-stabilised gold nanoparticles 
gave a hydrodynamic radius (RH) of approximately 5 nm and for “small TamiGold” a 
hydrodynamic radius (RH) of approximately 3 nm (derived from estimated diffusion 
coefficients) (see figure 54).  
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Figure 54. (A) DOSY-NMR spectra for “small TamiGold” and (B) DOSY-NMR spectra for 
“Small” methylphosphonate-stabilised gold nanoparticles; Solvent: D2O (solvent signal 
suppressed).  
 
D ~ 0.8 x 10-10 m2 s-1 
 
RH  3 nm 
D ~ 0.5 x 10-10 m2 s-1 
 
RH  5 nm 
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This data supports the HRTEM results as particle diameters of a similar order of 
magnitude are obtained. The larger particle diameter obtained by the DOSY-NMR 
method is due to the incorporation of the surrounding ligand shell and the hydration 
sphere of the respective nanoparticle.  
However, there is a larger difference in particle size of “small TamiGold” and “small” 
methylphosphonate-stabilised gold nanoparticles derived from DOSY-NMR data 
compared to those derived from HRTEM data. This can be explained by the different 
chemical nature of the terminating group, that is, phospha-oseltamivir versus terminal 
methylphosphonate, the latter of which may induce greater long-range ordering effects 
in solution which are accounted for by DOSY-NMR though not by HRTEM (where only 
the gold nanoparticle core is imaged). 
 
II.2.4.4. 1H NMR 
1H NMR spectra of “small” methylmonophosphonate stabilised gold nanoparticles and 
“small TamiGold” confirmed the slight upfield shift and broadening of resonances and 
the complete broadening of the -CH2- signals adjacent to the S-Au bond which were no 
longer visible in comparison to the starting material (see figure 55). Such NMR effects 
are mainly attributed to the effect of ligand-Au bonding on NMR relaxation times.235  
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Figure 55. (A) 1H-NMR-spectra overlay of “small TamiGold” with compound 45 and (B) 1H-
NMR-spectra overlay of small methylphosphonate-stabilised gold nanoparticles with compound 
49; Solvent: D2O. Line broadening of 1.5 Hz was applied to the nanoparticle spectra. 
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II.2.4.5. Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) analysis of “small” methylphosphonate-stabilised gold 
nanoparticles and “small TamiGold” was not successful.  
The intensity size distribution obtained for both samples indicated a polymodal 
distribution with scattering contributions from a significant population of large 
aggregates (above the 6000 nm threshold) even after 0.45 µm filtration. 
Attempts to lower the concentration of the gold nanoparticle samples (with the intention 
of reducing interparticle interactions which may result in aggregate formation) did not 
completely reduce the large particle aggregates observed. Sample dilution to < 0.01 
mg/mL led to a poor photon count rate which was insufficient for data collection and 
analysis.  
It was not possible to gather significant and reliable data gathered for volume- and 
number-based distributions for these nanoparticle samples because values for the 
refractive index (nR) and absorption (nI) (specific to the gold nanoparticle samples) 
needed for the necessary data analysis were not known (see appendix 2: Dynamic light 
scattering (DLS), page 263). 
 
II.2.4.6. Mass Spectrometry 
MALDI-MS of “small TamiGold” (in collaboration with the John Innes Centre, UK) 
resulted in the detection of the monomer thiol fragment of the gold nanoparticle (see 
figure 56). Under the conditions used, fragmentation of “small TamiGold” occurs and 
the molecular ion species [M+H]+ of the monomeric thiol ligand is consequently 
detected as the peak of highest intensity ([M+H]+ : m/z 436.946).  
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Figure 56. MALDI-MS of “small TamiGold”. Fragmentation leads to detection of monomeric thiol 
ligand.  
 
The observation of the thiol fragment (and not the disulfide) is indicative of the 
successful formation of phospha-oseltamivir functionalisation on gold nanoparticles. 
MALDI-MS of “small” methylphosphonate stabilised gold nanoparticles did not detect 
the functionalised gold nanoparticles or the free methylphosphonate ligand because 
the [M+H]+ peak was obscured by the matrix used in the MALDI technique. ESI-MS 
was also unsuccessful in determining the mass of both of the gold nanoparticle 
samples owing to their inability to be ionised successfully by this method. 
 
II.2.4.7. Energy dispersive X-ray (EDX) analysis 
Energy dispersive X-ray (EDX) analysis (in collaboration with the John Innes Centre, 
UK) was used to analyse “small” methylphosphonate stabilised gold nanoparticles and 
“small TamiGold”. 
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Figure 57. EDX analysis of small methylphosphonate-stabilised gold nanoparticles, resulting in 
a Au/S ratio of ~1:1.  
 
 
 
Figure 58. EDX analysis of “small TamiGold”, resulting in a Au/S ratio of ~1:1.  
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For “small TamiGold” (see figure 58), EDX confirmed the presence of Au, S and P as 
major constituents of the nanoparticles synthesised. Semi-quantitative EDX analysis 
determined an approximate Au/S ratio of 60% Au/10% S (% mass) which results in a 
molar ratio of approximately 1:1. A similar result is obtained for “small” 
methylphosphonate-stabilised gold nanoparticles (see figure 57) and similar values for 
alkylthiol-functionalised gold nanoparticles obtained by EDX have been reported.273  
The presence of sodium in the sample is not unusual or unexpected (even after 
prolonged dialysis with milliQ water) and has been reported elsewhere.274  
The approximate 1:1 Au/S ratio was subsequently used as basis for the calculation of 
phospha-oseltamivir ligand concentration (upon gold nanoparticles) for use in inhibition 
assays (vide infra). 
It should be noted that the Au/S ratio is likely to be an overestimate with respect to 
sulfur due to experimental error associated with small particle samples studied by EDX, 
which are known to be problematic.275  
Peak overlap problems (poor detector resolution, non-Gaussian distributions, lack of 
calibration standards) leads to difficulties in the determination of peak amplitudes for 
various elements therefore leading to problems with quantification (and subsequent 
under/over-estimation of elemental analysis). This is a particular problem with Au/S/P 
since there is significant peak overlap of their characteristic X-ray emissions. As such, 
the associated error is estimated to be in the order of at least 10-20% with regards to 
the semi-quantitative data obtained.275,276  
 
II.2.5. Gold nanoparticle characterisation: “large TamiGold” and control sample 
 
II.2.5.1. UV-Vis spectroscopy 
UV-Vis spectroscopy indicated that both “large” methylphosphonate stabilised gold 
nanoparticles and “large TamiGold” displayed the characteristic SPR band in their 
respective spectra.  Ligand exchange of citrate-capped (Turkevitch) particles by 
compound 49 and compound 45 resulted in a red-shift of the absorption band from 519 
nm (citrate-capped gold nanoparticles) to 524 nm (“large” methylphosphonate 
stabilised gold nanoparticles) and 525 nm (“large TamiGold”) respectively (see figure 
59).  
  
145 
 
A 
 
B 
 
 
Figure 59. (A) Comparison of UV-VIS spectra of citrate-capped gold nanoparticles and “large” 
methylphosphonate stabilised gold nanoparticles. (B) Comparison of UV-VIS spectra of citrate-
capped gold nanoparticles and “large TamiGold”. (AuNP-citrate = citrate-capped gold 
nanoparticles; MMP-AuNPs = “large” methylphosphonate stabilised gold nanoparticles) 
 
UV studies were carried out to determine the behaviour of the functionalised gold 
nanoparticles by varying the pH of solution. 
With respect to “large” methylphosphonate stabilised gold nanoparticles, the decrease 
of solution pH (pH 7.6 to ~pH 2) induces gold nanoparticle aggregation (through 
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hydrogen bonding networks between nanoparticle functionalised monophosphonate 
groups and Van der Waals attractive forces between the gold cores with decreasing 
interparticle distance).232,277  
However, once this pH adjustment has occurred it is difficult to resuspend “large” 
methylphosphonate stabilised gold nanoparticles by increasing the pH of the solution 
alone (see Figure 60). For successful “large” methylphosphonate gold nanoparticle 
resuspension the initial pH decrease must not be reduced to below pH 2-3. “Large” 
methylphosphonate stabilised gold nanoparticles can then regain the original SPR 
band (~524 nm) by a centrifugation and resuspension process (using a low volume of 
0.1 M NaOH (aq.) and phosphate buffer, pH 7.6) (see figure 61 ).  
 
 
Figure 58. pH-dependent aggregation of “large” methylphosphonate stabilised gold 
nanoparticles. The original SPR band (~524 nm) is not regained on increasing pH. 
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Figure 61. pH-dependent aggregation and resuspension of “large” methylphosphonate 
stabilised gold nanoparticles. 
 
With respect to “Large TamiGold”, the SPR-absorption also undergoes a red-shift and 
band broadening in the physical pH-range from 525 nm (pH 9.3) to 553 nm (pH 7.6). 
Transmission electron microscopy (TEM) images of the decrease in solution pH 
(dialysis over 3 days) show the aggregation of gold nanoparticles occurring (see figure 
62). The red-shift observed in the UV spectra of both “large” methylphosphonate 
stabilised gold nanoparticles and “large TamiGold” is indicative of a reduction in the 
interparticle distance which shifts the absorbance to lower energies.236,237  
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Figure 62. (A) UV-Vis spectra showing a “red-shift” of the SPR band after slow aggregation (3 
days) of “large TamiGold” when dialysed against phosphate buffer at physiological pH (pH 7.6); 
(B) TEM images before and after aggregation as described under A.  
 
As was the case with “large” methylphosphonate stabilised gold nanoparticles, this red-
shift was entirely reversible when the solution pH was adjusted to pH > 9. No 
centrifugation and resuspension process was required (see figure 63). 
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Figure 63. pH-dependent aggregation and resuspension of “large TamiGold”. 
 
From these studies it was apparent that “large” methylphosphonate stabilised gold 
nanoparticles were more sensitive to changes in solution pH than “large TamiGold”. 
This may also be explained by the different chemical nature of the terminating group on 
each functionalised gold nanoparticle (as described in DOSY-NMR results).  
The pH dependent behaviour of the SPR band of both “large” methylphosphonate- 
stabilised gold nanoparticles and “large TamiGold” also provides a confirmation of the 
change in gold surface functionalisation from citrate-capped (electrostatic) to 
methylphosphonate and phospha-oseltamivir functionalised (S-Au interaction of 
covalent character). A pH decrease results in irreversible aggregation of citrate-capped 
gold nanoparticles. As such it provides a qualitative way of telling whether the ligand 
exchange reaction has been successful in lieu of other spectroscopic data (see figure 
64). 
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Figure 64. Irreversible aggregation of citrate-capped gold nanoparticles on decreasing the pH 
of the colloidal suspension. 
 
II.2.5.2. Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) of “large” methylphosphonate-stabilised gold 
nanoparticles gave an average particle diameter of 14.4 nm with a particle size range 
of 12-18 nm (see figure 65). 
TEM analysis of “large TamiGold” gave an average particle diameter of 13.9 nm with a 
particle size range of 12-17 nm (see figure 66). This shows that both gold nanoparticle 
samples are of a similar size and distribution (approximately 14 nm) and do not show 
significant changes in particle size compared to the citrate-capped gold nanoparticle 
precursor (particle diameter of 13.9 nm with a particle size range of 12-18 nm) (see 
figure 67). 
  
 Figure 65. TEM image and size distribution histogram of “
gold nanoparticles. 
 
 
Figure 66. TEM image and size distribution histogram of “large TamiGold”.
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 Figure 67. TEM image and size distribution histogram of citrate
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intensity from particles and/or particle aggregates with a peak mean of 48.79 nm 
(99%). The Z-average particle diameter is 36.61 nm with a polydispersity of 0.240 (see 
figure 69). 
 
 
Z-average diameter (nm):   36.61 nm Polydispersity Index (PDI):   0.240 
 
Figure 69. Dynamic light scattering analysis of “large” methylphosphonate stabilised gold 
nanoparticles. 
 
Conversion to volume- and number-based distributions was problematic. Volume 
distribution and gave a polymodal distribution with peak means of 6.125 nm (25.9%), 
21.59 nm (72.5%) and 4646 nm (1.6%). 
The number-based analysis gave a bi-modal distribution, with a peak mean of 5.9 nm 
(64.3%) and 13.4 nm (35.7%). The repeatability of the DLS experiments with “large” 
methylphosphonate-stabilised gold nanoparticles proved difficult with respect to volume 
and number distribution.  
 
DLS analysis of “large TamiGold” resulted in intensity-distribution data also showing a 
broad monomodal distribution corresponding to a peak average of 34.90 nm (94%) with 
minor scattering contributions from larger aggregates with peak means of 598.6 nm 
(3.3%) and 2903 nm (2.6%) with a Z-average diameter of 28.19 nm with a 
polydispersity of 0.265 (see figure 70). 
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Z-average diameter (nm):   36.61 nm Polydispersity Index (PDI):   0.240 
 
Figure 70. Dynamic light scattering analysis of “large TamiGold” (pH 9.3). (A) Intensity 
distribution and (B) number distribution. 
 
Conversion to a volume-based distribution gives a mainly monomodal distribution with 
a peak mean of 17.70 nm (95.5% by volume). The number-based analysis (see figure 
68) gave a mono-modal distribution, with a peak mean of 13.2 nm (100%). Result 
reproducibility was very good. 
The number average particle size of “large TamiGold” (13.2 nm) is in good agreement 
with the TEM sizing (approximately 14nm) when considering the effect of data analysis 
on number-based particle size for nanoparticles (see appendix 2: Dynamic light 
scattering (DLS), page 263). 
DLS analysis of “large TamiGold” at physiological pH (refer to figure 71) resulted in an 
intensity size distribution showing a broad mono-modal distribution corresponding to a 
peak average of 113.8 nm (100%) with a Z-average particle diameter of 79.45 nm with 
a polydispersity of 0.280.  
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Z-average diameter (nm):   79.45 nm Polydispersity Index (PDI):   0.280 
 
Figure 71. Dynamic light scattering analysis of “large TamiGold” at physiological pH (pH 7.6).  
 
The Z-average particle diameter (at pH 7.6, 79.45 nm) is significantly larger than the Z-
average particle diameter at pH 9.3 (28.19 nm) due to nanoparticle aggregation. This 
corroborates the data obtained in UV-Vis and TEM studies regarding the aggregation 
of functionalised gold nanoparticles in solutions of varied pH.  
DLS data supports the size estimates of the TEM analysis. There is no significant size 
difference between the functionalised gold nanoparticle samples or the citrate capped 
gold nanoparticles (precursor). 
 
In comparing the DLS data of “large” methylphosphonate-stabilised gold nanoparticles 
to “large TamiGold” (Z-average diameters of 36.61 nm and 28.19 nm respectively) it is 
clear that both samples have a nanoparticle size of the same order of magnitude, 
however, the value for “large” methylphosphonate-stabilised gold nanoparticles is 
slightly larger. Considering the larger size of the phospha-oseltamivir moiety in 
comparison to the methylphosphonate group the opposite results may have been 
expected. But once again the nature of the terminating functional group (phospha-
oseltamivir vs. methylphosphonate) is of importance in determining the average 
nanoparticle size population since the terminal methylphosphonate has an unhindered 
ability (in comparison to phospha-oseltamivir) to form long-range (hydrogen-bonded) 
networks within solution which would contribute to a large aggregate population (and 
as such a larger Z-average particle diameter) for the methylphosphonate stabilised 
gold nanoparticles.  
Larger ligands (in comparison to those with small terminating groups) are known to 
disrupt the organisation of ligands on the gold surface and as such do not present the 
same degree of ligand packing or ligand directional orientation.193  
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II.2.5.4. 1H NMR 
It was not possible to obtain 1H NMR spectra of both “large” methylphosphonate- 
stabilised gold nanoparticles and “large TamiGold” due to the increased gold particle 
size (compared to gold nanoparticles produced by the Brüst-Shiffrin method). 1H NMR 
resonances are broadened out completely through NMR relaxation effects and as such 
are not observed for large gold nanoparticles. 
 
II.2.5.5. Physical observations  
“Large” methylphosphonate-stabilised gold nanoparticles and “large TamiGold” are not 
easily isolated (and stable) once removed from their respective buffer solutions. 
Lyophilisation of both leads to a slight but noticeable red-shift in the SPR band of both 
functionalised nanoparticles, though “large TamiGold” seems to appear more robust in 
their tolerance of such conditions. 
“Large TamiGold” in particular (but displayed by “large” methylphosphonate-stabilised 
gold nanoparticles to a lesser extent) displays hysteresis when the pH of the 
surrounding medium was varied. The final state of the gold nanoparticles (with regards 
to the SPR band) is only achieved when the nanoparticles pass an intermediate region 
of high pH. That is, the SPR band does not return to its original position (pre-pH 
variation) until the pH of the solution is increased beyond the optimal pH range for 
colloidal stabilisation.  More specifically, “Large TamiGold” is a stable colloidal solution 
and an SPR band at 525 nm at pH 9.3 (in Tris buffer, as described above) but on 
solution acidification and subsequent SPR red-shift, the 525nm is not returned until the 
pH of solution initially increased to pH > 9.3 and subsequently dialysed against pH 9.3 
(to return to initial solution pH). 
This aspect of gold nanoparticle behaviour has only been investigated qualitatively 
here with respect to the handling of the functionalised gold nanoparticles but this 
behaviour has been discussed in the literature, particularly with respect to ligands of a 
cationic nature.278  
There is a significant difference in the solubility and stability of “small/large TamiGold” 
and “small/large” methylphosphonate-stabilised gold nanoparticles. Both “small 
TamiGold” and “small” methylphosphonate-stabilised gold nanoparticles are 
suspendible in water whereas “large TamiGold” and “large” methylphosphonate-
stabilised gold nanoparticles require a buffered aqueous solution (pH > 9 and pH >7 
respectively). This difference in aqueous solution stability can be attributed to the 
degree of surface functionalisation of gold nanoparticles.  
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Large gold nanoparticles (because of the increased surface area available for ligand 
immobilisation) display a greater number of ligands on the particle surface. In this 
situation, the ionisable phosphonate- and amino-groups present within the phospha-
oseltamivir motif act to induce gold nanoparticle aggregation of “large TamiGold” 
(through hydrogen bond interactions and/or bridging of nanoparticles by ions present in 
solution) when the usually dominant electrostatic stabilising force of the ligands is 
lessened in aqueous solutions where the pH of solution is sub-optimal for colloidal 
stability.228,278,232  
The strength of these interactions is approximately equivalent to the number of bond 
made and as such, weak individual hydrogen bonding interactions are enhanced 
because of their multivalent nature.  Ligand-ligand interactions between gold 
nanoparticles are therefore more significant with respect to the colloidal stability of 
large gold nanoparticles compared to small gold nanoparticles and explain why the 
large nanoparticle systems synthesised in this project show increased sensitivity to the 
surrounding aqueous environment.203 It has also been speculated in the literature that 
residual citrate also contributes to gold nanoparticle cross-linking and thus particle 
aggregation.270   
 
II.2.5.6. Gold nanoparticle stability with respect to an application as an Influenza 
virus sensor 
Typically, a broad bell-shaped pH profile range of enzyme activity is observed with NA 
of various subtypes. Enzymatic activity at high pH has been observed (pH>8).  
Therefore, the stability of “large TamiGold” in basic aqueous suspensions is not 
expected to severely compromise the binding affinity of the immobilised phospha-
oseltamivir ligands for the influenza NA. The arginine triad within the active site is 
arguably the most essential recognition component for the oseltamivir 
pharmacophore.133,107 The pH at which “large TamiGold” is stable to aggregation (pH ~ 
9.3) should not detrimentally effect this important electrostatic interaction and as such 
substrate binding is expected to be maintained beyond optimum NA activity values (pH 
~5-6).279,280  
 
II.2.6. Investigation into NA inhibition by functionalised gold nanoparticles: 
“small TamiGold” 
 “Small TamiGold” (and “small” methylphosphonate-stabilised gold nanoparticles as the 
control sample) were investigated in fluorescence-based inhibition assays with 
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seasonal and pandemic influenza A virus (H1N1) strains (both oseltamivir-resistant (R) 
and oseltamivir-sensitive (S)) in collaboration with the NIMR (National Institute of 
medical research) in order to assess the ability of the functionalised phospha-
oseltamivir motif to bind to viral NA.281  
The particle size data obtained by HRTEM and the Au/S ratio determined by EDX 
analysis of “small” methylphosphonate gold nanoparticles and “small TamiGold” were 
used as a basis for the calculation of ligand (phospha-oseltamivir) concentration for the 
inhibition assays (see appendix 3: Gold nanoparticle inhibition assays: calculation of 
ligand surface coverage, page 266). The inhibitory values (IC50 values) determined 
refer to the estimated concentration of phospha-oseltamivir (not absolute values). 
 
 
Figure 72. Inhibition of the neuraminidase activity of seasonal influenza virus strains (H1N1) by 
‘small TamiGold’. Horizontal lines represent 50% inhibition for the individual experiments. IC50 
values (nM) are 14.7 and 12.3 for wild-type influenza virus strains A/Norway/1758/2007 and 
A/Brisbane/59/2007, respectively. For the oseltamivir-resistant strains the IC50 values (nM) are 
5.3 x 103 for A/Norway/1735/2007 and 14.1 x 103 nM for A/St. Petersburg/12/2008. 
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Figure 73. Inhibition of the neuraminidase activity of pandemic (2008) influenza virus strains 
(H1N1) by ‘small TamiGold’. IC50 values (nM) are 5.2 and 18.6 for wild-type influenza virus 
strains A/Denmark/524/2009 and A/Belgium/4283/2009, respectively. For the oseltamivir-
resistant strain A/Denmark/528/2009 the IC50 value (nM) is 5.5 x 103. 
 
The seasonal strains A/Norway/1758/2007 and A/Brisbane/59/2007 (oseltamivir-
sensitive) resulted in IC50 values of 14.7 nM and 12.3 nM respectively. This is in 
contrast to (oseltamivir-resistant) seasonal strains A/Norway/1735/2007 and 
A/StPetersburg/12/2008 which required higher nanoparticle concentrations for 50% 
inhibition which resulted in IC50 values of 5.3 x 103 nM and 14.1 x 103 nM, respectively 
(see figure 72). 
It should be noted that the IC50 value of influenza virus strain H1N1 A/St. 
Petersburg/12/2008 was slightly outside the maximum particle concentration tested. 
The value given is an extrapolation of the data points obtained, indicating clear 
inhibition of the influenza virus.  
Similar inhibitory results were obtained with the pandemic influenza virus strains 
investigated (see figure 73). The pandemic strains A/Denmark/524/2009 and 
A/Belgium/G4383/2009 (both oseltamivir-sensitive) resulted in IC50 values of 5.2 nM 
and 18.6 nM respectively whereas A/Denmark/528/2009 (oseltamivir-resistant) resulted 
in an IC50 value of 5.5 x 103 nM (therefore weaker inhibition). 
The inhibition assays carried out with “small” methylphosphonate-stabilised gold 
nanoparticles and the same influenza virus strains show no inhibition of influenza virus 
NA activity (see figure 74). 
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Figure 74. Inhibition of the neuraminidase activity of influenza virus strains (H1N1) by small 
methylphosphonate-stabilised gold nanoparticles. (A) Seasonal influenza virus strains (H1N1) 
and (B) pandemic influenza virus strains (H1N1). No inhibition was detected within the 
concentration range tested. 
 
The results of the inhibition assays indicate strong and selective binding of “small 
TamiGold” to the influenza virus strains via the NA surface protein and that “small 
TamiGold” even binds to oseltamivir-resistant strains (albeit at higher concentrations). 
The lack of inhibition detected with the H1N1 influenza virus strains with “small” 
methylphosphonate-stabilised gold nanoparticles (control) over the concentration range 
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tested all but excludes unspecific interaction with the influenza virus strains as a cause 
of NA inhibition. The conclusion can therefore be drawn that the binding properties of 
“small TamiGold” are an approximate 1:1-translation of the specificity and affinity of the 
phospha-oseltamivir motif onto the gold nanoparticle. 
The main contributing factors to the error in the inhibitory concentrations (IC50 values) 
of phospha-oseltamivir motifs on “small TamiGold” arise from three main factors; 1) not 
all phospha-oseltamivir moieties on a given gold nanoparticle are available for binding, 
2) the error in the Au/S ratio determined by EDX analysis (mentioned above) and c) the 
assumptions made regarding the morphology of the gold nanoparticles. 
 
II.2.7. Investigation into NA inhibition by functionalised gold nanoparticles: 
“large TamiGold” 
II.2.7.1. TEM study with influenza A virus (H1N1) 
A TEM study was carried out with deactivated influenza A virus (H1N1/PR8). The 
incubation of H1N1/PR8 with “large TamiGold” (~4 nM) at room temperature led to 
TEM images of “large TamiGold” binding to the surface of the virus (see figure 75). 
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Figure 75. (A,B) TEM images of binding of ‘large TamiGold’ to influenza virus (PR8/H1N1). (C) 
TEM image showing clustering of ‘large TamiGold’ on the virus surface. (D) Aggregation of 
‘large TamiGold’ in presence of monomeric inhibitor (monophosphonate derivative, Ki = 0.30 ± 
0.04 nM). The inhibitor is expected to saturate the neuraminidase active sites but may also 
impact on the aggregation due to changes in the ionic strength. 
 
The negative staining of influenza virus was not as successful with the second set of 
images (see figure 76). Despite this lower image quality the binding of “large TamiGold” 
to the influenza virus particle is clear (in comparison to images obtained from blank 
grids and control samples (see figure 75). 
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Figure 76. (A,B,C) TEM images of binding and clustering of ‘large TamiGold’ to influenza virus 
(PR8/H1N1). (D) Aggregation of ‘large TamiGold’ in presence of monomeric inhibitor 
(monophosphonate derivative, Ki = 0.30 ± 0.04 nM). The source of poor virus resolution was not 
determined.  
 
The selectivity of the binding was reversed by the addition of an excess of a known NA 
inhibitor (monophosphonate phospha-oseltamivir, Ki: 0.30 ± 0.04 nM, 60 mM), which is 
expected to saturate the NA active sites. However, the concentration of the NA inhibitor 
was relatively high and appeared to impact on the aggregation of “large TamiGold” 
through changes in solution ionic strength and/or through inhibitor cross-linking with the 
nanoparticles (see figure 77, A). 
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Figure 77. (A) TEM image of aggregated “large TamiGold” on addition of monomeric inhibitor in 
the absence of H1N1. (B,C,D) Natural aberrations present on the TEM grid (post-staining) which 
are distinctively different from the influenza A H1N1 containing TEM images with “large 
TamiGold”. B,C: Blank grid + Tris buffer (10mM, pH 9.3) + 2 % uranyl acetate. 
 
To summarise, the TEM study confirmed the interaction of the functionalised phospha-
oseltamivir motif with the NA of influenza virus. 
Unfortunately, due to a lack of availability of whole influenza virus, a similar TEM-study 
upon “large” methylphosphonate stabilised gold nanoparticles study was not carried 
out.  
 
  
 II.2.7.2. Preliminary UV
A qualitative assessment of the effect of virus on the wavelength of the SPR band of 
“large TamiGold” was carried out with the intention of assessing the potential for “large 
TamiGold” (~4 nM) to act as a p
The deactivated virus suspension (~1mg/mL in PBS) was added in small aliquots to 
“large TamiGold” (Tris buffer, pH 9.3). UV
any potential changes in “large TamiGold” SPR band. As a
was diluted with the same volume of PBS buffer (to exclude changes in solution 
concentration and pH unrelated to the influenza virus). 
 
 
Figure 78. Addition of increasing amounts of influenza virus (H1N1/PR8, ~1mg/mL) to ‘large 
TamiGold’, resulting in a very slight blue
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-Vis study with influenza A virus (H1N1)
rototype influenza virus sensor.  
-Vis spectra were then recorded to observe 
 control, “large TamiGold” 
 
-shift (~ 5 nm) of the absorption band. 
 
 
 
  
Figure 79.  Dilution of a solution of ‘large TamiGold’ (same sample concentrations as in
76.) with PBS buffer. No blue
 
Addition of increasing amounts of virus resulted in a very slight blue
desired red-shift) in the SPR absorption band (
(~ 5nm) was not observed with the control (influenza virus
dilution and as such the blue
solution (see figure 7
The source of this blue
In this situation, it appears as though the overall effect of influenza virus addition is to 
screen or shield “large TamiGold” particles from interacting (through coupling of the 
surface plasmons). As such, a blue
between the influenza virus and “large TamiGold” at a local level (observed in TEM 
images). However, it is worth not
nanoparticles have been observed in the detection of cancer cells and 
the saturation of gold nanoparticles at higher cell concentrations
speculated that for optimal sensing of the virus (through an SPR band red
concurrent visual nanoparticle aggregation) less disparity is required in terms of the 
size of the nanoparticles and the influenza virus (as well as optimised linker lengths).
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-shift was observed under these conditions.
see figure 78). This very slight blue
-free) sample at this level of 
-shift is attributed to the presence of the influenza virus in 
9). 
-shift has not been determined and deserves further study. 
-shift is observed even though binding is occurring 
ing that a “blue-shift” in the SPR bands of gold 
.
 
 figure 
 
-shift (and not the 
-shift 
 
is attributed to 
282
 It can therefore be 
-shift with 
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Though the results of this UV study (blue-shift of the SPR band of “large TamiGold”) 
were not expected, the UV study indicates that the presence of influenza virus does 
influence the phospha-oseltamivir-stabilised gold nanoparticles and provides a method 
of observing that interaction (via the SPR band).  
In conjunction with the TEM images, these data indicate that specific interaction does 
occur with “large TamiGold” and influenza NA. However, with regards to the 
development of an influenza sensor there are many practical hurdles to overcome. 
As with the TEM studies with influenza virus (see above), the lack of availability of 
whole influenza virus prevented further colorimetric studies with “large” 
methylphosphonate stabilised gold nanoparticles. This prevents drawing any further 
conclusions from the nature of the interaction between influenza virus NA and “large 
TamiGold” for the time being. 
 
II.2.8. Conclusions 
The synthesis of a simple dimeric phospha-oseltamivir presenting structure, compound 
45, has given some insight into the effect of multimeric phospha-oseltamivir inhibitors 
on NA binding. Although the binding observed with compound 45 and NA was slightly 
improved compared to oseltamivir itself, this most likely comes as a result of statistical 
rebinding effects and not through multivalent interactions.  
The syntheses and use of phospha-oseltamivir derivatives has been successfully 
implemented towards functionalised gold nanoparticles (“TamiGold”). Though not the 
first example of an immobilized oseltamivir analogue,189 the work carried out in this 
project is the first example of an immobilised oseltamivir analogue functionalised to a 
solid support (gold nanoparticles) without compromising the oseltamivir 
pharmacophore. 
Functionalised gold nanoparticles synthesised by the Brüst-Shiffrin method (“small 
TamiGold”) bind strongly and selectively to both seasonal and pandemic influenza virus 
strains investigated and at higher concentrations to oseltamivir-resistant strains and 
this binding is independent of non-specific binding effects.  
The interaction of functionalised gold nanoparticles synthesised by the ligand-
exchange/Turkevitch method (“large TamiGold”) have also shown to bind to influenza 
virus H1N1 (from TEM and qualitative UV studies), although a much better 
understanding of “TamiGold” binding and selectivity with influenza virus has yet to be 
achieved. The lack of availability of H1N1 proved a hindrance in the pursuit of further 
investigations of the binding interaction of “large TamiGold” with influenza virus. 
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However, the influenza NA has been made available as a target for multivalent tools 
and diagnostics for influenza research, providing an alternative to HA-targeting 
strategies.  
“TamiGold” may have a potential use as TEM image contrast agents for studying 
influenza viruses as well as serving as a prototype for novel virus sensors targeting the 
NA. However, it appears that biosensor systems based on functionalised gold 
nanoparticles (typically colorimetric in nature) are a complicated balance between a 
number of variables (nanoparticle size, size of detected analyte, the concentration of 
nanoparticles/analyte, pH, ionic strength). As such, more detailed studies of such 
variables are the next logical step for this research. 
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II.2.9. Towards phospha-oseltamivir based tools for the investigation of influenza 
virus neuraminidase 
II.2.10. Synthesis of “clickable” phospha-oseltamivir derivatives 
Using the same alkylation methodology as with phospha-oseltamivir derivative 42, the 
ω-azido hexyl derivative 53 was synthesised from the alkylation reaction of the 
monomethyl phosphonate 35 with triflate 52 (itself synthesised in 3 steps (66%) from 
compound 38). The resulting mixed diester could be fully deprotected using standard 
conditions to give the target ω-azido derivative 54 (see scheme 29).  
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Scheme 29. Reagents and conditions; (a) NaN3, DMF; (b) TBAF, AcOH, THF; (c) 
Trifluoromethanesulfonic anhydride, lutidine, DCM, -60 °C; (d) acetonitrile, 52; (e) i. NaI, 
acetone, reflux; ii. TFA/H2O (50%); iii. gel permeation chromatography. 
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In a similar fashion, the synthesis of ω-ethynylbutyl derivative 56 was achieved through 
the alkylation reaction of the monophosphonate 35 with triflate 55 (synthesised directly 
from commercially available hexyn-1-ol) in good yield (65%, based on recovered 
starting material) followed by deprotection to give target compound 57 (see scheme 
30). 
 
 
Scheme 30. Reagents and conditions; (a) Trifluoromethanesulfonic anhydride, lutidine, DCM, -
60 °C; (b) acetonitrile and compound 55; (c) i. NaI, acetone, reflux; ii. TFA/H2O (50%); iii. gel 
permeation chromatography. 
 
The introduction of these specific chemical handles (ω-azido and ω-ethynylbutyl) for 
ligation purposes provides freedom of application to the phospha-oseltamivir structure, 
whether via traditional amino-coupling chemistry (via reduction of the azido moiety to 
the corresponding primary amine) or, as mentioned, through “click” methodologies 
(considered rapid and high-yielding reactions, tolerant of a range of solvents conditions 
and often allowing orthogonality of reaction conditions)267,283 and therefore provides the 
rationale for the synthesis of compounds 54 and 57. 
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This flexibility in conjugation methodology (provided by compounds 54 and 57) enables 
the phospha-oseltamivir motif to accommodate any pre-existing ligation requirements 
of different chemical and biological systems without researchers having to rely upon a 
single conjugation method.  As such, the availability of these compounds to influenza 
researchers with differing chemical/conjugation requirements is achieved. 
At the time of submission, a dimeric “clicked” phospha-oseltamivir (Ki = 0.04 ± 0.01 nM) 
had been synthesised by Streicher et al. using compound 53.284 
 
II.2.10.1. Neuraminidase (NA) inhibition studies 
In conjunction with the NIMR, compounds 54 and 57 were tested for inhibition of the 
NA isolated from influenza X31 (H3N2) and were compared to the well-established and 
selective NA inhibitors oseltamivir-carboxylate and zanamivir.  
 
54 57 Oseltamivir Zanamivir 
0.224 ± 0.037 0.234 ± 0.036 0.130 ± 0.032 0.268 ± 0.039 
 
Table 5. Inhibition constants (Ki [nM]) for target phosphonates.  
(Inhibition of MUNANA hydrolysis catalysed by neuraminidase from influenza virus X (H3N2); 
inhibition constants were determined as described in experimental section; KM for MUNANA = 
6.4 ± 0.6 µM). 
 
Both target compounds 54 and 57 are found to be subnanomolar inhibitors of 
MUNANA hydrolysis by the NA from influenza X31 (H3N2) and are of the same order 
of magnitude as the benchmark NA inhibitors (see table 5). 
 
II.2.11. Conjugation to reporter groups 
The ω-azido derivative 53 was used to synthesise phospha-oseltamivir derivatives 
conjugated to two types of reporter groups; biotin and fluorescein, widely used in 
biological research. Fluorescein represents a family of fluorophores widely used in 
biochemistry and virology (for example, the Alexfluor® group. The application of biotin 
is well-established and usually in conjunction with its interaction with avidin or 
streptavidin proteins.181  
As the respective reporter groups were not readily available with the appropriate 
functionality to allow the Huisgen-1,3-dipolar cycloaddition reaction, the conjugation of 
these reporter groups was achieved through standard amino-coupling methods. 
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The reduction of the ω-azido derivative 53 was successfully achieved by a Staudinger 
reaction with PMe3 in THF (1 M) followed by aqueous hydrolysis to give the amine 58, 
which was then used as the precursor to the reporter group conjugates (see scheme 
31). 
 
 
 
Scheme 31. Reagents and conditions; (a) i. PMe3, THF; ii. H2O. 
 
The (+)-biotin conjugate 60 was synthesised by coupling the amine 58 with (+)-biotin 
using benzotriazol-1-yl-oxypyrrolidinephosphonium hexafluorophosphate (PyBOP) as 
the condensing agent. Deprotection of the methylphosphonate ester using Finkelstein 
conditions followed by tert-butyl carbamate removal with trifluoroacetic acid yielded (+)-
biotin conjugate 60 in good yield (64 %) (see scheme 32). 
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Scheme 32. Reagents and conditions; (a) d-biotin, PyBOP, DMF; (b) i. NaI, acetone, reflux; ii. 
TFA/H2O (50%); iii. gel permeation chromatography. 
 
In order to synthesise the target fluorescein conjugate 62, the amine 58 was reacted 
with 5-/6-carboxyfluorescein succinimidyl ester (NHS-Fluorescein; used as the 
commercially available mixture of isomers) in the presence of triethylamine to give 
fluorescein conjugate 61 as a mixture of regioisomers (see scheme 33). 
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Scheme 33. Reagents and conditions; (a) NHS-Fluorescein, DIPEA, DMF; (b) i. NaI, acetone, 
reflux; ii. TFA/H2O (50%); iii. reversed phase chromatography. 
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The separation of these isomers was not possible using standard chromatography 
techniques available and was never intended. 
Using similar deprotection conditions as above, target fluorescein conjugate 62 was 
obtained (as the mixture of regioisomers). Purification of the fully deprotected 
fluorescein conjugate 62 (both regioisomers) was problematic by gel permeation 
chromatography due to reduced solubility in ammonium phosphate buffer. It was 
possible to obtain a purified sample via reverse phase chromatography. The use of 
DMSO/H2O mixtures of fluorescein conjugate 62 (≥ 1:10 ratio) resulted in no solubility 
problems.  
 
II.2.11.1. Neuraminidase (NA) inhibition studies 
As with the “clickable” conjugates 54 and 57, the (+)-biotin conjugate 60 and 
fluorescein conjugate 62 were tested for inhibition of the NA isolated from influenza 
X31 (H3N2) (NIMR collaboration). 
 
60 62 Oseltamivir Zanamivir 
0.241 ± 0.052 0.162 ± 0.032 0.130 ± 0.032 0.268 ± 0.039 
 
Table 6. Inhibition constants (Ki [nM]) for target phosphonates. 
(Inhibition of MUNANA hydrolysis catalysed by neuraminidase from influenza virus X (H3N2); 
inhibition constants were determined as described in experimental section; KM for MUNANA = 
6.4 ± 0.6 µM) 
 
Both the (+)-biotin conjugate 60 and fluorescein conjugate 62 are subnanomolar 
inhibitors of MUNANA hydrolysis by influenza NA (see table 6).  
 
II.2.11.2. Fluorescence titrations with NA 
Slightly stronger binding was observed for the fluorescein conjugate 62 and (in 
collaboration with the NIMR) prompted a preliminary study on the impact of 
fluorescence observed when fluorescein conjugate 62 binds with influenza NA (see 
figure 80).  
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A      B 
 
Figure 80. Decrease in fluorescence intensity (510 nm) of compound 62 upon binding to 
influenza virus NA (A). The binding experiment was carried out at 5 °C and concentrations of 
compound 62 and NA were comparable (9 nM and 12 nM, respectively). Red-shift and 
reduction of fluorescence maximum of compound 62 upon binding to influenza NA (B); Black 
line: Unbound compound 62. Red line: compound 62 bound to NA. 
 
A decrease in the fluorescence intensity of compound 62 (and a slight shift in the 
emission fluorescence maxima) was observed on binding to NA. Only a slight 
perturbation in the fluorescence maxima on NA binding is observed. Fluorescein (in 
comparison to other fluorescent probes) is not considered to be overly environmentally-
sensitive fluorophore.285 As such, the change in fluorescence intensity observed is 
more than sufficient for binding studies. 
A fluorescence-based binding titration with compound 62 and influenza virus X (H3N2) 
determined quantitatively the dissociation constant (KI) for the interaction (0.23 ± 0.05 
nM), which shows reasonable agreement to the value determined by inhibition of 
MUNANA hydrolysis (0.162 ± 0.032 nM) (see figure  81).  
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Figure 81. Fluorescence titration of compound 62 against NA (X31 N2). The dissociation 
constant determined for compound 62 was 0.23 ± 0.05 nM. 
 
II.2.12. Conclusions 
The successful syntheses of “clickable” phospha-oseltamivir derivatives along with the 
conjugation of the phospha-oseltamivir structural motif to biologically useful reporter 
groups (+)-biotin and fluorescein has been achieved. 
These results expand upon previous synthetic work within the group and support the 
conclusion that manipulation at the phosphonate-ester by the introduction of “clickable” 
chemical handles and larger biologically useful reporter groups do not impair the 
binding affinity of the phospha-oseltamivir pharmacophore.  
With regards to the “clickable” derivatives compound 54 and 57, the potential of these 
compounds to act as precursors to multivalent chemical probes and phospha-
oseltamivir functionalised surfaces by exploiting their conjugation chemistry is now 
within reach. 
 
The (+)-biotin conjugate 60 may provide a new method of studying the binding of NA to 
immobilised phospha-oseltamivir. The use of biotin to immobilise or ligate bioactive 
compounds to various materials for biological study is well-established (for example, 
ELISA assay formats or Biacore systems) and a similar use has been proposed for 
zanamivir conjugates of biotin.286   
Compound 60 could be developed to provide a stable influenza virus immobilisation 
platform to permit the investigation of the binding of polyvalent sugar derivatives to the 
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virus surface proteins. For such studies, the linker length of compound 60 may need 
optimisation. This is entirely possible using the chemistry that has been applied in this 
project. 
The binding titration (see figure 81) illustrates that fluorescein conjugate 62 could be 
used to obtain small-molecule binding affinities with NA via a displacement titration and 
therefore provides a new alternative to the classical (but unselective) MUNANA based 
assay.  
The clear interaction of fluorescein conjugate 62 with NA (and the subsequent effect on 
fluorescence) suggests the possibility of using the compound as a tool for the 
quantification of influenza NA directly or to provide the basis for a fluorimetric method 
of influenza virus detection independent of standard immunoassay methodologies. 
Further experiments in collaboration with the NIMR are underway to investigate the 
fluorescence quenching effect on NA substrate binding and to assess the potential of 
fluorescein conjugate 62 towards applications such as the identification of irregular NA 
distribution (“neuraminidase patches”) on the virus surface and the distribution of NA 
on influenza virus subtypes. 
 
II.2.13. Future scope 
Although nanoparticle characterisation techniques have been applied to “TamiGold” 
(primarily for sizing purposes), further nanoparticle characterisation techniques are 
required in order to unequivocally determine the physical composition and 
characteristics of the gold nanoparticles. The determination of ligand surface coverage 
to a higher level of accuracy is of significant importance (with respect to determining 
the concentration of functionalised phospha-oseltamivir).  
Therefore, the compositional analysis of “TamiGold” will need to be addressed by other 
analytical methods (for example, XPS (X-ray photoelectron spectroscopy) or TGA 
(thermogravemetric analysis)) in addition to EDX.195  
Further TEM studies with “large TamiGold” and also with “large” methylphosphonate-
stabilised nanoparticles are required to further qualify the interaction of “large 
TamiGold” with influenza A H1N1 as selective and specific. 
Other studies of gold nanoparticles utilised as detecting agents for larger biomolecules 
or biological superstructures showed limited or no effect on the nanoparticle SPR band 
without increasing the nanoparticle size (therefore observing stronger affinity between 
functionalised nanoparticles and the target analyte) or by increasing the affinity of the 
interaction through the use of molecular crowding agents.282,287  
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Macromolecular crowding increases the association and extent of macromolecular 
interactions in solution.288,287 With respect to “large TamiGold” and its interaction with 
influenza NA, the use of a macromolecular crowding agent may promote the 
association of the two species and thus enhance the desired colorimetric observations 
(SPR red-shift) necessary for a novel sensor based on this interaction. 
 
Further work will therefore include more detailed investigations into the variables which 
affect the ability of “large TamiGold” to act as an influenza virus sensor. This may be 
achieved by increasing the size of the nanoparticle presenting the phospha-oseltamivir 
motif, varying the linker length of the functionalised ligand and by altering the chemical 
equillibria that govern macromolecular interactions. All may improve the sensitivity of 
nanoparticle-virus interactions.  
It is highly improbable that absolute selectivity is achieved regardless of the type of 
recognition system used for nanoparticle-analyte interactions. With respect to 
“TamiGold”, some limited non-selective binding will occur but is unlikely that such non-
specific interactions would cause the same level of SPR perturbation (significant red-
shift and particle aggregation) to “TamiGold”-NA binding once the nanoparticle sensor 
platform is fully optimised for influenza NA detection. 
The multiple presentation of the phospha-oseltamivir motif is not limited to gold 
particles. Other types of nanoparticles tailored for specific experimental applications 
can be synthesised using phospha-oseltamivir disulfide 45. Iron particles (for NMR 
studies) or semiconductor nanodots (for fluorescence studies and single virus 
detection) are a logical step forward regarding tools for the investigation of influenza 
NA.  
Recent work by Streicher et al. has used the Huisgen-1,3-dipolar cycloaddition reaction 
(“click" chemistry) successfully with the ω-azido derivative 53, as expected.284  
The application of this chemistry will therefore be continued towards the synthesis of 
multimeric phospha-oseltamivir displaying molecules (trimer, tetramers, hexamers, 
dendrimers) with the aim of binding to influenza NA with increased potency through 
multivalent interactions with NA active sites. Chemistry which makes use of the ω-
ethynylbutyl compounds 56 or 57, with complementary “click” functionality, will also be 
developed further (particularly if the ω-azido derivatives 53 or 54 are not synthetically 
applicable to a specific application). 
With regards to the (+)-biotin conjugate 60, the optimisation of linker lengths to prevent 
unwanted steric interactions between the NA and avidin/streptavidin proteins is also in 
the pipeline. A biotin-containing conjugate with optimised linker lengths to prevent such 
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unwanted steric interactions allows the immobilisation of influenza virus on surfaces (as 
mentioned above). Avidin/streptavidin-coated quantum dots could be used to 
immobilise (+)-biotin conjugate 60 (or related analogues) thus also allowing further 
fluorescence based experiments (FRET (fluorescence resonance energy transfer) and 
single virus detection) to investigate binding of the phospha-isosteres of oseltamivir to 
influenza NA.  
As mentioned above, further work with compound 62 is underway to investigate the 
fluorescence quenching effect on NA substrate binding and to assess the potential 
applications of the compound (for example, virus counting, NA distribution, etc.). 
Using the chemistry developed herein, other types of fluorophores may be conjugated 
to the phospha-oseltamivir motif. Fluorescein is only one of a large number of 
structurally related fluorophores and is not always the most useful in fluorescent 
applications in comparison to other fluorophores, such as the Alexafluor group® (often 
used as standard in influenza virology) which often exhibit better properties (for 
example, improved water solubility and photo-stability) for fluorescence applications in 
biological research.285  
The phospha-oseltamivir monoester methodology itself could be developed further with 
the aim of synthesising novel influenza NA inhibitors which exploit the “150-loop” in 
group-1 neuraminidases.88 The exploitation of this flexible, hydrophobic cavity in the 
active site of group-1 neuraminidases would make possible the synthesis of NA 
inhibitors of increased inhibitory potency and affinity towards the pandemic A/H1N1, 
avian A/H5N1 influenza viruses.87,128,129 
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III. Experimental section 
III.1. General procedures 
Where anhydrous solvents were required for reactions, MeOH and DMF were 
purchased (anhydrous) and used as received. DCM was doubly distilled (over CaH2) 
before use and THF was obtained anhydrous and was used without further drying. All 
other solvents were dried using appropriate drying reagents. Fine chemicals were 
purchased from Aldrich-, Sigma- or Acros-Chemicals and were of the highest purity 
available. Reactions were monitored via thin layer chromatography (TLC) using pre-
coated silica sheets with fluorescent indicator UV254. Compound detection was 
achieved by UV absorption and by developing plates by staining with a molybdenum 
phosphate reagent (20 g ammonium molybdate and 0.4 g cerium(IV) sulfate in 400 mL 
of 10% aqueous sulphuric acid) with subsequent heating. 
Chromatographic purification was performed using silica gel 60A ‘Davisil’ (particle size 
35-70µm) from Fisher Scientific, UK and silica gel 100 C18 reversed phase (particle 
size 40-63µm from Fluka Analytical, UK. Silica-based MPLC chromatography was 
carried out on the Büchi Sepacore system equipped with glass columns packed with 
LiChroprep Si 60 (15-25µm) from Merck, Darmstadt, Germany. Solvents for 
chromatography were used as received except for toluene and ethyl acetate, which 
were distilled before use. Gel permeation chromatography was carried out in the 1-10 
mg scale on a XK 16/70 column (bed volume 130 mL), from Amersham packed with 
Sephadex G-10 (particle size 40-120µm) and 0.1 M NH4HCO3 as buffer. Detection was 
achieved using a differential refractometer from Knauer, Berlin, Germany.  
1H NMR, 13C NMR, 31P NMR and all multidimensional spectra were recorded on Varian 
VNMRS spectrometers (600 MHz, 500 MHz or 400 MHz). Chemical shifts in 1H and 13C 
NMR spectra were referenced to the residual proton resonance of the respective 
deuterated solvents, CDCl3 (7.26 ppm), D2O (4.80 ppm) and CD3OD (3.31 ppm) 
respectively. For 31P NMR spectra H3PO4 was used as external standard (0 ppm).  
HR-ESI-MS spectra were recorded on a Bruker Daltonics Apex III in positive mode with 
MeOH and/or H2O as solvent. Where possible, HR-ESI-MS has been used to 
characterise compounds which have been synthesised. 
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III.2. Synthetic procedures towards α-O-sialoside derivatives 
 
Methyl 5-acetamido-3,5-dideoxy-D-glycero-D-galacto-2-nonulopyranosonate (1) 
  
 
 
MeOH (230 mL) was added to 5-acetamido-3,5-dideoxy-D-glycero-D-galacto-2-
nonulopyranosonicacid (Neu5Ac) (5.0 g, 16.0 mmol). To the resulting solution, 
Amberlite IR-120 ion-exchange resin (H+) was added. The solution was then 
vigorously shaken (mechanically) overnight. After shaking, the Amberlite IR-120 (H+) 
ion-exchange resin was filtered off, rinsed with MeOH and the resulting clear solution 
was then evaporated to dryness leaving a white crystalline solid, compound 1 (3.9 g, 
75%) which was then dried extensively in vacuo.  
Data corresponds to literature.63  
1H NMR (500 MHz, MeOH-D4) δH: 1.67 (0.1 H, dd, J = 11.9, 12.0 Hz, α-H3ax), 1.89 (1 H, 
dd, J = 12.0, 12.2 Hz, β-H3ax), 2.01 (s, 3H, -NCOCH3), 2.22 (1 H, dd, J = 4.5, 12.9 Hz, 
β-H3eq), 2.68 (0.1 H, dd, J = 43.7, 12.5 Hz, α-H3eq), 3.48 (1 H, d, J = 9.2 Hz, H7), 3.62 (1 
H, dd, J = 5.7, 11.3 Hz, H9), 3.70 (1 H, m, H8), 3.78 (3 H, s, -CO2CH3), 3.77 – 3.82 (1 H, 
m, H5, H9’), 4.00 (1 H, d, J = 10.7 Hz, H6), 4.04 (1 H, m, H4).  
13C NMR (125.7 MHz, MeOH-D4) δC: 22.64 (-NHCOCH3), 40.75 (C3),  
53.12 (-CO2CH3), 54.37 (C5), 64.88 (C9), 67.88 (C4), 70.26 (C7), 71.68 (C8), 72.14 
(C6), 96.70 (C2), 171.78 (C1), 175.12 (-NCOCH3)). 
 
Methyl (5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-acetyl-β-D-glycero-D-galacto-2-
nonulopyranosylchloride)onate (2) 
 
AcHN
OAc
O CO2Me
AcO
OAc
AcO
Cl
 
 
A solution of MeOH (0.60 mL) and AcCl (4.12 mL) was added to compound 1 (203.9 
mg, 0. 618 mmol) and cooled to 0 °C (ice-bath). AcOH (0.20 mL) was added and the 
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reaction was stirred at 0 °C for 15 hours (overnight). After the reaction was complete, 
the acidic solution was evaporated and the resulting product was co-evaporated with 
toluene several times, leaving a yellow-brown syrup which after filtering through a 0.2 
µm syringe filter and on further drying under high vacuum yielded an off-white foam 
(322 mg, ~quantitative). Rf : 0.32 (EA). No further purification was carried out. 
Data corresponds to literature.63  
1H NMR (500 MHz, CDCl3) δH: 190 – 2.16 (15 H, 5s, -NCOCH3, 4 x -OCOCH3), 2.29 (1 
H, dd, J = 11.7, 11.7 Hz, H3ax), 2.79 (1 H, dd, J = 4.8, 13.9 Hz, H3eq), 3.87 - 3.89 (3 H, s, 
-CO2CH3), 4.00 – 4.24 (2 H, m, H5, H9), 4.35 (1 H, dd, J = 1.6, 10.8 Hz, H6), 4.41 (1 H, 
ddd, J = 1.5, 9.0, 12.4 Hz, H9’), 5.18 (1 H, m, H8), 5.23 – 5.34 (1 H, m, -NH), 5.41 (1 H, 
ddd, J = 4.6, 10.7, 14.6 Hz, H4), 5347 (1 H, d, J = 7.0 Hz, H7). Toluene impurity 
present. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-acetyl-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (3) 
 
AcHN
OAc
O O
AcO
OAc
AcO
CO2Me
 
 
Ag2CO3 (2.55 g, 9.25 mmol) and AgClO4 (191.8 mg, 0.925 mmol) were dried in vacuo 
for 3 hours in the absence of light and were then placed under an N2 atmosphere. Dry 
allyl alcohol (5mL) was then added via syringe, forming a suspension which was left to 
stir for 20 minutes. Compound 2 (943.8 mg, 1.85 mmol) was then dissolved in dry allyl 
alcohol (4 mL) and was quickly added to the stirring suspension and left to stir (under 
N2 and in the absence of light) at room temperature for 20 hours (overnight). On 
completion, the resulting solution was filtered through celite filtering agent (with DCM), 
the celite being rinsed thoroughly with DCM. Subsequently, the solvent was evaporated 
in vacuo and after flash chromatography (EA), a clear oil was obtained, which on 
further drying in vacuo yielded a white crystalline foam, compound 3 (552.5 mg, 56 %). 
Rf : 0.30 (EA). Data corresponds to literature.63  
1H NMR (500 MHz, CDCl3) δH: 1.85, 2.00, 2.01, 2.11, 2.12 (15 H, 5s, -NHCOCH3, 4 x -
OCOCH3), 1.95 (1 H, dd, J = 12.6, 12.6 Hz, H3ax), 2.58 (1 H, dd, J = 4.5, 12.8 Hz, H3eq), 
3.75 (3 H, s, -CO2CH3), 3.85 (1 H, dd, J = 5.8, 12.8 Hz, -CHH’-CH=CH2), 4.03 (1 H, dd, 
J = 10.2, 10.3 Hz, H5), 4.05 - 4.11 (2 H, 2m, H6, H9), 4.22 - 4.31 (2 H, 2m, H9’, -CHH’-
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CH=CH2), 4.83 (1 H, ddd, J = 4.6, 9.7, 12.4 Hz, H4), 5.09 (1 H, d, J = 9.5 Hz, -NH), 5.14 
(1 H, dd, J = 1.1, 10.4 Hz, -CH2-CH=CHHcis), 5.26 (1 H, dd, J = 1.3, 17.2 Hz, -CH2-
CH=CHHtrans), 5.30 (1 H, dd, J = 1.8, 8.4 Hz, H7), 5.40 (1 H, m, H8), 5.84 (1 H, m, -CH2-
CH=CH2 ). 
13C NMR (125.7 MHz, CDCl3) δC: 20.87, 20.94, 20.96, 21.23 (4s, 4 x -OCOCH3), 23.30 
(-NHCOCH3), 38.20 (C3), 49.59 (C5), 52.77 (-CO2CH3), 62.55 (C9), 66.03  
(-CH2-CH=CH2), 67.53 (C7), 68.79 (C8), 69.24 (C4), 72.68 (C6), 98.63 (C2), 117.35 (-
CH2-CH=CH2), 133.71 (-CH2-CH=CH2), 168.50 (C1), 170.17, 170.25, 170.29, 170.72 (4 
x -OCOCH3), 171.10 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C23H33NO13 [M+Na]+ 554.1852, found 554.1849. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (4) 
 
 
 
Compound 3 (100mg, 0.224 mmol) was dissolved in anhydrous MeOH (1.5 mL) and 
freshly prepared NaOMe solution (0.6 mL, 0.33 M) was added. The resulting solution 
was left to stir for 4 hours. Once complete, the solution was neutralised with Amberlite 
IR-120 (H+) ion-exchange resin (mechanically shaken for 15 minutes). Subsequently, 
the resin was removed by filtration, rinsed with MeOH and the resulting clear solution 
was evaporated to dryness in vacuo. After flash chromatography purification 
(DCM:MeOH; 7:1), a clear oil was obtained which on further drying in vacuo, yielded a 
white crystalline foam compound 4 (69.2 mg, 85%). Rf : 0.16 (DCM:MeOH 7:1).  
Data corresponds to literature.63  
1H NMR (500 MHz, MeOH-D4) δH: 1.76 (1 H, dd, J = 12.5, 12.5 Hz, H3ax), 2.00 (3 H, s, -
NHCOCH3), 2.70 (1 H, dd, J = 4.6, 12.8 Hz, H3eq), 3.51 (1 H, d, J = 9.1 Hz, H7), 3.58 (1 
H, d, J = 10.5 Hz, H6), 3.61 - 3.68 (2 H, m, H4, H9), 3.77 (1 H, dd, J = 10.0, 10.2 Hz, H5), 
3.83 (3 H, s, -CO2CH3), 3.84 - 3.87 (2 H, m, H8, H9’), 3.99 (1 H, dd, J = 5.4, 12.6 Hz, -
CHH’-CH=CH2), 4.29 (1 H, dd, J = 5.2, 12.9 Hz, -CHH’-CH=CH2), 5.12 (1 H, d, J = 10.3 
Hz, -CHH’-CH=CHHcis), 5.23 (1 H, d, J = 17.3 Hz, -CHH’-CH=CHHtrans), 5.87 (1 H, m, -
CHH’-CH=CH2). 
13C NMR (125.7 MHz, MeOH-D4) δC: 22.67 (-NHCOCH3), 41.71 (C3), 53.35  
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(-CO2CH3), 53.84 (C5), 64.73 (C9), 66.22 (-CH2CH=CH2), 68.52 (C4), 70.23 (C7), 
72.45 (C8), 74.96 (C6), 100.01 (C2), 116.94 (-CH2CH=CH2), 135.43 (-CH2CH=CH2), 
171.00 (C1), 175.20 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C15H25NO9 [M+Na]+ 386.1421, found 386.1419. 
 
Ammonium (allyl 5-acetamido-3,5-dideoxy-4-O-methyl-D-glycero-α-D-galacto-2-
nonulopyranosidonate) (5) 
 
 
 
Compound 11 (19.9 mg, 0.0477 mmol) was dissolved in 80% AcOH(aq.) (1.5 mL) and 
was stirred for 2 hours, after which, the AcOH(aq.) solution was removed in vacuo and 
the oily product was then co-evaporated with toluene and dried in vacuo. NaOH(aq.) (1.5 
mL, 0.1 M) was then added to the oil and the resulting solution was left to stir for 2 
hours. After completion, the solution was neutralised using Amberlite IR-120 (H+) ion-
exchange resin, the resin was then removed and the solvent removed in vacuo yielding 
compound 5 (17.9 mg, ~quantitative). A sample of compound 5 (9.9 mg) was purified 
by gel permeation chromatography which was then lyophilised to give a white powder.  
1H NMR (600 MHz, D2O) δH: 1.65 (1 H, dd, J = 12.0, 12.1 Hz,  H3ax), 2.10 (3 H, s, -
NHCOCH3), 2.99 (1 H, dd, J = 4.5, 12.6 Hz, H3eq), 3.48 (3 H, s, -OCH3), 3.52 (1 H, m, 
H4), 3.65 (1 H, d, J = 8.9 Hz, H7), 3.72 (1 H, m, H9), 3.81 (1 H, dd, J = 1.5, 10.5 Hz, H6), 
3.91 – 4.00 (3 H, m, H5, H8, H9’), 4.12 (1 H, ddd, J = 1.2, 5.7, 12.2 Hz, CHH’-CH=CH2), 
4.33 (1 H, ddd, J = 1.1, 6.0, 12.1 Hz, CHH’-CH=CH2), 5.30 (1 H, d, J = 10.3 Hz, -CH2-
CH=CHcisH), 5.41 (1 H, dd, J = 1.4, 17.3 Hz, -CH=CHtransH), 6.02 (1 H, m, -CH2-
CH=CH2). 
13C NMR (150.8 MHz, D2O) δC: 21.97 (-NHCOCH3), 36.90 (C3), 50.22 (C5), 56.34 (-
OCH3), 62.68 (C9), 65.92 (-CH2CH=CH2), 68.19 (C7), 71.44 (C8), 72.77 (C6), 77.20 
(C4), 100.38 (C2), 118.22 (-CH2CH=CH2), 133.67, (-CH2CH=CH2), 172.94 (C1), 174.93 
(-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C15H25NO9 (acid form) [M+Na]+ 386.1422, found 
386.1422. 
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Ammonium (allyl 5-acetamido-4-O-(P-methylphosphonyl)-3,5-dideoxy-D-glycero-
α-D-galacto-2-nonulopyranosidonate) (6)  
 
 
 
Compound 14 (18 mg, 0.0305 mmol) was placed under an N2 (g) atmosphere and 
dissolved in anhydrous THF (0.7 mL). Triethylamine (60 µL, 0.427 mmol) was then 
added followed by a few minutes of stirring. Thiophenol (22 µL, 0.213 mmol) was then 
added and the solution was stirred overnight. Over the course of 4 days, gentle heating 
(35-40°C) and a further 4 portions of triethylamine (60 µL, 0.427 mmol) and thiophenol 
(22µL, 0.213 mmol) were added whilst maintaining the THF solvent volume (~ 0.5 - 
0.7mL). Once TLC analysis had indicated that the reaction had progressed no further, 
the solvent was directly evaporated in vacuo and purified on a short silica plug 
(EA:MeOH; 5:1  DCM:MeOH; 1:1  MeOH) to give the deprotected phosphonate 
intermediate which was lyophilised with dioxane/H2O (9 mg, 96%). The deprotected 
phosphonate intermediate was then heated to 50 °C with Py:NEt3:H2O (1:1:1, 0.75 mL). 
After stirring overnight, the solvent was evaporated in vacuo and a crude NMR taken 
which indicated the presence of the desired product. The residue was then purified by 
gel permeation chromatography to afford compound 6 (9 mg, 76%) as a white solid 
after lyophilisation.  
1H NMR (600 MHz, MeOH-D4) δH: 1.29 (1 H, d, J = 16.6 Hz, P-CH3), 1.84 (1 H, dd, 
12.1, 12.3 Hz, H3ax), 2.03 (3 H, s, -NHCOCH3), 2.91 (1 H, dd, J = 4.7, 12.6 Hz, H3eq), 
3.53 (1 H, dd, J = 1.5, 9.0 Hz, H7), 3.57 (1 H, dd, J = 1.5, 10.4 Hz, H6), 3.62 (1 H, dd, J 
= 5.8, 11.4 Hz, H9), 3.74 (1 H, dd, J = 10.1, 10.2 Hz, H5), 3.83 (1 H, dd, J = 2.5, 11.4 
Hz, H9’), 3.86 (1 H, m, H8), 4.01 (1 H, ddd, J = 1.2, 5.6, 12.6 Hz, -CHH’-CH=CH2), 4.26 
- 4.32 (2 H, m, H4, -CHH’-CH=CH2), 5.10 (1 H, dd, J = 1.4, 10.5 Hz, -CH2-CH=CHHcis), 
5.25 (1 H, dd, J = 1.7, 17.3 Hz, -CH2-CH=CHHtrans), 5.90 (1 H, m, -CH2-CH=CH2). 
13C NMR (150.8 MHz, MeOH-D4) δC: ~13.53 (d, J = 139.2 Hz, P-CH3), 22.79 (-
NHCOCH3), 41.34 (C3), 53.53 (C5), 64.61 (C9), 66.36 (-CH2CH=CH2), 70.37 (C7), 
71.34 (C4), 72.76 (C8), 75.13 (C6), 100.42 (C2), 116.77 (-CH2CH=CH2), 135.77 (-
CH2CH=CH2), 172.61 (C1), 175.90 (-NHCOCH3). 
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31P NMR (242.7 MHz, MeOH-D4) δP: 24.73 (s). 
HR-ESI-MS (m/z) calculated for C15H26NOP (acid form) [M+Na]+ 450.1136, found 
450.1131. 
 
Ammonium (allyl 5-acetamido-3,5-dideoxy-9-O-methyl-D-glycero-α-D-galacto-2- 
nonulopyranosidonate) (7) 
 
 
 
Compound 26 (5 mg, 0.0132 mmol) was dissolved in dioxane (0.5 mL) and was stirred. 
NaOH (0.05 M, 0.5 mL) was then added to the stirring solution. The resulting mixture 
was stirred for 2 hours at room temperature. The basic solution was then neutralised 
with Amberlite IR-120 (H+) ion-exchange resin, the resin removed and the solvent 
evaporated in vacuo. The residue was then purified by gel permeation chromatography 
to afford compound 7 (5 mg, qu.) as a lyophilised powder.  
1H NMR (600 MHz, D2O) δH: 1.76 (1 H, dd, J = 12.1, 12.3 Hz, H3ax), 2.11 (3 H, s, -
NHCOCH3), 2.82 (1 H, dd, J = 4.6, 12.5 Hz, H3eq), 3.48 (3 H, s, -OCH3), 3.61 – 3.68 (2 
H, m, H7, H9), 3.72 – 3.83 (3 H, m, H4, H6, H9’), 3.90 (1 H, dd, J = 10.1, 10.2 Hz, H5), 
4.05 (1 H, dd, J = 7.7, 7.7 Hz, H8), 4.10 (1 H, dd, J = 5.8, 12.2 Hz, -CHH’-CH=CH2), 
4.32 (1 H, dd, J = 6.1, 12.1 Hz, -CHH’-CH=CH2), 5.30 (1 H, d, J = 10.4 Hz, -CH2-
CH=CHcisH), 5.40 (1 H, d, J = 17.4 Hz, -CH=CHtransH), 6.02 (1 H, ddd, J = 6.0, 11.2, 
16.6 Hz, -CH2-CH=CH2). 
13C NMR (150.8 MHz, D2O) δC: 21.94 (-NHCOCH3), 40.40 (C3), 51.76 (C5), 58.35 (-
OCH3), 65.96 (-CH2-CH=CH2), 68.17, 68.19 (C4, C7), 70.03 (C8), 72.46 (C6), 73.14 
(C9), 100.53 (C2), 118.14 (-CH2-CH=CH2), 133.67 (-CH2-CH=CH2), 173.38 (C1), 
174.94 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C15H25NO9 (acid form) [M+Na]+ 386.1422, found 
386.1424. 
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Diammonium (allyl 5-acetamido-3,5-dideoxy-9-O-(P-methylphosphonyl)-D-
glycero-α-D-galacto-2-nonulopyranosidonate) (8) 
 
 
 
Compound 31 (14 mg, 0.0240 mmol) was placed under an N2 (g) atmosphere and 
dissolved in anhydrous THF (0.7 mL). Triethylamine (47 µL, 0.336 mmol) was then 
added followed by a few minutes of stirring. Thiophenol (1 7µL, 0.168 mmol) was then 
added and the solution was stirred overnight. Over the course of 4 days, a further 4 
portions of triethylamine (47 µL, 0.336 mmol) and thiophenol (17 µL, 0.168 mmol) were 
added whilst maintaining the THF solvent volume (~ 0.5 - 0.7 mL). Once TLC analysis 
had indicated that the reaction had progressed no further, the solvent was directly 
evaporated in vacuo and purified on a short silica plug (DCM:MeOH; 5:1  2:1  
MeOH) to give the deprotected phosphonate intermediate which was lyophilised with 
dioxane/H2O (10.2 mg, 74%). The deprotected phosphonate intermediate (10 mg) was 
then treated with a 1:1 mixture of dioxane  and 0.05M NaOH (aq.) at approximately  
4-5 °C for 2 hours after which the solution was neutralised with ion-exchange resin 
Amberlite IR-120. The solvent was removed and the residue was then purified by gel 
permeation chromatography to afford compound 8 (9.6 mg, ~qu.) after lyophilisation.  
1H NMR (600 MHz, D2O) δH: 1.41 (3 H, d, J = 16.4 Hz, P-CH3), 1.79 (1 H, dd, J = 12.1, 
12.2 Hz, H3ax), 2.11 (3 H, s, -NHCOCH3), 2.80 (1 H, dd, J = 4.3, 12.5 Hz, H3eq), 3.74 (1 
H, d, J = 8.4 Hz, H7), 3.76 – 3.82 (1 H, m, H4), 3.87 (1 H, d, J = 10.3 Hz, H6), 3.93 (1 H, 
dd, J = 9.9, 10.1 Hz, H5), 4.02 – 4.09 (2 H, m, H8, H9), 4.12 (1 H, dd, J = 5.7, 12.0 Hz, -
CHH’-CH=CH2), 4.15 – 4.22 (1 H, m, H9’), 4.34 (1 H, dd, J = 6.1, 12.1 Hz, -CHH’-
CH=CH2), 5.31 (1 H, d, J = 10.2 Hz, -CH2-CH=CHcisH), 5.41 (1 H, d, J = 17.3 Hz, -
CH=CHtransH), 6.01 (1 H, ddd, J = 5.7, 11.3, 16.1 Hz, -CH2-CH=CH2). 
13C NMR (150.8 MHz, D2O) δC: ~10.80 (d, J = 137 Hz, P-CH3), 22.07 (-NHCOCH3), 
40.02 (C3), 51.83 (C5), 65.04 (d, J = 5 Hz, C9), 65.90 (-CH2-CH=CH2), 67.64 (C7), 
68.01 (C4), 70.13 (d, J = 7 Hz, C8), 72.62 (C6), 99.96 (C2), 118.33 (-CH2-CH=CH2), 
133.57 (-CH2-CH=CH2), 172.61 (C1), 174.95 (-NHCOCH3). 
31P NMR (161.7 MHz, D2O) δP: 28.45 (s). 
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HR-ESI-MS (m/z) calculated for C15H26NOP (acid form) [M+Na]+ 450.1136, found 
450.1135. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-8,9-O-isopropylidene-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (9) 
 
 
 
Compound 4 (56 mg, 0.154 mmol) was dissolved in dry acetone (1.85 mL) under 
N2(g). DMP (200 µL) was then added to the resulting solution via syringe, followed by 
p-TsOH.H2O (7mg). The solution was then left to stir at room temperature, under N2 for 
2 hours. Once complete, NEt3 (few drops) was added to the solution to neutralise the 
reaction and the solvent was evaporated to dryness. After flash chromatography 
(Tol:Acetone; 1:1), a clear oil was obtained, which after further drying in vacuo yielded 
a white foam compound 9 (53 mg, 85%). Rf : 0.52 (Tol:Acetone; 1:1).  
1H NMR (500 MHz, CDCl3) δH: 1.34, 1.38 (6 H, 2s, -C(CH3)2), 1.79 (1 H, dd, J = 12.0, 
12.2 Hz,  H3ax), 2.02 (3 H, s, -NHCOCH3), 2.69 (1 H, dd, J = 4.7, 12.8 Hz, H3eq), 3.43 (1 
H, d, J = 10.4 Hz, H6), 3.60 (1 H, dd, J = 5.6, 5.7 Hz, H7), 3.69 (1 H, m, H4), 3.74 – 3.81 
(1 H, m, H5, -CO2CH3), 3.98 – 4.11 (4 H, m, H9, H9’, -OH, -CHH’-CH=CH2), 4.14 (1 H, 
d, J = 5.7 Hz, -OH), 4.21 – 4.27 (2 H, m, -CHH’-CH=CH2, H8), 5.13 (1 H, ddd, J = 1.1, 
1.4, 10.5 Hz, -CH2-CH=CHcisH), 5.23 (1 H, ddd, J = 1.4, 1.6, 17.2 Hz, -CH=CHtransH), 
5.83 (1 H, ddd, J = 5.6, 10.6, 16.3 Hz, -CH2-CH=CH2), 6.59 (1 H, d, J = 8.0 Hz, -NH). 
13C NMR (125.7 MHz, CDCl3) δC: 23.31 (-NHCOCH3), 25.65, 26.93 (-C(CH3)2), 40.62 
(C3), 52.68, 53.19, 53.54 (-CO2CH3, C5), 65.54 (-CH2CH=CH2), 66.55 (C9), 67.95 
(C4), 69.79 (C7),  74.67 (C6), 75.88 (C8), 99.15 (C2), 108.75 (-C(CH3)2), 117.27 (-
CH2CH=CH2), 134.02, (-CH2CH=CH2), 169.17 (C1), 173.50 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C18H29NO9Na [M+Na]+ 426.1734, found 426.1734. 
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Methyl (allyl 5-acetamido-3,5-dideoxy-4,7-di-O-acetyl-8,9-O-isopropylidene-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (10) 
 
 
 
Compound 9 (15.2 mg, 0.037 mmol) was stirred overnight in a solution of pyridine (0.5 
mL) and acetic anhydride (0.5 mL). The solvent was then evaporated in vacuo and 
purified by flash chromatography (EA) to give compound 10. (16.5 mg, 93%). Rf : 0.92 
(Tol:Acetone; 1:1).  
1H NMR (500 MHz, CDCl3) δH: 1.34, 1.35 (6 H, 2s, -C(CH3)2), 1.88 (3 H, s, -COCH3), 
1.97 (1 H, dd, J = 12.3, 12.5 Hz, H3ax), 2.03 (3 H, s, -COCH3), 2.14 (3 H, s, -COCH3), 
2.67 (1 H, dd, J = 4.9, 12.9 Hz, H3eq), 3.82 (3 H, s, -CO2CH3), 3.92 (1 H, dd, J = 1.8, 
10.7 Hz, H6), 3.96 – 4.04 (3 H, m, H9, H5, -CHH’-CH=CH2), 4.08 (1 H, m, H9’), 4.25 (1 
H, ddd, J = 1.3, 5.3, 12.6 Hz, CHH’-CH=CH2), 4.37 (1 H, m, H8), 4.99 (1 H, m, H4), 5.13 
– 5.21 (2 H, m, -NH, -CH2-CH=CHcisH), 5.28 (1 H, dd, J = 1.5, 17.2 Hz, -CH=CHtransH), 
5.39 (1 H, m, H7), 5.87 (1 H, ddd, J = 5.4, 10.6, 16.5 Hz, -CH2-CH=CH2); 
13C NMR (125.7 MHz, CDCl3) δC: 21.03, 21.09, 23.37, 25.48 (3 x -COCH3, -
NHCOCH3), 26.53 (-C(CH3)2), 37.72 (C3), 50.11 (C5), 52.93 (-CO2CH3), 65.70, 65.76 
(C9, -CH2-CH=CH2), 68.84 (C7), 69.02 (C8), 73.79 (C6), 76.17 (C4), 99.08 (C2), 
108.59 (-C(CH3)2), 117.44 (-CH2-CH=CH2), 133.62 (-CH2-CH=CH2), 168.50 (C1), 
170.36, 170.54, 171.03 (-NHCOCH3, 2 x -COCH3). 
HR-ESI-MS (m/z) calculated for C22H33NO11 [M+Na]+ 510.1922, found 510.1930. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4-O-methyl-8,9-O-isopropylidene-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (11) 
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Compound 9 (56 mg, 0.138 mmol) was dissolved in dry CH3CN (0.7 mL), under N2 (g) 
and was cooled to 0 °C (ice bath). DMSO4 (24.5 µL, 0.259 mmol) was then added to 
the solution followed by NaH(s) (6.6 mg, 0.276 mmol). The resulting suspension was 
allowed to stir for 4 hours at 0°C, at which point, more DMSO4 (24.5 µL, 0.259 mmol) 
was added and the suspension was left to stir overnight. On completion, excess 
NH4Cl(s) was added to quench the reaction and the solution was diluted with DCM (3 
mL) and filtered over celite and the solvent was evaporated to dryness. After flash 
chromatography (Tol:Acetone; 1:1) a clear oil, compound 11, was obtained (29 mg, 
50%). Rf : 0.24 (Tol:Acetone; 2:1). 
1H NMR (600 MHz, CDCl3) δH: 1.36, 1.39 (6 H, 2s, -C(CH3)2), 1.73 (1 H, dd, J = 12.1, 
12.2 Hz,  H3ax), 2.05 (3 H, s, -NHCOCH3), 2.87 (1 H, dd, J = 4.5, 12.8 Hz, H3eq), 3.34 (3 
H, s, -OCH3), 3.37 (1 H, d, J = 10.5 Hz, H6), 3.42 (1 H, ddd, J = 4.5, 10.7, 10.9, H4), 
3.56 (1 H, dd, J = 5.6, 5.7 Hz, H7), 3.78 (3 H, s, -CO2CH3), 3.87 (1 H, m, H5), 4.04 – 
4.13 (3 H, m, H9, H9’, - CHH’-CH=CH2), 4.28 – 4.33 (2 H, m, H8, CHH’-CH=CH2), 4.42 
(1 H, d, J = 4.9 Hz, -OH), 5.15 ( 1H, d, J = 10.5 Hz, -CH2-CH=CHcisH), 5.25 (1 H, d, J = 
17.2 Hz, -CH=CHtransH), 5.39 (1 H, d, J = 7.4 Hz, -NH), 5.86 (1 H, ddd, J = 55.6, 10.7, 
16.4 Hz, -CH2-CH=CH2). 
13C NMR (150.8 MHz, CDCl3) δC: 23.47 (-NHCOCH3), 25.75, 26.99 (-C(CH3)2), 36.42 
(C3), 51.27 (C5), 52.54 (-CO2CH3), 55.57 (-OCH3), 65.47 (-CH2CH=CH2), 66.93 (C9), 
69.86 (C7), 74.76 (C6), 75.44 (C8), 75.94 (C4), 99.21 (C2), 108.71 (-C(CH3)2), 117.31 
(-CH2CH=CH2), 134.03, (-CH2CH=CH2), 169.20 (C1), 173.85 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C19H31NO9 [M+Na]+ 440.1891, found 440.1898.   
 
Methyl (allyl 5-acetamido-3,5-dideoxy-8,9-O-carbonate-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (12) 
 
 
 
Compound 4 (345 mg, 0.949 mmol) and DMAP (278 mg, 2.28 mmol) were dried in 
vacuo for approximately 1 hour and then placed under an atmosphere of N2(g). Dry 
DCM (20 mL) was then added via syringe and the resulting suspension formed was 
ultrasonicated for a few minutes then cooled to approximately 0°C. Diphosgene (152 
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µL, 1.23 mmol) was then added via microsyringe to the white suspension with vigorous 
stirring. On completion, the reaction was quenched by pouring the solution into 40mL of 
cold 10% KH2PO4. The DCM layer was separated and the aqueous layer was extracted 
with ethyl acetate (4 x 25mL). The organic phases were then dried over MgSO4 and the 
solvents were removed.
 
 
After flash chromatography (EA:MeOH; 15:1) and the removal of organic solvents in 
vacuo, a clear oil, compound 12, was obtained (220 mg, 60%). Rf : 0.63 (EA:MeOH; 
5:1).  
1H NMR (500 MHz, MeOH-D4) δH: 1.74 (1 H, dd, J = 12.3, 12.3 Hz, H3ax), 2.01 (3 H, s, -
NHCOCH3), 2.66 (1 H, dd, J = 4.6, 12.8 Hz, H3eq), 3.53 ( 1H, d, J = 10.5 Hz, H6), 3.61 ( 
1H, ddd, J = 4.5, 10.6, 12.9 Hz, H4), 3.75 - 3.79 (1 H, m, H5), 3.80 (3 H, s, -CO2CH3), 
3.93 (1 H, m, H7), 3.97 (1 H, dd, J = 5.3, 12.6 Hz, -CHH’-CH=CH2), 4.19 (1 H, dd, J = 
4.2, 12.8 Hz, -CHH’-CH=CH2), 4.55 (1 H, dd, J = 8.4, 8.4 Hz, H9), 4.70 (1 H, dd, J = 
7.2, 7.9 Hz, H9’), 4.95 (1 H, m, H8), 5.14 (1H, d, J = 10.5 Hz, -CHH’-CH=CHHcis), 5.26 
(1 H, d, J = 17.4 Hz, -CHH’-CH=CHHtrans), 5.86 (1 H, dddd, J = 1.08, 5.2, 10.5, 16.8, -
CHH’-CH=CH2). 
13C NMR (100.5 MHz, MeOH-D4) δC: 22.76 (-NHCOCH3), 41.46 (C3), 53.10 (C5), 53.66 
(-CO2CH3), 66.29 (-CH2CH=CH2), 67.24 (C9), 68.17 (C4), 69.22 (C7), 76.20 (C6), 
79.63 (C8), 100.49 (C2), 116.94 (-CH2CH=CH2), 135.21 (-CH2CH=CH2), 157.38 (-O-
C(O)-O-), 169.90 (C1), 175.10 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C16H23NO10 [M+Na]+ 412.1214, found 412.1219. 
 
Methyl (allyl 5-acetamido-4,7-di-O-acetyl-3,5-dideoxy-8,9-O-carbonate-D-glycero-
α-D-galacto-2-nonulopyranosid)onate (13)  
 
 
 
Compound 12 (16 mg, 0.041 mmol) was placed into a flask. Pyridine (0.5 mL) and 
acetic anhydride (0.5mL) were then added. The flask was stoppered and allowed to stir 
overnight. Once the reaction was complete, the solvent was removed directly in vacuo. 
Co-evaporation with toluene several times followed by flash chromatography 
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(EA:MeOH 20:1  5:1) gave the desired product, compound 13 (19 mg, 95%). Rf : 0.54 
(EA:MeOH; 10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.86 (3 H, s, -NHCOCH3), 1.95 (1 H, dd, J = 12.4, 12.4 
Hz, H3ax), 2.01 (3 H, s, -OCOCH3), 2.16 (3 H, s, -OCOCH3), 2.66 (1 H, dd, J = 4.7, 12.8 
Hz, H3eq), 3.81 (3 H, s, -CO2CH3), 3.93 (1 H, dd, J = 5.2, 12.7 Hz, -CHH’-CH=CH2), 
3.97 - 4.05 (2 H, m, H5, H6), 4.14 (1 H, dd, J = 4.6, 12.6 Hz, -CHH’-CH=CH2), 4.51 (1 H, 
dd, J = 8.5, 8.7 Hz, H9), 4.60 (1 H, dd, J = 7.4, 8.2 Hz, H9’), 4.92 (1 H, m, H4), 5.03 (1 H, 
m, H8), 5.18 (1 H, d, J = 10.5 Hz, -CHH’-CH=CHHcis), 5.26 (1 H, d, J = 17.2 Hz, -CHH’-
CH=CHHtrans), 5.58 (1 H, d, J = 8.4 Hz, -NH), 5.82 (1 H, ddd, J = 5.3, 10.4, 16.5 Hz, -
CH2-CH=CH2). 
13C NMR (100.5 MHz, CDCl3) δC: 20.92 (-COCH3), 21.04 (-COCH3), 23.33 (-
NHCOCH3), 37.54 (C3), 49.62 (C5), 53.25 (-CO2CH3), 65.79 (-CH2-CH=CH2), 66.22 
(C9), 68.16 (C7), 68.90 (C4), 73.72 (C6), 76.66 (C8), 99.33 (C2), 117.63 (-CH2-
CH=CH2), 133.33 (-CH2-CH=CH2), 154.59 (-O-C(O)-O-), 168.33, 170.25, 170.81, 
170.93 (C1, -NHCOCH3, 2 x -OCOCH3). 
HR-ESI-MS (m/z) calculated for C20H27NO12 [M+Na]+ 496.1425, found 496.1428. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4-O-(O,P-dimethylphosphonyl)-8,9-O-
carbonate-D-glycero-α-D-galacto-2-nonulopyranosid)onate (14)  
 
 
 
Compound 12 (75 mg, 0.193 mmol) was placed in a flask under an N2 (g) atmosphere. 
Dry DCM (2 mL) was then added via syringe resulting in a suspension of compound 12 
which required ultrasonication. N,N-diisopropylethylamine (67 µL, 0.386 mmol) was 
added to the suspension followed by further ultrasonication. With continuous stirring, 
the suspension was cooled to approximately -15°C. Once acclimatised to the 
temperature, methyl methylphosphonochloridate (27 µL, 0.270 mmol) was added 
dropwise to the solution. The reaction was allowed to come up to room temperature 
where it was then stirred overnight. The reaction was again then cooled to -15°C, 
where a further portion of N,N-diisopropylethylamine (67 µL, 0.386 mmol) and methyl 
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methylphosphonochloridate (27 µL, 0.270 mmol) was added. Once TLC monitoring of 
the reaction had indicated completion, the reaction was quenched by the addition of 
MeOH (1mL) and a small spatula of NaHCO3 (s). After stirring for 10 minutes, the 
solvent was removed directly in vacuo and the product was directly purified by flash 
chromatography (EA:MeOH; EA  7:1 5:1) to give compound 14 (57 mg, 60%). Rf : 
0.21 (EA:MeOH; 10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.53, 1.47 (3 H, 2d, J = 17.7, 17.8 Hz, P-CH3), 2.01 (1 
H, m, H3ax), 2.06 (3 H, s, -NHCOCH3), 2.73, 2.78 (1 H, 2dd, J = 5.0, 12.8, 4.9, 12.9 Hz, 
H3eq), 3.25 (1 H, d, J = 10.3 Hz, H6), 3.66, 3.75 (3 H, 2d, J = 11.5, 11.2 Hz, P-OCH3), 
3.81, 3.82 (3 H, 2s, -CO2CH3), 3.83 - 3.92 (1 H, m, H5), 4.02 (1 H, dd, J = 5.4, 12.4 Hz, 
-CHH’-CH2=CH2), 4.22 (1 H, dd, J = 5.1, 12.6 Hz, CHH’-CH2=CH2), 4.40, 4.53 (1 H, m, 
H4), 4.49 (1 H, dd, J = 8.5 Hz, H9), 4.65 (1 H, m, H9’), 4.74 (1  H, bs, -OH), 4.87 (1 H, m, 
H8), 5.16 (1 H, d, J = 10.5 Hz, -CH2-CH=CHHcis), 5.24 (1 H, d, J = 17.3 Hz, -CH2-
CH=CHHtrans), 5.82 (1 H, ddd, J = 5.4, 10.5, 16.1 Hz, -CH2-CH=CH2), 7.43 (1 H, m, -
NH). 
13C NMR (125.7 MHz, CDCl3) δC: ~10.69, ~11.01 (2d, J = 143.41, 146.06 Hz, P-CH3), 
23.04, 23.07 (-NHCOCH3), 38.81 (m, C3), 51.90 (C5), ~52.15 (d, J = 7.4 Hz, P-OCH3), 
52.99, 53.05 (-CO2CH3), 65.51 (-CH2-CH=CH2), 66.66, 66.69 (C9), 68.82 (C7), ~70.41 
(d, J = 6.6 Hz, C4), ~71.46 (d, J = 5.0 Hz, C4), 74.89 (C6), 75.99, 76.05 (C8), 98.91, 
99.01 (C2), 117.40 (-CH2-CH=CH2), 133.47 (-CH2-CH=CH2), 155.11 (-O-C(O)-O-), 
168.28, 168.30 (C1), 174.02, 174.12 (-NHCOCH3). 
31P NMR (161.7 MHz, CDCl3) δP: 34.63 (s), 35.82 (s). 
HR-ESI-MS (m/z) calculated for C18H28NO12P [M+Na]+ 504.1218, found 504.1241. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-7-O-acetyl-4-O-(P-methylphosphonyl)-8,9-
O-carbonate-D-glycero-α-D-galacto-2-nonulopyranosid)onate (15) 
 
 
 
Compound 14 (11 mg, 0.0228 mmol) was placed into a flask. Pyridine (0.5 mL) and 
acetic anhydride (0.5 mL) were then added. The flask was stoppered and allowed to 
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stir overnight. Once the reaction was complete, the solvent was removed directly in 
vacuo. Co-evaporation with toluene several times followed by flash chromatography 
(EA:MeOH 20:1  5:1) gave the desired product, compound 15 (10.5 mg, 90%). Rf : 
0.50 (EA:MeOH; 10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.41, 1.46 (3 H, 2d, J = 17.4, 17.7 Hz, P-CH3), 1.93, 
1.94 (3 H, 2s, -OCOCH3), 2.02 (1 H, m, H3ax), 2.16 (3 H, s, -NHCOCH3), 2.76 (1 H, m, 
H3eq), 3.62, 3.67 (3 H, 2d, J = 11.3, 11.4 Hz, P-OCH3), 3.82 (3 H, s, -CO2CH3), 3.85 (1  
H, m, H6), 3.96 (1 H, m, -CHH’-CH=CH2), 4.01 (1 H, dd, J = 10.1, 10.1 Hz, H5), 4.16 (1 
H, ddd, J = 2.0, 3.4, 5.0 Hz, -CHH’-CH=CH2), 4.39 – 4.53 (1 H, m, H4), 4.49 (1 H, dd, J 
= 8.6, 8.6 Hz, H9), 4.58 (1 H, m, H9’), 4.97 (1 H, m, H8), 5.19 (1 H, dd, J = 0.8, 10.4 Hz, 
-CH2-CH=CHHcis), 5.27 (1 H, dd, J = 1.3, 17.2 Hz, -CH2-CH=CHHtrans), 5.48 (1 H, m, 
H7), 5.83 (1 H, ddd, J = 5.4, 10.6, 16.0 Hz, -CH2-CH=CH2), 6.19, (1 H, d, J = 9.4 Hz, -
NH). 
13C NMR (100.5 MHz, CDCl3) δC: ~10.60, ~11.10 (2d, J = 144, 146 Hz), 20.72, 20.75 (-
NHCOCH3), 23.28, 23.31 (-OCOCH3), 39.11, 39.21 (2d, J = 2.9, 4.0 Hz, C3), 49.99, 
50.13 (2d, J = 2.7, 3.4 Hz, C5), 52.28, 52.31 (2d, J = 6.3, 6.7 Hz, P-OCH3), 53.01, 
53.05 (-CO2CH3), 65.54, 65.56 (-CH2CH=CH2), 66.00, 66.02 (C9), 67.94 (C7), 71.06, 
71.65 (2d, J = 6.1, 7.2 Hz, C4), 73.38, 73.41 (C6), 76.02, 76.09 (C8), 99.00, 99.08 
(C2), 117.44, 117.46 (-CH2CH=CH2), 133.09, 133.11 (-CH2CH=CH2), 154.13 (-O-C(O)-
O-), 168.02, 168.04, 170.01, 170.04 (C1, -OCOCH3), 171.05, 171.06 (-NHCOCH3). 
31P NMR (400 MHz, CDCl3) δP: 31.70 (s), 33.38 (s). 
HR-ESI-MS (m/z) calculated for C20H30NO13P [M+Na]+ 546.1346, found 546.1330. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-9-O-tert-butyldimethylsilyl-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (16)  
 
 
 
Compound 4 (197 mg, 0.542 mmol) and imidazole (92 mg, 1.35 mmol) were dried in 
vacuo for an hour and then placed under an N2 (g) atmosphere. Dry DMF (2.25mL) 
was then added and the resulting suspension was cooled to 0°C. TBDMSCl (98 mg, 
0.650 mmol) was then quickly added to the stirring solution and the solution was 
allowed to stir for a further 5 hours. Once TLC analysis had indicated that the reaction 
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had reached completion, saturated NaHCO3 (aq.) (0.4 mL) was added to the solution 
and stirred. The DMF was then removed in vacuo and the product was purified by flash 
chromatography (Tol:EA; 2:1  1:10) to yield compound 16 (220 mg, 85%). Rf : 0.68 
(EA:MeOH; 5:1).  
1H NMR (500 MHz, MeOH-D4) δH: 0.09 (6 H, 2s, 2 x -Si-CH3), 0.92 (9 H, s, -Si-
C(CH3)3), 1.75 (1 H, dd, J = 12.3, 12.3 Hz, H3ax), 1.99 (3 H, s, -NHCOCH3), 2.70 (1 H, 
dd, J = 4.7, 12.9 Hz, H3eq), 3.55 (1 H, d, J = 10.3 Hz, H6), 3.59 (1 H, d, J = 8.9 Hz, H7), 
3.66 (1 H, m, H4), 3.75 (1 H, dd, J = 10.1, 10.2 Hz, H5), 3.79 - 3.84 (2 H, m, H9, H9’), 
3.82 (3 H, s, -CO2CH3), 3.90 (1 H, d, J = 8.7 Hz, H8), 3.99 (1 H, dd, J = 5.6, 12.8 Hz, -
CHH’-CH=CH2), 4.28 (1 H, dd, J = 5.3, 12.8 Hz, -CHH’-CH=CH2), 5.11 (1 H, d, J = 10.4 
Hz, -CH2-CH=CHHcis), 5.23 (1 H, d, J = 17.2 Hz, -CH2-CH=CHHtrans), 5.87 (1 H, ddd, J 
= 5.4, 10.6, 16.1 Hz, -CH2-CH=CH2). 
13C NMR (125.7 MHz, MeOH-D4) δC: -5.04, -4.99 (-Si-CH3), 22.81 (-NHCOCH3), 19.47 
(-Si-C(CH3)3), 26.64 (-Si-C(CH3)3), 41.88 (C3), 53.47 (-CO2CH3), 54.09 (C5), 65.86 
(C8), 66.38 (-CH2-CH=CH2), 68.54 (C4), 69.60 (C7), 72.69 (C9), 75.17 (C6), 100.18 
(C2), 117.08 (-CH2-CH=CH2), 135.61 (-CH2-CH=CH2), 171.13 (C1), 175.33 (-
NHCOCH3). 
HR-ESI-MS (m/z) calculated for C21H39NO9Si [M+Na]+ 500.2286, found 500.2268. 
 
Methyl (allyl 5-(N-acetyl-N-benzoyl)-amido-3,5-dideoxy-4,7,8-tri-O-benzoyl-9-O-
tert-butyldimethylsilyl-D-glycero-α-D-galacto-2-nonulopyranosid)onate (17) 
 
 
 
Compound 16 (99 mg, 0.208 mmol) was placed under an N2 (g) atmosphere and 
pyridine (3 mL) was added. The solution was then cooled to 0 °C and BzCl (97 µL, 
0.832 mmol) was added dropwise via microsyringe with stirring. The reaction was left 
to stir overnight where then a further portion of BzCl (48 µL, 0.416 mmol) was added. 
Once TLC analysis had indicated that the reaction had progressed no further, saturated 
NaHCO3 (aq.) (0.5 mL) was added to the solution and stirred. The pyridine was 
evaporated in vacuo and the resulting product was suspended in DCM (10 mL) and 
washed with semi-saturated NH4Cl (aq.), NaHCO3 (aq.) and brine. The organic phase 
was then dried over MgSO4 and the solvent was evaporated in vacuo. Flash 
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chromatography (Tol:EA; 20:1  2:1) gave compound 17 (87 mg, 53%). Rf : 0.81 
(Tol:EA; 2:1).  
1H NMR (500 MHz, CDCl3) δH: -0.18, -0.15 (6 H, 2s, -Si-CH3), 0.72 (9 H, s, -Si-
C(CH3)3), 1.64 - 1.83 (3 H, 2bs, -NHCOCH3), 2.01 (1 H, dd, J = 11.4, 11.6 Hz, H3ax), 
3.01 (1 H, dd, J = 4.8, 12.8 Hz, H3eq), 3.49 (3 H, s, -CO2CH3), 3.82 (1 H, dd, J = 3.8, 
11.7 Hz, H9), 4.05 - 4.09 (1 H, m, -CHH’-CH=CH2), 4.12 (1 H, dd, J = 5.7, 12.9 Hz, H9’), 
4.47 (1 H, dd, J = 4.4, 12.8 Hz, -CHH’-CH=CH2), 5.02 (1 H, dd, J = 9.2, 9.7 Hz, H5), 
5.15 - 5.20 (1 H, m, H6), 5.18 (1 H, d, J = 10.0 Hz, -CH2-CH=CHHcis), 5.32 (1 H, dd, J = 
1.3, 17.3 Hz, -CH2-CH=CHHtrans), 5.62 (1 H, m, H8), 5.75 - 5.89 (2 H, m, H4, H7), 5.94 (1 
H, ddd, J = 5.4, 10.6, 16.1 Hz, -CH2-CH=CH2), 7.13 - 8.17 (20 H, m, -COPh). 
13C NMR (125.7 MHz, CDCl3) δC: -5.45, -5.42 (-Si-CH3), 18.29 (-Si-C(CH3)3), 25.86 (-Si-
C(CH3)3), 27.11, 28.17 (-NHCOCH3), 39.11 (C30, 52.64 (-CO2CH3), 56.25 (C5), 61.50 
(C9), 65.78 (-CH2-CH=CH2), 68.22, 69.05 (C4, C7), 70.44 (C6), 72.25 (C8), 98.93 (C2), 
116.85 (-CH2-CH=CH2), 128.48, 128.66, 129.07, 129.26, 129.86, 130.02, 130.11, 
130.32, 130.67 (-COPh), 132.98, 133.33, 134.59 (-CH2-CH=CH2), 168.42, 165.33, 
165.68, (-COPh), 173.66 (C1), 174.13 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C49H55NO13Si [M+Na]+ 916.3335, found 916.3277. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8-tri-O-benzoyl-9-O-tert-
butyldimethylsilyl-D-glycero-α-D-galacto-2-nonulopyranosid)onate (18)  
 
 
 
Compound 16 (254 mg, 0.531 mmol) and DMAP (65 mg, 0.531 mmol) were placed 
under an N2 (g) atmosphere and pyridine (3mL) was added. The solution was then 
cooled to 0 °C and BzCl (432 µL, 3.72 mmol) was added dropwise via syringe with 
stirring. The reaction was left to stir overnight where then a further portion of BzCl (62 
µL, 0.533 mmol) was added. Once TLC analysis had indicated that the reaction had 
progressed no further, a few small spatulas of NaHCO3 (s) were added to the solution 
and stirred. The pyridine was evaporated in vacuo and the resulting product was 
suspended in DCM (20 mL) and washed successively with semi-saturated NH4Cl (aq.), 
NaHCO3 (aq.) and brine. The organic phase was then dried over MgSO4, co-
evaporated with toluene (2 x 5 mL) and the solvent was evaporated in vacuo. Flash 
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chromatography (cyclohexane:EA; 10:1  5:1  EA)) gave compound 18 (106 mg, 
25%). Rf : 0.72 (cyclohexane:EA; 1:1).  
1H NMR (500 MHz, CDCl3) δH: -0.12, -0.10 (6 H, 2s, 2 x -Si-CH3), 0.77 (9 H, s, -Si-
C(CH3)3), 1.85 (3 H, s, -NHCOCH3), 1.99 (1 H, dd, J = 12.2, 12.2 Hz, H3ax), 2.79 (1 H, 
dd, J = 4.8, 12.8 Hz, H3eq), 3.48 (3 H, s, -CO2CH3), 3.83 - 3.93 (2 H, m, H5, H9), 4.01 - 
4.06 (2 H, m, H9’, -CHH’-CH=CH2), 4.40 (1 H, dd, J = 5.1, 12.9 Hz, -CHH’-CH=CH2), 
4.57 (1H, dd, J = 1.2, 10.7 Hz, H6), 5.16 (1 H, dd, J = 0.8, 10.5 Hz, -CH2-CH=CHHcis), 
5.29 (1 H, dd, J = 1.2, 17.5 Hz, -CH2-CH=CHHtrans), 5.42 (1 H, dd, J = 4.8, 11.5 Hz, H4), 
5.52 (1 H, d, J = 8.9 Hz, -NH), 5.66 (1 H, m, H8), 5.80 (1 H, dd, J = 1.3, 7.9 Hz, H7), 
5.90 (1 H, ddd, J = 5.4, 10.6, 16.2 Hz, -CH2-CH=CH2), 7.34 - 8.09 (15 H, m, -COPh). 
13C NMR (125.7 MHz, CDCl3) δC: -5.34 (-Si-CH3), 18.32 (-Si-C(CH3)3), 23.56 (-
NHCOCH3), 25.89 (-Si-C(CH3)3), 38.39 (C3), 51.24 (C5), 52.65 (-CO2CH3), 62.11 (C9), 
65.95 (-CH2-CH=CH2), 69.07 (C7), 69.51 (C4), 72.31 (C6), 77.60 (C8), 98.94 (C2), 
117.03 (-CH2-CH=CH2), 128.56, 128.60, 128.71, 129.77, 129.99, 130.04, 130.10, 
130.18, 130.35, 130.72, 133.12, 133.42, 133.43 (-COPh), 134.45 (-CH2-CH=CH2), 
165.79, 165.88, 166.36 (-COPh), 168.79 (C1), 170.32 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C42H51NO12Si [M+Na]+ 812.3072, found 812.3051. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8,9-tetra-O-tert-butyldimethylsilyl-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (19)  
 
 
 
Compound 4 (102 mg, 0.282 mmol) was placed under an N2 (g) atmosphere and dry 
DCM (1.8 mL) and lutidine (264 µL, 2.27 mmol) were added. TBDMSOTf (292 µL, 1.27 
mmol) was added to the solution with stirring. After 7 hours, a further portion of 
TBDMSOTf (70 µL, 0.340 mmol) was added and the reaction was allowed to stir 
overnight. The solvent was removed in vacuo and the resulting crude material was 
purified by flash chromatography directly (hexane:EA; 10:1  5:1  1:1) to give 
compound 19 as a clear oil (203 mg, 88%). Rf : 0.51 (hexane:EA; 4:1).  
1H NMR (500 MHz, CDCl3) δH: -0.02, 0.03, 0.05, 0.07, 0.08, 0.15 (24 H, 6s, -Si-CH3), 
0.84, 0.87, 0.90 (36 H, s, -Si-C(CH3)3), 1.68 (1 H, dd, J = 12.0, 12.2 Hz, H3ax), 1.87 (3 
H, s, -NHCOCH3), 2.56 (1 H, dd, J = 4.6, 12.7 Hz, H3eq), 3.28 (1 H, m, H5), 3.52 (1 H, 
199 
 
dd, J = 7.5, 10.3 Hz, H9), 3.77 (3 H, s, -CO2CH3), 3.87 - 3.90 (2 H, m, H7, H8), 3.96 - 
4.05 (3 H, m, H4, H9’, -CHH’-CH=CH2), 4.07 (1 H, dd, J = 2.3, 10.7 Hz, H6), 4.24 (1 H, 
dddd, J = 1.4, 2.5, 6.5, 12.6 Hz, -CHH’-CH=CH2), 5.10 (1 H, dd, J = 1.2, 10.5 Hz, -CH2-
CH=CHHcis), 5.22 (1 H, dd, J = 1.6, 17.3 Hz, -CH2-CH=CHHtrans), 5.40 (1 H, d, J = 7.7 
Hz, -NH), 5.82 (1 H, ddd, J = 5.6, 10.6, 16.2 Hz, -CH2-CH=CH2). 
13C NMR (125.7 MHz, CDCl3) δC: -5.09, -5.01,-4.82, -4.72, -4.37, -4.34, -4.28, -3.64 (-
Si-CH3), 18.07, 18.45, 18.71, 18.75 (-Si-C(CH3)3), 24.07 (-NHCOCH3), 25.86, 26.24, 
26.29, 26.37, 27.15 (-Si-C(CH3)3), 41.46 (C3), 52.48 (-CO2CH3), 55.80 (C5), 65.11, 
65.21 (C9, -CH2-CH=CH2), 67.87, 74.40, 76.33 (C6, C7, C8), 98.91 (C2), 117.17 (-CH2-
CH=CH2), 134.34 (-CH2-CH=CH2), 169.11 (C1), 169.74 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C39H81NO9Si4 [M+Na]+ 842.4881, found 842.4860. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4,8,9-tri-O-tert-butyldimethylsilyl-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (20)  
 
 
 
Compound 19 (110.3 mg, 0.134 mmol) was placed under an N2 (g) atmosphere and 
dissolved in anhydrous MeOH (0.9 mL). The resulting solution was then transferred to 
a quartz reaction vessel (suitable for UV applications), also under an N2 (g) atmosphere 
and the solution was stirred. A solution of CBr4 (~2.7 mg, 0.00814 mmol added as 10 
mg/mL solution) in anhydrous MeOH was quickly transferred to the stirring methanolic 
solution of compound 19. The solution was then exposed for 20 minutes to a 6W UV 
lamp (λ ~254 nm), enclosed in a dark reaction container. After this time, the lamp was 
switched off and the reaction was monitored by TLC for a further 45 minutes to 1 hour. 
Once the reaction was complete, a small spatula o NaHCO3 (s) was added, the 
methanol was removed directly from the reaction vessel and the vessel itself was 
rinsed well with MeOH. The solvent was then evaporated in vacuo and the product was 
purified directly by flash chromatography (hexane:EA; 2:1) to give compound 20 (21.2 
mg, 22%). Rf : 0.42 (cyclohexane/EA; 4:1). 
1H NMR (500 MHz, CDCl3) δH: 0.04 – 0.11 (18 H, 7s, -Si-CH3), 0.86, 0.89, 0.90 (27 H, 
s, -Si-C(CH3)3), 1.84 (1 H, dd, J = 11.0, 11.0 Hz, H3ax), 1.96 (3 H, s, -NHCOCH3), 2.53 
(1 H, dd, J = 4.4, 12.9 Hz, H3eq), 3.58 – 3.67 (2 H, m, H6/7, -OH), 3.77 (3 H, s, -
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CO2CH3), 3.79 – 3.92 (5 H, m, H4, H5, H6/7, H9, H9’), 4.01 (1 H, dd, J = 5.9, 12.6 Hz, -
CHH’-CH=CH2), 4.31 (1 H, dd, J = 5.4, 12.7 Hz, -CHH’-CH=CH2), 5.13 (1 H, dd, J = 
1.3, 10.5 Hz, -CH2-CH=CHHcis), 5.19 (1 H, d, J = 8.0 Hz, -NH), 5.24 (1 H, dd, J = 1.5, 
17.2 Hz, -CH2-CH=CHHtrans), 5.87 (1 H, ddd, J = 5.5, 10.7, 16.9 Hz, -CH2-CH=CH2); 
13C NMR (100.5 MHz, CDCl3) δC: -5.22, -4.63, -4.53, -4.13, -3.89 (-Si-CH3), 1.17 
(unknown), 17.99, 18.44, 18.48 (-Si-C(CH3)3), 23.47 (-NHCOCH3), 25.72, 26.11, 26.25 
(-Si-C(CH3)3), 29.86 (unknown), 41.67 (C3), 52.41 (-CO2CH3), 54.04 (C5), 65.04, 65.31 
(C9, -CH2-CH=CH2), 68.20, 70.70, 73.13, 73.92 (C4, C6, C7, C8), 98.60 (C2), 117.01 (-
CH2-CH=CH2), 134.43 (-CH2-CH=CH2), 169.20, 169.57, 171.19 (C1, -NHCOCH3). 
HR-ESI-MS (m/z) calculated for C33H68NO9Si3 [M+H]+ 706.4196, found 706.4214. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-7-O-acetyl-4,8,9-tetra-O-tert-
butyldimethylsilyl-D-glycero-α-D-galacto-2-nonulopyranosid)onate (21)  
 
 
 
Compound 20 (15 mg, 0.021 mmol) was placed into a flask. Pyridine (0.5 mL) and 
acetic anhydride (0.5mL) were then added and the solution was stirred overnight. Once 
the reaction was complete, the solvent was removed directly in vacuo. Co-evaporation 
with toluene several times followed by flash chromatography (EA:MeOH 20:1  5:1) 
gave the desired product, compound 21 (15.1 mg, 95%). Rf : 0.24 (hexane/EA; 4:1). 
1H NMR (500 MHz, CDCl3) δH: -0.1 – 0.11 (18 H, 7s, -Si-CH3), 0.85, 0.87, 0.90 ((27 H, 
s, -Si-C(CH3)3), 1.68 (1 H, dd, J = 11.8, 12.5 Hz, H3ax), 1.91 (3 H, s, -NHCOCH3), 2.13 
(3 H, s, -COCH3), 2.35 (Toluene), 2.59 (1 H, dd, J = 4.6, 12.8 Hz, H3eq), 2.92 (1 H, dd, J 
= 9.6, 9.7 Hz, H5), 3.59 (1 H, dd, J = 6.5, 6.7 Hz, H9), 3.80 (3 H, s, -CO2CH3), 3.93 – 
4.06 (3 H, m, H8, H9’, -CHH’-CH=CH2), 4.23 – 4.41 (3 H, m, H4, H6, -CHH’-CH=CH2), 
5.11 – 5.18 (2 H, m, H7, -CH2-CH=CHHcis), 5.26 (1 H, dd, J = 1.3, 17.2 Hz, -CH2-
CH=CHHtrans),7.13 – 7.28 (Toluene); 
13C NMR (100.5 MHz, CDCl3) δC: -5.17, -4.86, -4.79, -4.54, -4.11 (-Si-CH3), 18.03, 
18.25, 18.50 (-Si-C(CH3)3), 21.30 (-COCH3), 23.88 (-NHCOCH3), 25.79, 26.02, 26.15 (-
Si-C(CH3)3), 29.85 (unknown), 42.01 (C3), 52.50 (-CO2CH3), 56.03 (C5), 64.64 (C9), 
65.37 (-CH2-CH=CH2), 66.25 (C4), 71.19 (C6), 73.39, 73.54 (C8, C7), 98.73 (C2), 
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117.08 ((-CH2-CH=CH2), 134.25 (-CH2-CH=CH2), 168.60 (C1), 170.04, 171.41 (-
COCH3, -NHCOCH3). 
HR-ESI-MS (m/z) calculated for C35H70NO10Si3 [M+H]+ 748.4302, found 748.4307. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8,-tri-O-tert-butyldimethylsilyl-D-
glycero-α-D-galacto-2-nonulopyranosid)onate (22)  
 
 
 
Compound 19 (173 mg, 0.211 mmol) was placed under an N2 (g) atmosphere and 
dissolved in anhydrous MeOH (1.4 mL). The resulting solution was then transferred to 
a quartz reaction vessel (suitable for UV applications), also under an N2 (g) atmosphere 
and the solution was stirred. A solution of CBr4 (~4.2 mg, 0.0127 mmol added as 10 
mg/mL solution) in anhydrous MeOH was quickly transferred to the stirring methanolic 
solution of compound 19. The solution was then exposed for 10 minutes to a 6W UV 
lamp (λ ~254 nm), enclosed in a dark reaction container. After this time, the lamp was 
switched off and the reaction was monitored by TLC for a further 45 minutes to 1 hour. 
Once the reaction was complete, the methanol was removed directly from the reaction 
vessel and the vessel itself was rinsed with a small amount of DCM (1 mL). The solvent 
was then evaporated in vacuo and the product was purified directly by flash 
chromatography (hexane:EA; 2:1) to give compound 19 as a white foam on further 
drying (88 mg, 60%). Rf : 0.18 (hexane:EA; 4:1). 
1H NMR (500 MHz, CDCl3) δH: -0.01, 0.03,0.05, 0.08, 0.09, 0.10,0.15 (18 H, 7s, -Si-
CH3), 0.84, 0.89, 0.91 (27 H, s, -Si-C(CH3)3), 1.71 (1 H, dd, J = 11.7, 11.7 Hz, H3ax), 
1.90 (3 H, s, -NHCOCH3), 2.52 (1 H, dd, J = 6.7, 6.8 Hz, -OH), 2.57 (1 H, dd, J = 4.6, 
12.8 Hz, H3eq), 3.36 (1 H, m, H5), 3.57 (1 H, m, H9), 3.79 (3 H, s, -CO2CH3), 3.82 (1 H, 
ddd, J = 1.7, 5.1, 6.8 Hz, H8), 3.88 - 3.93 (1 H, m, H9), 3.94 - 4.00 (3 H, m, H4, H7, -
CHH’-CH=CH2), 4.10 (1 H, m, H6), 4.25 (1 H, dddd, 1.3, 5.4, 6.8, 12.4 Hz, -CHH’-
CH=CH2), 5.12 (1 H, dd, J = 1.3, 10.4 Hz, -CH2-CH=CHHcis), 5.19 (1 H, d, J = 7.9 Hz, -
NH), 5.24 (1 H, ddd, J = 1.4, 3.0, 17.2 Hz, -CH2-CH=CHHtrans), 5.83 (1 H, ddd, J = 5.7, 
10.7, 16.3 Hz, -CH2-CH=CH2). 
13C NMR (125.7 MHz, CDCl3) δC: -4.92, -4.71, -4.57, -4.30, -3.64 (-Si-CH3), 18.06, 
18.51, 18.74 (-Si-C(CH3)3), 23.96 (-NHCOCH3), 25.82, 26.24 (-Si-C(CH3)3), 41.42 (C3), 
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52.75 (-CO2CH3), 56.89 (C5), 63.59 (C9), 65.35 (-CH2-CH=CH2), 67.53, 74.93 (C4, 
C7), 74.42 (C6), under CHCl3 resonance (C8), 99.07 (C2), 117.35 (-CH2-CH=CH2), 
134.09 (-CH2-CH=CH2), 169.10 (C1), 169.90 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C33H67NO9Si3 [M+Na]+ 728.4016, found 728.4028. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-9-O-tosyl-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (23) 
 
 
 
Compound 4 (560 mg, 1.54 mmol) was co-evaporated with dry pyridine and was then 
suspended in dry pyridine (12 mL) under N2(g). The resulting suspension was cooled to 
below 0 °C and p-toluenesulfonyl chloride (293 mg, 1.54 mmol) was added quickly to 
the stirring solution. 
After a short time the solution was allowed to warm up to room temperature and was 
subsequently stirred for a further 5 hours after which another portion of toluenesulfonyl 
chloride (293 mg, 1.54 mmol) was added. The solution was left to stir overnight. 
Once completed, solvent was removed in vacuo and the crude product was purified 
directly by flash chromatography (EA  EA:MeOH; 5:1) to yield a white foam, 
compound 23 (470 mg, 59%). Rf : 0.70 (EA:MeOH; 4:1).  
1H NMR (500 MHz, CDCl3) δH:  1.81 (1 H, dd, J = 11.7, 11.9 Hz, H3ax), 2.01 (3 H, s, -
NHCOCH3), 2.41 (3 H, s, -CarylCH3), 2.74 (1 H, dd, J = 3.8, 13.8 Hz, H3eq), 3.40 (1 H, d, 
J = 9.2 Hz, H6), 3.45 (1 H, d, J = 8.8 Hz, H7),  3.64 – 3.75 (2 H, m, H4, H5), 3.65 – 3.77 
(1 H, bs, -OH), 3.77 (3 H, s, -CO2CH3), 3.86 (1 H, dd, J = 5.7, 12.6 Hz, -CHH’-
CH=CH2), 3.91 (1 H, bs, -OH), 4.04 (1 H, m, H8), 4.12 – 4.20 (2 H, m, H9, -CHH’-
CH=CH2), 4.29 (1 H, m, H9’), 4.68 (1 H, bs, -OH), 5.10 (1 H, dd, J = 0.8, 10.5 Hz, -CH2-
CH=CHHcis), 5.18 (1 H, dd, J = 1.1, 17.3 Hz, -CH2-CH=CHHtrans), 5.77 (1 H, ddd, J = 
5.6, 10.8, 16.2 Hz, -CH2-CH=CH2), 6.61 (1 H, d, J = 7.0 Hz, -NH), 7.32 (2 H, d, J = 8.2 
Hz, -CarylH), 7.75 (2 H, d, J = 8.3 Hz, -SCaryl-CarylH). 
13C NMR (125.7 MHz, CDCl3) δC: 21.76 (-Caryl-CH3), 23.15 (-NHCOCH3), 40.52 (C3), 
52.92 (C5), 53.49 (-CO2CH3), 65.42 (-CH2CH=CH2), 67.62 (C4), 68.63 (C7), 69.22 
(C8), 72.15 (C9), 73.65 (C6), 98.69 (C2), 117.43 (-CH2CH=CH2), 128.06, 130.12 (H3C-
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Caryl-Caryl(H)-, H3C-Caryl-Caryl(H)- ), 132.54 (-S-Caryl-Caryl(H)-), 133.61 (-CH2CH=CH2), 
145.21 (-S-Caryl-Caryl(H)-), 169.82 (C1), 174.15 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C22H31NO11S [M+Na]+ 540.1510, found 540.1507. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8-tri-O-acetyl-9-O-tosyl-D-glycero-α-D-
galacto-2-nonulopyranosid)onate (24) 
 
 
 
Compound 23 (20 mg, 0.0386 mmol) was stirred overnight in a solution of pyridine (0.5 
mL) and acetic anhydride (0.5 mL). The solvent was then evaporated under high 
vacuum and purified by flash chromatography (Tol  Tol:EA; 1:1) to give compound 24 
(23 mg, 93 %). Rf : 0.71 (EA:MeOH, 10:1). 
1H NMR (500 MHz, CDCl3) δH: 1.87 (3 H, s, -COCH3), 1.95 (1 H, dd, J = 12.4, 12.6 Hz, 
H3ax), 2.02 (3 H, s, -NHCOCH3), 2.07, 2.08 (6 H, 2s, 2 x -COCH3), 2.44 (3 H, s, Ph-
CH3), 2.62 (1 H, dd, J = 4.5, 12.8 Hz, H3eq), 3.79 (3 H, s, -CO2CH3), 3.85 (1 H, dd, J = 
5.6, 12.7 Hz, -CHH’-CH=CH2), 3.91 – 4.10 (3 H, m, H5, H9, H6), 4.22 (1 H, dd, J = 5.1, 
12.7 Hz, -CHH’-CH=CH2), 4.35 (1 H, d, J = 11.1 Hz, H9’), 4.80 (1 H, dd, J = 4.5, 11.8 
Hz, H4), 5.09 – 5.20 (2 H, m, -NH, -CH2CH=CHHcis), 5.23 – 5.38 (3 H, m, H7, H8, -
CH2CH=CHtransH), 5.83 (1 H, ddd, J = 5.7, 11.0, 16.7 Hz, -CH2CH=CH2), 7.33 (2 H, d, J 
= 8.0 Hz, -Caryl-H), 7.77 (1 H, d, J = 8.0 Hz, -Caryl-H); 
13C NMR (100.5 MHz, CDCl3) δC: 20.83, 20.97, 21.08, 23.34 (3 x –COCH3, -
NHCOCH3), 21.76 (Caryl-CH3), 38.12 (C3), 49.61 (C5), 52.86 (-CO2CH3), 66.01 (-CH2-
CH=CH2), 67.50 (C8/7), 67.81 (C9), 68.86 (C8/7), 69.09 (C4), 72.74 (C6), 98.74 (C2), 
117.36 (-CH2CH=CH2), 128.15, 129.94 (2 x Caryl-H), 133.02, 133.65 ((-CH2CH=CH2), 
145.01, 168.36 (C1), 170.00, 170.17, 170.42, 171.03. 
HR-ESI-MS (m/z) calculated for C28H37NO14S [M+Na]+ 666.1826, found 666.1842. 
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Methyl (allyl 5-acetamido-3,5-dideoxy-8,9-anhydro-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (25) 
 
 
 
Compound 23 (194 mg, 0.375 mmol) was dissolved in anhydrous MeOH (2.4mL). 
Freshly prepared NaOMe (in anhydrous MeOH) (0.3 mL, 0.5 M) was added dropwise 
to the stirring solution. Further 0.1mL portions of NaOMe (0.5 M) were added as 
required (a total of 0.7 mL NaOMe was used). The reaction was monitored by TLC. On 
completion, a small amount of Amberlite IR-120 ion-exchange resin (H+) was added to 
the solution and was agitated until the pH was neutral. The resin was removed by 
filtration and the solvent was removed in vacuo. Flash chromatography of the crude 
material (EA:MeOH; 15:1 + 0.5% NEt3) gave compound 25 as a white foam (87 mg, 
68%). Rf : 0.34 (EA:MeOH; 10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.81 (1 H, dd, J = 12.1, 12.3 Hz, H3ax), 2.00 (3 H, s, -
NHCOCH3), 2.71 (1 H, dd, J = 4.6, 12.7 Hz, H3eq), 2.77 (1 H, dd, J = 2.5, 5.1 Hz, H9), 
2.83 (1 H, dd, J = 4.3, 4.6 Hz, H9’), 3.24 (1 H, m, H8), 3.38 (1 H, dd, J = 4.8, 4.8 Hz, H7), 
3.55 (1 H, dd, J = 0.9, 10.4 Hz, H6), 3.65 (1 H, m, H4), 3.76 - 3.82 (1 H, m, H5), 3.93 (1 
H, bs, -OH), 3.96 (1 H, dd, J = 5.9, 12.6 Hz, -CHH’-CH=CH2), 4.25 (1 H, m, -CHH’-
CH=CH2), 4.27 (1 H, d, J = 5.7 Hz, -OH), 5.12 (1 H, dd, J = 1.3, 10.5 Hz, -CH2-
CH=CHHcis), 5.21 (1 H, dd, J = 1.5, 17.2 Hz, -CH2-CH=CHHtrans), 5.82 (1 H, ddd, J = 
5.6, 10.8, 16.1 Hz, -CH2-CH=CH2), 6.57 (1 H, d, J = 7.7 Hz, -NH). 
13C NMR (125.7 MHz, CDCl3) δC: 23.24 (-NHCOCH3), 40.83 (C3), 46.08 (C9), 51.99 
(C8), 52.85 (C5), 53.03 (-CO2CH3), 65.57 (-CH2CH=CH2), 67.84 (C4), 69.48 (C7), 
75.37 (C6), 99.04 (C2), 117.28 (-CH2CH=CH2), 134.00 (-CH2CH=CH2), 169.22 (C1), 
173.65 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C15H23NO8 [M+Na]+  368.1315, found 368.1309. 
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Methyl (allyl 5-acetamido-3,5-dideoxy-9-O-methyl-D-glycero-α-D-galacto-2-
nonulopyranosid)onate (26)  
 
 
 
To a stirred solution of compound 25 (50 mg, 0.0966 mmol) in methanol (1.2 mL) was 
added freshly prepared methanolic NaOMe (~0.640 M, 0.2 mL). After stirring for 15 
minutes, methanolic NaOMe solution was again added (until the solution had a 
resulting pH~10 as observed on indicator paper). The reaction was monitored by TLC, 
observing the formation of the resulting epoxide in situ. Once formation of the epoxide 
reached completion, the mixture was acidified (to ~pH 2) with Amberlite IR-120 ion-
exchange resin (H+), the resin was filtered off and the solvent evaporated from the 
solution to leave an oily residue. The crude product was purified by flash 
chromatography directly (EA  EA:MeOH; 5:1) to yield (X) (16.4 mg, 45%). Rf : 0.38 
(EA:MeOH; 5:1).  
1H NMR (500 MHz, CDCl3) δH: 2.04 (3 H, s, -NHCOCH3), 1.96 (1 H, dd, J = 11.7, 12.2 
Hz, H3ax), 2.74 (1 H, bs, -OH), 2.81 (1 H, dd, J = 4.3, 13.3 Hz, H3eq), 3.39 – 3.43 (1 H, 
m, H6), 3.43 (3 H, s, -OCH3), 3.53 (1 H, dd, J = 3.3, 9.0 Hz, H7), 3.65 – 3.80 (5 H, m, 
H4, H5, H9, H9’, -OH), 3.85 (3 H, s, -CO2CH3), 3.92 (1 H, dd, J = 5.9, 12.5 Hz, -CHH’-
CH=CH2), 4.01 (1 H, dd, J = 3.5, 8.7 Hz, H8), 4.27 (1 H, dd, J = 5.4, 12.6 Hz, -CHH’-
CH=CH2), 4.67 (1 H, bs, -OH), 5.15 (1 H, d, J = 10.5 Hz, CH2-CH=CHcisH), 5.23 (1 H, 
dd, J = 1.0, 17.2 Hz, -CH=CHtransH), 5.83 (1 H, ddd, J = 5.7, 10.8, 16.3 Hz, -CH2-
CH=CH2), 6.73 (1 H, d, J = 6.8 Hz, -NH). 
13C NMR (100.5 MHz, CDCl3) δC: 23.07 (-NHCOCH3), 40.79 (C3), 53.33, 53.42 (C5, -
CO2CH3), 59.21 (-OCH3), 65.42 (-CH2-CH=CH2), 68.15 (C4), 68.79 (C7), 69.98 (C8), 
73.86, 73.87 (C6, C9), 98.58 (C2), 117.46 (-CH2-CH=CH2), 133.73 (-CH2-CH=CH2), 
169.82 (C1), 173.72 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C16H21NO9 [M+Na]+ 400.1578, found 400.1576. 
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Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8-tri-O-acetyl-9-O-methyl-D-glycero-α-
D-galacto-2-nonulopyranosid)onate (27)  
 
 
 
Compound 26 (5 mg, 0.0132 mmol) was stirred overnight in a solution of pyridine (0.5 
mL) and acetic anhydride (0.5 mL). The solvent was then evaporated in vacuo and 
purified by flash chromatography (EA) to give compound 27 (6 mg, 91%).  Rf : 0.23 
(EA).  
1H NMR (500 MHz, CDCl3) δH: 2.01, 2.12, 2.14 (9 H, 3s, -OCOCH3), 1.86 (3 H, s, -
NHCOCH3), 1.96 (1 H, dd, J = 12.5, 12.6 Hz, H3ax), 2.59 (1 H, dd, J = 4.6, 12.8 Hz, 
H3eq), 3.29 (3 H, s, -OCH3), 3.36 (1 H, dd, J = 4.6, 10.8 Hz, H9), 3.58 (1 H, dd, J = 2.5, 
10.7 Hz, H9’), 3.76 (3 H, s, -CO2CH3), 3.87 (1 H, dd, J = 5.8, 12.8 Hz, -CHH’-CH=CH2), 
4.02 - 4.11 (2 H, m, H5, H6), 4.28 (1 H, dd, J = 5.1, 12.7 Hz, -CHH’-CH=CH2), 4.86 (1 H, 
ddd, J = 4.5, 9.9, 12.3 Hz, H4), 5.07 (1 H, d, J = 9.7 Hz, -NH), 5.14 (1 H, d, J = 10.5 Hz, 
-CH2-CH=CHHcis), 5.25 - 5.36 (3 H, m, H7, H8, -CH2-CH=CHHtrans), 5.84 (1 H, ddd, J = 
5.6, 10.8, 16.7 Hz, -CH2-CH=CH2). 
13C NMR (100.5 MHz, CDCl3) δC: 21.11, 21.51 (-OCOCH3), 23.47 (-NHCOCH3), 29.93, 
38.33 (C3), 49.71 (C5), 52.87 (-CO2CH3), 59.38 (-OCH3), 66.12 (-CH2-CH=CH2), 68.03 
(C8), 69.22 (C7), 69.32 (C4), 71.37 (C9), 77.83 (C6), 98.65 (C2), 117.43 (-CH2-
CH=CH2), 133.88 (-CH2-CH=CH2), 168.60 (C1), 170.33, 170.41, 171.21 (-OCOCH3, -
NHCOCH3). 
HR-ESI-MS (m/z) calculated for C21H32NO12 [M+H]+  504.2076, found 504.2088. 
 
Methyl (allyl 5-acetamido-3,5-dideoxy-9-O-(O,P-dimethylphosphonyl)-D-glycero-
α-D-galacto-2-nonulopyranosid)onate (28) 
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Compound 4 (77 mg, 0.212 mmol) was placed in a flask under an N2 (g) atmosphere. 
Dry DCM (2 mL) was then added which required ultrasonication. N,N-
diisopropylethylamine (81 µL, 0.466 mmol) was added to the suspension followed by 
further ultrasonication. With continuous stirring, the suspension was cooled to 
approximately -15 °C and methyl methylphosphonochloridate (29 µL, 0.297 mmol) was 
added dropwise to the solution via microsyringe. After 5 hours the reaction was again 
then cooled to -15°C, where a further portion of N,N-diisopropylethylamine (81 µL, 
0.466 mmol) and methyl methylphosphonochloridate (29 µL, 0.297 mmol) was added. 
The reaction was left to stir overnight. Once TLC monitoring of the reaction had 
indicated completion, the reaction was quenched by the addition of MeOH (1 mL) and a 
small spatula of NaHCO3 (s). After stirring for 10 minutes, the solvent was removed 
directly in vacuo and the product was directly purified by flash chromatography 
(EA:MeOH; EA  10:1 5:1) to give compound 28 (27 mg, 30%). Rf : 0.25 (EA:MeOH; 
10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.54 (3 H, dd, J = 2.2, 17.6 Hz, P-CH3), 1.75 (1 H, dd, J 
= 12.2, 12.3 Hz, H3ax), 2.00 (3 H, s, -NHCOCH3), 2.69 (1 H, dd, J = 4.6, 12.8 Hz, H3eq), 
3.52 (1 H, ddd, J = 1.4, 9.9, 10.1 Hz, H7), 3.62 (1 H, dd, J = 1.4, 10.5 Hz, H6), 3.66 (1 
H, m, H4), 3.75 (3 H, dd, J = 1.7, 11.2 Hz, P-OCH3), 3.75 - 3.80 (1 H, m, H5), 3.98 - 
4.02 (1 H, m, H8), 3.98 - 4.02 (1 H, m, -CHH’-CH=CH2), 4.15 (1 H, m, H9), 4.26 - 4.33 
(1 H, m, -CHH’-CH=CH2), 4.26 - 4.33 (1 H, m, H9’), 5.12 (1 H, dd, J = 1.1, 10.5 Hz, -
CH2-CH=CHHcis), 5.24 (1 H, dd, J = 1.7, 17.2 Hz, -CH2-CH=CHHtrans), 5.87 (1 H, ddd, J 
= 5.5, 10.6, 16.2 Hz, -CH2-CH=CH2). 
13C NMR (100.5 MHz, CDCl3) δC: ~9.15, ~10.29 (2d, J = 144 Hz, P-CH3), 22.68 (-
NHCOCH3), 41.69 (C3), ~52.91, 53.83, 53.85 (s, m, C5, P-OCH3), 53.28 (-CO2CH3), 
66.26 (-CH2-CH=CH2), 68.46 (C4), 69.12, 69.30 (2d, J = 6.3, 6.4 Hz, C9), 69.80, 69.94 
(C7), 70.80, 70.90 (2d, J = 6.4, 6.8 Hz, C8), 74.70 (C6), 100.12 (C2), 116.94 (-CH2-
CH=CH2), 135.47 (-CH2-CH=CH2), 170.84 (C1), 175.16 (-NHCOCH3). 
31P NMR (161.7 MHz, CDCl3) δP: 34.24 (s), 34.34 (s). 
HR-ESI-MS (m/z) calculated for C17H30NO11P [M+Na]+ 478.1449, found 478.1449. 
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Methyl (allyl 5-acetamido-3,5-dideoxy-4,7,8-tri-O-acetyl-9-O-(O,P-
dimethylphosphonyl)-D-glycero-α-D-galacto-2-nonulopyranosid)onate (29) 
 
 
 
Compound 28 (23 mg, 0.0520 mmol) was placed into a flask. Pyridine (0.5 mL) and 
acetic anhydride (0.5 mL) were then added and the solution was stirred overnight. 
Once the reaction was complete, the solvent was removed directly in vacuo. Co-
evaporation with toluene several times followed by flash chromatography (EA:MeOH 
20:1  10:1) gave the desired product, compound 29 (26 mg, 90%). Rf : 0.45 
(EA:MeOH; 10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.45 (1 H, dd, J = 3.4, 17.6 Hz, P-CH3), 1.85, 2.12 - 2.14 
(9 H, s,m, 3 x -OCOCH3), 2.00 (3 H, s, -NHCOCH3), 1.95 (1 H, dd, J = 12.4, 12.6 Hz, 
H3ax), 2.60 (1 H, dd, J = 4.6, 12.8 Hz, H3eq), 3.68, 3.72 (3 H, 2d, J = 11.1, 11.2 Hz, P-
OCH3), 3.87 (1 H, dd, J = 5.9, 12.8 Hz, -CHH’-CH=CH2), 3.95 - 4.13 (3 H, m, H5, H6, 
H9), 4.21 - 4.33 (2 H, m, H9’, -CHH’-CH=CH2), 4.87 (1 H, m, H4), 5.14 (1 H, dd, J = 1.4, 
10.4 Hz, -CH2-CH=CHHcis), 5.22 (1 H, d, J = 10.0 Hz, -NH), 5.26 (1 H, d, J = 17.2 Hz, -
CH2-CH=CHHtrans), 5.30 (1 H, m, H7), 5.37 (1 H, m, H8), 5.84 ( 1H, ddd, J = 5.5, 10.7, 
16.1 Hz, -CH2-CH=CH2). 
13C NMR (100.5 MHz, CDCl3) δC: ~10.49, ~10.57 (2d, J = 145.1, 145.4 Hz, P-CH3), 
21.00, 21.27, 23.35 (3 x -OCOCH3, -NHCOCH3), 38.17 (C3), 49.69, 49.73 (C5), ~52.31 
(m, P-OCH3), 52.83 (-CO2CH3), 63.88 (m, C9), 66.02 (-CH2-CH=CH2), 67.54 (C7), 
69.18, 69.23 (C4), ~69.60, ~69.82 (2d, J = 6.5, 6.5 Hz, C8), 72.65, 72.68 (C6), 98.70 
(C2), 117.38 (-CH2-CH=CH2), 133.76 (-CH2-CH=CH2), 168.49, 168.52 (C1), 170.16, 
170.25, 170.35, 171.07 (3 x -OCOCH3, -NHCOCH3). 
31P NMR (161.7 MHz, CDCl3) δP: 32.51 (s), 32.73 (s). 
HR-ESI-MS (m/z) calculated for C23H36NO14P [M+Na]+ 604.1766, found 604.1756. 
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Methyl (allyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosidonate) (30) 
 
AcHN
OH
O O
HO
OH
HO
CO2 NH4
 
 
Compound 4 (10 mg, 0.0275 mmol) was dissolved in dioxane (0.5 mL) with stirring. 
NaOH (aq.) (0.1 M, 0.5 mL) was then added to the solution which was stirred for 2 
hours. The solution was then neutralised with Amberlite IR-120 ion-exchange resin (H+) 
and the solvent removed in vacuo. The crude residue was then purified by gel 
permeation chromatography and then lyophilised to give a white powder (9 mg, 
~quantitative). Data corresponds to literature.63  
1H NMR (500 MHz, D2O) δH: 1.74 (1 H, dd, J = 12.1, 12.1 Hz,  H3ax), 2.11 (3 H, s, -
NHCOCH3), 2.83 (1 H, dd, J = 4.4, 12.4 Hz, H3eq), 3.66 (1 H, d, J = 8.9 Hz, H7), 3.69 – 
3.82 (3 H, m, H4, H6, H9), 3.85 – 3.99 (3 H, m, H5, H8, H9’), 4.09 (1 H, dd, J = 5.7, 12.0 
Hz, -CHH’-CH=CH2), 4.32 (1 H, dd, J = 6.2, 12.0 Hz, -CHH’-CH=CH2), 5.30 (1 H, d, J = 
10.4 Hz, -CH2-CH=CHcisH), 5.40 (1 H, d, J = 17.3 Hz, -CH=CHtransH), 6.02 (1 H, ddd, J 
= 5.9, 11.4, 16.5 Hz, -CH2-CH=CH2). 
13C NMR (100.5 MHz, D2O) δC: 22.01 (-NHCOCH3), 40.45 (C3), 51.88 (C5), 62.60 
(C9), 65.95 (-CH2CH=CH2), 68.21 (C4, C7), 71.69 (C8), 72.65 (C6), 100.59 (C2), 
118.19 (-CH2CH=CH2), 133.76, (-CH2CH=CH2), 173.42 (C1), 175.06 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C14H23NO9 (acid form) [M+Na]+ 372.1265, found 
372.1280. 
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III.3. SOAE Inhibition assays 
 
III.3.1. Viruses and recombinant viral sialate-O-acetylesterases 
Influenza C virus C/JJ/50 was grown in embryonated chicken eggs. Bovine coronavirus 
(BCoV) was grown in Madin-Darby bovine kidney (MDBK) cells and mouse hepatitis 
virus strain S (MHV-S) was grown in mouse L cells. 
The INF-C virus HEF and SDAV-HE were expressed as chimeric recombinant 
influenza C/Cal/78 virus and sialodacryoadenitis virus haemagglutinin esterase, 
respectively, fused in frame to enhanced green fluorescent protein (HE12-GFP and 
SDAV-HE). Both HE12-GFP and SDAV-HE were expressed in insect Sf9 cells in 
serum-free media by recombinant baculoviruses. 
 
III.3.2. Enzyme and inhibitors 
The three different viruses (INF-C virus, BCoV and MHV-S) were concentrated and 
purified by ultracentrifugation through a 3 ml cushion of 20 % sucrose for 1.5 hours at  
4 °C at 26,000 rpm (110.000 x g) in a Beckman SW 41 rotor. The virus pellets were 
resuspended in 500 µl PBS (phosphate buffered saline) pH 7.4. 
The recombinant enzymes (HE12-GFP and SDAV-HE) were recovered from cell 
culture supernatants by ultracentrifugation for 1.5 hours at 4 °C at 26,000 rpm.  
 
Target sialosides (compounds 5 - 8) were dissolved in ddH2O to a final concentration of 
10 mM. Stock solutions of p-nitrophenyl acetate (100 mM) were prepared in 
acetonitrile, and 3,4-Dichloroisocoumarin (positive control) was dissolved in 
dimethylsulfoxide to a final concentration of 10 mM. 
 
III.3.3. p-nitrophenylacetate (pNPA) Inhibition assay 
The esterase activities of all viruses and recombinant proteins were determined with 
pNPA as described in the literature.46 
One milliunit of viral esterase activity was defined as the amount of enzymatic activity 
resulting in the hydrolysis of 1 nmol of pNPA per minute. 
An esterase activity was incubated in the presence of a sialoside at room temperature 
for 30 min. For control inhibition reactions, 100 µM 3,4-Dichloroisocoumarin was 
incubated with the different esterase activities 10 µl pNPA and PBS pH 7.4 was added 
to 1 ml and the A400 was monitored. 
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III.4. Synthetic procedures towards phospha-oseltamivir derivatives  
 
(3R,4R,5S)-4-acetamido-5-azido-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic 
acid (31)  
 
 
 
Tamiflu precursor (“acetamido-azide”) (1 g, 2.95 mmol) was dissolved in dioxane (6 
mL), a NaOH-solution (0.5 M, 6 mL) was added and the mixture was stirred overnight. 
The mixture was neutralized with Amberlite IR-120 (H+), filtered and lyophilized. The 
residue was purified by flash chromatography (Tol:EA; 1:1: +0.5% AcOH) to afford the 
free acid, compound 31 (889 mg, 97% yield) as a colourless solid. Rf : 0.27 (Tol:EA; 
1:1). 
1H NMR (500 MHz, MeOH-D4) δH:  0.86 (3 H, t, J = 7.4 Hz, -OCH(CH2CH3)2), 0.88 (3 H, 
t, J = 7.4 Hz, -OCH(CH2)2(CH3)2), 1.40 – 1.55 (4 H, m, -OCH(CH2CH3)2), 1.97 (3 H, s, -
NHCOCH3), 2.16 (1 H, m, H6ax), 2.78 (1 H, dd, J = 5.4, 16.8 Hz, H6ax), 3.31 – 3.37 (1 H, 
m, -OCH(CH2)2(CH3)2), 3.70 – 3.80 (2 H, m, H4, H5), 4.17 (1 H, d, J = 7.6 Hz, H3), 6.75 
(1 H, m, H2); 
13C NMR (125.8 MHz, MeOH-D4) δC: 9.56, 9.89 (-OCH(CH2CH3)2), 23.05 (-NHCOCH3), 
26.73, 27.24 (-OCH(CH2CH3)2), 31.36 (C6), 56.98 (C5), 60.12 (C4), 76.43 (C3), 83.70 
(-OCH(CH2CH3)2), 126.90 (C1), 139.27 (C2), 168.96 (-CO2H), 173.79 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C14H22N4O4 (M+Na)+ 333.1533, found 333.1533. 
 
(3R,4R,5S)-4-acetamido-5-azido-3-(1-ethylpropoxy)-1-iodocyclohexene (32)  
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Under an atmosphere of dry nitrogen, the free acid 31 (250 mg, 0.81 mmol) and 
(chloromethylene)dimethyliminium chloride (Vilsmeier reagent, 124 mg, 0.97 mmol) 
were dissolved in dry DCM (2 mL) and the mixture was stirred for 40 min at room 
temperature. Simultaneously, using a quartz tube, N-hydroxypyridine-2-thione (144 mg, 
0.97 mmol), DMAP (50 mg, 0.4 mmol) and 2-iodo-1,1,1-trifluoroethane (0.317 mL, 3.22 
mmol) were dissolved in dry DCM (2 mL) under an atmosphere of dry nitrogen using an 
ultrasonic bath. The mixture was irradiated and heated to reflux with a 250W flood lamp 
for 5 minutes, followed by addition of the acyl chloride mixture. Irradiation and refluxing 
was then continued for a further 30 min. After evaporation of the solvent, the mixture 
was purified by flash chromatography (Tol:EA; 5:1  2:1) to give the iodo derivative 32 
(129 mg, (41% (77% based on consumed starting material)) as a pale yellow crystalline 
solid. Rf : 0.53 (Tol:EA; 1:1).  
1H NMR (500 MHz, CDCl3) δH: 0.87 (6 H, m, -OCH(CH2CH3)2), 1.46 (4 H, m, -
OCH(CH2CH3)2), 2.02 (3 H, s, -NHCOCH3), 2.55 (1 H, dd, J = 9.1, 17.0 Hz, H6ax), 2.90 
(1 H, dd, J = 4.3, 17.4 Hz, H6eq), 3.25 (1 H, m, -OCH(CH2CH3)2), 3.46 (1 H, m, H4), 4.21 
(1 H, dd, J = 9.6, 14.6 Hz, H5), 4.28 (1 H, d, J = 5.4 Hz, H3), 6.27 (1 H, s, H2), 6.41 (1 H, 
bs, -NH); 
13C NMR (150.9 MHz, CDCl3) δC: 9.37, 9.68 (-OCH(CH2CH3)2), 23.55 (-NHCOCH3), 
25.75, 26.34 (-OCH(CH2CH3)2), 44.71 (C6), 56.99 (C4), 58.33 (C5), 76.08 (C3), 82.23 
(OCH(CH2CH3)2), 92.18 (C1), 139.03 (C2), 171.43 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C13H21IN4O2 [M+Na]+ 415.0601, found 415.0609. 
 
(3R,4R,5S)-4-acetamido-5-N-tert-Butoxycarbonyl-amino-3-(1-ethylpropoxy)-1-
iodocyclohexene (33)  
 
 
 
Under an atmosphere of dry nitrogen, the azido compound 32 (236 mg, 0.6 mmol) was 
dissolved in dry THF, PMe3 was added (0.661 mL of 1 M solution in THF, 0.66 mmol) 
and the mixture was stirred at room temperature for 1 hour. When TLC indicated the 
absence of starting material, the mixture was cooled to -16 °C and a solution of 2-(tert-
Butoxycarbonyloxyimino)-2-phenylacetonitrile (BocON, 222 mg, 0.9 mmol) in THF (1 
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mL) was added via cannula. The mixture was then stirred for 3.5 hours, during which it 
was allowed to come to room temperature. Water (2 mL) was added and the solution 
was stirred for additional few minutes. The solution was extracted with DCM (30 mL) 
and then washed with saturated aqueous NaCl (2x20 mL). The organic phase was 
dried over MgSO4, concentrated and the residue was purified by flash chromatography 
(Tol:EA; 5:1  1:1) to afford compound 33 (202 mg, 72%) as a pale yellow crystalline 
solid. Rf : 0.39 (Tol:EA; 1:1).  
1H NMR (500 MHz, CDCl3) δH: 0.88 (6 H, m, -OCH(CH2CH3)2), 1.42 (9 H, s, -
NHCOC(CH3)3), 1.44 – 1.53 (4 H, m, -OCH(CH2CH3)2), 1.98 (3 H, s, -NHCOCH3), 2.62 
(1 H, dd, J = 8.2, 17.7 Hz, H6ax), 2.87 (1 H, dd, J = 4.7, 18.0 Hz, H6eq), 3.30 (1 H, p, J = 
5.4, 5.6 Hz, -OCH(CH2CH3)2), 3.77 (1 H, dd, J = 5.9 Hz, H3), 3.84 (1 H, ddd, J = 5.3, 
8.7, 14.1 Hz, H5), 4.10 (1 H, dd, J = 8.8, 8.9 Hz, H4), 5.27 (1 H, d, J = 8.7 Hz, -
NHCOC(CH3)3), 5.54 (1 H, d, J = 8.9 Hz, -NHCOCH3), 6.33 (1 H, s, H2); 
13C NMR (100.5 MHz, CDCl3) δC: 9.38, 9.62 (-OCH(CH2CH3)2), 23.43 (-NHCOCH3), 
25.88, 26.26 (-OCH(CH2CH3)2), 28.47 (-NHCOC(CH3)2), 45.13 (C6), 50.60 (C5), 53.28 
(C4), 77.67 (C3), 79.80 (-NHCOC(CH3)2), 82.14 (-OCH(CH2CH3)2), 94.92 (C1), 138.14 
(C2), 156.12 (-NHCOC(CH3)2), 170.95 (-NHCOCH3). 
HR-ESI-MS (m/z) calculated for C18H31IN2O4 [M+Na]+ 489.1221, found 489.1218. 
 
Dimethyl (3R,4R,5S)-4-acetamido-5-N-tert-Butoxycarbonyl-amino-3-(1-
ethylpropoxy)-1-cyclohexene-1-phosphonate (34) 
 
 
 
Under an atmosphere of dry nitrogen, tetrakistriphenylphosphine palladium (230 mg, 
0.2 mmol) and vinyl iodide 33 (620 mg, 1.33 mmol) were dissolved in anhydrous 
toluene (10 mL). Triethylamine (0.74 mL, 5.32 mmol) and dimethylphosphite (0.49 mL, 
5.32 mmol) were added to the solution and the mixture was stirred at 80 °C for 90 
minutes. After cooling to room temperature, the reaction was quenched by addition of 
saturated aqueous NH4Cl (10 mL). DCM (50 mL) was added and the organic phase 
was extracted with NH4Cl (10 mL), washed with brine (2x10 mL), dried over MgSO4 
and evaporated. Purification by flash chromatography (EA:MeOH; 1:0  5:1) gave the 
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desired vinyl phosphonate 34 (475 mg, 80%) a white glassy solid. Rf : 0.42 (EA:MeOH; 
6:1). 
1H NMR (500 MHz, CDCl3) δH: 0.86 (6 H, m, -OCH(CH2CH3)2), 1.40 (9 H, s, -
NHCOC(CH3)3), 1.48 (4 H, m, -OCH(CH2CH3)2), 1.97 (3 H, s, -NHCOCH3), 2.21 (1 H, 
m, H6ax), ), 2.58 (1 H, m, H6eq), 3.34 (1 H, p, J = 5.1, 5.9 Hz, -OCH(CH2CH3)2), 3.70 (6 
H, 2d, J = 10.9 Hz, P-OCH3), 3.78 (1 H, m, H5), 3.93 (1 H, s, H3), 4.05 (1 H, dd, J = 8.8, 
17.9 Hz, H4), 5.21 (1 H, d, J = 8.5 Hz, -NHCOCH3), 6.08 (1 H, d, J = 8.4 Hz, -
NHCOC(CH3)3), 6.59 (1 H, d, JP-2 = 21.8 Hz, H2); 
13C NMR (100.5 MHz, CDCl3) δC: 9.27, 9.64 (-OCH(CH2CH3)2), 23.38 (-NHCOCH3), 
25.71, 26.22 (-OCH(CH2CH3)2), 28.45 (-NHCOC(CH3)2), ~31.2 (d, J = 9.6 Hz, C6), 
49.21, 49.32 (C5), ~52.7 (m, -P(OCH3)2), 54.37 (C4), ~76.1 (m, C3), 79.78 (-
NHCOC(CH3)2), 82.28 (-OCH(CH2CH3)2), ~126.5 (d, J = 182 Hz, C1), ~142.4 (d, J = 
7.8 Hz, C2), 156.34 (-NHCOC(CH3)2), 171.08 (-NHCOCH3); 
31P NMR (161.7 MHz, CDCl3) δP: 19.59 (s). 
HR-ESI-MS (m/z) calculated for C20H37N2O7P [M+Na]+ 471.2231, found 471.2237. 
 
Ammonium (Methyl [(3R,4R,5S)-4-acetamido-5-N-tert-Butoxycarbonyl-amino-3-(1-
ethylpropoxy)-1-cyclohexene]-1-phosphonic acid]) (35)  
 
P
BocHN
AcHN
O
O
OMe
O NH4
 
 
Dimethyl phosphonate 34 (100 mg, 0.22 mmol) was dissolved in dioxane (2 mL), 
NaOH solution (0.25 M, 2 mL) was added and the mixture was stirred overnight at 
room temperature, neutralised with Amberlite IR-120 ion-exchange resin (H+) and 
lyophilised. Purification by flash chromatography (EA:MeOH; 6:1  1:2) yielded 
phosphonic acid compound 35 as a white powder after gel permeation chromatography 
and subsequent lyophilisation (93 mg, 96%). Rf : 0.29 (DCM:MeOH, 2:1).  
1H NMR (500 MHz, D2O) δH: 0.91 (3 H, t, J = 7.1 Hz, -OCH(CH2CH3)2), 0.97 (3 H, t, J = 
6.8 Hz, -OCH(CH2CH3)2), 1.50 (3 H, s, -NHCOC(CH3)3), 1.63 (4 H, m, -
OCH(CH2CH3)2), 2.09 (3 H, s, -NHCOCH3), 2.30 (1 H, dd, J = 11.7, 13.5 Hz, H6ax), 
2.62 (1 H, m, H6eq), 3.55 – 3.62 (1 H, bm, -OCH(CH2CH3)2), 3.58 (3 H, d, J = 10.8 Hz, 
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P-OCH3), 3.81 (1 H, m, H5), 3.89 (1 H, dd, J = 9.2, 10.5 Hz, H4), 4.31 (1 H, bm, H3), 
6.38 (1 H, d, JP-2 = 19.7 Hz, H2); 
13C NMR (100.5 MHz, D2O) δC: 8.57, 8.67, -OCH(CH2CH3)2), 22.25 (-NHCOCH3), 
25.34, 25.66 (-OCH(CH2CH3)2), 27.62 (-NHCOC(CH3)2), 31.24 (d, J = 9.6 Hz, C6), 
49.32 (d, J = 14.1 Hz, C5), 51.68 (d, J = 5.0 Hz, -P(OCH3)2), 55.60 (C4), 76.80 (m, C3), 
80.97 (-NHCOC(CH3)2), 84.13 (-OCH(CH2CH3)2),  ~131.1 (d, J = 172 Hz, C1), 136.91 
(m, C2), 157.58 (-NHCOC(CH3)2), 174.18 (-NHCOCH3);  
31P NMR (161.7 MHz, D2O) δP: 15.23 (s).  
HR-ESI-MS (m/z) calculated for C19H35N2O7P [M+(2Na-H)]+ 479.1894, found 479.1917.  
 
Chloro(dimethyl)phosphine (36) 
 
 
 
Under an atmosphere of nitrogen, P(OMe)3 (16.2 mL, 137 mmol) was added dropwise 
to PCl3 (6 mL, 68.6 mmol) at 0°C. The colourless solution turned slightly orange as 
soon as the mixture was heated up gradually to 90°C. The mixture was stirred at 90 °C 
for 1 hour and 30 min. The residue was then distilled under reduced pressure (34°C, 42 
Torr).  
1H NMR (500 MHz, CDCl3) δH: 3.70 (6 H, d, J = 10.9 Hz); 
31P NMR (161.7 MHz, CDCl3) δP: 169.46 (s) (+ small impurity at 181.02 (s)). 
 
O-Triisopropylsilylhexane-1,6-diol (37) 
 
 
 
1,6-Hexanediol (2 g, 0.0169 mmol) and imidazole (3.46 g, 0.0507 mmol) were dried in 
vacuo in a round-bottomed flask for 1 hour, then placed under an N2 (g) atmosphere. 
Dry DCM (7 mL) was added and the resulting suspension was briefly sonicated. The 
suspension was cooled to 0 °C (ice-bath) and TIPSCl (4.4 mL, 0.0253 mmol) was then 
added dropwise.  Once TLC had indicated that the reaction was no longer progressing, 
the solvent was evaporated to dryness and the crude product was purified by column 
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chromatography (Tol/EA; 1:0  10:1) to give compound 37 as a clear oil (1.82 g, 40%). 
Rf : 0.23 (Tol/EA; 10:1). 
1H NMR (500 MHz, CDCl3) δH: 1.02 – 1.11 (21 H, m, -Si(CH(CH3)2)3, -Si(CH(CH3)2)3), 
1.38 (4 H, m, -CH2CH2CH2CH2OSi-), 1.57 (4 H, m, HOCH2CH2CH2CH2CH2CH2O-), 
3.62 – 3.70 (4 H, m, HOCH2-, -CH2OSi- ); 
13C NMR (125.7 MHz, CDCl3) δC: 12.21 (-Si(CH(CH3)2)3), 18.19 (-Si(CH(CH3)2)3),  
25.74, 25.82 (HOCH2CH2CH2CH2CH2CH2O-), 32.99, 33.13 
(HOCH2CH2CH2CH2CH2CH2O-), 63.18, 63.51 (HOCH2- , -CH2OSi-). 
HR-ESI-MS (m/z) calculated for C15H34O2Si [M+Na]+ 297.2220, found 297.2218. 
 
O-Toluenesulfonyl-O-triisopropylsilylhexane-1,6-diol (38) 
 
 
 
Under an atmosphere of dry nitrogen, alcohol 37 (3.86 g, 14.06 mmol) was dissolved in 
dry pyridine (12 mL). DMAP (172 mg, 1.41 mmol) and p-toluenesulfonyl chloride (4.02 
g, 21.09 mmol) were added to the solution and the mixture stirred a 0 °C for 4 hours. 
The reaction was quenched by addition of saturated aqueous NH4Cl (5 mL). After 
evaporation to dryness, the residue was dissolved in DCM (15 mL) which was then 
extracted with NH4Cl (5 mL), washed with brine (2 x 5 mL), the organic phase was 
dried over MgSO4 and the solvent evaporated. Purification by flash chromatography 
(cyclohexane/DE; 10:1) gave compound 38 (4.79 g, 80%) as a clear oil. Rf : 0.27 
(cyclohexane/DE; 10:1). 
1H NMR (500 MHz, CDCl3) δH: 1.00 - 1.10 (21 H, m, -Si(CH(CH3)2)3, -Si(CH(CH3)2)3), 
1.27 – 1.35 (4 H, m, HOCH2CH2CH2CH2-), 1.48 (2 H, m, -CH2CH2OSi-), 1.64 (2 H, m, -
CH2CH2OTs), 2.44 (3 H, s, H3C-Ph-), 3.63 (2 H, t, J = 6.4 Hz, -CH2OSi-), 4.02 (2 H, t, J 
= 6.4, 6.5 Hz, Ts-OCH2-), 7.33 (2 H, d, J = 8.0 Hz, HAryl), 7.78 (2 H, d, J = 8.1 Hz, HAryl); 
13C NMR (125.7 MHz, CDCl3) δC: 12.15 (-Si(CH(CH3)2)3), 18.16 (-Si(CH(CH3)2)3), 21.73 
(CH3-Ph-), 25.36, 25.40 (TsOCH2CH2CH2CH2CH2CH2O-), 29.01, 32.86 
(TsOCH2CH2CH2CH2CH2CH2O-), 63.31 (-CH2OSi-),70.75 (TsOCH2-), 128.00, 129.91 
(CHAryl ), 133.50, 144.71 (CAryl); 
HR-ESI-MS (m/z) calculated for C22H40O4SSi [M+Na]+ 451.2296, found 451.2309. 
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6-Triisopropylsilyloxy-S-acetyl-hexan-1-thiol (39) 
 
TIPSO SAc
4
 
 
Compound 38 (4.792 g, 0.011 mol) was dissolved in pyridine (65 mL) and KSAc (3.83 
g, 0.033 mol) was then added to the solution. The mixture was stirred for 5 hours at 
room temperature. Pyridine was removed under high vacuum and the residue was 
dissolved in DCM (50 mL). The solution was washed with saturated aqueous NH4Cl 
(2x15 mL), NaCl (20 mL), the organic phase was dried over MgSO4 and the solvent 
evaporated. Purification by flash chromatography (Tol) afforded compound 39 (3.208 g, 
86%) as a clear oil. Rf : 0.46 (Tol).  
1H NMR (500 MHz, CDCl3) δH: 1.02 – 1.12 (21 H, s, -Si(CH(CH3)2)3), -Si(CH(CH3) 2)3), 
1.37 (4 H, m, -CH2CH2CH2CH2S-), 1.50 – 1.62 (4 H, m, -OCH2CH2-, -SCH2CH2-), 2.32 
(3 H, s, -SCOCH3), 2.87 (2 H, t, J = 6.9, 7.1 Hz, -SCH2-), 3.67 (2 H, t, J = 6.2, 6.3 Hz, -
OCH2-); 
13C NMR (125.7 MHz, CDCl3) δC: 12.20 (-Si(CH(CH3)2)3), 18.20 (-Si(CH(CH3)2)3), 
25.56, 28.82 (-CH2CH2CH2CH2S-), 29.29 (-CH2S-), 29.88 (-CH2CH2S-), 30.77 (-
SCOCH3), 33.00 (-CH2CH2O-), 63.47 (-CH2O-);  
HR-ESI-MS (m/z) calculated for C17H36O2SSi [M+Na]+ 355.2097, found 355.2091. 
 
6-Hydroxy-S-acetyl-hexan-1-thiol (40) 
 
 
 
Compound 39 (0.874 g, 2.63 mmol) was dissolved in THF (20 mL), then AcOH (1 mL) 
and TBAF (3.32 g, 10.51 mmol) were successively added. The mixture was stirred 
overnight. The solution was washed with saturated aqueous NaHCO3 (2x15 mL), NaCl 
(20 mL), the organic phase was dried over MgSO4 and the solvent evaporated. 
Purification by flash chromatography (Tol) afforded compound 40 (0.333 g, 72%) as a 
clear oil. Rf : 0.17 (Tol:EA; 5:1). 
1H NMR (500 MHz, CDCl3) δH: 1.33 (4 H, m,-CH2CH2CH2CH2SAc), 1.51 (4 H, m, -
OCH2CH2-, -CH2CH2SAc), 2.26 (3 H, s, -SCOCH3), 2.81 (2 H, t, J = 7.3 Hz, -SCH2-), 
3.56 (2 H, t, J = 6.6 Hz, -OCH2-);  
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13C NMR (125.7 MHz, CDCl3) δC: 25.26, 28.53, 29.03, 29.47 (-CH2CH2CH2CH2SAc), 
30.62 (-SCOCH3), 32.53 (-OCH2CH2-), 62.63 (-OCH2-), 196.18 (-SCOCH3). 
HR-ESI-MS (m/z) calculated for C8H16O2S [M+Na]+ 199.0763, found 199.0768. 
 
O-methyl O-(6-Acetylthiohex-1-yl) phosphonic acid (41) 
 
 
 
Under an atmosphere of nitrogen, compound 40 (333 mg, 1.89 mmol) was dissolved in 
dry DCM (5 mL) at 0°C. DIPEA (0.99 mL, 5.67 mmol) was added to the solution. 
Chloro(dimethyl)phosphine 36 (0.6 mL) was added dropwise, the reaction mixture was 
allowed to come up to room temperature and stirred overnight. Solid NaHCO3 (one 
spatula) was added to the reaction mixture, followed by MeOH (2 mL) and silica (a few 
spatulas). The mixture was evaporated to dryness. Purification by flash 
chromatography (Tol:EA ; 5:1  1:3) gave compound 41 (208 mg, 41%) as a yellowish 
liquid/oil. Rf : 0.15 (Tol:EA; 1:1).  
1H NMR (500 MHz, CDCl3) δH: 1.38 – 1.43 (4 H, M, -CH2CH2CH2CH2SAc), 1.55 – 1.62 
(2 H, m, -CH2CH2SAc), 1.66 – 1.73 (2 H, m, -POCH2CH2-), 2.32 (3 H, s, -SCOCH3), 
2.87 (2 H, t, J = 7.3 Hz, -CH2CH2SAc), 3.77 (3 H, d, J = 11.9 Hz, P-OCH3), 4.03 – 4.11 
(2 H, m, -OCH2CH2-), ~6.78 (1 H, d, J = 695 Hz, P-H); 
13C NMR (125.7 MHz, CDCl3) δC: 25.10, 25.16, 28.34, 38.38 (-CH2CH2CH2CH2SAc), 
29.07 (-CH2SAc), 29.52 (-CH2CH2SAc), ~30.4 (d, J = 6.1 Hz, -OCH2CH2-), 30.76 (-
SCOCH3), ~52.1 (d, J = 5.7 Hz, P-OCH3), ~54.3 (d, J = 5.8 Hz, P-OCH3), ~65.8 (d, J = 
6.1 Hz, -OCH2CH2-), ~67.9 (d, J = 6.0 Hz, -OCH2CH2-), 195.98 (-SCOCH3); 
31P NMR (161.7 MHz, CDCl3) δP: 9.08. 
HR-ESI-MS (m/z) calculated for C9H19O4PS [M+Na]+ 277.0634, found 277.0631. 
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(6’-Acetylthiohex-1’-yl) methyl [(3R,4R,5S)-4-acetamido-5-(1,1 
dimethylethyloxycarbonylamino)-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate] (42)  
 
 
 
Palladium-mediated coupling 
Tetrakistriphenylphosphine palladium (14 mg, 0.012 mmol) and vinyl iodide 32 (37 mg, 
0.078 mmol) were added to the phosphinic acid 41 under an atmosphere of dry 
nitrogen. The mixture was dissolved in anhydrous toluene (3 mL) followed by the 
addition of triethylamine (8.8 µL, 0.063 mmol). The mixture was heated to 80°C, stirred 
and maintained at this temperature for 3 hours. After cooling to room temperature, the 
reaction was quenched by addition of saturated aqueous NH4Cl (3 mL). DCM (15 mL) 
was added to the solution which was then extracted with NH4Cl (3 mL), washed with 
brine (2x3 mL), the organic phase was dried over MgSO4 and the solvent evaporated. 
Purification by flash chromatography (EA:MeOH ; 1:0  5:1) gave the desired vinyl 
phosphonate 42 (17 mg, 0.0287 mmol, 52%). Rf : 0.51 (EA).  
 
Alkylation strategy 
Compound 43 (49 mg, 0.177 mmol) was placed under an N2 (g) atmosphere and dry 
acetonitrile (1.5 mL) was added. Compound 35 (70 mg, 0.131 mmol), previously 
lyophilised with NEt3 (1 eq.) was then quickly added to the stirring solution. After stirring 
overnight, TLC analysis indicated the reaction had not progressed any further and that 
triflate 43 had degraded in solution. The solvent was evaporated in vacuo and the 
residue was directly purified by flash chromatography (Tol:EA; 1:1  EA  EA:MeOH; 
5:1MeOH) to give compound 42 (31 mg, 71% based on recovered starting material). 
Rf : 0.51 (EA).  
1H NMR (500 MHz, CDCl3) δH: 0.86 (6 H, m, -OCH(CH2CH3)2), 1.37 (4 H, m, -
CH2CH2CH2CH2S-), 1.40 (9 H, s, -NHCOC(CH3)3), 1.48 (4 H, m, -OCH(CH2CH3)2), 1.56 
(2 H, m, -SCH2CH2-), 1.64 (2 H, m, -OCH2CH2-), 1.96 (3 H, s, -NHCOCH3), 2.20 (1 H, 
m, H6ax), 2.30 (3 H, m, -SCOCH3), 2.59 (1 H, m, H6eq), 2.85 (2 H, dd, J = 1.4, 7.8 Hz, -
SCH2-), 3.33 (1 H, m, -OCH(CH2CH3)2), 3.68 (3 H, 2d, J = 11.0 Hz, P-OCH3), 3.78 (1 H, 
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m, H5), 3.88 – 4.09 (4 H, m, -OCH2-, H3, H4), 5.16 (1 H, dd, J = 8.8, 9.3 Hz, -
NHCOCH3), 5.88 (1 H, d, J = 9.2 Hz, -NHCOC(CH3)3), 6.58 (1 H, d, JP-2 = 22.1 Hz, H2); 
13C NMR (100.5 MHz, CDCl3) δC: 9.25, 9.67 (-OCH(CH2CH3)2), 23.45 (-NHCOCH3), 
25.16, 26.22 (-CH2CH2CH2CH2S-), 25.70 (-OCH(CH2CH3)2), 28.32, 28.35, 28.45 (-
NHCOC(CH3)3), 29.02, 29.05 (-SCH2-), 29.49 (-SCH2CH2-), 30.38 (m, -OCH2CH2-), 
30.74 (-SCOCH3), ~31.31 (m, C6), ~49.29 (m, C5), 52.54, 52.64 (2d, J = 5.3, 5.8 Hz, 
P-OCH3), 54.55 (m, C4), ~66.10 (2d, J = 5.8, 6.1 Hz, P-OCH3), ~76.32 (m, C3), 79.89 
(-NHCOC(CH3)3), 82.27 (-OCH(CH2CH3)2), ~126.93 (d, JP-1 = 182 Hz, C1), 142.15 (m, 
C2), 156.36, 156.41 (-NHCOC(CH3)3), 174.91 (-NHCOCH3), 196.14 (-SCOCH3); 
31P NMR (161.7 MHz, CDCl3) δP: 18.28 (s). 
HR-ESI-MS (m/z) calculated for C27H49N2O8PS [M+Na]+ 615.2839, found 615.2837. 
 
6-Trifluoromethanesulfonyloxy-S-acetyl-hexan-1-thiol (43)  
 
 
 
Compound 40 (77 mg, 0.437 mmol) was placed under an N2 (g) atmosphere and 
suspended in dry DCM (1mL). Lutidine (94 µL, 0.874 mmol) was then added and the 
solution was cooled to -60°C. Triflic anhydride (96 µL, 0.568 mmol) was added to dry 
DCM (1mL), cooled to -60 °C for a few minutes and then added dropwise to the stirring 
solution of compound 40. The reaction was stirred at this temperature for 45 minutes 
by which time the reaction was complete. The DCM solution was then poured into a 
separating funnel containing cold saturated KH2PO4 (aq.) and washed. The organic 
layer was separated, dried over MgSO4 and the solvent evaporated (no heating). The 
crude material was the passed over a short silica plug (DCM). The solvent was 
evaporated in vacuo giving triflate 43 as a yellowish oil (135 mg, 67 %). Rf : 0.64 
(cyclohexane:DE; 1:1). The compound was used without further characterisation. 
1H NMR (500 MHz, CDCl3) δH: 1.37 – 1.49 (4 H, m, -OCH2CH2CH2CH2CH2CH2S-), 1.59 
(2 H, m, -CH2CH2S-), 1.83 (2 H, m, -OCH2CH2-), 2.32 (3 H, s, -SCOCH3), 2.86 (2 H, t, J 
= 7.0, 7.6 Hz), 4.52 (2 H, t, J = 6.4, 6.5 Hz). 
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6’,6’-Dithiobis (hex-1’-yl methyl [(3R,4R,5S)-4-acetamido-5-(1,1 
dimethylethyloxycarbonylamino)-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate]) (44)  
 
 
 
Compound 42 (28 mg, 0.0472 mmol) was placed under an O2 (g) atmosphere and was 
dissolved in anhydrous MeOH (3.5 mL). A methanolic NaOMe solution (~350 µL, 0.1M) 
was then added dropwise to the stirring solution of compound 42, ensuring that the O2 
(g) was bubbling through the solution and that indicator paper indicated a pH ~10. After 
stirring overnight, the solvent was evaporated in vacuo and the residue was directly 
purified by flash chromatography (EA:MeOH; 10:1) to give compound 44 (16 mg, 60%). 
Rf : 0.71 (EA:MeOH; 5:1).  
1H NMR (500 MHz, CDCl3) δH: 0.88 (m, 6H, -OCH(CH2CH3)2), 1.42 (s, 13H, (-
NHCOC(CH3)3, -OCH2CH2CH2CH2CH2CH2S-), 1.46 – 1.55 (m, 4H, -OCH(CH2CH3)2), 
1.64 – 1.73 (m, 4H, -OCH2CH2-, -SCH2CH2-), 1.98 (s, 3H, -NHCOCH3), 2.22 (m, 1H, 
H6ax), 2.60 (m, 1H, H6eq), 2.68 (dd, 2H, J = 7.2, 7.5 Hz, -CH2-SAc), 3.34 (m, 1H, -
OCH(CH2CH3)2), 3.70 (d, 3H, J = 10.9 Hz, P-OCH3), 3.80 (m, 1H, H5), 3.93 (m, 1H, H7), 
4.02 (m, 3H, H4, -OCH2-), 5.10 - 5.25 (m, 1H, -NH COCH3), 5.82 - 5.94 (m, 1H, -
NHCOCH3), 6.60 (d, 1H, JP-2 = 21.8 Hz, H2). 
13C NMR (100.5 MHz, CDCl3) δC: 9.29, 9.73 (-OCH(CH2CH3)2), 23.52 (-NHCOCH3), 
25.31, 25.72, 26.34 (-OCH(CH2CH3)2, -OCH2CH2CH2CH2CH2CH2S-), 28.13, 28.48 
29.15 (-NHCOC(CH3)3), 30.50 (m, -OCH2CH2-, -SCH2CH2-), ~31.37 (m, C6), 39.04, 
39.10 (-CH2S-), 49.31 (C5), 52.67 (2d, J = 5.5, 5.5 Hz, P-OCH3), 54.64 (C4), 66.13 (m, 
-OCH2-), 76.36 (m, C3), 79.86 (-NHCOC(CH3)3), 82.33 (-OCH(CH2CH3)2), ~ 126.87 (d, 
JP-1 = 182 Hz, C1), 142.23 (m, C2), 156.44 (-NHCOC(CH3)3), 171.00 (-NHCOCH3). 
31P NMR (161.7 MHz, CDCl3) δP: 18.28 (s), 18.32 (s). 
HR-ESI-MS (m/z) calculated for C50H92N4O14P2S2 [M+Na]+ 1121.5419, found 
1121.5437. 
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6’,6’-Dithiobis (hex-1’-yl [(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonic acid]) (45) 
 
 
 
Compound 44 (8.2 mg, 0.00746 mmol) and NaI (4.9 mg, 0.0328 mmol) was placed 
under an N2 (g) atmosphere in a reflux condenser and dissolved in dry acetone 
(1.5mL). The solution was heated to reflux for 8 hour periods over 3 days, with the 
addition of a further 2 portions of NaI (4.9 mg, 0.0328 mmol) and acetone to maintain 
the original volume. Once TLC analysis confirmed the reaction was complete, the 
solvent was evaporate in vacuo and the residue was purified by flash chromatography 
(EA:MeOH; 5:1  2:1  1:1  MeOH) to yield the desired demethylated intermediate 
(6.5 mg, 80%). The residue was then treated with dioxane (0.5 mL) and 50% TFA/H2O 
(0.5 mL) for 36 hours. The solvent was then evaporated in vacuo and the residue was 
purified by gel permeation chromatography to afford compound 45 (5.7 mg, 90%).  
1H NMR (500 MHz, D2O) δH: 0.92 (6 H, 2t, J = 7.1, 7.3 Hz, -OCH(CH2CH3)2), 1.38 – 
1.53 (4 H, m, -CH2CH2CH2CH2S-), 1.54 – 1.62 (4 H, m, -OCH(CH2CH3)2), 1.67 (2 H, m, 
-OCH2CH2-), 1.73 (2 H, m, -SCH2CH2-), 2.11 (3 H, s, -NHCOCH3), 2.48 (1 H, dd, J = 
12.0, 13.3 Hz, H6ax), 2.78 (1 H, dd, J = 7.0, 7.0 Hz, -SCH2-), 2.77 – 2.84 (1 H, m, H6eq), 
3.50 – 3.60 (2 H, m, H5, -OCH(CH2CH3)2), 3.85 (2 H, m, -OCH2-), 4.04 (1 H, dd, J = 
10.0, 10.2 Hz, H4), 4.28 (1 H, d, J = 6.9 Hz, H3), 6.30 (1 H, d, JP-2 = 19.3 Hz, H2); 
13C NMR (150.8 MHz, D2O) δC: 8.63, 8.91 (-OCH(CH2CH3)2), 22.36 (-NHCOCH3), 
24.91, 25.26, 25.70, 27.57 (-CH2CH2CH2CH2S-, -OCH(CH2CH3)2), 28.50 (-SCH2CH2-), 
29.55 (m, C6), ~30.00 (d, J = 6.7 Hz, -OCH2CH2-), 38.38 (-SCH2-), ~49.59 (d, J = 14.7 
Hz, C5), 53.24 (C4), 65.27 (-OCH2-), ~75.89 (1 H, d, J = 18.2 Hz, C3), 83.71  
(-OCH(CH2CH3)2), ~130.43 (1 H, d, JP-1 = 173 Hz, C1), 135.17 (m, C2), 174.91  (-
NHCOCH3); 
31P NMR (242.7 MHz, D2O) δP: 12.33 (s). 
HR-ESI-MS (m/z) calculated for C38H72N4O10P2S2 [M+Na]+ 893.4057, found 893.4084. 
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6’,6’-Dithiobis (hex-1’-anol) (46) 
 
 
 
Compound 40 (35mg, 0.198 mmol) was placed under an O2 (g) atmosphere and was 
dissolved in anhydrous MeOH (3.0 mL). A methanolic NaOMe solution (~350 µL, 0.1M) 
was then added dropwise to the stirring solution of compound 40, ensuring that O2 (g) 
was bubbling through the solution and that indicator paper indicated pH ~10. After 
stirring overnight, the reaction had not reached completion. However, the solvent was 
evaporated in vacuo and the residue was directly purified by flash chromatography 
(DE:cyclohexane; 3:1  10:1) to give compound 46 (16 mg, 40%). %). Rf : 0.15 
(DE:cyclohexane; 3:1).  
1H NMR (500 MHz, CDCl3) δH: 1.37 (4 H, m, -CH2CH2CH2CH2S-), 1.53 (2 H, dd, J = 
6.7, 13.4 Hz, -OCH2CH2-), 1.65 (2 H, dd, J = 7.1, 14.3 Hz, -SCH2CH2-), 1.86 (1 H, bs, -
OH), 2.65 (2 H, dd, J = 6.7, 7.6 Hz, -S-CH2-), 3.59 (2 H, dd, J = 6.2, 6.2 Hz, -OCH2-). 
13C NMR (125.7 MHz, CDCl3) δC: 25.55, 28.42 (-CH2CH2CH2CH2S-), 29.30 (-SCH2CH2-
), 32.72 (-OCH2CH2-), 39.23 (-SCH2-), 62.91 (-OCH2-). 
HR-ESI-MS (m/z) calculated for : C12H26O2S2 [M+Na]+ 289.1266. Found: 289.1247. 
 
(6-Acetylthio-hexy-1-yl) methyl (methylphosphonate) (47) 
 
 
 
Compound 40 (112 mg, 0.635 mmol) was placed under an N2 (g) atmosphere. Dry 
DCM (5 mL) was added followed by dry DIPEA (221 µL, 1.27 mmol). The resulting 
solution was cooled to -15 °C (ice/salt bath) and methyl methylphosphonochloridate (82 
µL, 0.825 mmol) was added dropwise. The reaction was allowed to warm to room 
temperature over the course of 3 hours after which time TLC analysis confirmed the 
completion of the reaction. MeOH (2 mL) was then added and the solution was stirred 
for a further 10 minutes. The solvent was removed under vacuum and the crude 
product was purified directly by flash chromatography (EA) to give compound 47 as an 
oil (135 mg, 79%).  
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Rf : 0.31 (EA). 
1H NMR (500 MHz, CDCl3) δH: 1.37 (4 H, m, -CH2CH2CH2CH2SAc), 1.44 (3 H, d, J = 
17.5 Hz, P-CH3), 1.55 (2 H, m, -SCH2CH2-), 1.64 (2 H, m, -OCH2CH2-), 2.29 (3 H, s, -S-
COCH3), 2.83 (3 H, t, J = 7.3 Hz, -SCH2-), 3.69 (3 H, d, J = 11.0 Hz, P-OCH3), 3.98 (2 
H, m, -OCH2-); 
13C NMR (125.7 MHz, CDCl3) δC: ~10.53 (d, J = 144 Hz, P-CH3), 25.15, 28.36 (-
CH2CH2CH2CH2SAc), 29.04 (-CH2S-), 29.49 (-CH2CH2S-), ~30.43 (d, J = 6.2 Hz, -
OCH2CH2-), 30.70 (-SCOCH3), ~52.15 (d, J = 6.4 Hz, P-OCH3), ~65.58 (d, J = 6.4 Hz, -
OCH2-), 195.92 (-SCOCH3); 
31P NMR (161.7 MHz, CDCl3) δP: 31.81 
HR-ESI-MS (m/z) calculated for C10H21O4PS [M+Na]+ 291.0790, found 291.0787. 
 
6’,6’-Dithiobis (hex-1’-yl methyl methylphosphonate) (48) 
 
 
 
Compound 47 (41 mg, 0.155 mmol) was placed under an O2 (g) atmosphere and was 
dissolved in anhydrous MeOH (1.5mL). A methanolic NaOMe solution (1.55 mL, 0.1 M) 
was then added dropwise to the stirring solution of compound 47, ensuring that the O2 
(g) was bubbling through the solution and that indicator paper indicated a pH ~10. After 
stirring overnight, the solvent was evaporated in vacuo and the residue was directly 
purified by flash chromatography (EA:MeOH; 10:1) to give compound 48 as an oil (32  
mg, 80%). %). Rf : 0.13 (EA:MeOH; 10:1). 
1H NMR (500 MHz, CDCl3) δH: 1.38 – 1.46 (8 H, m, -CH2CH2CH2CH2S-), 1.47 (6 H, d, J 
= 17.5 Hz, P-CH3), 1.69 (8 H, m, -OCH2CH2CH2CH2CH2CH2S-), 2.67 (4 H, t, J = 7.4 
Hz, -SCH2-), 3.72 (6 H, d, J = 11.1 Hz, P-OCH3), 4.02 (4 H, m, -OCH2-); 
13C NMR (125.7 MHz, CDCl3) δC: ~10.59 (d, J = 144 Hz, P-CH3), 25.34, 28.16 (-
OCH2CH2-CH2CH2-CH2CH2S-), 29.18 (-CH2CH2S-), ~30.54 (d, J = 6.2 Hz, -OCH2CH2-), 
39.03 (-CH2S-), ~52.22 (d, J = 6.3 Hz, P-OCH3), ~65.67 (d, J = 6.5 Hz, -OCH2-); 
31P NMR (161.7 MHz, CDCl3) δP: 31.87 (s). 
HR-ESI-MS (m/z) calculated for C16H36O6P2S2 [M+Na]+ 473.1321, found 473.1325. 
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6’,6’-Dithiobis (ammonium [hex-1’-yl methyl methylphosphonate]) (49) 
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Compound 48 (80 mg, 0.178 mmol) and sodium iodide (269 mg, 1.78 mmol) were dried 
under vacuum in the absence of light for 20 minutes and then placed under an N2 (g) 
atmosphere. Dry acetone (2 mL) was then added to the reaction flask followed by 
ultrasonication. The solution was then refluxed over 48 hours by which time TLC had 
indicated the absence of starting material and the formation of a new baseline spot. 
The solvent was removed under vacuum and purified by flash chromatography 
(EA:MeOH; 5:1  MeOH) to give compound 49 as a white solid after subsequent gel 
permeation chromatography and  lyophilisation (60 mg, 80%). Rf : 0.26 (EA/MeOH; 
1:1). 
1H NMR (500 MHz, MeOH-D4) δH: 1.22 (6 H, d, J = 16.4 Hz, P-CH3), 1.43 (8 H, m, -
CH2CH2CH2CH2S-), 1.62 (4 H, tt, J = 6.4, 7.0 Hz, -OCH2CH2-), 1.69 (4 H, p, J = 7.0 Hz, 
-CH2CH2S-), 2.69 (4 H, t, J = 7.1, 7.3 Hz, -CH2S-), 3.83 (4 H, dt, J = 6.5, 6.5 Hz,  
-OCH2-); 
13C NMR (100.5 MHz, MeOH-D4) δC: ~12.43 (d, J = 137 Hz, P-CH3), 26.59, 29.22 (-
CH2CH2-CH2CH2S-), 30.20 (-CH2-CH2S-), ~31.98 (d, J = 6.8 Hz, -OCH2CH2-), 39.63 (-
CH2S-), ~64.88 (d, J = 5.6 Hz, -OCH2-); 
31P NMR (161.7 MHz, MeOH-D4) δP: 24.19 (s). 
HR-ESI-MS (m/z) calculated for C14H32O6P2S2 [M+3Na]+ 489.0647, found 489.0645. 
 
6-Azido-O-triisopropylsilylhexane-1-ol (50) 
 
 
 
Compound 38 (59 mg, 0.138 mmol) was placed under an N2 (g) atmosphere and 
dissolved in DMF (1.0 mL). The solution was cooled to 0 °C and NaN3 (27 mg, 0.414 
mmol) was then quickly added. The solution was stirred for 4 hours at which time the 
reaction was complete. The DMF was evaporated in vacuo and the resulting residue 
was suspended in DCM and washed with cold H2O, semi-saturated NH4Cl (aq.) and 
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brine. The organic phase was dried over MgSO4 and purified by flash chromatography 
to give azide 50 as an oily liquid (35 mg, 84%). Rf : 0.84 (DE:cyclohexane; 1:10).  
1H NMR (500 MHz, CDCl3) δH: 1.03, 1.04 (21 H, 2s, -Si(CH(CH3)2)3, 1.38 (4 H, m, -
CH2CH2CH2CH2N3), 1.53 (2 H, m, -OCH2CH2-), 1.60 (2 H, m, N3CH2CH2-), 3.24 (2 H, t, 
J = 7.0 Hz, N3CH2-), 3.66 (2 H, t, 6.4 Hz, -OCH2-); 
13C NMR (125.7 MHz, CDCl3) δC: 12.27, 18.25 -Si(CH(CH3)2)3, 25.67 (-
CH2CH2CH2CH2N3), 26.80 (-Si(CH(CH3)2)3), 29.09 (N3CH2CH2-), 33.05 (-OCH2CH2-), 
51.69 (N3CH2-), 63.46 (-OCH2-); 
HR-ESI-MS (m/z) calculated for C15H33N3OSi [M+Na]+ 322.2285, found 322.2286. 
 
6-Azido-1-hexanol (51) 
 
HO N3
4
 
 
Compound 50 (489 mg, 1.63 mmol) was dissolved in THF (11.0 mL), then AcOH (0.1 
mL) and TBAF.3H2O (1.54 g, 4.89 mmol) were added to the solution and stirred 
overnight. On completion of the reaction, the solvent was evaporated in vacuo and the 
residue was suspended in DCM, washed with NaHCO3 (aq.) and brine. The organic 
phase was dried over MgSO4, the solvent was removed and the residue was purified 
by flash chromatography to give compound 51 as an oil (212 mg, 90%). Rf : 0.17 
(Tol:EA; 10:1).  
1H NMR (500 MHz, CDCl3) δH: 1.35 (bm, 4H, -CH2CH2CH2CH2N3), 1.53 (m, 2H, -
OCH2CH2-), 1.57 (m, 2H, N3CH2CH2-), 1.88 (bs, 1H, -OH), 3.22 (t, 2H, J = 6.8, 6.9 Hz, 
N3CH2-), 3.58 (t, 2H, J = 6.6 Hz, -OCH2-). 
13C NMR (125.7 MHz, CDCl3) δC: 25.47, 26.66 (-OCH2CH2CH2CH2CH2CH2N3), 28.94 
(N3CH2CH2-), 32.66 (-OCH2CH2-), 51.52 (N3CH2-), 62.78 (-OCH2-). 
HR-ESI-MS (m/z) calculated for C6H13N3O [M+Na]+ 166.0951, found 166.0952.  
 
6-Azido-O-trifluoromethanesulfonyl-hexan-1-ol (52) 
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Compound 51 (55.9 mg, 0.390 mmol) was placed under an N2 (g) atmosphere and 
suspended in dry DCM (1 mL). Lutidine (90 µL, 0.780 mmol) was then added and the 
solution was cooled to -40°C. Triflic anhydride (86 µL, 0.507 mmol) was added to dry 
DCM (1 mL), cooled to -40 °C for a few minutes and then added dropwise to the stirring 
solution of compound 51. The reaction was stirred at this temperature for 30 minutes 
by which time the reaction was complete. The DCM solution was then poured into a 
separating funnel containing cold saturated KH2PO4 (aq.) and washed. The organic 
layer was separated, dried over MgSO4 and the solvent evaporated to give the desired 
triflate 52 as brown oil (94 mg, 87%) which was used without further purification. 
1H NMR (500 MHz, CDCl3) δH: 1.46 (4 H, m, -CH2CH2CH2CH2N3), 1.62 (2 H, tt, J = 6.8, 
7.3 Hz, -CH2CH2N3), 1.85 (2 H, tt, J = 6.5, 6.9 Hz, -CH2CH2OTf), 3.29 (2 H, t, J = 6.6 
Hz, -CH2N3), 4.54 (2 H, t, J = 6.5 Hz, -CH2OTf). 
 
Methyl (6-azidohex-1-yl) [(3R,4R,5S)-4-acetamido-5-(1,1-
dimethylethyloxycarbonylamino)-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate]  (53) 
 
 
 
Monoester 35 was converted into the triethylammonium salt by treatment with 
Amberlite IR-120 ion exchange resin (H+) in water, filtration, addition of triethylamine 
and lyophilisation. The triethylammonium salt of compound 35 (35 mg, 0.0653 mmol) 
was then placed under an N2 (g) atmosphere and dry acetonitrile (0.4 mL) was added. 
Azido triflate 52 (21 mg, 0.763 mmol) was dissolved in dry acetonitrile (0.3 mL) under 
an N2 (g) atmosphere and then quickly added to the stirring solution of the 
triethylammonium salt of compound 35. After an hour, TLC analysis indicated the 
reaction had not progressed any further and that the azide triflate was degrading in 
solution. The solvent was evaporated in vacuo and the residue was directly purified by 
flash chromatography (Tol:EA; 1:1  EA  MeOH) to give compound 53 (17.0 mg, 
72% based on recovered starting material). Rf : 0.54 (EA).  
1H NMR (500 MHz, CDCl3) δH: 0.85 (6 H, dd, J = 7.5, 14.9 Hz, -OCH(CH2CH3)2), 1.37 - 
1.42 (13 H, s/bm, -NHCOC(CH3)3, -OCH2CH2CH2CH2N3), 1.47 (4 H, m, -
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OCH(CH2CH3)2), 1.58 (2 H, dd, J = 6.3, 12.9 Hz, N3CH2CH2-), 1.66 (2 H, m, -OCH2CH2-
), 1.96 (3 H, s, -NHCOCH3), 2.17 (1 H, m, H6ax), 2.58 (1 H, ddd, J = 5.9, 12.3, 17.3 Hz, 
H6eq), 3.25 (2 H, dd, J = 6.8, 6.8 Hz, -CH2N3), 3.31 (1 H, dd, J = 5.5, 11.1 Hz, -
OCH(CH2CH3)2), 3.68 (3 H, dd, J = 1.8, 11.0 Hz, P-OCH3), 3.77 (1 H, ddd, J = 5.3, 9.8, 
15.0 Hz, H5), 3.90 (1 H, m, H3), 3.94 - 4.08 (3 H, m, H4, -OCH2-), 5.17 (1 H, d, J = 8.4 
Hz, -NHCOC(CH3)3), 5.94, 6.00 (1 H, 2d, J = 9.0 Hz, -NHCOCH3), 6.58 (1 H, d, JP-2 = 
21.7 Hz, H2). 
13C NMR (100.5 MHz, CDCl3) δC: 9.26, 9.68 (-OCH(CH2CH3)2), 23.48 (-NHCOCH3),  
25.26, 25.71, 26.24, 26.42 (-OCH2CH2CH2CH2CH2CH2N3, -OCH(CH2CH3)2), 28.46 (-
NHCOC(CH3)3), 28.86 (N3CH2CH2-), 30.46 (d, J = 6.0 Hz, -OCH2CH2-), 31.44 (d, J = 
9.3 Hz, C6), 49.35 (d, J = 14.6 Hz, C5), 51.46 (-CH2N3), 52.48-52.77 (m, P-OCH3), 
54.60 (m, C4), 66.02 (d, J = 6.0 Hz, -OCH2-), 76.28, 76.50 (C3), 79.87 (-
NHCOC(CH3)2), 82.31 (-OCH(CH2CH3)2), ~126.9 (d, JP-1 = 182 Hz, C1), 142.20 (d, JP-2 
= 6.8 Hz, C2), 156.40 (-NHCOC(CH3)3), 170.97 (-NHCOCH3); 
31P NMR (161.7 MHz, CDCl3) δP: 18.29 (s), 18.32 (s).  
HR-ESI-MS (m/z) calculated for C25H46N5O7P [M+Na]+ 582.3027, found 582.3058.  
 
(6-Azido hexyl) (3R,4R,5S)-4-acetylamino-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonic acid (54) 
 
 
 
Azido-conjugate 53 (18 mg, 0.0322 mmol) and sodium iodide (50 mg, 0.333 mmol) 
were dried in vacuo in the absence of light for 20 minutes and then placed under an N2 
(g) atmosphere. Dry acetone (1 mL) was then added to the reaction flask followed by 
ultrasonication. The solution was then refluxed over 24 hours by which time TLC had 
indicated the absence of starting material and the formation of a new baseline spot. 
The resulting crude product was purified over a short silica plug (EA  EA/MeOH; 1:1) 
to give the demethylated product (10 mg, 58%). This deprotected intermediate (10 mg, 
0.0183 mmol) was then stirred in a solution of TFA/H2O (1:1) (1.2 mL) and 1,4-dioxane 
(0.8 mL) overnight. The solvent was then evaporated in vacuo and the residue was 
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purified by gel permeation chromatography to afford target compound 54 (7.4 mg, 
91%). 
1H NMR (600 MHz, D2O) δH: 0.87 (3 H, t, J = 7.4 Hz, -OCH(CH2CH3)2), 0.92 (3 H, t, J = 
7.4 Hz, -OCH(CH2CH3)2), 1.40 – 1.45 (4 H, bm, -CH2CH2CH2CH2N3), 1.46 – 1.52, 1.53 
– 1.61 (4 H, m, -OCH(CH2CH3)2), 1.54 – 1.61 (4 H, m, -OCH2CH2-, N3CH2CH2-), 2.10 
(3 H, s, -NHCOCH3), 2.40 (1 H, m, H6ax), 2.75 (1 H, m, H6eq), 3.35 (2 H, t, J = 6.9 Hz, 
N3CH2CH2-), 3.40 – 3.50 (1 H, m, H5), 3.55 (1 H, dd, J = 5.6, 11.4 Hz, -
OCH(CH2CH3)2), 3.83 (2 H, m, -OCH2-), 4.00 (1 H, m, H4), 4.26 (1 H, m, H3), 6.35 (1 H, 
d, JP-2 = 19.3 Hz, H2);  
13C NMR (150.8 MHz, D2O) δC: 8.47, 8.54  (-OCH(CH2CH3)2), 22.26 (-NHCOCH3), 
24.55, 25.14, 25.47, 25.56, 27.82, 29.70, 29.75 (-OCH2CH2CH2CH2CH2CH2N3,  -
OCH(CH2CH3)2,  N3CH2CH2-, -OCH2CH2-), ~30.81 (m, C6), ~49.6 (d, J = 13.7 Hz, C5), 
51.07 (N3CH2-), 54.61 (C4), 65.17 (m, -OCH2-), ~76.2 (m, C3), ~84.0 (m, -
OCH(CH2CH3)2), ~130.6 (d, JP-1 = 171.6 Hz, C1), 136.25 (m, C2), 160.15, 174.94 (-
NHCOCH3); 
31P NMR (242.7 MHz, D2O) δP: 12.77 (s). 
HR-ESI-MS (m/z) calculated for C19H36N2O5P [M+Na]+ 468.2346, found 468.2355. 
 
O-Trifluoromethanesulfonylhex-5-yn-1-ol  (55) 
 
 
 
5-Hexyn-1-ol (55.2 µL, 0.509 mmol) was placed under an N2 (g) atmosphere and 
suspended in dry DCM (1 mL). Lutidine (118 µL, 1.02 mmol) was then added and the 
solution was cooled to -60°C. Triflic anhydride (103µL, 0.611 mmol) was added to dry 
DCM (1 mL), cooled to -60 °C for a few minutes and then added dropwise to the stirring 
solution of the alcohol. The reaction was stirred at this temperature for 1 hour by which 
time the reaction was complete. The DCM solution was then poured into a separating 
funnel containing cold saturated KH2PO4 (aq.) and washed. The organic layer was 
separated, dried over MgSO4 and the solvent evaporated to give the desired triflate 55 
as a slightly coloured oil (113 mg, 96%) which was used without further purification.  
1H NMR (500 MHz, CDCl3) δH: 1.64 – 1.73 (2 H, m, -CH2CH2C≡CH), 1.94 – 2.02 (3 H, 
m, -OCH2CH2CH2CH2C≡CH), 2.29 (2 H, m, -CH2CH2C≡CH), 4.48 (2 H, t, J = 6.2 Hz, -
OCH2CH2-), 5.30 (s, residual DCM). 
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Methyl (hex-5-yn-1-yl) [(3R,4R,5S)-4-acetamido-5-(1,1-
dimethylethyloxycarbonylamino)-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate] (56) 
 
 
 
Hexyne-triflate 55 (51 mg, 0.221 mmol) was placed under an N2 (g) atmosphere and 
dry acetonitrile (0.7 mL) was added. The triethylammonium salt of 35 (80 mg, 0.184 
mmol, prepared as described for compound 42) was then quickly added to the stirring 
solution. After an hour, TLC analysis indicated the reaction had not progressed any 
further and that the hexyne-triflate was degrading in solution. The solvent was 
evaporated in vacuo and the residue was directly purified by flash chromatography 
(Tol:EA; 1:1  EA  MeOH) to give compound 56 (30.5 mg, 65% based on recovered 
starting material). Rf : 0.40 (EA). 
1H NMR (500 MHz, CDCl3) δH: 0.87 (6 H, m, -OCH(CH2CH3)2), 1.40 (9 H, s, -
NHCOC(CH3)3), 1.49 (4 H, m, -OCH(CH2CH3)2), 1.61 (2 H, m, -CH2CH2C≡CH), 1.79 (2 
H, m, -OCH2CH2-), 1.92 (1 H, bs, -CH2C≡CH), 1.97 (3 H, s, -NHCOCH3), 2.16-2.25 (3 
H, m, -CH2C≡CH, H6ax), 2.59 (1 H, m, H6eq), 3.33 (1 H, d, J = 5.0 Hz, -OCH(CH2CH3)2), 
3.69 (3 H, 2d, J = 10.9 Hz, P-OCH3), 3.79 (1 H, m, H5), 3.91 (1 H, m, H3), 3.98 – 4.09 
(3 H, m, -OCH2CH2-, H4), 5.11 (1 H, d, J = 7.1 Hz, -NHCOCH3), 5.85 (1 H, m, -
NHCOC(CH3)3), 6.59 (1 H, d, JP-2 = 21.8 Hz, H2); 
13C NMR (100.5 MHz, CDCl3) δC: 9.27, 9.67 (-OCH(CH2CH3)2), 18.07 (-CH2CH2C≡CH), 
23.46 (-NHCOCH3), 24.60 (-CH2CH2C≡CH), 25.71, 26.23 (-OCH(CH2CH3)2), 28.46 (-
NHCOC(CH3)2), ~29.5 (m, -OCH2CH2-), ~31.3 (d, J = 8.7 Hz, C6), ~49.3 (m, C5), ~52.6 
(m, -P(OCH3)2), ~54.5 (m, C4), ~65.6 (m, -OCH2-), 69.01, 69.07 (-C≡CH), ~76.3 (m, 
C3), 79.85 (-NHCOC(CH3)2), 82.30 (-OCH(CH2CH3)2), 83.83 (-C≡CH), ~126.8 (2d, JP-1 
= 182 Hz, C1), ~142.2 (d, JP-2 = 7.9 Hz, C2), 156.39 (-NHCOC(CH3)2), 170.97 (-
NHCOCH3); 
31P NMR (161.7 MHz, CDCl3) δP: 18.30 (s). 
HR-ESI-MS (m/z) calculated for C25H43N2O7P [M+Na]+ 537.2700, found 537.2709. 
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(Hex-5-yn-1-yl) (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonic acid (57) 
 
 
 
Hexyne-conjugate 56 (15 mg, 0.0291 mmol) and sodium iodide (44 mg, 0.291 mmol) 
were dried in vacuo in the absence of light for 20 minutes and then placed under an N2 
(g) atmosphere. Dry acetone (1 mL) was then added to the reaction flask followed by 
ultrasonication. The solution was then refluxed over 24 hours by which time TLC had 
indicated the absence of starting material and the formation of a new baseline spot. 
The resulting crude product was purified over a short silica plug (EA  EA/MeOH; 1:1) 
to give the demethylated product (12.5 mg, 86%). This deprotected intermediate (6 mg, 
0.0120 mmol) was then stirred in a solution of TFA/H2O (1:1) (1 mL) and 1,4-dioxane 
(0.2 mL) overnight. The solvent was then evaporated in vacuo and the residue was 
purified by gel permeation chromatography to afford compound target compound 57 
(4.1 mg, 85%). 
1H NMR (600 MHz, MeOH-D4) δH: 0.85 – 0.95 (6 H, m, -OCH(CH2CH3)2),  1.47 – 1.57 
(4 H, m, -OCH(CH2CH3)2), 1.58 – 1.65 (2 H, m, -CH2CH2C≡CH), 1.70 – 1.77 (1 H, m, -
OCH2CH2-), 2.03 (3 H, s, -NHCOCH3), 2.15 – 2.27 (3 H, m, -CH2C≡CH, -CH2C≡CH), 
2.39 (1 H, m, H6ax), 2.78 (1 H, m, H6eq), 3.36 – 3.45 (2 H, m, -OCH(CH2CH3)2 , H5), 3.81 
(2 H, dt, J = 6.2, 6.4 Hz, -OCH2CH2-), 3.95 (1 H, dd, J = 8.6, 8.6 Hz, H4), 4.10 (1 H, d, J 
= 7.3 Hz, H3), 6.40 (1 H, d, J = 18.7 Hz, H2); 
13C NMR (150.8 MHz, MeOH-D4) δC: 9.58, 9.89 (-OCH(CH2CH3)2 ), 18.75 (-CH2C≡CH), 
23.12 (-NHCOCH3), 26.20 (-CH2CH2≡CH), 26.64, 27.31 (-OCH(CH2CH3)2), 30.62 (d, J 
= 10.5 Hz, C6), 31.03 (d, J = 7.1 Hz, -OCH2CH2-), 51.49 (d, J = 13.2 Hz, C5), 54.63 
(C4), 65.03 (d, J = 5.3 Hz, -OCH2-), 69.73 (-C≡CH), 76.39 (d, J = 18.8 Hz, C3), 83.28 (-
OCH(CH2CH3)2), 84.78 (-C≡CH), ~132.4 (d, JP-1 = 174 Hz, C1), 136.34 (d, JP-2 = 6.4 Hz, 
C2), 174.66 (-NHCOCH3);  
31P NMR (242.7 MHz, MeOH-D4) δP: 8.05 (s). 
HR-ESI-MS (m/z) calculated for C19H33N2O5P [M+Na]+ 423.2019, found 423.2038. 
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(6-amino hexyl) (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-phosphonate (58) 
 
 
 
Azido-conjugate 53 (26 mg, 0.0473 mmol) was placed under an N2 (g) atmosphere and 
dry THF (1 mL) was added. PMe3 (1 M stock solution in THF, 61.5 µL) was then added 
dropwise to the stirring azido-conjugate solution. The reaction was monitored by TLC 
over the course of 4 hours after which time the reaction was complete. Deionised water 
(0.5 mL) was then added and the solution was stirred for an additional 30 minutes. The 
solvent was then removed directly in vacuo and the crude product was purified by flash 
chromatography (DCM/MeOH; 10:1 +3% NEt3) to give the isolated amino-conjugate 
(qu.). 1H NMR (MeOH-D4) indicates the upfield shifting of -CH2N- resonance with 
respect to compound 42, and a poorly resolved spectrum in CDCl3. Rf : 0.26 
(DCM:MeOH; 10:1 + 3% NEt3). 
1H NMR (500 MHz, MeOH-D4) δH: 0.83 – 0.95 (6 H, m, -OCH(CH2CH3)2), 1.43 (9 H, bs, 
-NHCOC(CH3)3,  1.32 – 1.59 (12 H, bm, -CH2CH2CH2CH2NH2, , -OCH(CH2CH3)2, -
CH2CH2NH2), 1.67 – 1.75 (2 H, m, -CH2CH2O-), 1.96 (3 H, s, -NHCOCH3), 2.23 (1 H, 
m, H6ax), 2.51 (1 H, m, H6eq), 2.65 – 2.71 (2 H, m, - CH2NH2), 3.38 – 3.44 (1 H, m, -
OCH(CH2CH3)2), 3.74 (3 H, d, J = 11.1 Hz, P-OCH3), 3.68 – 3.78 (1 H, m, H5), 3.86 (1 
H, dd, J = 8.9 Hz, H4), 4.06 (2 H, dt, J = 6.1, 6.2 Hz, -OCH2-), 4.09 – 4.14 (1 H, m, H3), 
6.58 (1 H, d, JP-2 = 22.0 Hz, H2); 
13C NMR (100.5 MHz, MeOH-D4) δC: 9.62, 9.91 (-OCH(CH2CH3)2), 22.9 (-NHCOCH3), 
26.42, 26.79, 27.27, 27.35 (-OCH2CH2CH2CH2CH2CH2N3, -OCH(CH2)2(CH3)2), 28.72 (-
NHCOC(CH3)3), ~31.36 (d, J = 5.9 Hz, -OCH2CH2-), ~32.10 (d, J = 8.7 Hz, C6), 32.78 
(-NH2CH2CH2-),  42.13 (-CH2NH2), 50.32, 50.47 (C5), ~53.37 (m, P-OCH3),  ~56.04 (m, 
C4), 67.62 (bm, -OCH2-), 77.27, 77.49 (m, C3), 80.30 (-NHCOC(CH3)2), 83.77 (-
OCH(CH2CH3), ~127.43(2d, JP-1 = 182 Hz, C1), ~144.13 (m, C2), 157.93 (-
NHCOC(CH3)3), 173.71 (-NHCOCH3); 
31P NMR (161.7 MHz, MeOH-D4) δP: 18.46 (s). 
HR-ESI-MS (m/z) calculated for C25H48N3O7P [M+H]+ 534.3303, found 534.3284. 
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Methyl (6-d-biotinamidohex-1-yl) [(3R,4R,5S)-4-acetamido-5-(1,1-
dimethylethyloxycarbonylamino)-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate] (59) 
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Azido-conjugate 58 (26 mg, 0.0473 mmol) was placed under an N2 (g) atmosphere and 
dry THF (1 mL) was added. PMe3 (1 M stock solution in THF, 61.5 µL) was then added 
dropwise to the stirring azido-conjugate solution. The reaction was monitored by TLC 
over the course of 4 hours after which time the reaction was complete. Deionised water 
(0.5 mL) was then added and the solution was stirred for an additional 30 minutes. The 
solvent was then removed directly in vacuo and the crude product was placed on a 
short silica plug (DCM/MeOH; 10:1 +3% NEt3) to give the isolated amino-conjugate 
without additional purification. d-Biotin (15.5 mg, 0.0633 mmol) and PyBOP (33 mg, 
0.0633 mmol) were dried in vacuo and then placed under an N2 (g) atmosphere. Dry 
DMF (1 mL) was then added followed by DIPEA (16 µL, 0.0974 mmol). The reaction 
flask was then sonicated briefly and cooled to 0 °C (ice-bath). After a few minutes the 
isolated amino-conjugate (25 mg, 0.0487 mmol) was dissolved in dry DMF (1 mL) and 
was added dropwise to the stirring d-Biotin solution. The solution was allowed to warm 
slowly to room temperature over 5 hours after which time TLC indicated the reaction 
was complete. The solvent was evaporated directly in vacuo and then purified by 
chromatography (EA/MeOH; 10:1 + 2% AcOH  2:1 + 2% AcOH) to give protected 
target compound 59 (23 mg, 90%). Rf : 0.36 (DCM/MeOH + 3% AcOH). 
1H NMR (500 MHz, MeOH-D4) δH: 0.88, 0.92 (6 H, 2t, J = 7.1 Hz, -OCH(CH2CH3)2), 
1.43 (9 H, s, -NHCOC(CH3)3), 1.34 – 1.78 (18 H, m, -OCH(CH2CH3)2, Hb, Hc, Hd, -
OCH2CH2-CH2CH2-CH2CH2NH-), 1.96 (3 H, s, -NHCOCH3), 2.20 (2 H, dd, J = 6.9, 7.0 
Hz, Ha), 2.18 – 2.27 (1 H, m, H6ax), 2.51 (1 H, m, H6eq), 2.71 (1 H, d, J = 12.7 Hz, Hh’), 
2.93 (1 H, dd, J = 4.7, 12.6 Hz, Hh), 3.15-3.24 (3 H, m, -CH2CH2NH-, He), 3.41 (1 H, m, 
-OCH(CH2CH3)2), 3.70 – 3.78 (1 H, m, H5), 3.74 (3 H, d, J = 11.0 Hz, P-OCH3), 3.86 (1 
H, dd, J = 9.5, 9.7 Hz, H4), 4.01 – 4.08 (2 H, m, -OCH2CH2-), 4.11 (1 H, m, H3), 4.30, (1 
H, dd, J = 4.3, 7.4 Hz, Hf), 4.49 (1 H, dd, J = 5.8, 6.0 Hz, Hg), 6.57 (1 H, d, JP-2 = 21.8 
Hz, H2);  
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13C NMR (100.5 MHz, MeOH-D4) δC: 9.63, 9.93 (-OCH(CH2CH3)2), 22.98 (-NHCOCH3), 
26.34, 26.81, 26.94, 29.55, 29.80, 30.32 (Cb, Cc, Cd, -OCH2CH2-CH2CH2-CH2CH2NH-
), 27.28, 27.46 (-OCH(CH2CH3)2), 28.73 (-NHCOC(CH3)2), ~31.4 (d, J = 5.9 Hz, -
OCH2CH2-), ~32.1 (m, C6), 36.86 (Ca), 40.23 (-CH2CH2NH-), 41.07 (Ch,h’), ~50.4 (m, 
C5), ~53.4 (d, J = 5.8 Hz, -P(OCH3)2), 56.10 (m, C4), 57.05 (Ce), 61.62 (Cg), 63.42 
(Cf), 67.69 (m, -OCH2CH2-), ~77.4 (m, C3), 80.35 (-NHCOC(CH3)2), 83.82 (-
OCH(CH2CH3)2), 124.29, ~127.4 (d, JP-1 = 183 Hz, C1), 144.17 (m, C2), 157.99 (-
NHCOC(CH3)2), 166.07 (-NH-C(O)-NH-), 173.75 (-NHCOCH3), 175.90 (-CH2-C(O)NH-
CH2-); 
31P NMR (161.7 MHz, MeOH-D4) δP: 22.77 (s). 
HR-ESI-MS (m/z) calculated for C35H62N5O9PS [M+Na]+ 782.3898, found 782.3900. 
 
(6-d-Biotinamidohex-1-yl) (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1- 
cyclohexene-1-phosphonic acid (60)   
 
 
 
Protected biotin-conjugate 59 (8.4 mg, 0.0110 mmol) and sodium iodide (30 mg, 0.200 
mmol) were dried in vacuo in the absence of light and then placed under an N2 (g) 
atmosphere. Dry acetone (1 mL) was then added to the reaction flask followed by 
ultrasonication. The solution was then refluxed over 36 hours (maintaining the volume 
of acetone in the reaction flask)  by which time TLC had indicated the absence of 
starting material. The resulting crude product was purified over a short silica plug 
(DCM/MeOH; 10:1 + 3% AcOH) to give the demethylated product (7 mg, 87%). This 
deprotected intermediate (7 mg, 0.00938 mmol) was then stirred in a solution of 
TFA/H2O (1:1) (1 mL) overnight. The solvent was then evaporated in vacuo and the 
residue was purified by gel permeation chromatography to afford target compound 60 
(5 mg, 74%). 
1H NMR (600 MHz, MeOH-D4) δH: 0.87, 0.92 (6 H, 2t, J = 7.4 Hz, -OCH(CH2CH3)2), 
1.34 – 1.79 (18 H, m, -OCH(CH2CH3)2, Hb, Hc, Hd, -OCH2CH2CH2CH2CH2CH2NH-), 
2.11 (3 H, s, -NHCOCH3), 2.27, (2 H, t, J = 7.1 Hz, Ha), 2.48 (1 H, m, H6ax), 2.77 – 2.84 
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(1 H, m, H6eq), 2.81 (1 H, d, J = 13.1 Hz, Hh’), 3.02 (1 H, dd, J = 5.0, 13.2 Hz, Hh), 3.21 
(2 H, t, J = 6.8 Hz, -CH2CH2NH-), 3.36 (1 H, dd, J = 4.7, 4.8 Hz, He), 3.54 – 3.61 (2 H, 
m, H5, -OCH(CH2CH3)2), 3.83 (2 H, m, -OCH2CH2-), 4.07 (1 H, dd, J = 9.0, 9.2 Hz, H4), 
4.28 (1 H, d, J = 8.5 Hz, H3), 4.45 (1 H, dd, J = 4.4, 4.5 Hz, Hf), 4.64 (1 H, dd, J = 4.9, 
5.0 Hz, Hg), 6.35 (1 H, d, JP-2 = 19.3 Hz, H2); 
13C NMR (150.8 MHz, MeOH-D4) δC: 8.46, 8.60 (-OCH(CH2CH3)2), 22.28 (-NHCOCH3), 
24.76, 25.12, 25.18, 25.50, 25.77, 27.66, 27.84, 28.22 (Cb, Cc, Cd, -OCH2CH2CH2CH2-
CH2CH2NH-, -OCH(CH2CH3)2), 29.25 (m, C6), 29.84 (-OCH2CH2-), 35.48 (Ca), 39.20 (-
CH2CH2NH-), 39.63 (Ch,h’), ~49.6 (d, J = 14.2 Hz, C5), 52.93 (C4), 55.39 (Ce), 60.17 
(Cg), 62.06 (Cf), 65.35 (m, -OCH2CH2-), ~75.8 (m, C3), 84.05 (-OCH(CH2CH3)2), 
~130.0 (d, JP-1 = 174 Hz, C1), 135.80 (C2), 165.25 (-NH-C(O)-NH-), 175.12 (-
NHCOCH3), 176.48 (-CH2-C(O)NH-CH2-);  
31P NMR (242.7 MHz, MeOH-D4) δP: 12.44 (s). 
HR-ESI-MS (m/z) calculated for C29H52N5O7PS [M+Na]+ 668.3217, found 668.3244. 
 
Methyl (6-(fluoresceinyl-5,6-carbonylamino)-hex-1-yl) [(3R,4R,5S)-4-acetamido-5-
(1,1-dimethylethyloxycarbonylamino)-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate] (61) 
 
 
 
Azido-conjugate 58 (16 mg, 0.0293 mmol) was placed under an N2 (g) atmosphere and 
dry THF (1 mL) was added. PMe3 (1M stock solution in THF, 40 µL) was then added 
dropwise to the stirring azido-conjugate solution. The reaction was monitored by TLC 
over the course of 4 hours after which time the reaction was complete. Deionised water 
(0.5 mL) was then added and the solution was stirred for an additional 30 minutes. The 
solvent was then removed directly in vacuo and the crude product was placed on a 
short silica plug (DCM/MeOH; 10:1 +3% NEt3) to give the isolated amino-conjugate 
without additional purification. The amino-conjugate (10 mg, 0.0187 mmol) and NHS-
Fluorescein (9 mg, 0.0206 mmol) were dried in vacuo in the absence of light then 
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placed under an N2 (g) atmosphere. Dry DMF (0.6 mL) was added to the flask (strong 
yellow coloured solution) to which was added dry triethylamine (~10 µL, 0.0748 mmol) 
(forming an orange coloured solution of pH~9). The solution was allowed to stir in the 
absence of light over 4 hours after which time the solvent was removed directly in 
vacuo (no heating). Chromatography of the crude product (EA + 3% AcOH  
EA/MeOH; 10:1 + 3% AcOH) gave the desired protected target compound 61 as a 
yellow solid (15 mg, 83%). Rf : 0.58 (EA/MeOH; 10:1 + 3% AcOH). 
1H NMR (500 MHz, MeOH-D4) δH: 0.82 – 0.93 (6 H, m, -OCH(CH2CH3)2), 1.41 (9 H, s, -
NHCOC(CH3)3), 1.30 – 1.55 (8 H, bm, -OCH(CH2CH3)2, -CH2CH2CH2CH2NH-), 1.55 – 
1.78 (4 H, m, -OCH2CH2CH2CH2CH2CH2NH-), 1.93 – 1.95 (3 H, 2s, -NHCOCH3), 2.23 
(1 H, m, H6ax), 2.52 (1 H, m, H6eq), 3.23 – 3.36, 3.42 – 3.48 (2 H, bm, -CH2CH2NH-
(partially under MeOH resonance), 3.36 – 3.42 (1 H, m, -OCH(CH2CH3)2), 3.66 – 3.80 
(3 H, 2d, J = 11.3 Hz, P-OCH3), 3.66 – 3.80 (1 H, m, H5), 3.86 (1 H, dd, J = 9.5, 10.4 
Hz, H4), 3.98 – 4.16 (3 H, m, -OCH2CH2-, H3), 6.35 – 6.76 (7 H, m, H2, H-Fluoroscein), 
7.24 – 8.48 (3 H, m, H-Fluoroscein); 
13C NMR (100.5 MHz, MeOH-D4) δC: 9.61, 9.92 (-OCH(CH2CH3)2), 22.98 (NHCOCH3), 
26.33, 26.39, 26.79, 27.27, 27.51 (-OCH2CH2CH2CH2-, -OCH(CH2CH3)2), 28.72 (-
NHCOC(CH3)2), 30.19, 30.32, 31.28, 31.34, 31.40 (-OCH2CH2CH2CH2CH2CH2NH-), 
32.11 (d, J = 9.2 Hz, C6), 41.06, 41.10 (-CH2CH2NH-), 50.37 (m, C5), 53.36 (m, -
P(OCH3)2), 56.08 (m, C4), 67.69, 67.70, 67.74 (m, -OCH2CH2-), 77.29, 77.51 (C3), 
80.34 (-NHCOC(CH3)2), 83.76, 83.79 (-OCH(CH2CH3)2), 103.70 (C-H (Fluorescein)), 
~111.6 (m), ~114.9 (m), ~124.9 ~125.5, ~126.5, ~126.9, ~128.4 (C1, C-H 
(Fluorescein)), 130.12, 130.18, 130.45, 130.65 (C-H (Fluorescein)), ~134.6 (m), 
137.93, ~144.1 (m, C2), ~154.8 (m), 157.96 (-NHCOC(CH3)2), 168.16, 168.41, 170.95, 
173.76 (-NHCOCH3, -CH2-C(O)NH-CH2-); 
31P NMR (242.7 MHz, MeOH-D4) δP: 18.91, 18.96, 18.98 (s). 
HR-ESI-MS (m/z) calculated for C46H58N3O13P [M+Na]+ 914.3599, found 914.3603. 
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(6-(Fluoresceinyl-5,6-carbonylamino)-hex-1-yl) (3R,4R,5S)-4-acetylamino-5-
amino-3-(1-ethylpropoxy)-1-cyclohexene-1-phosphonic acid (62) 
 
P
H3N
AcHN
O
O
O
O
NH
O
OHO O
CO2H
 
 
Protected fluorescein-conjugate 61 (9 mg, 0.0101 mmol) and sodium iodide (15 mg, 
0.0101 mmol) were dried in vacuo in the absence of light and then placed under an N2 
(g) atmosphere. Dry acetone (1 mL) was then added to the reaction flask followed by 
ultrasonication. The solution was then refluxed overnight by which time TLC had 
indicated the absence of starting material. The resulting crude product was purified 
over a short silica plug (EA/MeOH; 10:1 + 3% AcOH  1:1 + 3% AcOH ) to give the 
demethylated product (7 mg, 80%). This deprotected intermediate (6 mg, 0.00673 
mmol) was then stirred in a solution of TFA/H2O (1:1) (1 mL) overnight. The solvent 
was then evaporated in vacuo and the residue was purified by reversed-phase silica 
chromatography (short-plug) (MeOH/H2O; 1:1  3:1) to afford target compound 62 (5 
mg, 94%). 
1H NMR (600 MHz, MeOH-D4) δH: 0.87 (6 H, m, -OCH(CH2CH3)2), 1.40-1.60 (8 H, m,  
-OCH(CH2CH3)2, -OCH2CH2CH2CH2CH2CH2NH-), 1.61 – 1.70 (4 H, m, -OCH2CH2-
CH2CH2CH2CH2NH-), 1.97, 2.00 (3 H, 2s, -NHCOCH3), 2.38 (1 H, m, H6ax), 2.76 (1 H, 
m, H6eq), 3.26 – 3.45 (2 H, bm, -CH2CH2NH- (partially obscured by MeOH)), 3.35 - 3.45 
(2 H, m, H7, H5), 3.73 – 3.83 (2 H, m, -OCH2CH2-), 3.94 (1 H, m, H4), 4.08 (1 H, m, H3), 
6.38 (1 H, m, H2), 6.50 – 8.42 (9 H, m,  H-Fluoroscein); 
13C NMR (150.8 MHz, MeOH-D4) δC: 9.58, 9.53 (-OCH(CH2CH3)2), 23.14 (-NHCOCH3), 
26.25, 27.32, 27.69, 30.32, 30.35, 31.86 (-OCH2CH2CH2CH2CH2CH2NH-, -
OCH(CH2CH3)2), 30.73 (m, C6), 41.13 (-CH2CH2NH-), ~51.5 (d, J = 12.0 Hz, C5), 
54.67 (C4), 65.46 (-OCH2CH2-), ~76.5 (m, C3), 83.26 (-OCH(CH2CH3)2), 103.66 
(CH(Fluorescein)), 111.40, 114.51 (CH(Fluorescein)), 124.49, 125.26, 126.21, 126.67 
(CH(Fluorescein)), 130.37, 131.91, 133.06, 134.85 (C1, CH(Fluorescein)), ~136.3 (m, 
C2), 137.97, 154.54, 168.42 (-C(O)NH-CH2-), 170.81, 174.65 (-NHCOCH3); 
31P NMR (242.7 MHz, MeOH-D4) δP: 8.14 (s). 
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HR-ESI-MS (m/z) calculated for C40H48N3O11P [M+Na]+ 800.2919, found 800.2919; 
calculated for C40H48N3O11P [M+(2Na-H)]+ 822.2738, found 822.2767. 
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III.5. Nanoparticle syntheses 
 
“Small” phospha-oseltamivir stabilised gold nanoparticles (“small TamiGold”) 
Disulfide 45 (3.5 mg, 4.02 x 10-3 mmol) was dissolved in MeOH (0.4 mL). The 
methanolic solution was added to an aqueous solution of 0.025M HAuCl4.3H2O (1.34 x 
10-3 mmol) followed by acetic acid (5.4 µL, 0.0938 mmol). Vigorous stirring over 15 
minutes was followed by subsequent addition of freshly prepared aqueous 1M sodium 
borohydride (0.0268 mmol) in two portions over 5 minutes. The resulting brown/black 
solution was stirred overnight in the absence of light. The solvent was removed in 
vacuo to near dryness where the resulting waxy product was co-evaporated with MilliQ 
water (x2). MilliQ water (low volume) was added to the residue to aid the solubility of 
the nanoparticles for transfer to an eppendorf tube. Cycles of centrifugation (~12000g) 
and resuspension with ethyl acetate/methanol (10:1  5:1) were repeated until the 
supernatant showed no starting material (by TLC). The black/brown particulate 
suspension was resuspended in MilliQ water and dialysed against MilliQ water over 7 
days (7 x 1 L). 
 
“Small” monomethylphosphonate-stabilised gold nanoparticles (control) 
A procedure identical to that of phospha-oseltamivir-stabilised gold nanoparticles 
described above was used, with disulfide 49 as ligand. The black/brown residue formed 
in the reaction showed a lower solubility in MeOH as compared to “small TamiGold”. 
Ethyl acetate/methanol ratios used in the centrifugation process were adjusted 
accordingly. 
 
“Large” phospha-oseltamivir-stabilised gold nanoparticles (“large TamiGold”) 
Freshly prepared citrate-capped gold nanoparticles (for synthesis, see below) (~3 nM, 
10 mL) were added to a solution of disulfide 45 (6 mg, 0.00689 mmol) in 10mM 
phosphate buffer (pH ~7.6) (1 mL). After 30 minutes, UV spectroscopy confirmed a 
slight red-shift of the gold nanoparticle suspension (519 nm to 525 nm). The solution 
was stirred vigorously for a further 72 hours in the absence of light to ensure the place 
exchange reaction reached completion. The volume of the AuNP solution was then 
reduced in vacuo (no heating) to ~4 mL. The red coloured solution was then 
transferred to a 50 mL centrifuge tube and acidified to pH 2-3 (indicator paper) with 0.1 
M HCl (aq.) in order to induce nanoparticle aggregation (red to purple colour change).  
The solution was then centrifuged after which the supernatant was removed carefully. 
Deionised H2O (acidified to ~ pH 3) was added to the purple aggregate which was then 
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agitated, followed by further centrifugation. This process was repeated until disulfide 45 
was no longer detected (TLC and 1H NMR of supernatant residue). A few drops of 0.1 
M NaOH (aq.) were added to the purple aggregate (which turned red) followed by 1 mL 
of Tris buffer (10 mM, pH 9.3) (2 mL). If necessary another drop of 0.1 M NaOH (aq.) 
was added to ensure all aggregated particles were resuspended (solution ~pH 9.5 – 
10, indicator paper). The resulting red solution was diluted with Tris buffer (final volume 
5 mL) and underwent prolonged dialysis with Tris buffer (10 mM, pH 9.3) (2 L x 7 
days). A final solution pH of ~9.3 was confirmed with the use of a pH meter. 
 
“Large” methylphosphonate-stabilised gold nanoparticles 
A procedure identical to that of “large TamiGold” described above was used, with 
disulfide 49 as ligand.  
 
Synthesis of citrate-capped gold nanoparticles 
A 100 mL aqueous solution of HAuCl4.3H2O (13.8 mg, 0.0350 mmol) was continuously 
stirred and heated to 60°C. A 50 mL aqueous trisodium citrate solution (55.5 mg, 0.215 
mmol) was heated to 60 °C and then rapidly added to the stirring chloroauric acid 
solution. Heating and vigorous stirring was maintained for ~ 2 hours until a wine red 
solution was obtained with characteristic UV band (~ 519 nm).  
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III.6. Nanoparticle characterisation 
 
Transmission electron microscopy (TEM and HR-TEM) 
Transmission electron microscopy (TEM) and high resolution transmission electron 
microscopy (HR-TEM) were carried out using a Hitachi-7100 Transmission Electron 
Microscope (accelerating voltage of 100kV) and a JEOL 4000EX HREM (accelerating 
voltage of 400kV) respectively. Samples were prepared by dropping aqueous 
nanoparticle suspensions on Formvar-coated holey copper grids (TEM) or lacey carbon 
grids (HRTEM) and allowing the samples to air-dry. Samples for HRTEM were baked 
on a 60 W lamp before imaging. Staining was carried out using uranyl acetate (2%). 
Electron micrograph images were analysed using ImageJ (Rasband, W.S., ImageJ, U. 
S. NIH, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2011). Images 
underwent limited editing to improve contrast for counting purposes where necessary. 
Particles were counted with the automated particle analysis tool or manually where 
necessary (by measuring the longest vertical particle diameter). All image analysis was 
carried out by the same operator using ~100-250 particles for statistical analysis. 
 
Diffusion Ordered Spectroscopy (DOSY) NMR 
Stokes-Einstein equation for the calculation of the hydrodynamic radius of a spherical 
particle from its diffusion coefficient: 
 
D = kT / 6 pi η rH 
 
D = diffusion coefficient from DOSY experiment 
η (viscosity) = 8.9 x 10-4 Pa s (for H2O at 298 K) 
k = Boltzmann’s constant 
rH ~ hydrodynamic radius  
 
The data was acquired with the Oneshot sequence (M.D. Pelta, G.A. Morris, M.J. 
Stchedroff, and S.J. Hammond, A one-shot sequence for high resolution diffusion-
ordered spectroscopy, 2002, Magn. Reson. Chem., 40, S147-S152) and processed 
using the DOSY Toolbox (M. Nilsson, et al., The DOSY Toolbox: A new tool for 
processing PFG NMR diffusion data, 2009, J. Mag. Res., 200, 296-302). 
 
 
242 
 
 
Energy dispersive X-ray analysis (EDX) 
Energy dispersive x-ray analysis (EDX) was performed using an Oxford INCA Energy 
200 Premium instrument connected to a JEOL JSM 5900LV scanning electron 
microscope. The solid sample was deposited onto an aluminium pin stub using double-
sided adhesive carbon discs (Agar Scientific Ltd). The sample was viewed using 3 kV 
primary beam accelerating voltage and an in-lens distance of 5 mm. Data recording 
from the selected positions was performed over a period of 50 seconds. 
 
Dynamic light scattering (DLS) 
Size measurements were performed using dynamic light scattering (DLS) on a Malvern 
Zetasizer Nano-S (Malvern Instruments, Malvern, UK). Samples were irradiated with 
red light (HeNe laser, wavelength λ = 632.8 nm) and the intensity fluctuations of the 
scattered light (detected at a backscattering angle of 173°) was analysed (avalanche 
photodiode (APD) detector) to obtain an autocorrelation function. The software (DTS 
v5.00) provided both the size mean and polydispersity, using the cumulants analysis 
and a size distribution using a regularization scheme by intensity (and by volume and 
number where applicable). Samples were filtered before analysis, once over a cotton 
plug followed by a disposable 0.45µm filter to remove any unwanted contaminants and 
large aggregates. 
The following assumptions were made in the analysis: the solution viscosity was 
assumed to be that of water, corrected for temperature (η = 0.8872 mPa.s); the 
solution refractive index was that of water (n = 1.33); the refractive index of the particle 
was selected to be nR = 0.34 with absorption of nI = 2.37. Samples were measured in 
disposable Eppendorf UVette 50-2000 µL polystyrene cuvettes at a temperature of 
25°C, and this temperature was actively maintained within 0.1 °C . Data were acquired 
in automatic mode (3 measurements x 12 runs), ensuring enough photons were 
accumulated for the result to be statistically relevant. The software incorporated a ‘data 
quality report’ that indicated good quality for all data obtained. 
 
UV-Visible spectroscopy 
UV-Visible spectra were recorded on a Varian Cary 50 Scan spectrometer using the 
fast scan setting. Spectra of nanoparticle suspensions were recorded with deionised 
water, Tris buffer (10 mM, pH 9.3) or phosphate buffer (10 mM, pH 7.6) as a blank 
reference in a 1 mL cuvette (1 cm path length). 
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III.7. Inhibition of neuraminidase (NA) activity 
A whole virus assay using allantoic fluid from infected eggs was used to assess the 
inhibition of NA by compound 45 and isolated NA (purified NA from influenza virus X31 
(H3N2)) was use to assess the inhibition of NA by compounds 54, 57, 60 and 62. 
In brief, neuraminidase (NA) enzymatic activity was studied using the fluorescent 
substrate 2’-4-methylumbelliferyl)-α-D-N-acetylneuraminic acid (MUNANA). 
Measurements were made at 37 °C in 32.5 mM MES (pH 6.5) + 4 mM CaCl2 using a 
JASCO FP-6300 fluorimeter with excitation at 365 nm and emission at 450 nm.  
 
Compound 45: Michaelis-Menten constants for the enzyme, Km = (k2 + k-1)/k1, were 
determined using standard initial rate measurements with estimated neuraminidase 
concentrations in the range 0.1 to 0.5 nM and MUNANA concentrations in the range 2 
to 200 µM.  
 
Compounds 54, 57, 60 and 62: Michaelis-Menten constants for the enzyme, Km = (k2 + 
k
-1)/k1, were determined by measuring the extent to which different concentrations of 
inhibitor (8, 16, 24 nM) reduced the steady-state rate of MUNANA hydrolysis (25 µM 
MUNANA, 0.16 nM NA). 
 
Inhibition constants (KI) were determined by measuring the extent to which different 
concentrations of inhibitor reduced the steady-state rate of MUNANA hydrolysis. The 
data were interpreted using the following simple model for competitive inhibition in 
which E, S, and I represent neuraminidase, MUNANA, and inhibitor, respectively: 
 
 
 
The reduced rate of hydrolysis of MUNANA observed in the presence of inhibitor is 
predicted by the following equation (Rameix-Welti et al.):87  
E S ES+ E P+
k1
k-1
k2
I
EI
+
k3 k-3
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where VI is the steady-state rate for MUNANA hydrolysis in the presence of inhibitor at 
concentration [I], V0 is the steady-state rate for MUNANA hydrolysis in the absence of 
inhibitor, [S] is the MUNANA concentration, Km is the Michaelis-Menten constant for 
hydrolysis of MUNANA, and Ki is the dissociation constant for the enzyme-inhibitor 
complex. Because these inhibitors show a slow approach to the new steady state 
rate287 it was necessary to confirm that the new steady-state rate had been reached; 
this was done by demonstrating that the first derivative of the fluorescence change 
(proportional to the NA activity) became constant at long times.  
 
III.8. Fluorescence experiments 
The fluorescence binding experiment was carried out at 5 °C, using a JASCO FP-6300 
fluorimeter and concentrations of compound 62 and NA were comparable (9 nM and 12 
nM, respectively). 
 
III.8.1. Fluorescence titration 
The binding experiment was carried out at 37 °C, using a JASCO FP-6300 fluorimeter 
by titrating compound 62 (2 nM) with X31 N2 in 32.5 mM MES (pH 6.5) + 100 mM 
NaCl. The dissociation constant determined using standard non-linear least-squares 
methods was 0.23 ± 0.05 nM, in reasonable agreement with the value determined by 
inhibition of MUNANA hydrolysis. 
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V. Appendices 
V.1. Appendix 1. PLE experiments 
 
* Substrate concentration given as percentage of total volume of PBS buffer. 
1% substrate concentration (all experiments). 
+ The amount of PLE is expressed in Units (1 U = 1 µmol min-1). PLE used as a 
lyophilised poweder (measured activity of 27 Umg-1) 
# pH (monitored by indicator paper range 7-11). pH 8 is the unmodified pH of PBS buffer 
solution 
 
Table A1. Table of experimental conditions used in the unsuccessful hydrolysis of the methyl 
ester of compound 4 and compound 25 
 
 
 
 
α-
sialoside 
substrate 
 
Method 
of 
analysis 
 
PLE 
conc.+ 
 
pH# Temp. (°C) 
Total time of 
experiment 
(hrs) 
 
Results 
 
4 1H NMR 400 mU 8 RT 168 No hydrolysis 
25 1H NMR 400 mU 8 RT 168 No hydrolysis 
4 1H NMR 1 U 8 30 120 No hydrolysis 
4 1H NMR 10 U 8 30 120 No hydrolysis 
4 1H NMR 100 U 8 30 120 No hydrolysis 
25 1H NMR 1 U 8 30 120 No hydrolysis 
25 1H NMR 10 U 8 30 120 No hydrolysis 
25 1H NMR 100 U 8 30 120 No hydrolysis 
4 TLC 54 U 6 35 168 No hydrolysis 
4 TLC 54 U 7 35 168 No hydrolysis 
4 TLC 54 U 8 35 168 No hydrolysis 
4 TLC 54 U 9 35 168 No hydrolysis 
25 TLC 54 U 6 35 168 No hydrolysis 
25 TLC 54 U 7 35 168 No hydrolysis 
25 TLC 54 U 8 35 168 No hydrolysis 
25 TLC 54 U 9 35 168 No hydrolysis 
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Experimental comments 
 
NMR experiments  
PLE was suspended in deuterated PBS buffer. Reference 1H NMR (32 scans) were 
taken of the substrates (α-O-allyl sialoside 4 and 8,9-epoxide derivative 25) in PBS 
alone and PBS incubated with PLE.  1H NMR spectra (32 scans) were taken over the 
course of the reaction (every 30 minutes then hourly, then daily). Conditions were 
varied for different experiments (amount of PLE, pH and incubation temperature). 
 
No reduction was observed in the methyl-ester 1H NMR resonance (δ 3.85 ppm in D2O 
for α-O-allyl sialoside 4 and 8,9-epoxide derivative 25) in any experiment. 
 
TLC experiments 
The pH of solution was varied (by addition of 0.5 M HCl(aq) or NaOH(aq)) for PLE 
hydrolysis reactions with α-O-allyl sialoside 4 and 8,9-epoxide derivative 25. 
The reactions were monitored over time by spotting TLC plates at appropriate intervals 
and eluting with an appropriate TLC solvent system (EA/MeOH 5:1 for α-O-allyl 
sialoside 4 and EA/MeOH 10:1 8,9-epoxide derivative 25). 
 
No hydrolysis product was observed by TLC analysis for α-O-allyl sialoside 4 and 8,9-
epoxide derivative 25. 
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PLE enzymatic hydrolysis of 3-cyclohexene-1-carboxylic acid methyl ester to 3-
cyclohexene-1-carboxylic acid determined by 1H NMR 
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Figure A1. 1H NMR of 3-cyclohexene-1-carboxylic acid (reference sample).  
NMR solvent: CDCl3 
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Figure A2. 1H NMR of 3-cyclohexene-1-carboxylic acid methyl ester (pre-PLE hydrolysis). The 
methyl-ester (-CO2CH3) resonance is observed at δ 3.68 ppm (s). NMR solvent: CDCl3 
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Figure A3. 1H NMR of hydrolysis product. The hydrolysis of 3-cyclohexene-1-carboxylic acid 
methyl ester as observed by the reduction in the methyl-ester (-CO2CH3) 1H resonance (δ 3.68 
ppm (s)). Ethyl acetate impurity present in NMR spectrum (δ 4.12 ppm (q), 2.04 ppm (s) and 
1.25 ppm (t)). NMR solvent: CDCl3 
 
Rudimentary 1H NMR analysis (see figure A3) indicated that PLE hydrolysis of 3-
cyclohexene-1-carboxylic acid methyl ester led to the formation of 3-cyclohexene-1-
carboxylic acid. This was determined from the reduction in intensity of the methyl-ester 
1H resonance (δ 3.68 ppm) in comparison to other relevant 1H resonance signals for 
the 3-cyclohexene-1-carboxylic acid scaffold. This indicates that the PLE enzyme is 
active. 
The amount of product formed by this hydrolysis reaction and their diasteromeric 
determination were not carried out. The importance of this experiment was to observe 
the PLE enzyme working upon a known substrate. The lack of enzymatic hydrolysis 
with α-O-allyl sialoside 4 and the 8,9-epoxide derivative 25 suggests that these α-
sialosides are not suitable PLE substrates.  
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V.2. Appendix 2. Dynamic light scattering (DLS)  
 
Introduction 
Dynamic light scattering (DLS) is a non-invasive technique which can be used for 
measuring the size of nanoparticles in a dispersion.1,2,3 The technique measures the 
time-dependent fluctuations in the intensity of scattered light from a suspension of 
particles undergoing Brownian motion.1  
The DLS instrument measures the intensity of light scattered from the nanoparticle 
over time (δt) and then correlates the detected light intensity at the t0 (initial time or 
“time zero”) with [t0 + δt] as an “autocorrelation function”. As such, small particles lose 
their correlation more rapidly than larger particles due to a faster rate of diffusion.2,4  
The “autocorrelation function” (g(τ)) of scattered light intensity is given by the relation; 
 
g(τ) = |G(τ) - 〈I〉2 / γ|1/2 = Ae-2Γτ    
 
G(τ): field autocorrelation function 
〈I〉2:  base line 
γ:  coherence factor 
A:  instrument specific constant 
Γ:  decay rate 
τ: delay time 
 
The diffusion coefficient for a nanoparticle (D) can be determined using the relation; 
 
D = Γ/q2  ...where, q: wave vector 
 
q = 4piηsin (pi/4)/λ 
 
η:  refractive index of surrounding medium 
λ: wavelength of incident light 
 
Therefore, analysis of the intensity fluctuations (obtained by plotting the intensity of 
scattered light as an “autocorrelation function”) allows for the determination of the 
nanoparticle diffusion coefficient (D), which in turn yields the particle size (i.e., the 
hydrodynamic radius (Rh)) through the Stokes- Einstein equation; 
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Rh = kT / 6piηD 
 
k: Boltzmann’s constant 
T: Absolute temperature 
 
Dynamic light scattering is a low resolution technique with the ability to resolve 
materials with a factor of three difference in their sizes. It is therefore not possible to 
resolve different sized peaks for various particle species (i.e. single particle, two 
particles and multiple-particle aggregates).3  
 
Data obtained from DLS 
The direct output from the DLS experiment is a distribution by intensity, that is, the area 
of each of the modes is related to the intensity of light scattered. The result obtained, 
the Z-average diameter (the mean hydrodynamic diameter) and the polydispersity 
index (an estimate of the sample distribution width) are intensity-weighed values and 
will therefore be sensitive to any larger size species in the sample.1,3  
For an ideal monodisperse sample, the peak in the intensity distribution is expected to 
be very close to the Z-average size from the Cumulant fit (Cumulants analysis being a 
mathematical tool to extract useful information from the autocorrelation function). As a 
consequence of sample polydispersity, the mean size of the peak by intensity is 
different from the Cumulant size. The Z-average is an intensity weighted average, 
therefore any polydispersity or breadth of particle size distribution will bias the Z-
average toward the larger particle sizes3,5 as the scattering intensity of a nanoparticle 
suspension is proportional to R6 (where R is the nanoparticle radius). As a result, a 
small population of large particulates can dictate the appearence of the intensity 
distribution obtained therefore making the particle distribution misleading.6,5  
 
The intensity distribution may be further manipulated mathematically to transform the 
result into a volume and a number distribution.4 Correct material properties (refractive 
index and absorption) are required to obtain accuracy in the results relating to volume 
and number distributions.  Interpretation of DLS data beyond the intensity distribution is 
problematic. Along with the inherent uncertainty introduced to the DLS intensity data 
from band spreading (due to the mathematically ill-defined problem of deconvoluting 
the autocorrelation function) and the assumptions of nanoparticle morphology 
(homogenous and spherical), the mathematical conversion from intensity to volume 
and/or number-based distributions derived from intensity data typically skews particle 
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size to some degree.7 For accuracy of results, information about the optical properties 
of the dispersing medium and the dispersed phase is needed for the mathematical 
transformation. The effect is that for particle sizes below approximately 100 nm, the 
volume and number averages are smaller than the intensity average. As such, volume 
and number distributions derived from DLS measurements are best implemented for 
comparison purposes and do not correspond to absolute values.7,8  
 
DLS in relation to TEM imaging 
For polydisperse samples, results obtained from DLS analysis will be larger than those 
obtained from TEM imaging due to the contribution of scattering from the larger particle 
aggregates. Number based metrologies are typically microscopy techniques, such as 
TEM, where particle images are counted and sorted into size bins. Again, when 
comparing size results obtained using electron microscopy, it must be noted that the 
corresponding size distribution for comparison is the number distribution.3,9   
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 V.3. Appendix 3.  
Calculation of concentration of ‘small TamiGold’ and phospha-oseltamivir 
moieties in inhibition assays 
 
Ratio (Au/phospha-oseltamivir moiety) = 1:1 based on EDX-analysis of the Au/S ratio. 
 
Number of Au atoms/particle for a diameter of 2 nm: ~ 200.1 
Calculation of the number of gold atoms in a spherical nanoparticle; 
 
nAu = 4pi (d/2)3/3Vg 
 
d: diameter of particle  
Vg: volume of gold atom (fcc) = 17 Å3  
 
This results in an estimate of 200 Au atoms and 200 phospha-oseltamivir moieties per 
particle, thus allowing calculation of the molecular weight per particle (mParticle); 
 
mParticle = 126500 Da (200 x mAu + 200 x (mCompound 4)/2). 
 
mAu: molecular weight of gold 
mCompound: molecular weight of phospha-oseltamivir derivative 
 
Concentrations of ‘small TamiGold’ and phospha-oseltamivir moieties in stock solution 
used for inhibition assays; 
 
Particle concentration: 1 mg/mL (particle) = 7.9 x 10-6 mM/mL (particle). 
 
Phospha-oseltamivir concentration for 1 mg/mL (particle)  = 1.6 x 10-3 mM/mL  
= 1.6 mM 
 
The same assumptions and calculations were used for the methylphosphonate-
stabilised control particles, resulting in a 2.3 mM stock solution. 
 
References 
(1)  Daniel, M.-C.; Astruc, D. Chemical Reviews 2004, 104, 293-346. 
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V.4. NMR data 
V.4.1. 1H NMR 
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1H NMR (500 MHz, CDCl3) of compound 3 
 
0
.9
9
2
.9
4
1
.0
0
1
.0
2
1
.0
0
2
.0
4
1
.0
4
4
.9
2
1
.0
2
0
.9
9
0
.8
9
0
.8
7
0
.7
8
 
1H NMR (500 MHz, MeOH-D4) of compound 4 
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1H NMR (600 MHz, D2O) of compound 5 
 
 
1H NMR (600 MHz, MeOH-D4) of compound 6 
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1H NMR (600 MHz, D2O) of compound 7 
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1H NMR (600 MHz, D2O) of compound 8 
273 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
5
.6
5
1
.0
3
2
.7
7
1
.0
0
0
.9
7
0
.9
5
1
.0
7
3
.5
4
3
.7
6
0
.9
8
1
.8
6
0
.9
5
0
.9
6
0
.9
8
1
.0
4
 
1H NMR (500 MHz, CDCl3) of compound 9 
 
 
1H NMR (500 MHz, CDCl3) of compound 10 
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1H NMR (600 MHz, CDCl3) of compound 11 
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1H NMR (500 MHz, MeOH-D4) of compound 12 
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1H NMR (500 MHz, CDCl3)  of compound 13 
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1H NMR (500 MHz, CDCl3) of compound 14 
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1H NMR (500 MHz, CDCl3) of compound 15 
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1H NMR (500 MHz, MeOH-D4) of compound 16 
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1H NMR (500 MHz, CDCl3) of compound 19 
 
 
1H NMR (500 MHz, CDCl3) of compound 20 
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1H NMR (500 MHz, CDCl3) of compound 21 
 
 
1H NMR (500 MHz, CDCl3) of compound 22 
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1H NMR (500 MHz, CDCl3) of compound 27 
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1H NMR (500 MHz, CDCl3) of compound 28 
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1H NMR (500 MHz, CDCl3) of compound 29 
 
 
1H NMR (500 MHz, D2O) of compound 30 
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1H NMR (500 MHz, MeOH-D4) of compound 31 
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1H NMR (500 MHz, CDCl3) of compound 32 
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1H NMR (500 MHz, CDCl3) of compound 33 
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1H NMR (500 MHz, CDCl3) of compound 34 
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1H NMR (500 MHz, D2O) of compound 35 
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1H NMR (500 MHz, CDCl3) of compound 36 
 
287 
 
2
1
.3
2
4
.2
4
4
.4
0
4
.0
0
 
1H NMR (500 MHz, CDCl3) of compound 37 
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1H NMR (500 MHz, CDCl3) of compound 38 
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1H NMR (500 MHz, CDCl3) of compound 39 
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1H NMR (500 MHz, CDCl3) of compound 40 
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1H NMR (500 MHz, CDCl3) of compound 41 
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1H NMR (500 MHz, CDCl3) of compound 42 
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1H NMR (500 MHz, CDCl3) of compound 43 
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1H NMR (500 MHz, CDCl3) of compound 44 
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1H NMR (500 MHz, D2O) of compound 45 
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1H NMR (500 MHz, CDCl3) of compound 46 
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1H NMR (500 MHz, CDCl3) of compound 47 
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1H NMR (500 MHz, CDCl3) of compound 48 
 
293 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
2
.9
9
4
.1
6
4
.0
9
1
.9
7
2
.0
0
 
1H NMR (500 MHz, MeOH-D4) of compound 49 
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1H NMR (500 MHz, CDCl3) of compound 50 
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1H NMR (500 MHz, CDCl3) of compound 51 
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1H NMR (500 MHz, CDCl3) of compound 52 
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1H NMR (500 MHz, CDCl3) of compound 53 
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1H NMR (600 MHz, D2O) of compound 54 
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1H NMR (500 MHz, CDCl3) of compound 55 
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1H NMR (500 MHz, CDCl3) of compound 56 
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1H NMR (600 MHz, MeOH-D4) of compound 57 
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1H NMR (500 MHz, MeOH-D4) of compound 61 
 
 
1H NMR (600 MHz, MeOH-D4) of compound 62 
300 
 
V.4.2. 13C NMR of target compounds 
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13C NMR (150.8 MHz, MeOH-D4) of compound 6 
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V.4.3. 31P NMR of target compounds 
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31P NMR (161.7 MHz, D2O) of compound 8 
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31P NMR (161.7MHz, MeOH-D4) of compound 49 
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31P NMR (242.7 MHz, MeOH-D4) of compound 57 
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31P NMR (161.7MHz, MeOH-D4) of compound 60 
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31P NMR (242.7 MHz, MeOH-D4) of compound 62 
 
